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SUMMARY 
 
Oral drug delivery is perceived by many as the ideal method of drug delivery due to its versatility, ease and 
convenience. However, the bioavailability of drugs delivered via the oral route remains questionable. 
Typically, conventional marketed drug delivery systems release drugs in variable and erratic fashions, causing 
sub-therapeutic or even toxic doses. As a result, patient compliance is threatened, ultimately affecting the 
success of the therapeutic intervention. Furthermore, the harsh gastric environment further compromises oral 
bioavailability due to the presence of a highly acidic environment and proteolytic enzymes.  
 
A multi-component, membranous drug delivery system (MMDDS) was thus designed, formulated and 
evaluated for the site-specific delivery of two (or more) drugs in a prolonged release manner, ultimately easing 
complicated treatment regimens, and improving patient compliance. The MMDDS essentially comprises of a 
gastric-targeted and an intestinal-targeted component, each containing a protective coat, a drug-loaded layer 
incorporating the respective drugs, and a pH-responsive mucoadhesive layer for site-specific mucoadhesion. 
The MMDDS employs a combination of controlled and targeted drug release mechanisms, in addition to 
gastro-retentive or intestinal retentive mechanisms. Furthermore, the system physically protects the drug 
delivery system from acidic or proteolytic degradation within the human gastro-intestinal tract. The present 
study employed the use of pH-dependant mucoadhesion for site-specific, segregated and gastroretentive drug 
delivery while crosslinking was employed for rate-modulated drug delivery. Rifampicin and isoniazid were 
selected as the model drugs in this study as they are known for interacting when administered simultaneously 
(detrimentally affecting the bioavailability of rifampicin). Notwithstanding this interaction, rifampicin and 
isoniazid must be taken concurrently for successful TB therapy. Therefore these drugs would benefit from the 
site-specific drug delivery offered by the MMDDS.  
 
The primary aim of the pH-responsive mucoadhesive layer was to ensure prolonged adhesion of the MMDDS 
at a specific site within the human gastro-intestinal tract. The pH-responsive mucoadhesive layer was the 
fundamental aspect that promoted site-specific and segregated drug delivery. Preliminary in vitro 
investigations led to the identification of a combination of polymers best suited to develop the respective pH-
responsive mucoadhesive layers. A central composite design was employed to determine the optimal ratios of 
the polymers selected which would impart the largest degree of mucoadhesion within the respective pH 
ranges. Each mucoadhesive layer was thereafter optimized and subject to various in vitro investigations to 
determine the effects of the GIT on the properties of the mucoadhesive layer, as well as determine the 
behaviour of the mucoadhesive layer when subject to simulated gastrointestinal conditions. 
 
Electrospinning, a versatile technique employed in the fabrication of fibres in the nanometre size range, was 
employed to develop the drug loaded layer. Poly(vinyl alcohol) (PVA) nanofibres were thereafter crosslinked 
employing glutaraldehyde vapours to ensure controlled release of the incorporated drugs. The drug-loaded 
layer demonstrated good versatility in incorporating vastly different drugs, with only minor adjustments to the 
fabrication procedure. Furthermore, PVA demonstrated good loading of rifampicin and isoniazid, and near 
zero-order drug release was achieved after the crosslinking procedure. Prolongation of drug release 
fundamentally decreases the numbers of doses required to be taken daily, and as such, patient compliance is 
improved. 
 
Furthermore, in vitro analysis revealed that the developed MMDDS behaved superiorly in terms of controlling 
drug delivery in a site-specific and prolonged fashion in comparison to a marketed gold standard formulation, 
Rifinah
®
. These findings were further substantiated by in vivo analysis, which was conducted in a swine 
model. Results indicated that minimal release of isoniazid was observed in the stomach, based on the plasma 
concentrations of the drug. Release of isoniazid was initiated only when the intestinal-targeted component 
entered the intestine of the pig, corresponding to higher plasma concentrations of isoniazid. In this manner, 
the delivery of isoniazid and rifampicin was segregated, thus improving the oral bioavailability of rifampicin.  
 
To summarize, the MMDDS was able to overcome the many challenges associated with oral drug delivery, by 
easing complicated treatment regimens, and improving the bioavailability of drugs delivered orally. The 
benefits associated with oral drug delivery have clearly been exploited by the present study, producing a 
versatile drug delivery “tool” which can successfully be adapted to incorporate any number of drugs (including 
an entire treatment regimen in one dosage form!) for targeted delivery within the human gastro-intestinal tract 
in a prolonged manner.  
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CHAPTER 1  
INTRODUCTION AND MOTIVATION FOR STUDY 
 
“To raise new questions, new possibilities, to regard old problems from a new angle, 
requires creative imagination and marks real advance in science.” 
 
-   Albert Einstein (1879-1955) 
 
1.1 Background to the Study 
 
With new discoveries and further improvement each year, drug delivery is a quickly 
progressing and rapidly advancing pharmaceutical industry. Innovation in the 
pharmaceutical industry has led to the development of numerous technologies in drug 
delivery, leading to new and improved methods of drug delivery such as implantable 
systems, inhalation therapy, and transdermal, intranasal, ocular, oral, buccal and 
sublingual delivery systems (Leung and Ko, 2011). Global Business Intelligence (GBI) 
Research has reported that oral drug delivery controlled 52% (R49 billion) of the global 
drug delivery market share in 2009 and is expected to increase to R92 billion by 2016 
(GBI Research Report, November, 2010). This rapid increase can be attributed to the fact 
that the oral route of drug administration is one of the most favoured and extensively 
employed methods of drug delivery in the pharmaceutical industry by both the patients 
and pharmaceutical manufacturers alike (Grabovac et al., 2008).  
 
Factors promoting oral drug delivery includes the convenient and natural mode of 
administration; versatility in application; the avoidance of pain, discomfort and risk of 
infection as associated with injections; all contributing to higher patient compliance, and 
ultimately, lower costs (Sastry et al., 2000; Yamagata et al., 2006; Grabovac et al., 2008). 
Furthermore, the relatively large fluid volume available, the increased mucosal area 
available for absorption and the profuse blood supply to the gastric mucosa aids the 
absorption of many drugs (Helliwell, 1993).   
 
Although oral drug delivery is an easy and convenient means of administering drugs and 
bioactives to the body, there are limitations on which drugs can be delivered through this 
route due to the physiological makeup of the gastro-intestinal tract (GIT), as illustrated in 
Figure 1.1. In addition, the bioavailability of drugs or bioactives delivered through the oral 
route remains questionable. Apart from having a relatively poor bioavailability in 
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comparison to intravenous and inhaled dosage forms, drug bioavailability of oral 
formulations differs in the presence or absence of food and other drugs within the GIT; 
between patients such as geriatrics or paediatrics; and can be drastically affected by the 
presence of disease states such as constipation, diarrhoea or renal disease. Such 
differences in bioavailability can lead to serious side effects, toxicity or treatment failure 
(Thomas, 1995; González Canga et al., 2010; Mason; 2010; Zvonar et al., 2010).  
 
 
Figure 1.1: Schematic illustration of the GIT, including the limitations to oral drug delivery. 
 
In a highly competitive environment, there is an ongoing race for pharmaceutical 
industries to develop new drugs boasting improved bioavailabilities with a reduced side 
effect profile. However, “pharmagenesis” or the discovery of a new drug is a costly and 
time consuming process. The cost, the bulk of which originates from extensive research 
and development, contributes to the escalating prices of drug products so pharmaceutical 
companies can recover their expenses. With international governments pressurising 
pharmaceutical industries to regulate these prices, there is no incentive for 
pharmaceutical industries to spend large amounts of money producing drugs without 
salvaging their costs. Furthermore, despite extensive testing and regulation, the possibility 
of detecting unpredicted side effects is present even after years of use, while the risk and 
uncertainty associated with marketing a new drug product hinders new drug development 
(Barrett, 1999; Sekel, 1999).  
 
Complicated 
treatment 
regimens cause 
poor patient 
compliance
Enzymatic 
degradation 
of bioactives
and drugs
Presence of certain 
disease states, food or 
changes in bowel 
movements affects a 
drugs oral bioavailability
Highly acidic gastric 
environment limits 
oral delivery of 
proteins and peptides
Narrow Absorption 
Window drugs absorbed 
only in certain areas 
within the GIT
Drugs with low 
mucosal 
permeability are 
poorly absorbed 
resulting in poor 
bioavailability
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It is therefore not surprising that many pharmaceutical technology researchers have 
shifted from new drug discovery and development, to ‘‘re-inventing’’ established drugs by 
redesigning dosage forms to provide safer, more effective or convenient alternatives, 
hence the term ‘‘new drugs from old’’. Crowley and Martini (2004) highlighted the 
reformulation strategies that are currently employed to enhance the efficacy of existing 
drugs, which include improving absorption or prolonging the effects of drugs, enhancing 
patient convenience or designing novel ways to administer a drug (Speers, 1999; Crowley 
and Martini, 2004; Mythri et al., 2011). In this manner, drug delivery systems can be 
engineered to realise the full potential of existing (old) drugs without incurring hefty costs.   
 
The bioavailability of orally administered drugs is principally dependant on the transit of a 
drug delivery system (DDS) through the GIT. Conventional oral DDS are transported 
through the GIT, releasing drug into non-specific regions within the GIT (Helliwell, 1993). 
If the drug is not released in sufficient quantities at the site of absorption, the drug will not 
reach effective plasma concentrations to achieve the desired therapeutic effect (Davis, 
2005). Oral bioavailability is further compromised in Narrow Absorption Window Drugs 
(NAW), where these drugs are absorbed at only specific sites within the GIT. Thus many 
drugs are poorly absorbed (NAW drugs) or are sensitive to gastric juices and enzymes 
(proteins and peptides), and therefore conventional oral drug delivery systems need to be 
modified or novel drug delivery systems need to be developed in order to effectively 
administer these drugs (Shen et al., 2002). In a bid to improve oral bioavailability, Figure 
1.2 depicts how researchers have aimed at developing oral DDS based on mechanical 
protection of gastric sensitive agents from the harsh gastric environment with the use of 
microparticles (Shen et al., 2002), polymers acting as protective carriers (Dupeyrón et al., 
2005), liposomes, biochemical protection with the aid of enzyme inhibitors (Youn et al., 
2006; Grabovac et al., 2008) or by increasing gastric residence time of the DDS (Davis, 
2005). 
 
Apart from the physiological setbacks to oral drug delivery, poor patient compliance 
across multiple indications, has drastically affected therapeutic outcomes. Poor patient 
compliance due to various factors including the ease of drug administration, complex 
dosing regimens and severity of side-effects, has severe consequences such as bacterial 
and viral resistance in infectious diseases i.e. TB and HIV treatment (Kruk et al., 2006). 
Studies conducted by Dankwerts and co-authors, and Prakabaran and co-authors have 
investigated simple dosing, where a single dosage form has the ability to deliver multiple 
drugs for an extended period of time, thus decreasing dosage frequency and quantity 
(Dankwerts et al., 2003; Prakabaran et al; 2004).  
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Figure 1.2: Various studies which have aimed to overcome the limitations of oral drug 
delivery. 
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LIMITATIONS TO ORAL DRUG DELIVERY
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Prolonged release systems would result in the extended release of drug into the systemic 
circulation over an extended duration of time, thus achieving sustained and 
therapeutically effective concentrations of the drug, which can be easily achieved through 
crosslinking (Tanaka et al., 2006). During crosslinking, a covalent bond is formed between 
the crosslinking agent and polymeric chains. When polymeric chains are crosslinked, 
there is a decrease in the solubility of the polymer network due to slower chain relaxation 
within the polymeric network upon hydration, hence retarding drug release (Hennink et al., 
2002; Rastogi et al., 2007). However, oral prolonged release formulations may provide 
lower bioavailability as compared to immediate release formulations, as drug release from 
the prolonged release formulations is not completed during transit of the delivery system 
through the GIT (Nakamura et al., 2006). Manipulating the prolonged drug delivery 
system to be gastroretentive can overcome this challenge by increasing the GIT transit 
time of the system, thus allowing for complete release of drug or bioactives from the DDS.  
 
As reported by Davis (2005), there are currently two methods based on the concept of 
increasing gastric residence time that have been proposed to improve the oral 
bioavailability of drugs,  
 
i) By slowing down gastric transit through the GIT with the aid of mucoadhesive 
systems, and/or  
ii) Attempting to retain the drug formulation above the absorption window through 
gastro-retention (Davis, 2005).  
 
These orally delivered mucoadhesive systems are able adhere to the mucosa within the 
GIT, ensuring that there is a constant concentration of drug at the site of absorption thus 
maintaining therapeutically effective plasma concentrations of the drug. Bioavailability is 
improved as the time available for absorption is increased (Grabovac et al., 2008; Surana 
and Kotecha, 2010).   
 
Mucoadhesive drug delivery systems include multiparticulate mucoadhesive 
microspheres (Patel et al., 2007), mucoadhesive tablets (Guggi et al., 2003) and 
mucoadhesive membranes (Eaimtrakarn, 2002). In multiparticulate mucoadhesive 
systems, the entire particle surface is exposed to the surrounding gastric and intestinal 
fluid and therefore there is a loss of drug into the surrounding luminal fluid and certain 
enzyme sensitive agents may not obtain sufficient protection from proteolytic degradation 
(Shen et al., 2002). Mucoadhesive tablets have shown to have difficulty adhering to the 
stomach wall (Davis, 2005), and thus drug does not enter the systemic circulation and will 
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not achieve the desired therapeutic effect. A membranous DDS as opposed to other 
mucoadhesive systems has the advantage of being layered with the incorporation of 
various excipients into different layers, where the layers of the system can perform 
different functions, including mucoadhesion, drug encapsulation, and protection of the 
drug delivery system from enzymes and biodegradation in the GIT (Shen et al., 2002), 
and therefore the DDS proposed in this dissertation will consist of a multi-layered 
membranous system. Several studies have of late successfully improved the oral 
bioavailability of insulin (Grabovac et al., 2008), low molecular mass heparins (Schmitz et 
al., 2005), recombinant human granulocyte-stimulating factor (G-CSF) (Eaimtrakarn et al., 
2002) with the use of multi-layered membranous DDS. These studies have shown 
promising results in further improving a drug’s oral bioavailability.  
 
A recent advance in drug delivery technology is the application of ‘smart’, ‘active’ or 
stimuli-responsive polymeric materials, which are capable of responding in any desirable 
manner to a change in temperature, pH, electric and/or magnetic fields (Lue et al., 2008; 
Kumar, 2009). These polymers that offer altered physicomechanical properties under 
differing environmental conditions can be utilised in drug delivery systems such as 
surgical implants, scaffolds for tissue engineering, supports for in vitro cell culture and 
biotechnological screening, as well as in drug delivery systems (Anseth et al., 2002; Tang 
et al., 2003; Packhaeuser et al., 2004; Furth et al., 2007; Nagahama et al., 2008; 
Stamatialis et al., 2008).  In drug delivery, stimuli-responsive polymers may be used to 
target drugs to specific sites (site affected by disease or site of absorption) in the body or 
as a ‘smart’ surface which can be switched from an adhesive to a non-adhesive state or 
from a hydrophilic to a hydrophobic state and thus can swell or shrink, thereby controlling 
properties such as drug release. The changes are reversible which implies that the 
polymer is capable of returning to its initial state as soon as the trigger is removed 
(Stayton et al., 2005; Schmaljohann, 2006). 
 
Targeting of the DDS to specific regions within the GIT can potentially improve the 
bioavailability of NAW drugs or drugs and bioactives which are absorbed principally in the 
stomach (i.e. basic drugs) or intestine (i.e. acidic drugs), and can provide segregated drug 
delivery in the case where multiple drugs are delivered in one system (Nakamura et al., 
2006). Due to the physiological pH changes occurring along the GIT, pH is commonly 
identified as a stimulus to target drug delivery with the use of pH-responsive polymers in 
oral drug delivery. Polymer swelling and changes in mucoadhesive characteristics in 
response to pH changes have been employed to induce the controlled and targeted 
release of drugs and bioactives at specific sites within the GIT (Schmaljohann, 2006).  
7 
 
Several studies have exploited the use of targeted or site-specific drug delivery to prevent 
any deleterious drug-drug interactions that occur amongst certain bioactives within a 
given treatment regimen thus providing segregated drug delivery within the GIT and 
consequently, improved oral bioavailability. Segregation is achieved because drugs can 
be targeted with the aid of pH-responsive polymers, to differing pH ranges within the GIT, 
thereby isolating the release of the individual drugs and thus preventing any drug 
interactions (Gohel and Sarvaiya, 2007; du Toit et al., 2008; Pund et al., 2010). pH-
responsive polymers were employed in this study to ensure that the differing components 
of the membranous system are targeted to specific regions of the GIT, i.e. the gastric or 
intestinal region, and thus segregating and prolonging drug delivery by adhering to the 
mucosal surface within that region only.    
 
Membranes intended for drug delivery can be formulated by a range of methods including 
phase separation (Sun et al., 2007a; Kao et al., 2008), electrospinning (Kim et al., 2007, 
Sill and Von Recum, 2008), foaming (Krause et al., 2002; Matsuyama et al., 2002; Sun et 
al., 2007a), particle leaching (Sanguanruksa et al., 2004; RoyChowdhury and Kumar, 
2005), emulsion freeze-drying (Ho et al., 2004; Cheng et al., 2008) and sintering (Rezwan 
et al., 2006; Stamatialis et al., 2008), the methods which are further discussed in Chapter 
2 of the present dissertation. The type of the polymer and method employed, as well as 
the conditions during formulation determines the final morphology of the membranes 
(Witte et al., 1996; Altinkaya et al., 2005). Several studies have examined the possibility 
of utilizing electrospun membranous matrices as a controlled release system for the 
delivery of various drugs including antibiotics, anti-cancer drugs and vitamins in addition 
to tissue engineering applications for the delivery of proteins and DNA (Luu et al., 2003; 
Kim et al., 2004; Casper et al., 2005; Chew et al., 2005; Zeng et al., 2005a; Taepaiboon 
et al., 2007; Sill and Von Recum, 2008). Electrospun fibrous matrices possess a three 
dimensional porous structure ideal for controlling drug delivery due to its relatively large 
surface area. Controlling parameters during electrospinning influences drug release 
patterns, and hence, electrospun membranous matrices can be customized to achieve 
desired drug release patterns (Kim et al., 2007; Sill and Von Recum 2008).  
 
To overcome many of the challenges associated with oral drug delivery, the drug delivery 
system proposed in the present dissertation is designed to deliver multiple drugs of 
differing solubility, targeted to differing regions within the GIT for a prolonged period of 
time in a prolonged release manner. The proposed Multi-component Membranous Drug 
Delivery System (MMDDS) consists of a pH-responsive mucoadhesive layer allowing for 
site-specific drug delivery, a crosslinked electrospun layer encapsulating drug, and a 
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water insoluble backing layer offering mechanical protection. In order to orally deliver the 
MMDDS, it will be encapsulated within a capsule shell.  
 
1.2 Rationale and Motivation for the Study 
 
An ideal drug delivery system aims to deliver drug to a specific site, for a particular period 
of time with a specific drug release pattern. Conventional drug delivery systems often 
deliver drug in a peak-to-trough pattern, with the peaks usually being above the required 
dose, followed by ineffective plasma concentrations. A successful therapeutic outcome is 
dependent on patient compliance, and where adverse effects due to high plasma drug 
concentrations are experienced by patients, patient compliance is threatened, causing 
potential setbacks to successful treatment (Stamatialis, 2008). Formulating a 
membranous DDS, as shown in Figure 1.3, is beneficial as the challenges associated with 
conventional drug delivery systems can be overcome by formulating a crosslinked, pH-
responsive, mucoadhesive membranous DDS. 
 
 
Figure 1.3: Componential configuration of multilayered mucoadhesive archetype, where 
a) represents the protective coating; b) represents the electrospun drug-loaded layer, 
containing the respective drugs; and c) represents the stimuli-responsive mucoadhesive 
layer, specific to the gastric or intestinal targeted component. Both components are then 
rolled and inserted into a capsule. 
 
Figure 1.3 represents a) a water insoluble protective coat protecting the MMDDS from the 
harsh gastric environment, b) a crosslinked, electrospun drug containing layer containing 
drug encapsulated within nanofibres, c) a pH-responsive mucoadhesive layer providing 
site-specific mucoadhesion. pH-responsive polymers incorporated within this layer targets 
the system to a specific area of the GIT. In an attempt to improve oral drug bioavailability, 
the postulated MMDDS employed the use of the technology outlined in Figure 1.4 to 
develop a single dosage form for multiple and segregated drug delivery. 
 
 
a)
c)
b)
Layers attached 
together Rolling of membrane
Rolled membrane 
inserted into capsule
 
Layers attached 
t  
Rolling of 
membrane 
Rolled membrane 
inserted into capsule 
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Figure 1.4: Technology applied in the development of the MMDDS thereby improving oral 
drug bioavailability. 
 
The use of site-specific drug delivery to prevent deleterious drug interactions within the 
GIT has been outlined previously. Even within prescribed treatment regimens, deleterious 
drug interactions occur which ultimately affects the oral bioavailability of one or more 
drugs. These drugs are often administered a few hours apart to ensure complete 
absorption of the one drug before the other is administered. Subsequently, complex 
dosing regimens are developed and patient compliance is threatened (Shishoo et al., 
2001; Gohel and Sarvaiya, 2007; du Toit et al., 2008; Tanno et al., 2008; Pund et al., 
2010; Pund et al., 2011).   
 
One such example includes anti-tuberculosis (TB) therapy, where standard treatment 
warrants the use of isoniazid (INH) and rifampicin (RIF) concurrently. However, in acidic 
conditions, RIF is hydrolysed in the upper gastric region of the GIT into a poorly 
absorbable form, 3-formyl rifamycin (3-FR) (via a pseudo second order reaction), which 
INH interacts with, forming isonicotinyl hydrazone (IHZ). IHZ, being unstable is then 
reverted back to INH and 3-FR following a pseudo first order reaction as illustrated in 
Figure 1.5. RIF bioavailability is compromised because all the reactions in the illustrated 
sequence favours the formation of 3-FR (faster initial degradation of RIF into 3-FR 
combined with a faster first order reaction of the IHZ to INH and 3-FR than the second 
order reaction where INH forms the IHZ), and there is thus further increase in the 
formation of the 3-FR, ultimately threatening RIF bioavailability (Singh et al., 2000a; Singh 
pH-responsive 
mucoadhesion  
•Site-specific drug 
delivery which allows for 
drug release only at the 
absorption window of the 
respective drug. 
•Segregated drug 
delivery hence 
eliminating any 
deleterious drug 
interactions. 
•Gastroretention thereby 
maintaining the DDS at 
the window of drug 
absorption for an 
extended duration of 
time, thus maintaining 
steady plasma drug 
levels. 
Crosslinking 
 
 
•Prolonged drug delivery 
over an extended 
duration of time, 
achieves simple dosing 
(one pill, once daily) 
ultimately improving 
patient compliance. 
 
•Prevents dose dumping 
tendencies, atrributed to 
many marketed 
formulations. 
Coating 
 
•Physical protection of 
the DDS from acidic 
degradation in the 
stomach or proteolytic 
degradation in the 
intestine. 
 
•Unidirectional release 
will ensure an increase 
in local drug 
concentrations at the 
site of absorption hence 
enhancing the 
absorption efficacy of 
drugs having poor oral 
bioavailabilities. 
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et al., 2000b; Singh et al., 2001; Shishoo et al., 2001; Mohan et al., 2003; Mariappan et 
al., 2004). This compromised RIF bioavailability has the potential to lead to multi-drug 
resistant strains of TB, a serious setback in global eradication of the disease (Singh et al., 
2001; Mariappan and Singh, 2003).  
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Figure 1.5: Decomposition mechanism of rifampicin in the presence of isoniazid within 
the acidic conditions of the stomach. 
 
Mariappan and Singh (2003) investigated the variations in absorption of RIF and INH 
along the GIT and their findings revealed that RIF is well absorbed from the stomach 
because of its high solubility between pH 1 and 2, while INH being relatively poorly 
absorbed from the stomach, is well absorbed from all 3 segments of the intestine 
(Mariappan and Singh; 2003). Site-specific drug delivery would negate the above, and 
other interactions, from occurring, even though both drugs are administered in a single 
dosage form (Gohel and Sarvaiya, 2007; du Toit et al., 2008; Pund et al., 2010). These 
drugs would therefore benefit from such site-specific drug delivery, by targeting the drug 
to its respective absorption window. The proposed MMDDS can successfully achieve 
such segregated drug delivery, whereby the system releases RIF in the stomach, while, to 
ensure the intestinal delivery of INH, the system retards INH release in the stomach. 
Furthermore, the MMDDS has potential in wide range of other drug delivery applications, 
illustrated in Figure 1.6. 
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In terms of local ulcer treatment, the advantages of employing the MMDDS to deliver the 
indicated drugs are two-fold. Duodenal ulcers can be treated with a combination of drugs 
including a proton pump inhibitor (omeprazole) or a Histamine2 receptor antagonist 
(ranitidine) which require delivery to the stomach lining (to decrease acid secretion) in 
combination with a locally acting agent such as bismuth subcitrate or sucralfate which 
require release at the site of the ulcer to promote healing of the ulcer wound. Therefore 
the MMDDS would achieve site-specific drug delivery of both drugs, as well as improve 
patient compliance by offering a simple dosage form that contains both drugs. A 
didanosine/ketoconazole combination can also be delivered using the MMDDS in order to 
avoid the drug interaction occurring between these drugs. Didanosine, employed in 
antiretroviral (ARV) therapy, is highly susceptible to the acidic environment of the upper 
GIT region, and is thus prepared as a buffered formulation containing an antacid which 
improves the oral bioavailability of didanosine. Due to their suppressed immune systems, 
HIV-positive patients are commonly afflicted with infections, for which antifungals like 
ketoconazole are often prescribed. Ketoconazole absorption is limited by the presence of 
the antacids present in didanosine formulations, and hence requires segregation of 
administration by at least two hours (Gibbon, 2005). By incorporating ketoconazole into 
the gastric-targeted component of the MMDDS, ketoconazole absorption would be 
improved in the upper gastric region of the GIT, while by being incorporated in the 
intestinal component of the MMDDS; didanosine delivery will be limited to the intestine, 
thus protecting it from the harsh gastric environment.  
Potential 
MMDDS 
Applications 
Therapeutic regimens 
containing multiple 
drugs e.g. Malaria, TB or 
HIV treatment 
Local treatment of 
various gastric or 
intestinal disorders e.g. 
IBS or ulcer treatment 
Improving the 
bioavailability of Narrow 
Absorption Window 
drugs e.g. Gabapentin 
Improving the 
bioavailability of poorly 
aqueous soluble drugs 
e.g. Diazepam 
Segregated delivery of 
interacting drugs e.g. 
ARVs: Indinavir and 
Didanosine 
Intestinal delivery of 
drugs implicated in 
gastric irritation e.g. 
Probenicid 
Extended release 
formulations decreasing 
dosage frequency & 
improving patient 
compliance 
Intestinal delivery of 
bioactives susceptible to 
the acidic gastric 
environment e.g. 
Didanosine, Insulin 
Figure 1.6: Prospective applications of the MMDDS. 
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1.3 Consideration of the Gastrointestinal Physiology in the Development of a 
Smart Drug Delivery System Intended to Enhance Oral Bioavailability 
 
As of late, the GIT physiology is being considered as a key parameter which affects the 
release and absorption, and hence bioavailability, of orally delivered drugs. Previously, 
the GIT physiology did not denote how drug delivery systems were designed to ensure 
optimal bioavailability of orally delivered drugs. It should be noted that dosage forms 
fabricated or modelled without comprehending and understanding the complexity of the 
GIT physiology and its ramifications on oral drug delivery systems, will not be functional 
and/or behave in a consistent manner in terms of the oral bioavailability of drugs. 
Conventional drug delivery systems have of late been reformed with the advent of newer 
scientific data and technologies. Such novel DDS are able to enhance oral bioavailability 
by exploiting the conditions of the GIT, consequently improving the therapeutic efficacy of 
many existing drugs. Not only will comprehension of the GIT environment allow for better 
dosage form design, it will also augment the predictability of dosage forms by improving in 
vitro and pre-clinical in vivo testing thus allowing for better in vitro-in vivo correlations. 
Furthermore, novel areas and opportunities in oral drug delivery can be brought to light, 
making oral drug delivery safer, easier and more effective (McConnel et al., 2008).  
 
1.3.1 The GIT physiology and its ramifications on drug delivery 
In simple terms, the GIT or gut is essentially a tube, nine metres in length, that runs 
through the middle of the body from the mouth to the anus, and includes the throat 
(pharynx), oesophagus, stomach, small intestine (duodenum, jejunum and ileum) and 
large intestine (cecum, appendix, colon and rectum). The mucosal wall of the GIT is 
typically similar in structure throughout most of its length from the oesophagus to the 
anus, with some local variations for each region (Chanda et al., 2010). Each distinct 
section within the GIT has its individual physiological function and is varied in terms of pH, 
composition and nature of the luminal contents, surface area and length, and the 
presence of drug transporter systems (e.g. P-glycoprotein) and drug metabolising 
enzymes (e.g. CYP3A4) (Mouly and Paine, 2003; Yuen 2010). It is widely accepted that 
oral bioavailability of drugs is affected by physiological factors such as gastric emptying, 
intestinal transit, local pH, and nutritional status, intestinal efflux and carrier-mediated 
transport, first-pass metabolism in the gut, and subsequent first-pass hepatic extraction, 
as well as pharmaceutical factors such as rate of dissolution from the DDS, a drug’s 
inherent permeability and particle sizes of the dosage form (Agoram et al., 2001).  
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The volume of fluid in the GIT is paramount for disintegration, dispersion, dissolution and 
absorption of a drug delivered through the oral route, while differences in the pH range 
throughout the GIT affects the ionisable state of a drug. A drug, in its ionised form, has a 
higher solubility and hence a faster dissolution rate out of the DDS, while in its unionised 
form, a drug is readily absorbed though the GIT mucosa (Kararli, 1995). Transit within the 
GIT differs and is largely dependent of gut motility and flow, which depends and varies on 
the type and timings of meal ingestion and the nature of the formulation, rather than the 
size of a formulation. However, the transit of a dosage form through the gut is not 
continuous and retro-propulsion may occur (Weitschies et al., 2005; Goodman et al., 
2010; Varum et al., 2010). Furthermore, gastrointestinal fluid is not always consistent in 
quantity, and therefore DDSs may be subjected to periods without gastric fluid contact as 
it moves through the gut, detrimentally altering drug release characteristics (Schiller et al., 
2005). To summarise, Varum and co-workers (2010) adequately concluded that 
“Gastrointestinal transit for a modified-release dosage form could be thought of as a 
starting and stopping process, sometimes moving quickly, sometimes slowly, sometimes 
passing through fluid of varying composition, and being subject to peristaltic pressures 
and forces”. 
 
The inherent characteristics of the GIT physiology include significant variations in 
environment (pH ranges, gastrointestinal transit time, surface area, enzymatic activity and 
colonic microflora) which influence drug release and absorption from a DDS. The modality 
of site-specific drug delivery using the oral route is based on exploiting these variations 
along the GIT, achieving controlled and modified drug delivery. In this manner, drugs can 
therefore be delivered to a specific site or region within the GIT, by preventing premature 
drug release (before it reaches its absorption site/window). Furthermore, the dosage form 
can be maintained at the site of absorption for a prolonged period of time with the aid of 
gastroretentive technologies (Rouge et al., 1996). When a dosage form is administered 
via the peroral route, it is subject to the differing GIT conditions in the order illustrated in 
Table 1.1. This table also describes the various technologies and methods used for 
bioavailability enhancing and drug targeting to the various regions within the GIT.
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Table 1.1: The physiological effects of the GIT on an orally delivered DDS, and technologies exploiting said parameters for targeted drug 
delivery. 
Anatomical 
unit and 
parameter 
Parameters  
(normal 
conditions) 
Effects of human 
physiology on the 
DDS, or  incorporated 
drugs  
Design of drug delivery systems which consider  and 
exploit the GIT physiology for enhanced 
bioavailability 
Conclusions References 
Mouth Cavity  
 15-20cm  
 ±0.07m
2
 
 5.5-7.0 
 Saliva, 
Mucus, 
Amylase 
 10-20sec 
With the transit of a 
DDS through mouth cavity 
being so quick, they are 
generally not affected by 
this region.  
However, if the DDS 
is subject to mastication, it 
may lead to premature 
disintegration of the DDS, 
thus adversely affecting 
drug release profiles. 
Furthermore, drugs 
delivered locally are 
exposed to saliva of which 
the composition may 
contribute to some drugs 
undergoing chemical 
modification.  
Chewing dosage forms are commonly used to topical drug 
delivery of drugs (e.g. antimycotics) to the oral cavity. For drugs 
with higher solubility’s, release is generally quick from system, 
while the rate of release of a drug with lower solubility is 
dependent on chewing time.  
DDSs, such as single or multi-layered films, tablets or gels, 
adhering to the buccal mucosa provide prolonged drug delivery 
to the oral cavity. These DDSs often contain cellulosic polymers 
or Carbopol
®
 for prolonged adhesion to the buccal cavity.  
Fast dissolving systems are prepared for immediate and 
acute relief of symptoms especially in asthma and myocardial 
infarction for absorption sublingually. Films are commonly 
prepared via phase separation and include superdisintegrants. 
Fast disintegrating dosage forms are effectively employed 
for geriatrics or paediatrics, which have difficulty swallowing 
tablets and capsules. The dosage form rapidly disintegrates in 
the mouth upon contact with saliva releases microparticles or 
solubilised drug that is easily swallowed and enters the stomach 
or intestine for absorption. Lyophilisation, superdisintegrants and 
effervescency are technologies used to ensure fast 
disintegration. 
 
Drug delivered to the mouth 
cavity provides fast absorption of 
drugs which bypasses first pass 
metabolism ensuring enhanced 
bioavailability, especially for lipid 
soluble drugs. These systems 
are also effective at treating 
conditions within the oral cavity 
such as periodontal disease.  
However, factors such as 
the low permeability of the 
membranes that line the oral 
cavity results in a low flux of 
drug as well as the continual 
secretion and swallowing of 
saliva and mastication are 
unique problems which need to 
be considered during pre-
formulation to ensure successful 
delivery of a drug via this route.  
Rathbone et al., 1994; 
Kararli, 1995; Seeley 
et al., 1995, pg 798-
799; Shojaei, 1998; 
Jacobsen et al., 1999; 
Liang & Chen, 2001; 
Giunchedi et al., 2002; 
Baldi &  Malfertheiner; 
2003; Attia et al., 2004; 
Maffei et al., 2004; 
Ameye et al., 2005; 
Maggi et al., 2005; 
Owens et al., 2005; 
Abu-Huwaij et al., 
2007; Garg & Kumar, 
2007; Segale et al., 
2007; Goswami et al., 
2008; Messina et al., 
2008;  Madhav et al., 
2009; Pinto, 2010. 
 Length 
 Surface area  
 pH 
 Secretions 
 
 
 Transit Time 
Oesophagus  
 25cm 
 ±0.02m
2
 
 ±7.0 
 Mucus 
 5-8sec 
There is a slight 
chance that a DDS may 
adhere to the oesophageal 
mucosa, but generally, 
they are propelled to the 
stomach via strong 
peristaltic contractions. 
These contractions have 
minimal effects on the 
physical properties of the 
DDS. The absence of 
enzymatic secretions 
prevents chemical 
modification of drugs. 
Bioadhesive liquid dosage forms are commonly employed to 
coat the oesophagus for protection against trauma or local 
delivery or alginate solutions for the treatment of GORD (Gastro-
oesophageal reflux disease), while bioadhesive gels are 
employed for local drug delivery in the treatment of Barrett’s 
Oesophagus. These bioadhesive systems contain cellulosic 
polymers, Carbopol
®
 or Chitosan for prolonged adhesion to the 
oesophagus and the structure of these systems ensures that 
there is no blockage of the oesophagus, while the dislodging of 
the dosage form is minimised with further ingestion of foods. 
Other approaches for targeting the oesophagus have been 
suggested, including orally retained lozenges, chewing gums, 
films, as well as endoscopically delivered drugs.  
 
The oesophagus is 
generally not targeted for site-
specific drug delivery due to the 
short transit time and low 
mucosal permeability. In addition 
bulky systems may cause 
discomfort and local irritation. 
However, it is a desirable organ 
to be targeted for local 
oesophageal disorders. 
Strictly speaking, retention 
of a DDS within the oesophagus 
can only be achieved by a 
medical device e.g. using 
photodynamic therapy for 
oesophageal cancer treatment. 
 
Swisher et al., 1984; 
Kararli, 1995; Seeley 
et al., 1995, pg 798-
799; Overholt et al., 
1996; Batchelor et al., 
2002; Batchelor et al., 
2004; Tutuian and 
Castell, 2006; Collaud 
et al., 2007; Zhang et 
al., 2008; Pinto, 2010. 
 
 Length 
 Surface area 
 pH 
 Secretions 
 Transit Time 
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Stomach  
 20cm 
 ±0.11m
2
 
 1-3.5 
 Mucus, HCl, 
IF, Pepsin 
and Gastrin 
 1.3-2.5 
hours for 
liquids; 3-4 
hours for 
solids 
Enzymes present in 
gastric fluid chemically 
modify some drugs, and 
proteins, to the extent that 
they are no longer able to 
exert the required effect.  
The low pH of the 
stomach region affects the 
ionisable state and hence 
dissolution and absorption 
qualities of drugs. Low pH 
ranges may cause 
degradation of some 
drugs. 
The presence of food 
prolongs the transit time 
within the gastric region, 
with detrimental effects on 
time-dependant colon 
targeted systems. 
However, food can 
enhance the dissolution of 
basic drugs as the volume 
of the gastric contents is 
larger than that of a fasting 
individual. 
The primary role of 
the stomach is the mixing 
of food with gastric fluid, 
promoting digestion, rather 
than absorption. A DDS 
should be designed to 
withstand such conditions. 
Gastroretentive systems (GR) based on density related 
floating relies on the entrapment of air within the system or the 
use of highly porous structures, such as tablets, microparticles or 
hydrogels, which float upon contact with gastric fluid. These 
systems release drug in a controlled, chronotherapeutic or 
modified manner. The highly porous structures can be 
developed by lyophilisation.  
 GR systems based on effervescing characteristics, such as 
tablets, microspheres, granules, which, upon contact with gastric 
fluid, generate gas to produce a low density matrix able to float 
upon contact with gastric fluid, releasing drug in a controlled or 
pulsatile manner. These systems require a base, generally 
sodium bicarbonate, and an acid such as citric acid for the 
effervescent properties of the system. 
GR systems developed by incorporating highly swellable 
polymers rely on the system, (i.e. tablet) swelling to decrease 
density and hence float, with the potential to release drug for up 
to 20 hours in the stomach. The size increase prevents the 
system from being prematurely evacuated from the stomach, 
and these systems generally incorporate highly swellable 
cellulosic polymers, which eventually decreases in size and is 
evacuated from the stomach. 
Mucoadhesive systems contain adhesive polymers such as 
Chitosan, Carbopol
®
, and other cellulosic polymers, and are 
administered in the form of microspheres, patches or tablets. 
These systems, upon swelling, are able to adhere to the gastric 
mucosa for prolonged periods of time, releasing drug in a 
controlled manner. Other adherents that are used as potential 
drug carriers include ion exchange resins.     
Enteric coated systems, generally used to protect gastric 
sensitive agents from the harsh gastric environment, are based 
on the use of pH-responsive polymers (Eudragit
®
) which dissolve 
and release drug only in the higher pH ranges of the intestine. 
 
Stomach targeted systems 
generally exploit physiological 
factors such as the low pH, 
motility and gastric emptying 
time to ensure a system is 
retained and releases drug in 
the gastric region of the GIT for 
a prolonged period of time. 
However these factors are highly 
variable and vary with the 
presence of food, disease states 
or even other drugs, and hence 
will affect the release profiles of 
drug delivery systems. 
Stomach targeted systems 
are beneficial in the treatment of 
local disorders such as H. Pylori 
infections or ulcers. 
The surface area of the 
stomach is larger than the mouth 
or oesophagus aiding in 
absorption of acidic drugs  
absorbed through the gastric 
wall. 
Gastric retention provides 
advantages such as the delivery 
narrow absorption window drugs 
in the gastric or small intestinal 
region, for local action in the 
upper part of the small intestine, 
and improved bioavailability is 
expected for drugs absorbed 
readily upon release in the GIT.  
Kawashima et al., 
1992; Desai and 
Bolton, 1993; Seeley et 
al., 1995, pg 798-799; 
Kararli, 1995; 
Deshpande et al., 
1997; Baumgartner et 
al., 1998; Krogel and 
Bodmeier, 1999; 
Jackson and Perkins, 
2001; Eaimtrakarn et 
al., 2003; Streubel et 
al., 2003; Elkheshen et 
al., 2004; Dhaliwal et 
al., 2008; McConnell et 
al., 2008; Zou et al., 
2008; Meka et al., 
2009; Chanda et al., 
2010; Pinto et al., 
2010; Surana and 
Kotecha, 2010; Yuen, 
2010. 
 
 Length 
 Surface area 
 pH 
 Secretions 
 
 
 Transit Time 
Small Intestine  
 ±625cm 
 ±120.m
2
 
 5-7 
 Mucus, 
Enzymes 
(trypsin, 
peptidase, 
lactase, 
sucrose, 
amylase, 
lipase, 
gastrin 
Enzymes present in 
intestinal fluid chemically 
modify some drugs and 
proteins to the extent that 
they are no longer 
effective. 
Basic drugs are better 
absorbed in the intestine 
due to its unionised state. 
The pH range of the 
intestine has a minimal 
effect on drug stability. 
The presence of food 
pH-sensitive polymers i.e. Eudragit
®
 are commonly used as 
enteric coatings in tablets, capsules or microspheres to ensure 
that the drug is not released before reaching the intestinal area. 
These polymers, which are acidic in nature, disintegrate/dissolve 
at the relatively higher pH ranges of the intestine, only releasing 
the entrapped drug upon contact with intestinal fluids. 
Bioadhesive tablets, pellets and hydrogels incorporating 
polymers with mucoadhesive characteristics, including 
Carbopol
®
, methacrylic and cellulosic polymers, demonstrate 
maximal mucoadhesion in intestinal pH ranges, thereby 
bypassing the stomach without adhering to or releasing drug in 
the stomach. 
Remote controlled systems such as the InteliSite
®
 capsule 
Due to the large surface 
area and long length of the 
intestine, it is the major organ for 
absorption of many drugs. It 
should be noted that the mobility 
of the intestine, and thus its 
contents, is quite constant in 
comparison to other GIT organs, 
therefore not surprising that only 
a few strategies have been 
described to control the mobility 
of dosage forms within the small 
intestine. 
Seeley et al., 1995, pg 
798-799; Kararli, 1995; 
Pithavala et al., 1998; 
Carelli et al., 2000; 
Awad et al., 2002; 
Bernkop-Schnurch et 
al., 2004; Fedorak and 
Bistritz, 2005; Goto et 
al., 2006; Hinderling et 
al., 2007; Schellekens 
et al., 2008; Pinto, 
2010; Yuen, 2010 
 
 Length 
 Surface area 
 pH 
 Secretions 
 
 
 
 
 
 
 
 
Table 1.1 continued 
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 Transit Time 
secretin), 
bile, 
bicarbonate 
ions 
 3-5 hrs 
within the intestinal region 
has not been associated 
with drastic changes in 
transit time, and its effects 
are said to be negligible. 
 
are able to release drugs at differing sites within the GIT using 
capsules which release drugs in the presence of a stimulus. 
These capsules can deliver drugs to a defined region of the 
intestine after application of a magnetic signal.  
 
 
Colon  
 ±150cm 
 ±0.25m
2
 
 5.5-7 
 Mucus 
 18-24 hrs 
If a drug passes 
through the GIT intact, any 
remaining drug within a 
DDS will be embedded in 
semi-solid faecal matter, 
drastically limiting 
dissolution and hence 
absorption.  
Due to the strong 
contractions within the 
colon, DDSs targeted to 
the colonic area may 
rupture, detrimentally 
affecting the drug release 
profile. 
The fluid volume and 
composition within the 
colon is quite variable, and 
further influenced by 
pathology. For instance, in 
individuals suffering with 
constipation, there is 
increased water resorption 
in the gut leading to more 
viscous or solid colonic 
contents. Its aetiology is 
usually related to delayed 
transit or obstruction to 
defecation and its 
presence may make drug 
dispersal or dissolution 
problematic, consequently 
affecting oral 
bioavailability. 
Prodrugs delivered via the oral route require a specific 
enzyme, present only in the colon, for absorption or activation, 
and hence will pass through the stomach and small intestine 
unchanged. These systems have the potential for local delivery 
to the colon and include drugs such as sulphasalazine or 
dexamethasone glucoside. 
Polymeric coatings such as Pectin and galactomannan 
degrade in the presence of colonic microflora and have thus 
been utilised to protect the drug-containing core and prevent 
release of the DDS from the upper GIT conditions. The success 
of these systems has been further enhanced by promoting 
hydrophobicity within these polysaccharides via chemical 
modification, ensuring drug release only in the colon.  
pH responsive polymers (Eudragit
®
 FS) dissolving at a pH > 
7 are also utilised as protective coatings over solid dosage forms 
such as tablets, capsules or pellets. The polymeric coating 
provides protection and until it reaches the colon where the 
polymer is dissolved, releasing the entrapped drug. These 
systems are similar to intestinal targeted enteric coated systems, 
but differ on the targeted site and polymers incorporated. 
Drug delivery systems which are time dependent are based 
on the principle of incorporating a lag time, which delays the 
release of the drug for 3-4 h after leaving the stomach. These 
systems generally incorporate multiple layers of coatings that 
may have pH responsive tendencies. However, most of these 
systems are based on the assumption that transit times within 
the GIT are consistent even though it is widely accepted that 
transit times differ considerably. If designed correctly, these 
systems can be useful in the therapy of diseases related to 
circadian rhythms. 
Pressure controlled systems require high pressures caused 
by strong contractions, present only within the colon to collapse 
the DDS and hence release drug. Such systems include 
capsules, of which the outer shell collapses and releases drug in 
response to the increased pressure of the colon. 
Osmotically driven systems require the rapid uptake of 
water into the DDS, causing the forceful ejection of the drug, 
either by polymer swelling or fluid displacement. These systems, 
such as the OROS-CT (Alza Corporation), are intricately 
designed incorporating lag times and enteric coatings to ensure 
colon-targeted drug delivery for anything between 4-24 hours.  
The colon is particularly 
useful to target not just for local 
diseases, but for the delivery of 
therapeutic proteins and 
vaccines sensitive to the 
stomach and small intestine 
environments. Furthermore, the 
colon has a long retention time 
and appears highly responsive 
to agents enhancing absorption 
of poorly absorbed drugs.  
However, there are more 
restrictive tight junctions in the 
colon rendering drug absorption 
more difficult via this route. In 
addition, due to the variations in 
the fluid volume distribution 
within the colon, colon targeted 
DDS can be exposed to 
anything between 1 and 100mls 
of fluid at any given time, 
causing significant variations in 
the bioavailability of these DDS. 
Absorption within the colon is 
significantly smaller than that of 
the small intestine, and due to 
the highly variable transit times 
in this region, absorption is 
generally incomplete and erratic. 
It should be noted that the 
design of controlled release 
systems for optimal drug 
delivery to the colon requires 
comprehensive understanding of 
the relationship between particle 
size, colonic dispersion and 
colonic transit rates, in addition 
to other factors (e.g. disease or 
other drugs) which influence 
colonic transit rates and 
consequent drug bioavailability.  
Seeley et al., 1995, pg 
798-799; Kararli, 1995; 
Ahrabi et al., 1997; 
Vandamme et al., 
2002; Yang et al., 
2002; Chourasia and 
Jain, 2003, Chourasia 
and Jain,  2004; 
McConnell et al., 2008; 
Pinto et al., 2010;  
Yuen, 2010; Kumar et 
al., 2011a 
 
 Length 
 Surface area 
 pH 
 Secretions 
 Transit Time 
Table 1.1 continued 
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1.3.2 pH as a stimulus employed for targeting in oral drug delivery  
As highlighted previously, each segment of the GIT varies from the other in pH, ranging 
from the acidic stomach, to the more alkaline duodenum and ileum. The use of pH as a 
stimulus triggering or retarding drug release is a commonly adopted approach to targeting 
or achieving organ-specific drug delivery. pH, as opposed to other methods including 
enzyme-responsive systems for drug targeting, is preferred in the formulation of the 
MMDDS due to the ease at which the system can be adapted for targeting within an 
alternative region of the GIT, simply by replacing the existing pH-responsive polymer to 
one responsive to more alkaline/acidic pH environments. These pH-responsive systems 
have been employed for achieving preferential release in a particular organ based on a 
drugs’ sensitivity to a particular gastric environment or the local treatment of a disease. 
Furthermore, there is particular interest in applying pH-responsive systems for 
segregating interacting drugs (Gao et al., 2010). A detailed review highlighting the 
polymers employed in pH-responsive drug delivery is outlined in Chapter 2.   
 
In terms of oral drug delivery, it is desirable to select a polymer that requires a pH change 
falling within the physiological pH range of the GIT. In this manner, drug release from 
these systems would not necessitate the use of an external trigger, complicating oral drug 
delivery. Furthermore, if the externally applied trigger is removed, the stimuli-responsive 
polymer would revert back to its original state, changing the rate of drug release (Carreria 
et al., 2010). Due to the pH of the differing areas within the GIT, the trigger for 
stimulating/retarding drug release is almost always present when required. In order to 
achieve prolonged release with a pH-responsive oral DDS, said system should be 
maintained at the site of absorption (through gastrorentention) for a period of time 
sufficient to produce desired therapeutic concentrations.    
 
1.3.3 Architectural strategy employed to exploit and overcome the GIT 
physiology 
Although many DDSs on the market today boast novel technologies which provide 
controlled release, these systems ultimately rely on dissolution/bio-erosion, diffusion or a 
combination thereof to instigate controlled release of drug at the desired site. Other 
factors including the drug’s physicochemical properties, rate of absorption, metabolism, 
and elimination are integral in how a pharmaceutical dosage form should be designed to 
ensure optimal efficacy whilst ensuring minimal toxicity (Ranade, 1991). The MMDDS 
proposed by the present dissertation, illustrated in Figure 1.3, takes into account the GIT 
physiology and the drugs’ properties, allowing the DDS to overcome many of the 
limitations in oral drug delivery.  
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The strategy employed, lies in the multi-layered design of the system (Figure 1.7), 
providing several functions and taking advantage of several aspects of the various 
components within the DDS, in particular the improved bioavailability offered from 
unidirectional release provided by the protective coating of the system. Furthermore, the 
mucoadhesive layer provides intimate contact between the DDS and the site of 
absorption, a driving force promoting passive uptake and absorption from the DDS which 
is not altered by variations in gastric transit time (Schmitz et al., 2005). Targeting, 
achieved by pH dependant mucoadhesion, ensures that the drug/drugs incorporated are 
delivered to its specific site, avoiding any deleterious drug interactions or harmful GIT 
affects, thereby promoting bioavailability. To ensure segregated delivery of interacting 
drugs, two components were developed, each targeted to a different region of the GIT, 
differing solely on the drug incorporated and consequent pH-responsive polymer 
employed for drug targeting. The system is therefore versatile, in that it may be applied to 
a wide variety of drugs, each being targeted to the relative site of absorption, while 
multiple drugs can be incorporated in one system, easing therapeutic regimens. 
 
 
 
1.4 Novelty of the Study 
 
The novelty of this study lies in the mode of segregated drug delivery proposed, which 
was achieved through the use of pH-responsive mucoadhesion. The componential 
system was able to negate deleterious interactions even though the interacting drugs 
were administered in a single dosage form. Furthermore, it employs the technique of 
Protective coating: Prepared via film-
casting of hydrophobic polymer, 
ethylcellulose 
Drug-loaded electrospun matrix: 
Prepared via electrospinning PVA, 
with further modification through 
crosslinking 
Mucoadhesive layer: Prepared via 
film-casting chitosan and pectin, 
which display pH-dependant 
mucoadhesion  
Vasculature 
supplying 
GIT lining 
Unidirectional release of the drug 
into the mucosal lining, indirectly 
offering protection against the 
harsh gastric environment 
Hydrophobic nature of the protective 
coat prevents enzymatic 
degradation, loss of drug to the 
luminal contents and protection 
against acid hydrolysis 
Mucosal lining of the GIT 
Figure 1.7: Simplified illustration of the proposed mode of drug delivery of the MMDDS 
with a depiction of the architectural strategy employed to overcome and exploit the human 
GIT physiology. 
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electrospinning in order to create a fibrous, highly porous structure with an increased 
surface area able to effectively control the rate of drug release from the MMDDS. 
Furthermore, the electrospinning process is a simple and easily fabricated method for the 
production of nano- or microfibers, without the use of complex or costly equipment (Choi 
et al., 2008). The crosslinking procedure was novel in that it ensures that there was no 
need for post-treatment of the nanofibrous matrices required to remove residual 
glutaraldehyde, substantially limiting its toxicity.  
 
1.5 Aim and Objectives of the Study: Description of the Oral Multi-component 
Membranous Drug Delivery System 
 
In order to develop an ideal DDS, the aim of the study was to design and formulate a 
MMDDS for prolonged and site-specific drug delivery of two or more drugs in a single 
system. The proposed MMDDS ensures differentiated release of the incorporated drugs 
as illustrated in Figure 1.8.  
 
The above aim was achieved by outlining the following objectives: 
1. Identifying a novel means of segregating drug delivery by employing stimuli-
responsive mucoadhesion and determining the most appropriate stimulus to be 
targeted for stimuli-responsive mucoadhesion. 
2. Reviewing and evaluating various stimuli-responsive polymers and assessing their 
feasibility in segregated drug delivery.  
3. Selection of appropriate polymer combinations and other excipients to formulate the 
mucoadhesive layer within the gastric targeted and intestinal targeted components. 
4. Experimentally synthesizing variants of the preferred mucoadhesive layer for each 
component employing a 2-Factor Central Composite Design followed by 
physicochemical and physicomechanical analysis.  
5. Determination of the optimum parameters required to synthesise the desired 
mucoadhesive layer for both components based on statistical optimisation 
implemented via the Response Surface Methodology. 
6. Identifying suitable polymers and parameters employed during electrospinning for the 
development of drug-loaded electrospun nanofibrous matrices for both components. 
7. Selection of suitable crosslinking agents and description of the crosslinking 
methodology for modification of the nanofibrous matrices required to achieve the 
preferred drug release profiles. 
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8. Performing in vitro drug release studies in order to determine the drug release 
behaviour from both components in the MMDDS in comparison to the marketed ‘gold-
standard’ formulations of both drugs. 
9. Undertaking in vivo animal studies on a pig model to determine the release behaviour 
and to assess the pharmacokinetics of the MMDDS in relation to the marketed ‘gold-
standard’ formulations of both drugs. 
                                                      
Figure 1.8: Schematic illustration depicting differential release, representing a) the gastric 
targeted component for the delivery of RIF to the stomach, containing a gastric targeted 
pH-responsive mucoadhesive layer, a RIF-loaded nanofibrous matrix and a protective 
coat; b) the intestinal targeted component for the delivery of INH to the intestine 
containing an intestinal targeted pH-responsive mucoadhesive layer, an INH-loaded 
electrospun matrix and a protective coat; and c) proposed strategy employed to ensure 
site-specific, segregated and prolonged delivery of both drugs. 
 
 
c) 
a) 
b) 
Intestinal targeted component 
passes through the stomach 
unchanged, retarding drug 
release 
Gastric targeted component 
swells in the stomach and 
adheres to the stomach lining, 
releasing drug for a prolonged 
period of time 
Intestinal targeted component 
swells in the intestine only, and 
adheres to the intestinal lining, 
releasing drug for a prolonged 
duration of time 
Capsule disintegrates, 
releasing the individual 
MMDDS components  
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1.6 Synopsis of the Dissertation 
 
Chapter One of this dissertation provides a summary to the dissertation. It outlines an 
introduction to the study that covers the background, delineates the problems associated 
with oral drug delivery and highlights the rationale for the study. It briefly describes the 
architectural structure of the proposed drug delivery system and how it overcomes the 
limitations to oral drug delivery. Aspects of the gastric physiology are considered in terms 
selection of an appropriate stimulus employed for drug targeting within the GIT. A 
summary of the aim and objectives is included in this chapter. 
 
Chapter Two of this dissertation provides a comprehensive literature survey, focusing on 
the use of smart polymers in drug delivery, specifically membranous systems. 
Furthermore, there is a detailed outline of the various methods in membrane fabrication, 
with impetus placed on the electrospinning method.  
 
Chapter Three of this dissertation provides a brief introduction to mucoadhesion, 
including the different mechanisms responsible for mucoadhesion in the GIT. It describes 
the pre-formulation and development of the respective pH-responsive layers. Preliminary 
formulation methods investigated the ideal polymers and respective quantities required to 
ensure mucoadhesion was sustained over a prolonged period of time. In addition, 
formulation parameters were established to allow for the construction of a Central 
Composite Design.  
 
Chapter Four of this dissertation describes the preparation of variants of the respective 
pH-responsive layers as constructed according to a randomized, Face-centered Central 
Composite Design, followed by optimization using Response Surface Methodology. The 
applicability of the respective design was analysed. Furthermore, physicomechanical and 
physiochemical properties were analyzed in order to determine the influence of simulated 
gastro-intestinal conditions. 
 
Chapter Five of this dissertation describes the preliminary formulation and development 
of the drug-loaded electrospun layer of the MMDDS. It describes the rational approach to 
selection of a suitable polymer for electrospinning. In addition, it includes a 
comprehensive outline of the electrospinning procedure and factors which affect the final 
morphology of resultant nanofibres. 
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Chapter Six of this dissertation is a comprehensive description in vitro analysis of the 
drug-loaded electrospun layer. An in depth analysis of the post-spun modification 
procedure is provided with the resultant alterations to the physicomechanical and 
physiochemical properties of the electrospun layer. An ideal formulation based on the in 
vitro results was highlighted as a candidate formulation for further analysis. 
 
Chapter Seven of this dissertation provides a comparative analysis of the MMDDS with a 
“gold-standard” marketed formulation in terms of both in vitro and in vivo drug release 
behaviour. Furthermore, it contains an explanation of the in vivo animal studies 
undertaken in the pig model. Assessment of the MMDDS biocompatibility and drug 
release behaviour were highlights of this chapter. In addition, dosage administration and 
sample collection of blood is described. 
 
Chapter Eight of this dissertation presents the conclusions and recommendations for 
future work.  
 
1.7 Concluding Remarks 
 
This chapter sought to highlight the problems and challenges associated with the oral 
route of drug delivery, in particular, the effects of the gastric physiology on drug 
bioavailability, while the approaches to overcoming said limitations were identified. 
Furthermore, the rationale for drug targeting within the GIT was explored while aspects of 
the gastric physiology were considered in terms of the selection of an appropriate 
stimulus for drug targeting within the GIT. The focus of the chapter was a description of 
the MMDDS, with particular emphasis on the architectural structure and functioning of the 
different layers. The advantages in drug targeting were explored, with particular reference 
to interacting drugs rifampicin and isoniazid, which require segregated drug delivery.  
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CHAPTER 2  
A REVIEW ENCOMPASSING STIMULI-RESPONSIVE POLYMERS WITH 
SPECIFIC APPLICATION IN MEMBRANOUS SYSTEMS AND THE 
FORMULATION THEREOF 
 
 
2.1 Introduction 
 
The membrane industry is a rapidly growing field of research that has found extensive 
application in industrial and medical fields (Baker, 2004; Stamatialis et al., 2008). 
Industrially, membranes have found application in ultrafiltration, microfiltration, reverse 
osmosis, gas separation, prevaporation and electrodialysis, while medically; applications 
include incorporation into artificial organs, haemodialysis, drug delivery systems, 
diagnostics, coatings for medical devices, tissue regeneration and biosensors amongst 
others (Baker, 2004; Stamatialis et al., 2008). It is imperative to have an understanding of 
the method of membrane fabrication as it affects the final morphology, and hence the 
potential applications of the polymeric membranes. 
 
The earliest application of membrane systems in drug delivery included osmotically 
controlled systems, developed by Rose and Nelson in 1955 that delivered medication to 
the gut of sheep and cattle in a zero-order release rate over a prolonged period. The 
Higuchi-Theeuwes pump, developed by the Alza Corporation, improved this technology 
by overcoming the limitations such as the short shelf-life and the need for immediate 
administration (Santus and Baker, 1995). Eventually, the Alza Corporation successfully 
managed to deliver drugs transdermally by developing an adhesive patch containing 
scopolamine, with a zero-order release rate, for the treatment of motion sickness 
(Lonsdale, 1982). The OROS® (osmotic-controlled release oral delivery system) 
technology (Alza Corporation) is used today for the delivery of many drugs including 
Adalat CR® (controlled-release nifedipine) and led to the development of various other 
prolonged release delivery systems for the delivery of drugs such as Acutrim® 
(phenylpropanololamine), Minipress XL® (prazosin) and Volmax® (salbutamol) (Santus 
and Baker, 1995). The potential for membrane technology in medical industry supersedes 
its other applications due to its versatility in medical applications (Stamatialis et al., 2008). 
 
Membranes have been vastly utilized in the medical and pharmaceutical fields, in 
particular drug delivery, due to their ability to control the permeation rate of chemical 
substances (Stamatialis et al., 2008). Synthetic functional polymers have witnessed much 
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advancement in the last two decades, and said polymers are capable of responding in a 
desirable manner to a change in temperature, pH, electric or magnetic fields (Kumar, 
2009). These stimuli-responsive polymers are also referred to as smart, intelligent, or 
environmentally-sensitive/responsive polymers (Lue et al., 2008). Polymers with physical 
and chemical properties that can be manipulated by the surrounding environment, such 
as hydrogels, have potential applications in surgical implants, scaffolds for tissue 
engineering, supports for in vitro cell culture and biotechnological screening, as well as in 
drug delivery systems (Stamatialis et al., 2008; Kumar, 2009).  In drug delivery, they may 
be used to target drugs to specific sites in the body or as a ‘smart’ surface which can be 
switched from an adhesive to a non-adhesive state or from a hydrophilic to a hydrophobic 
state and thus can swell or shrink. The changes are reversible, implying that the polymer 
is capable of returning to its initial state upon removal of the trigger (Schmaljohann, 2006).  
 
2.2 Membrane Applications in Drug Delivery  
 
Membranes are extensively employed in the medical filed for drug delivery, haemodialysis 
artificial organs (oxygenators, pancreas etc) and tissue engineering. The development 
and formulation of these membranous systems requires biocompatible and sometimes 
biodegradable materials as the systems would ultimately be in contact with biological 
fluids and tissues. In addition, these materials require other imperative properties, such as 
blood compatibility, size, shape and porosity, to be carefully controlled. Controlled drug 
permeability and good release properties are the characteristics required for a 
membranous system to function as an efficient drug delivery system. Drug release is 
directly related to the degradation rate of the materials used i.e. the faster the material 
degrades, the higher the blood levels of the drug, resulting in toxic doses which may often 
be fatal. Therefore, for implantable drug delivery systems, erosion and degradability are 
key parameters. In addition, the swelling dynamics of certain polymers are also crucial for 
the mass transport of drug (diffusion) and also needs to be considered. This is also true 
for polymeric membranes utilized in tissue engineering (Stamatialis et al., 2008). 
Incorporation of stimuli-responsive polymers in membranes systems can further widen 
their repertoire of application in drug delivery and biomedicine by improving key qualities 
such as the biocompatibility/biodegradability of the membrane system, providing site-
specific and/or modified release drug delivery or improving tissue engineering features.  
 
Conventional drug delivery systems available on the market i.e. tablets, injections, liquids 
and so forth often provide drug delivery with fluctuating plasma concentrations which 
results in sub-therapeutic or toxic plasma levels of the drug. An ideal drug delivery system 
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should ensure a sustained drug release pattern for a specific period of time at a specific 
site. A key advantage of site-specific drug delivery is that molecules that have problematic 
toxicology profiles, localized delivery can often mitigate such issues and is therefore a key 
driver for the development of biocompatible and/or biodegradable sustained release drug 
delivery systems. Membrane based drug delivery systems have the potential to ensure 
sustained drug release based on mechanisms of osmosis or diffusion (Stamatialis et al., 
2008). 
 
Diffusion-controlled membrane drug delivery systems depend on drug diffusion across the 
membrane, operating according to Fick’s law, and on membrane thickness (Stamatialis et 
al., 2008). These systems have been applied in pills, implants and patches. Smart 
polymers are extensively used in membrane systems as permeation switches or “gates” 
(Discher and Ahmend, 2006). The pores within the membrane become blocked when 
swelling is initiated in response to a stimulus, thereby preventing the release of the drug.  
Conversely, they may open and release the drug when the polymeric surface collapses.  
 
2.3 Methods Employed in the Fabrication of Polymeric Membranes  
 
Various methods have been employed in the preparation of polymeric membranes. The 
type of the polymer and method employed, as well as the conditions during formulation 
determines the final morphology, and hence potential application, of the membranes. 
Phase separation, electrospinning, foaming, particle leaching, emulsion freeze-drying and 
sintering are some of the common methods that have been used in the production of 
membranes (Witte et al., 1996; Altinkaya et al., 2005).  
 
2.3.1 Phase separation  
Phase separation, a membrane fabrication technique, has been widely applied in the 
production of scaffold membranes typically employed in tissue engineering. This 
fabrication method may be applied to pure polymers as well as polymeric composites 
(Sun et al., 2007a; Stamatialis et al., 2008). The technique involves the formation of an 
initial homogenous polymeric solution that becomes thermodynamically unstable upon 
exposure to an external stimulus. Upon reaching thermodynamic instability, the polymeric 
solution divides into two phases, a high and low polymer concentration phase. The 
concentrated phase then solidifies after phase separation, resulting in the formation of a 
polymeric membrane structure (Stamatialis et al., 2008). The resultant membrane often 
has pores which become filled by the less concentrated polymer phase. Studies have 
indicated that phase separation can be induced by a variety of external effects. These 
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effects have been divided into four key techniques based on the concept of phase 
separation. The fundamental difference between each technique is the desolvation ability 
(Witte et al., 1996; Altinkaya et al., 2005).  
 
2.3.1.1 Vapour-induced phase separation  
Vapour-induced phase separation (VIPS) is a phase separation technique that involves 
the penetration of non-solvent vapour into the polymeric solution. It is a dry-wet casting 
process where the vapour of the non-solvent (usually water) allows for the slow transfer of 
non-solvent molecules into the polymeric solution (Witte et al., 1996). The polymeric 
membrane then forms as a result of thermodynamic instability caused from exposure of 
the polymeric solution to the non-solvent vapour (Witte et al., 1996; Matsuyama et al., 
1999; Sun et al., 2007a; Kao et al., 2008). VIPS is frequently used in the production of 
asymmetric membranes, comprising of a dense skin layer and a porous sub-layer. These 
membranes are typically applied in the separation of gaseous and liquid mixtures.  
 
2.3.1.2 Thermal-induced phase separation  
Thermal-induced phase separation (TIPS) is applicable to polymers that cannot form 
membranes through other phase separation methods due to inadequate solubility (Witte 
et al., 1996).  The effects of temperature changes on the solvent used to initially dissolve 
the polymer leads to the formation of the polymeric membrane (Hanks and Lloyd, 2007). 
A polymer is initially mixed at high temperatures to form a homogenous solution, followed 
by casting of the hot polymeric solution onto a cold surface of desired dimensions. The 
decrease in the surrounding temperature causes a decrease in the quality of the solvent 
used. Subsequently, phase separation of the polymeric solution occurs forming a 
microporous membrane (Witte et al., 1996; Matsuyama et al., 2001a; Matsuyama et al., 
2003; Li et al., 2006a, Hanks and Lloyd, 2007). Porous films of isotropic, anisotropic or 
asymmetric membrane structures can be formed, with high porosity percentages, using 
the TIPS method. Other methods of phase separation involve a multi-component mass 
transfer reaction for phase separation to occur. In the TIPS method, heat transfer 
primarily induces phase separation, and therefore this method can be adapted to a wider 
range of membrane applications (Li et al., 2006a).  
 
2.3.1.3 Immersion precipitation  
This method involves the casting of a polymeric solution into a mould or support as a thin 
film. The thin film-like polymeric solution is then immersed into a non-solvent containing 
bath which eventually leads to the precipitation of the polymeric solution. This occurs 
through a series of liquid-solid and/or liquid-liquid phase separation events (Witte et al., 
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1996). Solvent molecules from the polymeric solution are replaced by the non-solvent 
molecules, as illustrated in Figure 2.1, resulting in the formation of a porous polymeric 
membrane that is subsequently dried to remove the liquid phase (Witte et al., 1996; 
Hester et al., 2002; Lin et al., 2006). Membranes produced via this method are widely 
applied in microfiltration/ultrafiltration.  
 
 
 
2.3.1.4 Film/dry-casting technique   
Film- or dry-casting essentially involves dissolving of the polymer in a volatile solvent and 
a less volatile non-solvent. The polymer becomes less soluble in the non-solvent as the 
solvent evaporates, culminating into phase separation that eventually results in the 
formation of a polymeric membrane (Witte et al., 1996; Altinkaya et al., 2005; Lai et al., 
2006). This technique can be successfully applied in the formation of coatings which 
require a stimulus to control the rate of drug release (Sun et al., 2001). 
 
The primary disadvantage of phase separation is that it involves the use of organic 
solvents in the formulation and development of membrane systems. Incomplete removal 
of these solvents may result in toxicity when these membrane systems are used in 
biomedical and pharmaceutical applications. The removal of organic solvents from these 
membranes is thus necessary; however, it is a costly exercise. Additionally, the formation 
of polymeric membranes using phase separation is a lengthy process with the solvents 
often being environmentally harmful. Furthermore, slight changes in the membrane 
fabrication process may significantly affect the final membrane morphology and hence 
drug release performance (Krause et al., 2002; Altinkaya et al., 2005; Sun et al., 2007a).  
 
Polymer Solution 
Support 
Solvent 
Molecules 
Non-solvent 
Molecules 
Coagulation bath 
Figure 2.1: Schematic illustration of the mass transfer of solvent and non-solvent 
occurring during immersion precipitation (Adapted from Pereira et al., 2000). 
28 
 
2.3.2 Electrospinning 
Electrospinning is based on charging a polymeric solution followed by ejecting the 
solution through a fine capillary tip or needle. The syringe pump forces the polymeric 
solution through a small-diameter capillary, thereby forming a pendant drop at the tip. A 
voltage is applied to the tip of the syringe in order to create a charge of certain polarity in 
the solution. The collecting surface is usually of opposite polarity. As a result of the 
applied electric field, a leading edge or Taylor cone forms, that eventually forms a fibre jet. 
The fibre jet then travels towards the collecting surface where solid fibres are deposited 
as the solvent evaporates. This ultimately leads to the formation of a membranous 
structure through the continuous deposition of polymeric fibres on the collecting surface. 
Figure 2.2 illustrates the polymer electrospinning process. The parameters during 
electrospinning including distance of the needle from the collecting surface, the applied 
voltage as well as the solution flow rate can be carefully manipulated and thus 
electrospun membranous matrices can be customized to achieve desired drug release 
patterns (Kim et al., 2007; Sill and Von Recum, 2008). 
 
 
Figure 2.2: A schematic illustration of the electrospinning process, where d = distance 
between capillary tip and collecting surface and θ = Capillary angle. 
 
Electrospun nanofibrous membranes have many promising applications in the 
pharmaceutical industry, including tissue engineering, drug delivery and filtration. Thus 
far, several studies examined the potential of electrospun matrices for use as controlled 
drug delivery systems for the delivery of drugs such as antibiotics and anticancer drugs; 
as well as for tissue engineering applications (Sill and Von Recum, 2008). Approximately 
θ d 
High voltage 
power supply 
Grounded aluminium 
collecting surface 
Taylor cone 
Copper Rod 
Fibre jet 
Whipping 
instability 
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one hundred polymers have successfully been manipulated through electrospinning to 
form nanofibrous matrices in a scaffold or membranous matrix-like structure. The various 
polymers that are used to form nanofibrous matrices currently used in the medical 
industry are depicted in Chapter 5, Table 5.1.  
 
Electrospun nanofibrous matrices are able to modulate drug delivery due to their three 
dimensional porous structure that provides a relatively large surface area thus making 
them valuable scaffolds in tissue engineering. A key advantage of utilizing electrospinning 
in the formation of membrane systems is that the obtained membrane has high flexibility 
and good mechanical properties. Furthermore, the electrospun fibres can be aligned and 
functionalized to induce tissue alignment. However, a drawback associated with this 
technique arises during fabrication of electrospun membranes, there is a possibility that 
fibres may break, leading to the formation of poor quality nanofibrous membranes (Sill 
and Von Recum, 2008; Stamatialis et al., 2008). 
 
2.3.3 Foaming 
This method requires a soluble inert gas such as CO2 or N2. The process involves the 
saturation of the polymer with the gas at a high pressure. The polymer and gas mixture is 
subsequently quenched into a supersaturated state either by a reduction of the pressure 
or an increase of the temperature. The properties of the formed membranes may be 
varied by changing the foaming process conditions. This technique is applicable to 
substances with high Tg (glass transition) values such as pure polymers as well as 
polymer composites and ceramics. It does not require solvent use and thereby eliminates 
the risk of residues. However, the technique requires very high temperatures, which could 
lead to the degradation of the polymers employed and these membranes are not suitable 
for the application in tissue engineering due to their small pore size range (Matsuyama et 
al., 2001b; Krause et al., 2002; Matsuyama et al., 2002; Sun et al., 2007a; Stamatialis et 
al., 2008).  
 
2.3.4 Particle leaching 
Particle leaching is generally carried out in combination with other methods of membrane 
formation methods such as foaming and film-casting. The process involves the 
incorporation of salts, sugars, or other specifically prepared spheres into a polymer 
sample. The polymer is then processed into a membrane using an appropriate method 
(e.g. foaming, film-casting etc). The particles within the membrane are then dissolved and 
washed out to create additional pores in the membrane. This method ensures that 
membranes with highly controlled porosity and pore sizes are produced (Sanguanruksa et 
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al., 2004). However, a drawback associated with this method is that it may not be 
applicable to all materials (e.g. soluble protein scaffolds). Furthermore, the washing out 
post-process is time-consuming and there is a risk of residues remaining from the method 
of processing (i.e. organic solvents) (Stamatialis et al., 2008). Thus, this method is 
preferred for polymers that are not readily soluble in common organic solvents 
(Sanguanruksa et al., 2004; RoyChowdhury and Kumar, 2005; Stamatialis et al., 2008).  
 
2.3.5 Emulsion freeze-drying 
This method involves an emulsification process which is attained through homogenization 
of a polymer-solvent and water system in which the polymer-rich phase is the continuous 
phase while water is the dispersed phase. The produced emulsion is cooled down rapidly 
and frozen, a process that results in the direct solidification of the polymer from the liquid 
phase, thus creating a porous polymeric structure or scaffold. Ultimately, the structure is 
freeze-dried in order to remove water and solvent. Studies indicated that this technique 
produces membranous scaffolds which are ideal for use in tissue engineering since the 
pores produced are large, and the membranes are relatively thicker than membranes 
formed through other methods (Ho et al., 2004; Cheng et al., 2008). Furthermore, 
incorporating proteins during fabrication is possible. However, there is a possibility of 
pores forming which are not highly interconnected. This creates a challenge when using 
certain ceramics as the resultant membranous scaffold becomes brittle (Cheng et al., 
2008; Stamatialis et al., 2008).  
 
2.3.6 Sintering  
This method involves heating powdered polymeric material causing the particles to 
adhere to one another, thereby forming a membranous scaffold. These kinds of 
membranous scaffolds show potential in tissue engineering applications, and separation 
processes. This technique is applied to certain polymers and their composites, and 
ceramic powders. The principle advantage of this method is that sintering allows for the 
production of polymeric membranes with a controlled and graded porosity (Stamatialis et 
al., 2008). Sintering ceramic powders produces membranes with greater properties 
including higher thermal and mechanical stabilities and a better chemical and microbial 
resistance. In addition to their potential use in harsh environments (higher temperatures 
and exposure to various chemicals), ceramic membranes have a relatively long life of 
use, and are typically applied to separation processes due to their permeation 
characteristics. Pore size, porosity, and pore tortuosity can be carefully controlled by 
adjusting the conditions of the sintering procedure such as the temperature, pressure, 
particle size, green density and the addition of sintering additives (Qiu et al., 2009). Liu 
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and Li (2005) investigated the effects of sintering temperature and time on the final 
membrane morphology. The study concluded that higher sintering temperatures result in 
membranes with lower porosities, whereas lower sintering temperatures produces highly 
porous membranes. Medically, sintering can be conducted to form three dimensional 
porous scaffolds by sintering polymeric microspheres onto existing moulds. Such porous 
scaffolds produced are widely applied in bone tissue engineering, with Bioglass® 
composite microspheres as a key component (Rezwan et al., 2006). 
 
2.4 Stimuli-responsive Polymers and their Application in Drug Delivery 
Systems  
 
Biopolymers are basic components found in all living organisms. Biopolymers, such as 
proteins, polysaccharides, and nucleic acids respond to changes in stimuli by undergoing 
a change in their properties. Stimuli-responsive polymers are able to mimic these 
biopolymers. Fundamentally, stimuli-responsive polymers are those polymers that when 
exposed to a slight change in the surrounding environment, undergo a relatively 
significant and immediate change in its properties. This change occurs as a result of the 
polymer recognizing a specific stimulus as a signal, judging the magnitude of this signal, 
and then changing its chain conformation in direct response (Gil and Hudson, 2004; 
Schmaljohann, 2006). These changes in response to stimuli, which are continuous 
throughout its polymer network, are exploited in many applications, specifically drug 
delivery for a plethora of applications, as illustrated in Figure 2.3. The driving force behind 
these changes include neutralization of charged groups by either a pH shift or addition of 
an oppositely charged polymer, changes in the efficiency of hydrogen bonding with an 
increase in temperature or ionic strength and collapse of hydrogels and interpenetrating 
polymeric networks. Electric, magnetic, light and radiation stimuli are also capable of 
inducing reversible phase transitions and are currently being considered as possible 
driving forces (Kumar, 2009).  
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In terms of drug delivery, smart polymers have been commonly used to achieve pulsatile 
or modulated release patterns which mimic biological demands, minimizing drug 
degradation and loss, the prevention of harmful side-effects and increasing drug 
bioavailability and the fraction of the drug accumulated in the required zone. Among the 
most important stimuli that are applicable in drug delivery systems are temperature and 
pH, however, external triggers, including electric current, photoirradiation or externally 
applied thermal changes, can be used to trigger the required change. Responses to 
stimuli may present as a change in physical conformation (size, shape, formation of an 
intricate molecular assembly), solubility (a sol-gel transition), mucoadhesion and surface 
characteristics, hydration state (swelling or shrinking), and increase or decrease in 
polymer permeability or release of a bioactive molecule (e.g. drug molecule) 
(Schmaljohann, 2006; Kumar et al., 2007). These changes are typically reversible and 
can occur as a combination of several responses occurring simultaneously in response to 
one or more stimuli (i.e. dual responsiveness). Figure 2.4 illustrates the potential stimuli 
that may cause changes in the physical properties of stimuli-responsive polymers (Gil and 
Hudson, 2004; Schmaljohann, 2006; Kumar et al., 2007; Kumar 2009).  
Uses of 
stimuli-
responsive 
polymers  
Delivery of 
peptides and 
proteins 
Delivery of 
multiple drugs, 
interacting or not, 
in one system  
Exclusive 
delivery to 
specific 
compartments 
and/or diseases 
Controlled rate 
and modality of 
delivery to 
pharmacological 
receptor 
Protection from 
unwanted drug 
deposition which 
cause adverse 
reactions  
Access to 
previously 
inaccessible sites  
Achievement of 
different release 
profiles i.e. 
pulsatile, 
modified, 
controlled or 
chrono-release 
profiles 
Figure 2.3: Common uses of stimuli-responsive polymers in terms of drug delivery 
(Adapted from Tomlinson, 1987). 
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Some polymeric systems have been developed to combine two or more responsive 
mechanisms into one polymer (e.g. a polymer that responds to temperature may also be 
responsive to a change in pH). Simultaneous exposure to the stimuli is not always a pre-
requisite for the required response in these polymers (Gil and Hudson, 2004). These 
smart polymers in drug delivery have been applied in the delivery of proteins such as 
insulin (Chen et al., 2005), and coenzyme A (Guo and Gao, 2007); anticancer drugs such 
as doxorubicin (Liu et al., 2007) and paclitaxel (Liu et al., 2005); and levonorgestrel (Chen 
and Singh, 2005a) among others.  
 
Stimuli-responsive polymers can be used for intracellular delivery, exploiting the drop in 
pH from 6.2 in plasma and extracellular fluid to 5.0 in intracellular cytoplasm. Cellular 
absorption of polymers involves fluid-phase pinocytosis or receptor mediated endocytosis 
that leads into the formation of endosomes. Endosomes eventually fuse with lysozomes 
Temperature 
(Potential in DDSs 
applicable to disease states 
which manifest as a 
change in temperature e.g. 
fever, tumor sites) 
Cholesterol 
(Potential in DDSs 
applicable to disease 
states with high 
cholesterol levels) 
Urea 
(Potential in DDSs 
applicable to disease 
states which manifest as a 
change in urea levels e.g. 
gout, kidney stones) 
pH 
(Potential in DDSs 
applicable to disease 
states which manifest as 
a change in pH) 
Metals 
Glucose 
(Potential in DDSs 
aimed at controlling 
glucose levels e.g. 
Diabetes) 
 
Ionic Strength, Ultrasonic 
radiation, Magnetic Field, Light 
Radiation and Electric Field (can 
act as external stimuli which control 
the delivery of drugs from 
implants/hydrogels) 
 
 
Unswollen  
Polymer 
Swollen 
Polymer 
Antibody 
(Potential in DDSs which 
release drug in response to 
certain antibodies e.g. cancer 
antibodies) 
Inflammation 
(Potential in DDSs applicable 
to disease states which 
manifest with inflammation 
e.g. wounds, ulcers, 
infections) 
Figure 2.4: Factors that can transform unswollen polymer into swollen polymer (Adapted 
from Dispenza, 2009). 
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which contain enzymes, causing a pH change which is utilized as a trigger for the release 
molecules into the cellular cytoplasm. These pH-responsive polymers are cationic in 
nature and can therefore be used for the intracellular delivery of nucleic acids. The 
cationic polymer binds to the negatively charged nucleic acid, and as this complex enters 
the endosomes, the cationic polymers are deprotonated. This deprotonation eventually 
leads to the disruption of the endosomal membrane, prior to the fusion with the lysozome, 
thereby allowing the release of drug molecules into the cytoplasm. Intracellular delivery of 
drugs using pH-responsive polymers may eventually lead to safer and more efficient drug 
delivery systems (Schmaljohann, 2006). 
 
Polymers, silica and metal surfaces can be functionalised by stimuli-responsive polymers 
to produce highly responsive interfaces between two phases, usually a solid and a liquid. 
The modified interface produces a dynamic “on-off” system, through changing either the 
hydrophilic and/or hydrophobic balance of the surface. Table 2.1 provides the most 
commonly employed polymers used in pH-responsive and thermo-responsive systems 
which have been explored for drug delivery or other medical applications. Polymers may 
be conjugated to form polymeric conjugates with a modulated stimuli-responsive ability. 
Conjugation may also help in improving desirable properties such as mechanical strength 
and biodegradability of polymeric systems (Gil and Hudson, 2004).  
 
Over the past two decades, there has been a great focus on research directed towards 
synthetic environmentally-responsive membranes (Obaidat and Park., 1997; Park et al., 
2001; Hester et al., 2002; Ying et al., 2004). These membranes are able to reversibly vary 
their own permeation characteristics in response to various environmental stimuli. They 
have potential applications in the treatment of wastewater streams, water softening, 
fractionation of macromolecules, drug delivery, cell encapsulation, electronic devices and 
sensors (Hester et al., 2002).  
 
Typically, drug release from membrane systems depends on various parameters such as 
initial drug-loading, membrane thickness, pH of the surrounding medium and the 
mechanism involved in membrane fabrication (Singh and Ray, 1999). Several of the 
membranous DDSs that have been developed respond to various stimuli including 
glucose concentration (Obaidat and Park, 1997; Chu et al., 2004a), temperature (Ying et 
al., 2004; Zhang et al., 2006a), and pH (Park et al., 2001; Varshosaz and Falamarzian, 
2001; Hester et al., 2002). These systems are further elaborated in this chapter. 
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Table 2.1: Stimuli-responsive polymers and their drug delivery and other medical applications. 
Polymer Drug delivery and other medical applications Reference 
Thermo-responsive polymers   
p(NIPAAm) copolymers    
p(NIPAAm-co-DMAAm-co-AMA)-b-PUA  Doxurubicin and folic acid Liu et al., 2007a 
P(NIPAAm-co-DMAAm)-b-poly(PLGA) Doxurubicin Liu et al., 2005a 
Alginate-g-p(NIPAAm)  Blue dextran Kim et al., 2005b 
p(HEMA-g-NIPAAm) Theophylline and Inulin Ankareddi and Brazel, 2007 
p(NIPAAm)–HA  Control of post-surgical tissue adhesions Ohya et al., 2005 
p(NIPAM)-grafted gelatin (PNIPAM–g-gelatin). Haemostatic aid in uncontrolled bleeding during surgery Ohya et al., 2005 
DMAEMA and p(NIPAAm) DNA delivery Hinrichs et al., 1999 
PEG / PLGA block copolymers   
PLGA-PEG-PLGA Delivery of proteins (model protein lysozyme used) Chen et al., 2005 
PLGA-PEG-PLGA triblock copolymers with varying ratio of lactide/glycolide Testosterone Chen and Singh; 2005b 
PLGA-PEG-PLGA microspheres Zinc crystalline recombinant human insulin Kwon and Kim, 2004 
PEG-PLGA-PEG triblock copolymers In situ generated implants Jeong et al., 2000 
Poly(organophosphazenes)   
Poly(organophosphazene) hydrogel Tissue engineering matrix (mouse pre-osteoblasts and 
collagen injected subcutaneously into nude mice forming an 
in situ gelation-injected site) 
Yoon et al; 2007 
Poly(organophosphazene) hydrogel Tissue engineering (delivery of spheroidal hepatocytes). Park and Song, 2006 
Poly(organophosphazene) hydrogel Doxorubicin Kang et al., 2006a 
Poly(organophosphazene) hydrogel Dextran and albumin Kang et al., 2006b 
PEG/biodegradable polyester copolymers   
P(HPMAmDL-b-PEG). Paclitaxel Soga et al., 2005 
PEG and PPG In situ generated implants  Cohn et al., 2005 
PEG (Mw: 2000g/mol) with PLLA  (PLLA/PEG/PLLA) Doxorubicin Na et al., 2006 
Poly(PEG/PPG/PCL urethanes) Potential for application as a non-toxic polymer for use in 
biomedical applications 
Loh et al., 2008 
PEO / PPO block copolymers    
Pluronic
®
 F127 (MW=12,600, 70wt% PEO) with hexamethylene diisocyanate Delivery of an anti-restenosis model drug (RG-13577) Cohn et al., 2003 
Pluronic
®
 F127 (PEO99–PPO67–PEO99) Metronidazole and methylene blue Sosnik and Cohn, 2004 
Cross-linked PEO-PPO  In situ generated implants produced by end-capping them 
with triethoxysilane or methacrylate reactive groups 
Cohn et al., 2005 
Pluronic
®
 F127 
 
In situ forming implant delivering of human growth hormone Chung et al., 2008 
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pH-responsive polymers   
Methacrylic acid copolymers   
Eudragit
®
 L100-55  (pH 5.5) Mesalazine Khan et al., 1999 
Eudragit
®
 L100 (pH 6.0) Mesalazine  Khan et al., 2000 
Eudragit
®
 S100 (pH 7.0) Mesalazine  Khan et al., 1999 
Eudragit
®
 P-4135F (i) Norfloxacine 
(ii) Ellagic acid  
(i) Hu et al., 1999;  
(ii) Jeong et al., 2001 
GMD/PAA 5-aminosalicylic acid Kim and Oh, 2005 
MEMA/MAA copolymer Indomethacin and ephedrine HCl with the use of 
ethylenglycol dimethacrylate as a cross-linker 
Varshosaz and Hajian, 2004 
p(MAA–EA)  Procaine hydrochloride and Imipramine hydrochloride with di-
allyl phthalate (DAP) as a cross-linker 
Tan et al., 2007 
p(MMA-DMA) Aminopyrine, caffeine and theobromine with divinylbenzene 
as a cross-linker 
Varshosaz and 
Falamarzian, 2001 
Poly(MMA) Microparticles incorporated into the hydrogel were grafted 
with PEG chains that are capable of complexing with the 
hydroxyl groups of the polyacid and interpenetrating into the 
mucus gel layer upon entry into the small intestine 
Thomas et al., 2007 
Copolymers composed of different aminoethyl methacrylate monomers 
synthesized from a PEG macroinitiator by ATRP 
Heparin Dufresne and Leroux, 2004 
PEG-b-poly(alkyl acrylate-co-methacrylic acid)  Fenofibrate and progesterone. Sant et al., 2005 
p(HEMA) (i) Salicylic acid with tripropyleneglycol diacrylate (TPGDA) 
as a cross-linker; 
(ii) Oral Insulin delivery with methacrylic acid 
(i) Ferreira et al., 2000; 
 
(ii) Mahkam, 2005 
p(HEMA)  (i) Theophylline, proxyphylline and oxprenolol HCl combined 
with acrylic acid or methacrylic acid; 
(ii) Insulin and Protamine with tetraethyleneglycol diacrylate 
(TEGDA) as a cross-linker 
(i) Khare and Peppas, 1993; 
 
(ii) Brahim et al., 2003 
Poly(EA/MAA/BDDA) and Poly(MMA/MAA/EGDMA)  Biomaterials for structural support of soft connective tissues 
(degenerated intervertebral discs) 
Lally et al., 2007 
Poly(MAA-g-EG) Comparison of complexed and uncomplexed hydrogels and 
their effects on the release of dextran and proxyphylline 
Lowman and Peppas, 1999 
PEG-b-p(AlA-co-tBMA)) block copolymers Poorly water-soluble model drugs: indomethacin, fenofibrate 
and progesterone 
Sant et al., 2004 
Poly(HEMA-co-MAA) hydrogels Phenylpropanolamine with tetraethylene glycol 
dimethacrylate (TEGDMA) as a cross-linker 
Kou et al., 1988 
PEG-b-poly(alkyl(meth)acrylate-co-MAA) Candesartan cilexetil Satturwar et al., 2007 
poly(MMA-co-MAA)  Oxprenolol HCl Kim and Lee, 1992 
Table 2.1 continued 
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Psyllium and methacrylamide Tetracycline HCl Singh et al., 2007 
PCL-p(MAA-EG) hydrogel Hydrogels which swell at pH 7.2 and shrank at pH 1.2 Chao et al., 2007 
Poly(acrylate) derivatives   
PVP and linear PAA pH sensitivity in the pH range of 2.25 to 4.00 at 37°C Jin et al., 2006 
PA-g-guar gum Diltiazem hydrochloride and nifedipine Soppimath et al., 2001 
p(NPA) Folic acid Sáez-Martínez et al., 2008 
Alginate derivatives   
Alginate–guar gum hydrogel Delivery of proteins and peptides (i.e. BSA) with 
glutaraldehyde as a cross-linker 
George and Abrahams, 
2007 
Chitosan   
CHT-tetra ethyl ortho silicate (TEOS) Lidocaine HCl, sodium salicylate and 4-acetamidophenol Park et al., 2001 
Polyphosphazenes   
Polyphosphazene-PS, polyphosphazene-polysiloxane, and polyphosphazene-
ROMP of norbornene copolymers 
No drug delivery application. A dye Biebrich Scarlet was 
used to test release from these copolymers 
Allcock and Ambrosio, 1996  
 
P(NIPAAm): Poly(N-isopropylacrylamide); DMAAm: Dimethylacrylamide; AMA: 2-aminoethyl methacrylate; PLGA: Poly(D,L-lactide-co-glycolic acid); HEMA: 2-hydroxyethyl 
methacrylate; HA: Hyaluronan; DMAEMA: 2-(dimethylamino)ethyl methacrylate; PEG: poly(ethylene glycol); HPMAmDL: 2-hydroxypropyl methacrylamide lactate; PPG: 
Poly(propylene glycol); PLLA:Poly(L-lactic-acid); PCL: Poly(caprolactone); PEO: Poly(ethylene oxide); PPO: Poly(propylene oxide); GMD: Glycidyl methacrylate dextran; PAA: 
Poly(acrylic acid); MAA: Methacrylic acid; MMA: methyl methacrylate; EA: ethyl acrylate; DMA: dimethylaminoethyl methacrylate; ATRP: atom transfer radical polymerization; 
BDDA: butanediol diacrylate; AlA: alkyl acrylate; EG: ethylene glycol; MA: methacrylamide; EGDMA: ethyleneglycol dimethacrylate; CL: caprolactonetBMA: t-butyl 
methacrylate; AlMA: alkyl (meth)acrylate; PVP: Poly(N-vinylpyrrolidone); PA: Polyacrylamide; NPA: p-nitrophenyl acrylate; CHT: Chitosan; TEOS: tetra ethyl ortho silicate; PS: 
Polystyrene. 
 
Table 2.1 continued 
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2.4.1 Thermo-responsive polymers and their applications in membranous drug 
delivery systems 
As of late, thermo-responsive DDSs have gained much attention since many disease 
states manifest themselves by a change in temperature, which can be employed to trigger 
conformational changes within the polymeric structure and hence affect drug release 
(Zhang et al., 2006a). Thermo-responsive polymers exhibit a sol-gel behavior in response 
to temperature changes, and have been applied in drug and gene delivery, prevention of 
tissue adhesions, wound dressings, as cell carriers in tissue regeneration and in situ-
forming systems (e.g. the “molecular condom” used in the prevention of STI’s and HIV 
transmission) (Ichikawa and Fukumori, 2000; Ohya et al., 2005; Zhang and Misra, 2007; 
Ndesendo et al., 2008). The change in the characteristics of the polymer arises from a 
lower critical solution temperature (LCST) behavior, where if a certain temperature 
threshold is surpassed; the polymer will undergo a reversible phase separation. These 
polymers are typically soluble in a solvent (usually water) at lower temperatures, however, 
once the LCST has been reached; the polymers begin to solidify and are rendered 
insoluble at temperatures above the LCST (Schmaljohann, 2006).  
 
Drug delivery through these hydrogels usually occurs at the soluble stage of the polymer 
i.e. at temperatures lower than the LCST (Liang et al., 1999; Ying et al., 2004; Lue et al., 
2008). In principle, the LCST of a given polymer can be ‘‘tuned’’ to create the desired 
property by varying the hydrophilic or hydrophobic co-monomer content (Lue et al., 2008). 
Thermo-responsive polymers commonly employed are listed in Table 2.1, with poly(N-
isopropylacrylamide) [p(NIPAAm)] and its copolymers being the prevalent alternative. The 
majority of thermo-responsive polymer applications utilize the change from room to body 
temperature, or externally applied hyper/hypothermia to trigger the conformational change 
to a gel phase (Schmaljohann, 2006). These polymers are commonly grafted into the 
pores (Figure 2.5a) or surface (Figure 2.5b) of a membrane structure, controlling drug 
release in responses to changes in the surrounding temperature. Porous substrates are 
usually inert and provide physical strength and support, whereby the drug diffusion is 
controlled by the stimuli-responsive polymers present on the membrane surfaces or within 
pores (Chun and Kim, 1996; Ng et al., 2001; Ying et al., 2004; Lue et al., 2007; Mizutani 
et al., 2008). 
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Commonly, p(NIPAAm) is grafted onto the surface of the pores in the form of polymeric 
brushes (Ying et al., 2004; Lue et al., 2008) forming an ‘on-off’ valve mechanism ideal for 
numerous applications (Table 2.2). The ‘off’ stage occurs when the polymeric brushes 
become soluble in water at temperatures below the LCST which leads to swelling that 
ultimately leads to closing of the membrane system pores, retarding drug release. The 
‘on’ stage occurs when the polymer becomes insoluble in water at temperatures above 
Low Temperatures High Temperatures 
Surface grafted p(NIPAAm)-
valve swells and opens thus 
releasing drug molecules 
Surface grafted p(NIPAAm)-valve remains 
closed (unswollen) thus trapping drug 
molecules within the capsule 
Release of drug 
molecules Trapped drug 
molecules  
Capsule membrane 
b)  
Figure 2.5: Schematic illustration of a) the ‘on-off’ valve mechanism of polymeric brushes 
grafted onto porous support, and b) the permeability changes occurring as a result of 
temperature changes of surface grafted polymeric chains (Adapted from Lue et al., 2008). 
Drug unable to 
pass through pores 
Drug passing 
through pores 
Surrounding temperature > LCST 
= ON stage 
(polymers shrink as solubility 
decreases) 
Inert porous 
membrane 
a)  Surrounding temperature < LCST 
= OFF stage 
(swelling is initiated) 
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the LCST and shrinks, thus causing the opening of the pores within the membrane 
system, allowing drug release (Liang et al., 1999; Ying et al., 2004; Lue et al., 2008). 
Alternatively, the pores in ‘on-off’ valve systems can be filled with liquid crystals which 
melt, thereby releasing drug at a certain temperature threshold (Dinarvand and Ansari, 
2003; Makai et al., 2003; Atyabi et al., 2007); or by aminated polymers demonstrating 
improved and more sensitive thermo-responsive behaviour (Zhang et al., 2006a). Such 
stimuli-responsive DDSs that release drug only above certain temperatures may be 
usefully applied as drug reservoir systems, specifically as implants (Ng et al., 2001), 
transdermal patches (Csóka et al., 2007; Dong et al., 2008), and in wound healing (Ohya 
et al., 2005). An area of vast potential is use of these systems chemotherapeutics delivery 
under local hyperthermia (Atyabi et al., 2007).  
 
Table 2.2: Application of thermo-responsive polymer p(NIPAAm) in ‘on-off’ valve 
mechanisms. 
Grafting 
mechanism 
Porous membranes or 
substrate 
Drug delivery and Medical 
applications 
Reference 
Ultraviolet 
photopolymerization 
Hydrophilic PP 
microfiltration membranes 
Solute separations  Liang et al., 
1999 
Photoimmobilization 
via photoirradiation 
PC membranes Permeation of Tryptophan 
 
Park et al., 
1998 
Irradiation PVDF membranes Potential for polynucleotide, 
peptide and protein delivery 
Åkerman et 
al., 1998 
Photografting using 
UV light 
PET track membranes None used Yang and 
Yang, 2003 
Plasma-induced 
graft polymerization 
PE membranes Separation and filtration 
 
Huang et al., 
2002 
Plasma-induced 
graft polymerization 
Track-etched PC films 4-acetamidophenol and 
ranitidine HCl 
Lue et al., 
2007 
Plasma-induced 
graft polymerization 
PA microcapsules NaCl and Vitamin B12 Chu et al., 
2001 
Radiation-induced 
graft polymerization 
PET and PP membranes  Separation and filtration 
 
Shtanko et al., 
2000 
Surface-initiated 
polymerization by 
aqueous FRP and 
ATRP 
PET membranes Separation and filtration Alem et al., 
2008 
In situ 
polymerization of 
hydrogel within 
pores of the 
sintered glass. 
Disc-shaped sintered glass 
filter 
Permeation of salicylic acid 
and bovine albumin 
Li and 
D’Emanuele, 
2001 
Surface initiated 
ATRP 
PS substrates Cell-based therapy for 
severe disorders 
Mizutani et 
al., 2008 
PP: polypropylene; PC: Polycarbonate; PVDF: Poly(vinylidene fluoride); PET: Polyethylene terephtalate; ; PE: 
Polyethylene; PA: Polyamide; FRP: free radical polymerization; ATRP: atom transfer radical polymerization; 
PS: Polystyrene 
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2.4.2 pH-responsive polymers and their applications in membranous drug 
delivery systems  
The use of pH-responsive hydrogels as stimuli-responsive drug delivery systems is based 
on the variability of the physiological pH is at different sites of the body, including the GIT, 
vagina and blood vessels (Iemma et al., 2006). pH-responsive polymers are used to 
target drug delivery to damaged, wounded or inflamed tissues and certain cancer cells. 
Table 2.3 lists commonly targeted drug delivery sites in the body and their respective pH 
ranges. For a polymer to portray pH-responsive properties, they should be ionisable and 
preferably have a pKa value of 3-10 (Iemma et al., 2006; Schmaljohann, 2006). A change 
in pH results in a deviation in the ionisation state of these polymers (via 
protonation/deprotonation events thus imparting a charge over the molecule) and 
therefore a conformational change, which culminates in the changing of the solubility and 
swelling behavior of the polymer. This pH-responsive swelling ability has been exploited 
to induce the controlled release of drugs and proteins (Iemma et al., 2006; Schmaljohann, 
2006; Kumar et al., 2007).  
 
The pH sensitivity of a pH-responsive polymer is a direct result of the presence of weakly 
acidic (e.g. carboxylic and sulfonic acids) and/or weakly basic (e.g. ammonium salts or 
amino groups) functional groups on the polymeric backbone, which allow for reversible 
swelling/deswelling behavior in acidic or basic media. These functional groups undergo 
protonation/deprotonation with changes in pH as small as 0.2-0.3 units, thus resulting in 
water uptake by the polymer, increasing the solubility of solutes within the polymeric 
matrix, thus releasing said solutes (Lee and Shim, 1997; Soppimath et al., 2001). The 
ionisation of these polymers (which depends on the pH and ionic strength of the external 
medium), renders them pH-responsive thus making them useful in drug delivery systems 
known as pH-dependant ‘switch-on and -off’ systems (Iemma et al., 2006). Thus far, 
these pH-responsive hydrogels have shown vast potential in the delivery of drugs and 
therapeutic agents into various areas of the body (Lee and Shim, 1997; Soppimath et al., 
2001; Varshosaz and Falamarzian, 2001; Iemma et al., 2006). Table 2.2 summarizes 
certain pH-responsive polymers that have been employed in smart drug delivery systems.  
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Table 2.3: Variations in pH values in different tissue and cellular compartments (Adapted 
from Schmaljohann, 2006; Mania-Pramanik et al., 2008). 
Tissue/cellular compartment pH 
Blood 7.35-7.45 
Stomach 1.0-3.0 
Duodenum 4.8-8.2  
Colon 7.0-7.5 
Early endosome 6.0-6.5 
Late endosome 5.0-6.0 
Lysosome 4.5-5.0 
Golgi 6.4 
Tumour, extracellular 7.2-6.5 
Vagina 3.5-5.0 
 
Poly(vinyl alcohol) (PVA) and poly(acrylic acid) (PAA) have been used to prepare pH-
responsive interpenetrating polymeric network (IPN) membranes by employing varying 
crosslinking ratios for application in drug and selective protein separation (Gudeman and 
Peppas 1995). Methacrylate based polymers are commonly employed as coatings, which 
control drug release over the physiological pH range. The permeability of such coatings, 
referred to as enteric coatings, differ over the physiological pH range, and hence is ideal 
for use in use in drug targeting (Sun et al., 2001). Poly(ethylene-co-vinyl-alcohol) (EVAL) 
blended with PAA or glycine demonstrate potential for colonic drug delivery in the local 
treatment of ulcerative colitis (Shieh et al., 2000) or colorectal cancer (Lai et al., 2006). 
The ‘on-off’ valve mechanism can also be successfully achieved with pH-responsive 
hydrogels where drug permeability differs with changes in pH (Mika et al., 1999; Kai and 
Min, 2001; Varshosaz and Falamarzian, 2001; Hu and Dickson, 2008). pH-responsive 
polymers can be grafted onto the surfaces of said membranes through a variety of 
mechanisms including UV irradiation (Kai and Min, 2001) and γ-ray irradiation (Singh and 
Ray, 1999). 
 
2.4.3 Glucose-responsive polymers and their applications in membranous drug 
delivery systems 
Recently, studies have aimed at developing biomaterials that exhibit sensitivity to 
biomolecules, demonstrating potential in the development of drug delivery systems with 
improved therapeutic efficacies and a lower side effect profile. These systems have the 
potential to release the drug or bioactive only when the body requires it. Thus far, there is 
no sufficiently effective system for the control of blood glucose levels. In insulin-
dependent diabetes, an increase in blood glucose levels requires the administration of 
insulin to effectively control blood glucose levels. Daily insulin injections cause discomfort 
and other complications and therefore improved and novel means of delivering insulin 
would be beneficial in diabetes treatment (Tang et al., 2003).  
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Hydrogels, implantable or injectable, which respond to glucose by swelling or deswelling, 
have potential for a self-regulating insulin delivery system as an alternative in the 
treatment of diabetes. Typically, self-regulating glucose-responsive systems should mimic 
the physiological response of insulin release from the pancreas in response to blood 
glucose concentrations (Tang et al., 2003). To date, competitive binding, substrate-
enzyme reactions, pH-dependant polymer erosion or drug solubility are employed as 
glucose sensing mechanisms (Podual et al., 2000; Miyata et al., 2002; Zhang and Wu, 
2002; Tang et al., 2003).  
 
Lectin incorporated systems rely on the concept of competitive binding, whereby insulin 
molecules are initially attached to a lectin molecule. The lectin molecules have a higher 
affinity for glucose molecules, and hence will detach from the insulin molecules in the 
presence of glucose and therefore releasing insulin as a function of free glucose 
concentration in the environment. The concept of competitive binding for insulin release 
has also been employed in phenylboronic acid incorporated systems. The phenylboronic 
acid is initially attached to polymeric molecules, illustrated in Figure 2.6, and in the 
presence of glucose, dissociates from the polymer, disrupting the polymeric network, and 
promoting insulin permeability (Kitano et al., 1992; Obaidat and Park, 1996; Miyata et al., 
2002; Tang et al., 2003). 
Figure 2.6: A glucose-responsive insulin releasing system based on PVA/poly(NVP-co-
PBA) (Adapted from Kitano et al., 1992). 
  Glucose 
 =  Insulin                        =  Glucose                                  
Insulin is released as a 
result of changes in 
membrane permeability 
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In enzyme incorporated systems, the stimuli-responsive behaviour is not exclusive to the 
presence of glucose molecules, but rather from a change in pH caused by glucose 
oxidase enzymes in the presence of glucose molecules. Glucose oxidase converts 
glucose to gluconic acid and hydrogen peroxide, lowering the pH of the environment 
surrounding the DDS (Podual et al., 2000; Chu et al., 2004a). This pH change acts as a 
trigger for the incorporated pH-responsive polymeric chain grafts to undergo a 
conformational change leading to insulin release. As the pH of the body drops with 
increasing concentrations of glucose, insulin release increases (Podual et al., 2000).  
 
Catalase is incorporated into these glucose-responsive systems to eliminate hydrogen 
peroxide and therefore prevent toxicity, by ensuring that oxygen depletion is prevented 
(Zhang and Wu, 2002; Miyata et al., 2002). Various polymers including polyacrylates, 
polymethacrylates, polyethylene, polypyrroles, silica, and poly(vinyl alcohol) have been 
successfully used as substrates for the immobilization of glucose oxidase (Podual et al., 
2000). The clinical efficacy of glucose-responsive systems was studied by Traitel and co-
workers who reported that a poly(HEMA-co-N,N-dimethylaminoethyl methacrylate) 
[p(HEMA-co-DMAEMA)] hydrogel entrapped with glucose oxidase, catalase and insulin 
was both biocompatible and effective in reducing blood glucose levels in rats (Traitel et 
al., 2000). 
 
 
Glucose  
Porous 
membrane of 
microcapsule 
Insulin  
Immobilized 
glucose oxidase 
Chain Grafts 
Addition of glucose  
Figure 2.7: Schematic representation of a typical glucose-responsive microcapsule. The 
pores contain surface immobilised enzyme glucose oxidase with grafted pH-responsive 
PAA chains which, upon exposure to glucose, causes the pore opening and consequent 
insulin release (Adapted from Chu et al., 2004b). 
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2.4.4 Dual-responsive systems 
The combination of two stimuli-responsive mechanisms in one polymeric system results in 
the development of a dual-responsive system that responds only when exposed to two 
stimuli simultaneously (Ashok et al., 2007). Injections of thermo-responsive hydrogels into 
deep anatomical sites within the body are not suitable due to the premature gelling of the 
hydrogel within the catheter used to deliver the hydrogel (Shim et al., 2006). This 
challenge can be overcome by combining a thermo-responsive polymer with a pH-
responsive polymer to form a copolymer that is responsive to both pH and temperature 
changes, which gels only in response to simultaneous exposure to pH and temperature, 
preventing any premature gelation (Liu et al., 2007b).  
 
Shim and co-workers (2006) reported a novel pH- and thermo-responsive block 
copolymer prepared by adding pH-responsive sulfamethazine oligomer (SMO) to thermo-
responsive poly(caprolactone-co-lactide)-PEG-poly(caprolactone-co-lactide) resulting in a 
copolymer solution which demonstrated a reversible sol-gel transition triggered by a 
change in the pH in the range of 7.2-8.0 at a temperature of 37°C (body temperature) 
(Shim et al., 2006). Hoffman and Dong, (1992) crosslinked various ratios of p(NIPAAm) 
and poly(N,N'-dimethyl aminopropyl methacrylamide) to form a positively charged pH-
/thermo-responsive hydrogel. Dual-responsive systems in the form of beads have also 
been developed by Kim and co-workers for the release of insulin. These beads were 
composed of poly(NIPAAm-co-butylmethacrylate-co-acrylic-acid) and PAA, which 
controlled rate of insulin release (pH 7.4; 37°C) (Kim et al., 1994). 
 
Dual-responsive membranes can be prepared by co-grafting thermo- and pH-responsive 
polymers, in the form of chains or nanoparticles, on porous membrane substrates. Porous 
polyamide membranes grafted with both PAA and p(NIPAAm) were found to be 
responsive to both temperature and pH. These were amongst the first dual-responsive 
membranes produced. Permeability of solutes (peptides, Leuprolide, vitamin B12, insulin, 
and lysozyme) across these membranes increased with increasing temperatures or 
particle concentration and decreased with increasing pH (Lee and Shim, 1997; Zhang and 
Wu, 2004).   
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Chitosan (CHT) based hydrogel films possessing both thermal and pH-sensitivity were 
prepared by blending CHT with p(NIPAAm) and polyethylene glycol (PEG). PEG was 
added to enhance thermo-mechanical and swelling properties of the film. The data 
obtained from the study revealed that the blended CHT/PEG/p(NIPAAm) films had a 
LCST at around 32°C due to the p(NIPAAm) component and demonstrated pH-
responsiveness due to the amino groups of CHT component (Sun et al., 2007b). 
 
Membranes with dual-responsive systems not originating from pH- and/or thermo- 
responsive properties have also been investigated (Kontturi et al., 1996; Zhang and 
Misra, 2007). In an attempt by Kontturi and co-workers, a PVDF hydrophobic membrane 
was grafted with PAA via radiation grafting. The resultant PVDF/PAA membranes 
demonstrated convective permeability which changed significantly with the pH and/or the 
salt concentration of surrounding fluids, thus representing an appropriate dual-responsive 
mechanism (Kontturi et al., 1996). The effects of a thermo-responsive polymer combined 
with a magnetic drug-targeting carrier were also investigated (Zhang and Misra, 2007; 
Yang et al., 2008).  
 
These types of responsive systems offers substantial potential for application in the field 
of drug targeting such as delivery of anti-cancer drugs to tumour sites, and they are 
associated with reduced side-effects and controlled drug release in response to 
temperature changes, as well as magnetic flux. These microcapsules are directed to the 
target and remain there with the aid of the magnetic field. The permeability of the 
microcapsule membrane changes in response to environmental temperature, thus 
Nanoparticle shrinking  T > LCST; pH < pKa 
Nanoparticle swelling T < LCST; pH > pKa 
Figure 2.8: A simplified schematic illustrating the permeation of solutes through a 
nanoparticulate thermo- and pH-responsive membrane (Adapted from: Zhang and Wu, 
2004). 
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controlling the rate of drug release (Zhang and Misra, 2007). Other applications of such 
dual-responsive systems include controlled-release of chemicals, and the production of 
biomedical and/or chemical sensors and microreactors (Yang et al., 2008). 
 
2.5 Concluding Remarks 
 
The focus of this chapter was placed on reviewing stimuli-responsive polymers, in 
particular pH- and thermo-responsive membranous systems. ‘Smart’ drug delivery 
systems have shown great potential in combating many disease states due to their 
targetability and in-built drug release mechanisms. Rather than acting exclusively as a 
drug carrier, these systems are able to respond to their environments, allowing drugs to 
be delivered solely to the target site and in response to a disease related stimulus. This, 
in turn, allows for safer and more potent therapeutic interventions in many disease states 
thus improving the health-related quality of life in countless patients. Commonly employed 
pH- and thermo-responsive polymers were identified and their applications in drug 
delivery were further elaborated. The concept of the ‘on-off’ gating mechanism was 
comprehensively reviewed with reference to stimuli-responsive polymers able to achieve 
said mechanism. The various methods employed in fabrication of membrane systems 
were briefly discussed, with impetus placed on the electrospinning method. Furthermore, 
the polymers and solvents employed in electrospinning were identified with their potential 
drug delivery and other medical applications. In conclusion, membranous drug delivery 
systems developed from the architecture of various drug delivery technologies have 
significant potential in solving the problem of uncontrolled and untargeted delivery of 
drugs to different body sites. Research should therefore be aimed at developing more 
refined membranous drug delivery systems with enhanced intelligent capabilities using 
stimuli-responsive polymers for the treatment of various diseases.  
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CHAPTER 3  
PRELIMINARY DESIGN OF THE STIMULI-RESPONSIVE MUCOADHESIVE 
LAYERS OF THE MULTI-COMPONENT MEMBRANOUS DRUG DELIVERY 
SYSTEM 
 
 
3.1 Introduction 
 
As of late, there is growing interest in the development of drug delivery systems 
employing mucoadhesive polymers which are able to attach to a desired tissue (or to the 
surface coating of the tissue, mucin) within the human body, thereby providing a targeted 
system. As such, the bioavailabilities of existing drug molecules, especially those with 
narrow therapeutic absorption windows are enhanced, thereby maximising their 
therapeutic effectiveness ultimately improving their cost-effectiveness. Mucoadhesive 
systems in oral drug delivery promise the advantage of a prolonged gastric or small 
intestinal residence time, an intimate contact of the delivery system with the absorption 
site and the basis for interactions of multifunctional polymers with the mucosa such as 
permeation enhancement or enzyme inhibition. Mucoadhesive drug delivery systems 
(MDDSs) improve many administration routes, like the ocular, nasal, buccal and gingival, 
gastrointestinal (oral), vaginal and rectal routes, through the mechanisms illustrated in 
Figure 3.1. A polymer is mucoadhesive if it is able to adhere (for an extended duration of 
time) to a mucosal surface within the human body. Such mucoadhesion arises through 
interfacial molecular attractive forces present at the interface between a mucoadhesive 
polymer and a mucosal membrane (Harris et al., 1990; Bernkop-Schnürch, 2005; Roy et 
al., 2009; Khutoryanskiy, 2010; Yadav et al., 2010; Mythri et al., 2011).  
 
 
Figure 3.1: Mechanisms of which mucoadhesion improves oral bioavailability of drugs. 
Improvement 
in oral 
bioavailability 
Delay in the GIT transit 
time of the DDS, thereby 
prolonging time for 
absorption to occur 
Immediate absorption from the 
DDS without previous dilution and 
possible degradation in the luminal 
fluids 
Increase in the local drug 
concentraiton at the site of 
adhesion/absorption 
Decrease in the diffusion path 
from the DDS to the absorbing 
biological membrane compared 
to non-adhesive DDS 
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Although not entirely understood, the use of mucoadhesive polymers dates back as early 
as 1947, when Scrivener and Schantz reported the use of gum tragacanth combined with 
a dental adhesive to administer penicillin to the oral cavity (Scrivener and Schantz, 1947). 
This pioneering study ultimately led to further developments in MDDSs, using novel 
mucoadhesive polymers with varying molecular architectures in various drug delivery 
approaches. The repertoire of advantages associated with mucoadhesive polymers 
includes an increase in residence time of the MDDS at the site of absorption thus 
improving drug bioavailability and reducing dosage frequency, simplifying the 
administration of a dosage form and termination of a therapy (for transdermal, buccal or 
ocular systems), and the possibility of targeting particular body sites and tissues (Harding 
et al., 1999; Roy et al., 2009; Khutoryanskiy, 2010). Prior to the selection and 
identification of appropriate mucoadhesive polymers for the MMDDS, it was important to 
fully comprehend the mechanisms of mucoadhesion, define the various classes of 
mucoadhesives, and identify any factors that would affect the mucoadhesive properties of 
polymers.   
 
3.1.1 Theories of mucoadhesion 
In spite of copious research, scientists cannot fully elucidate the phenomenon responsible 
for mucoadhesion. As a result, there are various theories attempting to account for 
mucoadhesion, as follows: 
 
3.1.1.1 The electronic theory 
The electronic theory postulates that attractive forces arise resulting from the transfer of 
electrons between the mucoadhesive polymer and mucus (having different electronic 
characteristics) causing the formation of an electrical double layer thereby giving rise to 
electrostatic attraction (Hogerstrom, et. al., 2003; Dodou et al., 2005; Khutoryanskiy, 
2010; Mythri et al., 2011). 
 
3.1.1.2 The adsorption theory 
The adsorption theory proposes that intermolecular forces such as hydrogen bonding, 
Van der Waals forces and chemisorption (through covalent bonds), provide the adhesive 
attraction between mucus and mucoadhesive polymers. Furthermore, the adsorption 
theory also considers that hydrophobic effects, especially in amphiphilic polymers, play an 
important role in mucoadhesion (Hogerstrom, et. al., 2003; Dodou et al., 2005; 
Khutoryanskiy, 2010; Mythri et al., 2011).  
 
50 
 
3.1.1.3 The wetting theory 
The wetting theory correlates the surface tension of the mucus and the mucoadhesive 
polymer with its spreading ability. The lower the contact angle of the liquid on the mucus 
surface, the higher its affinity for that surface. This theory is mainly applicable to liquid 
mucoadhesive forms, but if two solid substrates are brought into contact in the presence 
of a liquid, the liquid may act as an adhesive between the two surfaces (Hogerstrom, et. 
al., 2003; Dodou et al., 2005; Khutoryanskiy, 2010; Mythri et al., 2011).  
 
3.1.1.4 The diffusion theory 
The diffusion theory proposes that mucoadhesion depends on the formation of a 
networked or interpenetrated structure between the mucoadhesive polymeric chains and 
the mucus layer. Mucoadhesive macromolecules are able to penetrate the mucus layer 
and soluble mucins are able to diffuse into the dosage form or mucoadhesive system due 
to the presence of a concentration gradient between the two interfaces, forming a semi-
permanent bond through physical entanglement. The theory further postulates that 
mucoadhesion is dependent on the molecular weight of mucoadhesive macromolecules, 
their hydrodynamic size and mobility, and that the depth of interpenetration is dependent 
on the diffusion coefficient and the contact time. It defines that efficient adhesion can be 
achieved when the interpenetration layer reaches 0.2-0.5mm in thickness (Hogerstrom, 
et. al., 2003; Dodou et al., 2005; Khutoryanskiy, 2010; Mythri et al., 2011).  
 
3.1.1.5 The fracture theory 
The fracture theory elucidates that the difficulty of separation of two surfaces after 
adhesion is related to the adhesive bond strength of the mucoadhesive polymer. This 
theory is considered suitable in the calculation of the fracture strength of adhesive bonds 
which involve solid and rigid mucoadhesive materials. The fracture theory is considered to 
be the most widely accepted theory of mucoadhesion (Hogerstrom, et. al., 2003; Dodou et 
al., 2005; Khutoryanskiy, 2010; Mythri et al., 2011).  
 
3.1.1.6 The mechanical theory 
The mechanical theory relates the effect of surface morphology such as micro-cracks and 
surface irregularities or roughness with an increase in contact area, thereby promoting 
mucoadhesion. Liquid or gel-like adhesives are able to diffuse into said micro-cracks and 
irregularities, forming an interlocked network which promotes adhesion (Dodou et al., 
2005; Smart, 2005; Roy et al., 2009; Khutoryanskiy, 2010; Harsulkar et al., 2011; Tangri 
and Madav, 2011). 
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Due to the complexity of the mucoadhesive process, none of these theories are able to 
fully describe the concept of mucoadhesion when they are considered in isolation. 
Mucoadhesion most probably results from a number of mechanisms combined. As a 
result, authors prefer to define the mucoadhesive process as sequential process of 
phases, each associated with a different mechanism. It has been reported that 
mucoadhesion can be divided into two phases, namely the contact and consolidation 
phases as illustrated in Figure 3.2 (Hogerstrom, et. al., 2003; Dodou et al., 2005; 
Khutoryanskiy, 2010; Mythri et al., 2011).  
 
 
The contact phase is initiated with contact between the mucoadhesive polymer and the 
mucus membrane. This phase is characterised by swelling (wetting theory) and spreading 
of the polymer over the mucosal layer. As a result, deep or intimate contact between the 
polymeric network and the mucosal layer is achieved. The following consolidation phase 
is characterised by the presence of moisture which plasticizes the system, allowing 
polymer chains to interpenetrate with the mucus layer (diffusion theory) resulting in the 
free mucoadhesive molecules forming weak Van der Waals and hydrogen bonds 
(adsorption and electronic theories), thus maintaining mucoadhesion (Hogerstrom, et. al., 
2003; Dodou et al., 2005; Khutoryanskiy, 2010; Mythri et al., 2011). 
 
3.1.2 Classification and properties of mucoadhesive polymers 
Mucoadhesives are generally classified using a variety of criteria, including charged state, 
source, binding ability or binding forces. The criteria employed in classifying 
mucoadhesives differs depending on the authors preferences, e.g. Grabovac and co-
workers (2005) prefer to classify mucoadhesives into four broad categories based on 
1. Contact phase 
i) Initial contact of the polymer 
with the mucus layer, followed 
by ii) swelling and wetting 
 
2. Consolidation phase 
Polymeric chain and mucus 
interpenetration, followed by 
bond formation 
 
i)  ii)  
Soluble mucins 
Bound mucins 
Epithelial cells 
Polymeric chains  
Figure 3.2: Schematic demonstration of the mucoadhesive process (divided into the 
contact and consolidation phases) (Adapted from Khutoryanskiy, 2010). 
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charge viz. anionic, cationic, non-ionic and thiolated polymers, while Helliwell and 
coworkers prefer to classify mucoadhesives into the specific and non-specific groups, 
based on their binding ability to various substrates (Helliwell et al., 1992; Grabovac et al., 
2005). The various classification criteria commonly employed by authors are illustrated in 
Table 3.1.  
 
For a polymer to exhibit sufficient mucoadhesive properties, it should contain strong 
hydrogen bonding groups, strong anionic or cationic charges, high molecular weight, 
chain flexibility, and surface energy properties favouring spreading on a mucosal layer 
while demonstrating suitable wetting and swelling of the polymer which favours 
mucoadhesion. Ideally, a mucoadhesive polymeric matrix should be biodegradable and 
rapidly adhere to the mucosal layer without any change in the physical characteristics of 
the DDS (with no impact on the bioactive release rate) while inhibiting enzymes present at 
the delivery site and enhancing the penetration of the active agent. Swelling and hydration 
permits mutual interpenetration and subsequent establishment of bonds and interactions 
between polymeric chains and mucin molecules. Generally, an increase in physical 
entanglement strengthens the network in the interfacial/contact area, improving 
mucoadhesion (Salamat-Miller et al., 2005; Sudhakar et al., 2006; Roy et al., 2009).  
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Table 3.1: Classification of various mucoadhesive polymers (Adapted from Salamat-Miller et al., 2005). 
Criteria Categories Comments Examples References 
Source Natural/ 
Semi-
Synthetic 
Majority of the natural polymers, or conventional 
mucoadhesives, typically display non-specific mucoadhesion, 
and relatively poorer mucoadhesive characteristics than their 
synthetic counterparts. 
Agarose, CHT, gelatin 
Hyaluronic acid 
Various gums: guar, sodium alginate, hakea, gellan, 
pectin, xanthan,  carrageenan  
Salamat-Miller 
et al., 2005 
Synthetic Mucoadhesive polymers undergo chemical modification to 
further improve their targeting, mucoadhesive characteristics, 
toxicity profiles and biocompatibility. 
Cellulosic derivatives: CMC, thiolated CMC, NaCMC, 
HEC, HPC, HPMC, MC etc. 
PAA-based polymers: PAA, polyacrylates, P(MVE-MAA), 
pHEMA, PAA-EHA, PMA, PACA, PHCA, PBCA, 
copolymers of acrylic acid and PEG 
Others: PHPMAm, PVA, PVP, polyoxyethylene, thiolated 
polymers 
Aqueous 
Solubility 
Hydrophilic Water-soluble polymers swell indefinitely in contact with 
water, eventually undergoing complete dissolution. 
Hydrogels, on the other hand are water swellable materials, 
usually a cross-linked polymer with limited swelling capacity. 
These hydrogels swell by absorbing water present in the 
mucus layer, hence interacting with the mucus by means of 
means of adhesion. 
Hydrophilic polymers: MC, HEC, HPMC, sodium CMC, 
carbomers, PAA and plant gums.  
Hydrogels: poly(acrylic acid-co-acrylamide) copolymers, 
carrageenan, sodium alginate, guar gum and modified 
guar gum. 
Chowdary and 
Srinivasa Rao, 
2004; Salamat-
Miller et al., 
2005; 
Sudhakar et 
al., 2006 
Hydrophobic Water-insoluble polymers provide greater flexibility in dosage 
form design in comparison water-soluble polymers. 
CHT (soluble in dilute aqueous acids), EC, PC 
Charge Cationic CHT is the most commonly employed cationic polymer due to 
its favourable biocompatibility, biodegradability and relatively 
lower toxicological properties. Furthermore, CHT has 
demonstrated permeation enhancing properties via the 
paracellular route through neutralisation of fixed anionic sites 
within the tight junctions between mucosal cells.  
Aminodextran, CHT, dimethylaminoethyl (DEAE)-dextran, 
trimethylated CHT, Selected synthetic polymethacrylates 
Grabovac et 
al., 2005; 
Salamat-Miller 
et al., 2005; 
Andrews et al., 
2009; 
Khutoryanskiy 
et al;., 2010; 
Harsulkar et 
al., 2011 
Anionic Anionic polymers display the greatest interaction with 
mucus/mucosal layers and are commonly utilised due to their 
low toxicity. These polymers typically present with carboxyl 
and sulphate functional groups which provide a net overall 
negative charge at pH values exceeding the pKa of the 
polymer. Mucoadhesion arises from the presence of the 
carboxylic groups forming hydrogen-bonds with the 
oligosaccharide chains of mucins. 
CHT-EDTA, CP, CMC, pectin, PAA, PC, sodium alginate, 
NaCMC, xanthan gum 
Amphoteric Mucoadhesive properties of polyampholytes (polymers 
simultaneously bearing cationic and anionic functional 
groups) have been explored only in few studies. Although 
boasting permeation enhancing properties, pH changes in the 
surrounding media cause structural and physicochemical 
Gelatin  
N-carboxymethylchitosan 
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transformations which are expected to affect the 
mucoadhesive and penetration enhancing `properties of 
polyampholyte-based formulations. 
Non-ionic Non-ionic polymers typically display poorer mucoadhesive 
tendencies than their charged counterparts.  Mucoadhesion 
typically arises through diffusion of their macromolecules and 
formation of an interpenetration layer with mucus gel 
(diffusion theory). 
Hydroxyethyl starch, HPC, PEO, PVA, PVP, scleroglucan 
Potential 
adhesive 
forces 
Covalent Polymers demonstrating mucoadhesive characteristics based 
on covalent bonding demonstrate significantly enhanced 
mucoadhesive characteristics than conventional 
mucoadhesives. Thiolated polymers are capable of forming 
covalent bonds (disulfide bridges) with cystein-rich sub-
domains of mucus glycoproteins either via thiol/disulfide 
exchange reactions or through a simple oxidation of free thiol 
groups. 
Cyanoacrylate, thiolated polymers, Polymers with acrylate 
end groups 
Dodou et al., 
2005; Salamat-
Miller et al., 
2005; Andrews 
et al., 2009; 
Khutoryanskiy 
et al;., 2010 
Hydrogen 
Bond 
These polymers generally contain functional which form 
hydrogen bonds with mucus. For sufficient hydrogen bonding 
to occur, flexibility of the polymer is vital, and can further 
improve mucoadhesion by providing further hydrogen 
bonding potential.  
Acrylates: hydroxylated methacrylate, p(MAA), CP, PC, 
PVA 
Electrostatic 
Interaction 
CHT has been reported to bind via ionic interactions between 
primary amino functional groups and the sialic acid and 
sulphonic acid substructures of mucus. The electrostatic 
attraction arises from the difference in electrostatic charge 
between CHT (cationic) and mucus (anionic).  
CHT 
Substrate 
binding 
ability 
Specific Mucoadhesion is generally achieved by means of specific, 
receptor mediated interactions between the mucosal cell 
surface and the mucoadhesive. Such polymers are able to 
produce mucoadhesive DDSs with highly specific and 
targeting capabilities, and hence reduced side effect profiles. 
Antibodies, lectins, fimbrial proteins, liposomes, many 
chemically modified or synthesized polymers, in particular, 
thiolated polymers 
Helliwell et al., 
1993; Andrews 
et al., 2009 
Non-specific Non-specific polymers are those that bind to mucin or mucus 
throughout the human body rather than at specific sites. The 
major disadvantage in using non-specific mucoadhesive 
polymers is that adhesion may occur at sites other than those 
intended, causing undesirable side effects. 
Traditional mucoadhesives such as alginates, cellulose 
derivatives, dextrans, gelatin, pectin, chitosan, poly(acrylic 
acids) and xanthan gum. 
CHT: Chitosan; CMC: Carboxymethyl cellulose; NaCMC: Sodium carboxy methylcellulose; HEC: Hydroxyethyl cellulose; HPC: Hydroxypropyl cellulose; HPMC: Hydroxypropyl methylcellulose; MC: 
Methylcellulose; PAA: Polyacrylic acid; P(MVE-MAA): poly(methylvinylether-co-methacrylic acid); pHEMA: poly(2-hydroxyethyl methacrylate); PAA-EHA: poly(acrylic acid-co-ethylhexylacrylate); 
PMA: poly(methacrylate); PACA: poly(alkylcyanoacrylate); PHCA: poly(isohexylcyanoacrylate), PBCA: poly(isobutylcyanoacrylate); PEG: Poly(ethylene glycol); PHPMAm: Poly(N-2-hydroxypropyl 
methacrylamide); PVA: Polyvinyl alcohol; PVP: Polyvinylpyrrolidone; PEO: poly(ethylene oxide); p(MAA): Poly(methacrylic acid). 
Table 3.1 continued 
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3.1.3 Factors affecting mucoadhesion 
There are several factors that influence one or more material properties of mucoadhesive 
polymers, causing either an improvement or a decrease in their mucoadhesive abilities. 
Structural characteristics, also known as intrinsic factors, such as the molecular weight, 
crosslinking extent, the presence of functional groups and the concentration of the 
mucoadhesive dispersion, are usually manipulated during the polymerization process to 
improve mucoadhesive characteristics.  External or environmental factors known to cause 
variations in mucoadhesive abilities include the surrounding pH, the temperature, the 
shear rate and the contact time with the mucosal membrane (Dodou et al., 2005). If the 
polymer is undergoes a change in its properties, in this case mucoadhesion, as a result of 
a change in environmental conditions, one can conclude that these polymers display 
stimuli-responsive tendencies.  
 
When considering the differences in pH along the GIT, it is of particular importance to 
determine the effects it would have on MDDSs delivered via the peroral route. According 
to Dodou and co-workers, pH affects the material properties of mucoadhesive polymers 
such as swelling, molecular bonding, spatial confirmation and rheological properties, 
ultimately affecting the mucoadhesive characteristics of the respective polymers and 
DDSs (Dodou et al., 2005). Thus, the mucoadhesion of various polymers varies as a 
function of pH, which is exploited by the present study to produce a targeted MMDDS, 
aimed at improving poor oral bioavailability. 
 
3.1.4 Preliminary formulation design  
The rational identification of a candidate system for further optimisation was the primordial 
focus the current chapter. The ensuing experimental investigations were conducted to 
provide a logical comparison of the mucoadhesive properties of the various formulations 
developed, and determine their potential in designing a targeted drug delivery system.  
 
Preliminary formulation studies involved, initially selecting and evaluating various 
mucoadhesive polymers for their pH-responsive, mucoadhesive and film-forming 
properties. Further modification and inclusion of excipients/other polymers was then 
undertaken to develop a candidate system. The identification of variables with upper and 
lower limits was paramount for further optimisation of the of both the gastric-responsive 
and intestinal-responsive mucoadhesive layers of the MMDDS.      
 
 
56 
 
3.2 Materials and Methods 
 
3.2.1 Materials 
Biocompatible and mucoadhesive polymers investigated included poly(acrylic acid) (PAA) 
(Mw: 1800g/mol) and chitosan (CHT) (medium molecular weight) obtained from Sigma 
Aldrich (Pty) Ltd (St Louis, MO, USA), Pectin Classic CU 701 (PEC) (Herbstreith & Fox 
KG, Neuenbürg/Württ, Germany), hydroxypropyl cellulose (HPC) (Merck-Schuchardt®, 
Hohenbrunn, Germany) and polyvinylpyrrolidone-40 (PVP-40; Mw: 40000g/mol) (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany). Poly(vinyl alcohol) (PVA) (Avg Mw=146000-
186000g/mol; 98-99% hydrolyzed) was purchased from Sigma Aldrich (Pty) Ltd 
(Milwaukee, WI, USA).  
 
Glycerol purchased from Associated Chemical Enterprises (Pty) Ltd. (Southdale, South 
Africa) was employed as a plasticizer, while an antifoaming agent, silicone, (BDH, VWR 
International Ltd, London, UK) was employed to prevent entrapment of air bubbles within 
the membranes. Solvent acetic acid was obtained from Sigma Aldrich Chemie GmbH 
(Steinheim, Germany). All other reagents employed were of analytical grade and used 
without further purification. De-ionized water was obtained from a Milli-Q water purification 
system (Milli-Q, Millipore, Billerica, MA, USA). Simulated gastric and intestinal 
membranes employed were dialysis flat sheet membranes (Mw=12,000-14,000g/mol) 
purchased from Spectrum Laboratories Inc. (Rancho Dominguez, CA, USA). Phosphate 
buffered saline (PBS) was prepared using sodium hydroxide (NaOH, Mw=40.00g/mol) and 
sodium chloride (NaCl, Mw=58.44g/mol) obtained from Saarchem (Wadeville, Gauteng, 
South Africa), hydrochloric acid (HCl, 32%w/v) purchased from Rochelle Chemicals 
(Johannesburg, South Africa) and potassium dihydrogen phosphate (KH2PO4, 
Mw=136.09g/mol) obtained from Riedel-de Haen (Sigma-Aldrich Laborchemikalein GmbH, 
Germany) in double-deionised water (Milli-Q System, Millipore, Bedford MA, USA). 
Paraffin liquid, employed as a lubricant to facilitate membrane removal from moulds was 
obtained from Saarchem (Wadeville, Gauteng, South Africa). 
 
3.2.2 Formulation and evaluation of various mucoadhesive polymers for their 
pH-responsive properties 
Polymers selected for the pH-responsive, mucoadhesive layer (Figure 3.3) were 
representative of the various classes of mucoadhesive polymers (Table 3.1). The 
mucoadhesive layer was fabricated using the film casting technique of membrane 
fabrication. Film-casting was selected as membranes formed via this technique are 
relatively more elastic and the technique avoids the use of toxic solvents and costly 
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equipment as compared to other methods of membrane fabrication. Furthermore, the 
method is relatively cost-effective, versatile with application in a wide range of polymers, 
demonstrating potential in scale-up procedures, which may ultimately facilitate bulk-
manufacturing and marketing measures. 
 
 
Figure 3.3: Mucoadhesive polymers, their respective concentrations and solvents 
employed in the preliminary design of the pH-responsive mucoadhesive layer. 
 
Briefly, the film-casting method included solubilising the polymers in their respective 
concentrations and solvents followed by addition of glycerol as a plasticizer (2:1 of 
polymer: plasticizer) and the antifoaming agent, silicone (1 drop per 100mL). 40mL 
aliquots of the clear, homogenous polymeric solution were then film-cast into moulds 
(dimensions: of 120x120mm) and subject to ambient conditions for 24 hours. Phase 
separation, occurring as the solvent (water) evaporates, resulted in the formation of a thin, 
transparent and uniform polymeric membrane. To facilitate the removal of membranes 
upon drying, moulds were lubricated with liquid paraffin prior to film-casting to prevent any 
physical alteration incurred on the membrane during the removal process. Membranes 
were then cut into 18x30mm dimensions and stored with desiccants in airtight containers 
until further testing was completed. The size range selected for the mucoadhesive layer 
was based on the dimensions of a typical capsule since the MMDDS would be 
incorporated into a capsule to ease oral administration.  
 
3.2.3 The effect of employing a combination of mucoadhesive polymers in the 
development of the pH-responsive mucoadhesive layer 
Following the identification of the polymers demonstrating the highest potential in the 
development of the pH-responsive mucoadhesive layers, studies were undertaken to 
elucidate the effect of adding a hydrophilic, mucoadhesive polymer for further improving 
pH-responsive mucoadhesion, while their effects on the pH-responsive nature of the 
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formulations investigated were carefully monitored. Polymers were dissolved in their 
respective concentrations and solvents illustrated in Figure 3.3 and combined in 
accordance with the ratios depicted in Table 3.2, followed by the film-casting method 
described in Chapter 3, Section 3.2.2.  
 
Table 3.2: Experimental formulations evaluated for the identification of the optimal 
combination of mucoadhesive polymers for application in the respective pH-responsive 
mucoadhesive layers. 
Formulation No Concentration of 
Polymer 1 (%
w
/v) 
Concentration of 
Polymer 2 (%
w
/v) 
Ratio* 
Gastric-targeted 
component 
1 
 
CHT 
 
PAA 
 
CHT:PAA 
GT1 1.60 1.60 1:1 
GT2 1.33 2.66 1:2 
GT3 1.00 4.00 1:4 
GT4 0.66 5.34 1:8 
GT5 0.40 6.40 1:16 
 CHT HPC CHT: HPC 
GT6 1.60 1.60 1:1 
GT7 1.33 2.66 1:2 
GT8 1.00 4.00 1:4 
GT9 0.66 5.34 1:8 
GT10 0.40 6.40 1:16 
Intestinal-targeted 
component 
2 
 
PEC 
 
PAA 
 
PEC: PAA 
IT1 2.67 2.67 1:1 
IT2 2.00 4.00 1:2 
IT3 1.33 5.34 1:4 
IT4 0.80 6.40 1:8 
IT5 0.45 7.20 1:16 
 PEC HPC PEC: HPC 
IT6 2.67 2.67 1:1 
IT7 2.00 4.00 1:2 
IT8 1.33 5.34 1:4 
IT9 0.80 6.40 1:8 
IT10 0.45 7.20 1:16 
* The ratios selected were based on the ability to combine the highest polymer concentrations 
without producing a polymeric solution too viscous to film-cast.  
1
 Results obtained from preliminary mucoadhesive evaluation studies indicated that CHT 
demonstrated the highest potential in gastric targeting. 
2
 results obtained from preliminary mucoadhesive evaluation studies indicated that PEC 
demonstrated the highest potential in intestinal targeting. 
 
3.2.4 The influence of PVA addition to develop a durable mucoadhesive layer 
able to withstand the conditions of the GIT 
Following the identification of the most effective polymer combinations for the gastric- and 
intestinal-targeted components demonstrating the most promising mucoadhesive 
properties, studies were undertaken to elucidate the influence of the incorporation of 
various quantities of PVA on the mucoadhesive properties of the experimental 
formulations. PVA was incorporated to ensure the mucoadhesive layer is able to 
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withstand the conditions of the GIT without premature erosion. The incorporation of PVA 
was essentially performed by dissolving PVA in differing concentrations, combining the 
polymers in their various ratios depicted in Table 3.3, followed by film-casting according to 
the method depicted in Chapter 3, Section 3.2.2.   
 
Table 3.3: Experimental formulations evaluated for the optimal PVA quantity required to 
impart enduring mucoadhesive properties. 
Experimental 
Formulation 
Concentration of 
pH-responsive 
polymer (%
w
/v) 
Concentration of 
mucoadhesive 
polymer (%
w
/v) 
Concentration 
of poly(vinyl 
alcohol) (%
w
/v) 
Ratio* 
Gastric-targeted 
component 
 
CHT 
 
PAA 
 
PVA 
 
CHT:PAA:PVA 
GT11 1 8 4.68 1:8:4.68 
GT12 1.5 4 3.2 1:2.67:2.1 
GT13 2 4 2.3 1:2:1.15 
Intestinal-targeted 
component 
 
PEC 
 
PAA 
 
PVA 
 
CHT:PAA:PVA 
IT11 1.3 8 4.68 1:6.15:3.6 
IT12 2 4 3.2 1:2:1.6 
IT13 2.6 4 2.3 1:1.5:0.88 
* The ratios selected were based on the ability to combine the highest polymer concentrations 
without producing a polymeric solution too viscous to film-cast.  
 
3.2.5 The influence of PAA substitution with PVP for the further improvement of 
mucoadhesive properties over a prolonged period of time 
Following the incorporation of PVA in experimental formulations, the influence of 
poly(vinyl pyrrollidone) (PVP), a non-ionic mucoadhesive polymer as a substitute for PAA 
was investigated. Substitution with PVP was attempted to ensure that the membranes 
were viable for longer durations within the GIT, while imparting pH-responsive 
mucoadhesive properties. The incorporation of PVP was essentially performed by 
dissolving PVP in differing concentrations, combining the polymers in their various ratios 
(Table 3.4), followed by film-casting according to the method depicted in Section 3.2.2.   
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Table 3.4: Experimental formulations investigating the effects of substitution with PVP on 
mucoadhesive characteristics. 
Experimental 
Formulation 
Concentration of 
pH-responsive 
polymer (%
w
/v) 
Concentration of 
mucoadhesive 
polymer (%
w
/v) 
Concentration 
of PVA (%
w
/v) 
Ratio* 
Gastric-targeted 
component 
 
CHT 
 
PVP 
 
PVA 
 
CHT:PAA:PVA 
GT14 1 8 4.68 1:8:4.68 
GT15 1.5 4 3.2 1:2.67:2.1 
GT16 2 4 2.3 1:2:1.15 
Intestinal-targeted 
component 
 
PEC 
 
PVP 
 
PVA 
 
CHT:PAA:PVA 
IT14 1.3 8 4.68 1:6.15:3.6 
IT15 2 4 3.2 1:2:1.6 
IT16 2.6 4 2.3 1:1.5:0.88 
* The ratios selected were based on the ability to combine the highest polymer concentrations 
without producing a polymeric solution too viscous to film-cast.  
 
3.2.6 Determining the upper and lower variables of the formulation required for 
input into the Central Composite Design 
Following the identification of the most appropriate polymer combinations to be employed 
in the respective pH-responsive DDS, upper and lower limits of the formulation variables 
where determined for input into the Central Composite Design. Determination of the 
variables involved combining the polymers in various ratios and film-casting as detailed in 
Chapter 3, Section 3.2.2 and thereafter assessing whether the formulations fulfilled the 
following criteria:  
 
- demonstrated good film-forming properties 
- demonstrated promising mucoadhesive properties 
- maintained pH-responsive mucoadhesion 
- did not prematurely disintegrate/erode when subject to prolonged exposure to 
simulated GIT conditions.  
 
3.2.7 Determination of mucoadhesive properties through textural analysis   
In order to evaluate the mucoadhesive properties of the mucoadhesive layer, the Work of 
Adhesion (WA) and the Maximum Detachment Force (MDF) required to detach a 
hydrated mucoadhesive layer from a portion of Simulated Gastric Membrane (SGM) was 
determined, using Texture Analyser TA.XTplus (Stable Microsystems, England), 
employing the test parameters depicted in Table 3.5. Portions of SGMs were secured to a 
flat-tipped probe (diameter: 15mm), while a hydrated section of the mucoadhesive layer 
was secured to the stand as illustrated in Figure 3.4. Polymeric SGMs were pre-
impregnated with PBS; pH 1.2±0.1 or pH 6.8±0.1 prior to mucoadhesive testing; 
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simulating the gastric or intestinal regions respectively. The probe was lowered to make 
contact with the SGM mount inducing a test force, and thereafter raised, while 
simultaneously measuring the MDF. Data was captured at a rate of 200pps via the 
Texture Expert Software v3.2, producing a force: distance curve.  
 
Table 3.5: Textural analysis settings for mucoadhesive test sequence. 
Mucoadhesive test parameter Mucoadhesive test settings 
Pre-test speed 0.5mm/sec 
Test speed 0.5mm/sec 
Post-test speed 10mm/sec 
Applied force 5N 
Contact time  10 seconds 
Trigger force 0.05N 
 
 
Figure 3.4: Schematic illustration of the textural analysis method employed to generate 
force: distance profiles for mucoadhesive analysis, where a) is lowering of the probe onto 
the mucoadhesive layer, and b) is the contact between the SGM and mucoadhesive layer.  
 
The WA (mJ) was determined from the Area Under the Curve of the force: distance curve 
(AUCFD) and the MDF (N) required to detach the polymeric layer from the SGM was 
determined by measuring the maximum peak force from the resultant force: distance 
curve. The Work of Adhesion per unit area (WA αβδ), was characterized by the work 
executed on the matrices when the two contact phases i.e. the SGM (α) and the 
mucoadhesive layer (β), formed an interface of unit area which were subsequently 
separated reversibly to form unit areas of each of the αδ- and βδ- interfaces. This 
relationship is mathematically described by Equation 3.1. 
 
 WA  
Equation 3.1 
                      
where, γαβ, γαδ and γβδ are the surface tensions between the two bulk phases 
comprising the SGM and the mucoadhesive layer, α, β; α, δ and β, δ respectively.  
TA Probe  
(Diameter: 15mm) 
Mucoadhesive 
layer 
SGM 
a) b) 
 
Contact between 
mucoadhesive 
layer and SGM 
TA stand 
62 
 
The tensile related mucoadhesive test described is able to reproduce in vivo-occurring 
processes to some extent. This form of tensile testing provides information on the relative 
mucoadhesiveness of dosage forms and thus allows classifying mucoadhesive properties 
based on their performance. It is now recognised that detachment between the dosage 
form and substrate is a complex physical process, depending on both the deformation 
and mechanical properties of both the dosage form and the substrate (characterised by 
the WA), as well as the adhesiveness (characterised by the MDF) (Khutoryanskiy, 2010). 
Although many studies report the use of biological substrates in mucoadhesive analysis 
(Park and Robinson, 1987; Rathi et al., 1991), the results obtained from these studies are 
often characterized by relatively poor reproducibility due to variable properties of 
biological substrates. It is thus important to make use of an alternative testing method, 
which does not involve biological substrates in assessment of mucoadhesives (Merkle et 
al., 1990; Khutoryanskiy, 2010) and thus several studies have reported the use of dialysis 
flat sheet membranes in mucoadhesive analysis as a surrogate environment simulating in 
vivo conditions. This prompted the use of dialysis flat sheet membranes as a substrate in 
the present study as a simulated gastric or intestinal membrane (Lele and Hoffman, 2000; 
Ndesendo et al., 2009; Murphy et al., 2011). 
 
3.2.8 Evaluation of variations in mucoadhesive properties as a function of time 
In order to determine the effects of the GIT on the mucoadhesive characteristics, the 
mucoadhesive layers were subject to conditions typical of in vitro drug release studies in a 
six station USP Dissolution Apparatus (Erweka DT 700 GmbH Germany). The USP 25 
rotating paddle method of dissolution was selected where the mucoadhesive layers were 
exposed to 900mL of PBS (pH 1.2±0.1 or pH 6.8±0.1) for 12 hours at 37±0.5°C at 
50rpms. At two hour intervals (0, 2, 4, 6, 8, 10, 12), the layers were removed from the 
dissolution media and subject to mucoadhesive analysis as described in Chapter 3, 
Section 3.2.7. Fresh samples were used for each individual time point. 
 
3.3 Results and Discussion 
 
3.3.1 Most appropriate mucoadhesive polymer demonstrating pH-responsive 
properties for the respective mucoadhesive layers 
Film-casting produced membranes that were clear, flexible and uniform throughout its 
structure for PEC, HPC and CHT membranes. Solutions of PAA and PVP, when film-cast, 
did not produce membranes or films, but rather a semi-solid hydrogel type structure upon 
which further mucoadhesive analysis could not be undertaken, and therefore results for 
these polymers are not represented. Figure 3.5 illustrates a typical force: distance curve 
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obtained through mucoadhesive textural analysis. The MDF (N) (highlighted in green) and 
the WA (mJ) (highlighted in red) are related to mucoadhesive properties, where the higher 
the WA and MDF, the stronger the mucoadhesive properties. 
 
 
Figure 3.5: Typical textural profiles elucidating the MDF (N) and WA (AUCFD) (mJ). 
 
pH-responsive mucoadhesion was achieved from the CHT and PEC membranes in acidic 
and more alkaline pH ranges respectively (Figure 3.6a-b). Although mucoadhesion in 
HPC membranes were not poor, they were relatively consistent with variations in pH 
(Figure 3.6a-b), and hence HPC membranes were unable to demonstrate pH-responsive 
mucoadhesion. It is speculated that mucoadhesive properties of non-ionic polymers 
(Table 3.1) arises from the diffusion theory, where polymeric chains interpenetrate within 
the mucin layer, promoting adhesion, which based on the results elaborated below, does 
not seem to be drastically affected by changes in the surrounding pH range. As the 
proposed DDS requires pH-responsive mucoadhesion to ensure site-specific drug 
delivery, it was concluded that HPC demonstrated little, if not, no potential as a candidate 
polymer, and no further studies were conducted employing HPC as the primary polymer 
in the development of the mucoadhesive layer.  
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Figure 3.6: A comparison of a) the Maximum Detachment Force (MDF) (N) and b) Work 
of Adhesion (AUCFD) (mJ) of the preliminary mucoadhesive layers in acidic and alkaline 
pH ranges (n=3; SD < 0.028 in all cases). 
 
Mucoadhesive analysis revealed that CHT displayed higher mucoadhesion in acidic pH 
ranges (MDF=0.61975±0.00415N; AUCFD=0.899±0.001mJ) as compared to alkaline pH 
ranges (MDF=0.1744±0.0224N; AUCFD= 0.0685±0.0035mJ) (Figure 3.6a-b). The pH-
responsive nature of CHT can be related to its state of ionisation in the respective pH 
range. Since CHT (pKa=6.3) is cationic in nature, mucoadhesion typically arises from an 
electrostatic interaction between the CHT and negatively charged mucin (Sogias et al., 
2008). Furthermore, a sufficient quantity of water is necessary to allow proper hydration 
and expansion (swelling) of the mucoadhesive network, which occurs only in low pH 
ranges, to expose available adhesive sites (promoting bond formation) and facilitate 
polymer chain relaxation (promoting chain interpenetration) (Leung and Robinson, 1990). 
The drastic change in the mucoadhesive properties of CHT occurring during variations in 
the pH of the surrounding medium is related to its ionisation state as is illustrated in 
Figure 3.7.  
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As illustrated in Figure 3.6, PEC displayed superior mucoadhesive properties in alkaline 
pH ranges (MDF= 0.70885±0.10145N; AUCFD= 1.0125± 0.0265mJ) as compared to acidic 
pH ranges (MDF=0.3081±0.0598N; AUCFD=0.218±0.035mJ), the difference of which, 
once again, can be attributed to the change in ionisation state occurring as a function of 
pH. The mucoadhesive properties of PEC (pKa of 3-4), an anionic polysaccharide, arises 
from the presence of carboxylic functional groups which interact with the oligosaccharide 
chains of mucin via hydrogen bonds (Table 3.1). Typically, in alkaline pH ranges, the 
carboxylic group of PEC is ionised, improving both mucoadhesion (through bond 
formation) and hydration (promoting interpenetration between PEC and mucin chains) 
(Peppas and Sahlin, 1996; Sriamornsak et al., 2007; Hodges et al., 2009). However, in 
acidic pH ranges, illustrated in Figure 3.8, PEC is rapidly converted from its anionic nature 
to unionised forms, lowering the mucoadhesive characteristics through both a reduction in 
hydration and the presence of functional groups required for hydrogen bonding 
(Sriamornsak et al., 2007).  
 
+ 
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Acidic pH ranges = water soluble Alkaline pH ranges = water insoluble 
Cationic nature of CHT in low pH 
ranges provides functional groups 
(NH3
+
) which facilitate mucoadhesion 
through electrostatic interaction.  
Mucoadhesion is further improved 
due to high CHT solubility, providing 
sufficient polymer and mucin chain 
interpenetration.   
 
Cationic nature is no longer present 
in higher pH ranges, preventing 
electrostatic interaction, and hence 
abating mucoadhesion. 
Mucoadhesion is further decreased 
due to low CHT solubility, preventing 
sufficient polymer and mucin chain 
interpenetration.   
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Figure 3.7: Variations in the ionisation state of the CHT molecules as a function of 
changes in the pH range (Adapted from Luo et al., 2010). 
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3.3.2 Identification of the most effective polymer combination in the respective 
pH-responsive mucoadhesive layers 
The addition of hydrophilic polymers had vastly different effects on the mucoadhesive 
properties of the experimental formulations, depending on the polymer employed. 
Formulations GR5, IR5 and IR10; comprising of extremely high concentrations of the 
hydrophilic polymer relative to the pH-responsive polymer resulted in the formation of 
membranes that were extremely sticky and difficult to handle, thus averting mucoadhesive 
analysis. Typically, the addition of HPC to CHT- and PEC-based formulations caused 
surprisingly poorer mucoadhesive characteristics (Figure 3.9).  
 
The resultant decrease in mucoadhesive properties of CHT-based formulations can be 
attributed to the formation of hydrogen bonds between the functional groups (amino and 
amide groups) of CHT and HPC. Since the cationic nature of CHT is lost, there are fewer 
electrostatic interactions occurring between the polymer chains and mucin, causing an 
overall decrease in mucoadhesion (Pawlak and Mucha, 2003). It was speculated by 
Satoh and co-workers that combining HPC with anionic polymers, results in the formation 
of a complex between the carboxylic groups of the anionic polymer with HPC molecules. 
As such, the carboxylic groups of the anionic polymer (e.g. PEC) are no longer able to 
form hydrogen bonds with the mucin molecules, causing the resultant reduction in 
mucoadhesion (Satoh et al., 1989).  
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Figure 3.8: Variations in the ionisation state of the PEC molecules as a function of 
changes in the pH range. 
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PAA and its derivatives are known to possess exceptional mucoadhesive properties (Lehr 
et al., 1992; Helliwell, 1993) and hence it is no surprise that the addition of PAA caused a 
drastic increase in the mucoadhesive properties of the both the CHT- and PEC-based 
formulations (for the gastric- and intestinal-targeted components respectively) (Figure 
3.9a-b). Although an increasing trend in mucoadhesion was observed with an increase in 
the PAA ratio, a gradual decline in the pH-responsive nature of CHT-based formulations 
was observed. Granted, higher mucoadhesion would result in the formulation of a DDS 
with superior properties, however, the cost of losing its site-specifity would be detrimental 
for the proposed MMDDS (i.e. it would be unable to segregate drugs).  
 
A similar trend was observed in PEC-based formulations (Figure 3.9c-d), where the pH-
responsive nature of the experimental formulations investigated was lost with an increase 
in the PAA ratio. PAA typically demonstrates highest mucoadhesion in more neutral pH 
ranges, where the carboxyl groups are ionised (COO-), thus facilitating electrostatic 
interactions. However, at low pH ranges, mucoadhesion is promoted by H-bond formation 
between the unionised carboxyl groups (COOH) of PAA and mucus (Helliwell, 1993). 
Therefore, PAA displays superior mucoadhesion in both pH ranges investigated, 
accounting for the loss in the pH-responsive nature of the experimental formulations 
analysed. As such, it was imperative to obtain a balance between both the pH-responsive 
and mucoadhesive polymers that would provide optimum mucoadhesion without 
compromising site-specific drug delivery of both components. 
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Figure 3.9: A comparison of a) the Maximum Detachment Force (MDF) (N) and b) Work 
of Adhesion (AUCFD) (mJ) of the experimental CHT-based formulations; and c) the 
Maximum Detachment Force (MDF) (N) and d) Work of Adhesion (AUCFD) (mJ) of the 
experimental PEC-based formulations (n=3; SD < 0.037 in all cases). 
 
3.3.3 Effect of PVA incorporation in the respective pH-responsive mucoadhesive 
layers  
When attempting to evaluate the variations of the mucoadhesive characteristics as a 
function of time, it was revealed that experimental Formulations GT1-10 and IT1-10 were 
unable to withstand the conditions of in vitro dissolution testing (all formulations dissolved 
or disintegrated within the first two hours of analysis). PVA was thus incorporated into the 
experimental formulations to retard premature disintegration of the respective pH-
responsive layers within the GIT. As illustrated in Figure 3.10a-d, although the addition of 
the PVA in the experimental formulations had little effect on the pH-responsive nature of 
the formulations, a decrease in both the MDF and AUCFD was observed.  
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Figure 3.10: A comparison of the effect of PVA incorporation on a) the Maximum 
Detachment Force (MDF) (N) and b) Work of Adhesion (AUCFD) (mJ) of the experimental 
CHT-based formulations; and c) the Maximum Detachment Force (MDF) (N) and d) Work 
of Adhesion (AUCFD) (mJ) of the experimental PEC-based formulations (n=3; SD < 0.075 
in all cases). 
 
The interaction of functional groups between PAA and PVA may be accountable for the 
decline in mucoadhesive properties. It was postulated by Daniliuc and coworkers that 
when in solution, PVA and PAA tend to form inter- and intra-molecular hydrogen bonds, 
resulting in poorer solubility characteristics (Daniliuc et al., 1992; Daniliuc and David, 
1996). Theoretically, any interaction which decreases solubility would decrease 
mucoadhesive properties by retarding swelling and ultimately hindering chain 
interpenetration between the DDS and mucus. Furthermore, it is theoretically possible 
that the hydrogen bonding between the polymer molecules further impedes 
mucoadhesion as the polymers no longer contain free functional groups able to form 
hydrogen bonds with mucus molecules. CHT-based formulations displayed a notably 
larger drop in mucoadhesive characteristics than PEC-based formulations. This may be 
attributed to the cationic nature of CHT forming electrostatic interactions with anionic 
PAA, decreasing the solubility and sites available for adhesion, and hence mucoadhesive 
characteristics of the formulations.  
 
PVA incorporation did, however, provide the qualities necessary to ensure that the CHT-
based experimental formulations, specifically Formulations GR12 and GR13, would 
withstand the conditions of the GIT (Table 3.6). Granted the formulations containing PVA 
still displayed mucoadhesive characteristics, they were remarkably lower than that of the 
formulations without PVA due to the PVA/PAA interaction. PEC-based formulations, 
however, were unable to withstand the conditions of the GIT. In all cases, the PEC-based 
c) d) 
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mucoadhesive layers eroded within two hours of the study, regardless of PVA quantity 
(Table 3.6). The variations in the durability of PEC- and CHT-based formulations can be 
attributed to the electrostatic interaction taking place between CHT and PAA, which 
further decreases solubility as opposed to the electrostatic repulsion between anionic 
PEC and anionic PAA, which increases the rate of dissolution of the polymer structure. 
Typically, formulations containing higher concentrations of PAA did not last longer than 2-
4 hours when exposed to simulated GIT conditions. 
 
Table 3.6: Periods of which the experimental formulations were able to withstand the GIT 
conditions. 
Experimental Formulation Ratio Time (hours)* 
Gastric-targeted component CHT:PAA:PVA pH 1.2 pH 6.8 
GT1-GT10 Varying 2-4 >10 
GT11 1:8:4.68 2-4 >10 
GT12 1:2.67:2.1 >10 >10 
GT13 1:2:1.15 >10 >10 
Intestinal-targeted component CHT:PAA:PVA pH 1.2 pH 6.8 
IT1-IT10 Varying >10 <2 
IT11 1:6.15:3.6 >10 <2 
IT12 1:2:1.6 >10 <2 
IT13 1:1.5:0.88 >10 <2 
* Duration the experimental formulation was able to withstand the conditions of the GIT without 
showing any visible signs of erosion or disintegration and were able to undergo mucoadhesive 
analysis. 
 
Despite the initial mucoadhesive characteristics (at t=0 hours) of PVA incorporated 
membranes being relatively low, the subsequent increase in swelling over time promoted 
mucoadhesion via polymer chain interpenetration (diffusion theory) and the resultant 
expansion in the polymeric network exposed additional adhesive sites which were initially 
unable to interact with mucus. Figure 3.11a-b illustrates the variations in the 
mucoadhesive properties which was typical for both GT12 and GT13. The initial rise in 
mucoadhesion can be attributed to the increase in swelling, thereby promoting 
mucoadhesion, followed by a more consistent level of mucoadhesive characteristics. The 
eventual decrease in the mucoadhesive characteristics can possibly be attributed to the 
slow erosion or dissolution of the mucoadhesive polymer out of the mucoadhesive layer. It 
is important to note, however, that the pH-responsive characteristics are maintained 
throughout the duration of the study. 
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Figure 3.11: Variations in a) the Maximum Detachment Force (MDF) (N), and b) Work of 
Adhesion (AUCFD) (mJ) (mJ) of experimental Formulation GT12 as a function of time 
(n=3; SD < 0.034 in all cases). 
 
3.3.4 Effect of PAA substitution with PVP in the pH-responsive mucoadhesive 
layer 
Although the incorporation of PVA produced mucoadhesive membranes that were able to 
withstand simulated GIT conditions for some CHT-based formulations, PEC-based 
formulations containing PAA did not last for periods greater than 2 hours due to the 
possibility of the electrostatic repulsion increasing the dissolution rate. Therefore, in order 
to ensure the mucoadhesive membranes would remain viable for longer periods within the 
GIT, the effects of PAA substitution with a non-ionic polymer, PVP was determined. 
Substitution with PVP was conducted to prevent any electrostatic-related interactions from 
affecting either the mucoadhesive characteristics or the durability of the membranes from 
being detrimentally affected. As illustrated in Figure 3.12a-b substitution of PVA with PVP 
improved both the AUCFD and the MDF of the CHT-based formulations while maintaining 
the pH-responsive nature.   
a) b) 
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Figure 3.12: A comparison of the effect of PAA substitution with PVP on a) the Maximum 
Detachment Force (MDF) (N) and b) Work of Adhesion (AUCFD) (mJ) of the experimental 
CHT-based formulations; and c) the Maximum Detachment Force (MDF) (N) and d) Work 
of Adhesion (AUCFD) (mJ) of the experimental PEC-based formulations (n=3; SD < 0.023 
in all cases).  
 
Although the mucoadhesive characteristics of PEC-based formulations dropped with PVP 
substitution (Figure 3.12c-d), these membranes were more likely to remain viable for 
prolonged periods of exposure to the GIT (Figure 3.13c-d). Furthermore, the 
mucoadhesive characteristics of all experimental formulations containing PVP improved 
as the formulations swelled, causing expansion of the polymeric network thus promoting 
mucoadhesion through polymer chain interpenetration and exposure of additional 
adhesive sites within the network (Figure 3.13a-d).  
 
a) b) 
c) d) 
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The eventual decline in mucoadhesion can be attributed to the slow dissolving of the 
mucoadhesive polymer, PVP. Experimental formulations containing PVP successfully met 
the criteria of good film-forming properties, while remaining viable during prolonged 
periods of exposure to simulated GIT conditions and maintaining pH-responsive 
mucoadhesion. Overall, substitution with PVP led to the identification of the most 
appropriate combination of polymers required to develop a candidate system for further 
development and optimisation (of both the gastric-targeted and intestinal-targeted 
components of the MMDDS). 
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Figure 3.13: Variations in a) the MDF (N), and b) the AUCFD (mJ) of experimental 
Formulation GT15 and c) the MDF (N), and d) the AUCFD (mJ) of experimental 
Formulation IT15 as a function of time (n=3; SD < 0.088 in all cases). 
 
a) b) 
c) d) 
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3.3.5 Determining the upper and lower limits of the formulation variables 
required for input into the Central Composite Design 
Following the identification of the polymer combinations for the gastric- and intestinal-
targeted components respectively, the upper and lower limit variables of the formulation 
was determined. The resultant variables are illustrated in Table 3.7. The limits were 
determined by ensuring the membranes formed met the criteria identified in Section 3.2.6, 
Chapter 3. For optimization purposes, further elaborated in Chapter 4, the ratio of PVP to 
CHT was kept constant at a ratio of 1:4, while for PEC-based formulations; the ratio was 
maintained at 1:3. Any further increase in the ratio was detrimental to the pH-responsive 
nature and any decrease in the ratio demonstrated relatively poorer characteristics.  
 
Table 3.7: The identified variables and their corresponding upper and lower limits for 
input into the Central Composite Design. 
Polymer Lower Limit (%w/v) Upper Limit (%
w/v) 
 Gastric-targeted component  
CHT  1%w/v 
 Anything <1%w/v did not demonstrate a 
satisfactory pH-responsive nature. 
Furthermore, these formulations tended to 
erode prematurely and were thus not viable 
for a sufficient period. 
 2%w/v 
 Formulations containing >2%w/v resulted in 
solutions that were too viscous to film-cast 
properly, and membranes formed were not 
uniform and consistent in structure. 
PVP  4%w/v 
 Formulations containing less than <4%w/v 
demonstrated relatively poorer  
mucoadhesive properties. 
 8%w/v 
 Formulations containing >8%w/v did not form 
viable membranes (the structure was too 
sticky to handle). Furthermore, the pH-
responsive nature was being lost as PVP 
concentration increased. 
PVA  2%w/v 
 Formulations containing less than <2%w/v 
eroded or disintegrated prematurely, and 
were thus not viable for a sufficient period. 
 4.75%w/v 
 Formulations containing >4.75%w/v resulted in 
solutions that were too viscous to film-cast 
properly, and membranes formed were not 
uniform and consistent in structure. 
Furthermore, poor mucoadhesion was 
demonstrated by these formulations. 
 Ratio between CHT and PVP was kept constant at 1:4. If the ratio increased, detrimental effects to 
the pH-responsive nature of the formulation were observed.   
 Intestinal-responsive component  
PEC  1.3%w/v 
 Anything <1.3%w/v did not demonstrate a 
satisfactory pH-responsive nature. 
Furthermore, these formulations tended to 
erode prematurely and were thus not viable 
for a sufficient period. 
 2.7%w/v 
 Formulations containing >2.7%w/v resulted in 
solutions that were too viscous to film-cast 
properly, and membranes formed were not 
uniform and consistent in structure. 
PVP  3.9%w/v 
 Formulations containing less than <3.9%w/v 
demonstrated relatively poorer 
mucoadhesive properties. 
 8.1%w/v 
 Formulations containing >8.1%w/v did not form 
viable membranes (the structure was too 
sticky to handle). Furthermore, the pH-
responsive nature was being lost as PVP 
concentration increased. 
PVA  2%w/v 
 Formulations containing less than <2%w/v 
eroded or disintegrated prematurely, and 
were thus not viable for a sufficient period. 
 4.75%w/v 
 Formulations containing >4.75%w/v resulted in 
solutions that were too viscous to film-cast 
properly, and membranes formed were not 
uniform and consistent in structure. 
Furthermore, poor mucoadhesion was 
demonstrated by these formulations. 
 Ratio between PEC and PVP was kept constant at 1:3. If the ratio increased, detrimental effects to 
the pH-responsive nature of the formulation were observed. 
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3.4 Concluding Remarks 
 
Preliminary studies led to the rational identification of the formulation variables most 
suited for the development and further optimization of the gastric- and intestinal-targeted 
mucoadhesive systems respectively. Due to their pH-responsive nature, CHT (1-2%w/v) 
and PEC (1.3-2.7%w/v) were identified as the primary polymers necessary for the 
development of the gastric- and intestinal-targeted systems respectively. Screening of 
various mucoadhesive polymers led to the selection of PVP (4-8%w/v and 3.9-8.1%
w/v for 
the gastric- and intestinal-targeted components respectively) as the most ideal polymer 
able to further improve the mucoadhesive characteristics of the respective mucoadhesive 
layers without impacting the pH-responsive nature of the formulations. The ratio between 
the pH-responsive polymer and PVP was found to be optimal if kept at 1:4 and 1:3 for the 
gastric- and intestinal-targeted components respectively.  
 
An important outcome of this chapter was to ensure that the mucoadhesive membranes 
maintained their pH-responsive mucoadhesive characteristics, while not undergoing 
premature disintegration with prolonged periods of exposure to simulated GIT conditions. 
Inclusion of PVA (2-4.75%w/v) was thus beneficial, as the mucoadhesive membranes were 
able to withstand prolonged periods of exposure to simulated GIT conditions, while still 
maintaining both the mucoadhesive and pH-responsive nature of the mucoadhesive 
membranes. This chapter served to identify the candidate formulation which led to the 
identification of 2 variables, with their corresponding upper and lower limits, for input into 
a Central Composite Design. The Central Composite Design, detailed in Chapter 4, was 
conducted for further optimization of gastric-targeted and intestinal-targeted components 
respectively.  
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CHAPTER 4  
FABRICATION AND STATISTICAL OPTIMIZATION OF THE STIMULI-
RESPONSIVE MUCOADHESIVE LAYERS OF THE MULTI-COMPONENT 
MEMBRANOUS DRUG DELIVERY SYSTEM EMPLOYING AN EXPERIMENTAL 
DESIGN STRATEGY 
 
 
4.1 Introduction 
 
Statistical formulation optimization approaches, employing a systematic Design of 
Experiments (DoE), are extensively practiced to improve the outcomes of formulation 
design in DDS development, as it is an efficient and cost-effective tool that is able to 
provide the most optimal formulation in response to the most desired characteristics. In 
order to ensure the successful implementation of an experimental design, the objectives 
of the experiment and the factors to be investigated need to be clearly defined (Singh et 
al., 2004). Through extensive preliminary studies, detailed in Chapter 3, a prototypical 
formulation led to the identification of independent variables (polymer quantity) which 
impacted the measured responses (i.e. mucoadhesive characteristics).  
 
In order to achieve the preferred characteristics and qualities of a DDS, it is necessary to 
recognize whether the factors included in the formulation will impact any characteristics of 
the formulation. During preliminary studies, one or more process variables or factors were 
deliberately changed to determine the effect that the change may have on measured 
responses (the-one-variable-at-a-time or OVAT approach). Results indicated that varying 
any of the components, specifically, the polymer quantity of the system caused 
interactions that would impact the mucoadhesive characteristics of the system. However, 
utilising the OVAT approach in designing a formulation is a costly and time-consuming 
process and achieving the optimized formulation is not guaranteed. This was overcome 
by employing a statistically robust experimental Central Composite Design, an 
optimization procedure which utilizes fewer experimental runs, is less time consuming and 
provides a true optimized formulation by a systematic approach (Singh et al., 2004). 
 
The Response Surface Methodology (RSM) was selected in design implementation as the 
factors affecting the formulation characteristics were already identified in Chapter 3, 
therefore facilitating the optimization process. The ultimate goal of employing the RSM 
was to identify the best combination of the formulation components that would achieve an 
optimal formulation for both the gastric-targeted and intestinal-targeted mucoadhesive 
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layers. RSM is useful for the elucidation of complex processes in many fields (chemical 
and engineering processes, industrial research, biological investigations and agricultural 
processes) with the final goal of optimizing a system and is commonly employed in 
Central Composite Designs to enables the investigator to identify the optimal settings of 
the experimental factors that give the maximum (or minimum) value of the response (He 
et al., 2005; Kumar et al., 2011b). Essentially, RSM is a collection of mathematical and 
statistical techniques for empirical model building based on physical experiments or 
experimental observations (Raissi and Eslami Farsani, 2009). 
 
4.1.1 Selection of independent variables for input into a Central Composite 
Design 
Based on the preliminary results obtained from Chapter 3, the formulation components 
(input variables) that impacted the mucoadhesive characteristics of the formulation 
(measured response) were identified along with their upper and lower limits. Factors 
along with the factor levels were selected for each of the mucoadhesive layers of the 
MMDDS such that individualised mathematical models were generated. The primary 
difference between the gastric-and intestinal-targeted components included the type of 
pH-responsive polymer employed, i.e. CHT or PEC.  
 
CHT, a natural polysaccharide with low toxicity, was employed as the pH-responsive 
component of the gastric-targeted component. The myriad of pharmaceutical uses, 
including disintegrant, binder, mucoadhesive and permeation enhancing effects of CHT 
arises from the variations in the different grades of CHT, each differing in the degree of 
deacetylation (40-98%), molecular weight (50 kDa to 2000 kDa), viscosity and pKa. It is 
produced via the partial deacetylation of chitin, producing a polysaccharide copolymer of 
glucosamine and N-acetyl glucosamine (Singla and Chawla; 2001). The pH-dependant 
solubility of CHT has been exploited in the present study to ensure pH-dependent 
mucoadhesion, as in acidic mediums, the amine groups (NH3
+) are protonated which 
promotes mucoadhesion in the gastric pH-range. The concentration range selected for 
optimization of the gastric-targeted component was based on preliminary studies (Chapter 
3) and determined to be 1-2%w/v. 
 
PEC, a high-molecular-weight, complex polysaccharide, was employed as the pH-
responsive polymer for the intestinal-targeted component. PEC consists primarily of 
chains of esterified D-galacturonic acid units linked as 1,4-α-glucosides, with a molecular 
weight of 30 000–100 000g/mol. It is typically used as an adsorbent, emulsifying agent, 
gelling agent, thickening agent, or stabilizing agent, and is commonly employed in oral 
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formulations due to its non-toxic and non-irritant nature. It is often employed as pH-
sensitive polymeric coating, which retards drug release in the upper GIT region, due to its 
limited solubility in lower pH ranges. This pH-dependant solubility is exploited in the 
present study to ensure pH-dependent mucoadhesion, as in alkaline pH ranges, the 
carboxyl groups (COO-) are ionised, which promotes mucoadhesion in the intestinal pH-
range (Rowe et al., 2009). The concentration range selected for optimization of the 
intestinal-targeted component was based on preliminary studies (Chapter 3) and 
determined to be 1.3-2.7%w/v. 
 
Polyvinyl alcohol (PVA), a water-soluble synthetic polymer represented by the formula 
(C2H4O)n, was utilized to prevent premature erosion and disintegration of both the gastric-
targeted and intestinal-targeted mucoadhesive layers. The concentration range selected 
for optimization was based on preliminary studies (Chapter 3) and determined to be 2-
4.75%w/v (Rowe et al., 2009).  
 
Poly(vinylpyrrolidone) (PVP), a synthetic polymer consisting essentially of linear 1-vinyl-2-
pyrrolidinone groups, is highly biocompatible and commonly used as a mucoadhesive 
(Rowe et al., 2009; Alsarra et al., 2011). For the purposes of this study, PVP was 
incorporated to further improve the mucoadhesive characteristics of the formulations on a 
fixed ratio of 1:4 and 1:3 of CHT:PVP and PEC:PVP respectively, ranging in 
concentrations of 4-8%w/v for further optimization.    
 
The focus of this chapter lies in development and optimization of both pH-responsive 
mucoadhesive layers through a systematic approach of experimental runs, employing a 
two-level, two-factorial, randomized Central Composite Design for each component. The 
optimized formulation of each component will provide the most ideal mucoadhesive 
characteristics over a prolonged period of time. The present chapter is divided into three 
Sections to facilitate a sequential and logical representation of the data obtained as 
follows: Part I: Fabrication and statistical optimization of gastric-responsive layer of the 
MMDDS; Part II: Fabrication and statistical optimization of intestinal-responsive layer of 
the MMDDS and Part III: Physicochemical and physicomechanical characterization of the 
optimized gastric- and intestinal-targeted mucoadhesive layers of the MMDDS.  
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Part I – Fabrication and statistical optimization of gastric-targeted mucoadhesive 
layer of the MMDDS 
 
4.2 Material and Methods 
 
4.2.1 Materials 
The materials including chitosan (CHT), polyvinylpyrrolidone-40 (PVP), polyvinyl alcohol 
(PVA), glycerol, silicone, acetic acid, dialysis flat sheet membranes, sodium chloride, 
hydrochloric acid and liquid paraffin were obtained as described in Section 3.2.1. All other 
reagents employed were of analytical grade and used as purchased without further 
purification. Double-deionised water was obtained from a Milli-Q Water Purification 
System (Millipore, Bedford MA, USA).   
 
4.2.2 Construction of a randomized Central Composite Design for the 
optimization of the gastric-targeted component 
A Face-centered Central Composite Experimental Design (FCCCD) with 2 factors and 
cube points was generated by Minitab®, V15 (Minitab® Inc, Pennsylvania, USA) in order to 
statistically optimize the gastric-targeted mucoadhesive layer of the MMDDS. The input 
factors or independent variables, concentration of CHT: PVP, and concentration of PVA, 
were studied at two levels each, and the DoE generated 13 experimental runs (or 
formulations), consisting of the design points illustrated in Table 4.1. These experimental 
runs aimed to produce a minimum amount of runs that would ascertain maximum efficacy 
of information for prediction of responses. Table 4.2 represents the independent variables 
and their corresponding levels in the design. The dependent variable was identified as the 
Area Under the Curve (AUC) of the Work of Adhesion (WA) profile plotted against a time 
of 12 hours. RSM based on the constructed FCCCD was employed to evaluate the 
formulation factors that affected the dependant variable, the AUC of the WA (mJ) against 
time (hours) curve. The experimental range of each variable was selected based on the 
results of preliminary experiments detailed in Chapter 3. To reduce systematic errors, the 
experiments were completely randomized. All experiments were conducted in triplicate 
(n=3). 
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Table 4.1: Design points employed in the generation of the 2 factor, face-centred central 
composite design. 
Two-level full factorial design  
Cube points 4 
Centre points in cube 5 
Axial points (points parallel to each variable axis on a circle of radius equal to 
1.0 and origin at the centre-point) 
4 
Centre points in axial 0 
Alpha (α) 1 
 
4.2.3 Fabrication of the gastric-targeted mucoadhesive layer 
The mucoadhesive layer was fabricated using the film-casting technique of membrane 
fabrication, as described in Section 3.2.2. Briefly, the film-casting method included 
solubilising the required quantity of the polymers in accordance with the randomized 
Central Composite Design template (Table 4.2), followed by glycerol (2:1 of polymer: 
plasticizer) and the antifoaming agent, silicone (1 drop per 100mL) addition. 40mL 
aliquots of the polymeric solution was then film-cast into moulds and subject to ambient 
conditions for 24 hours, resulting in the formation of thin, transparent and uniform 
polymeric membranes, which were cut into 20x30mm dimensions. Membranes were 
stored with desiccants in airtight containers until further testing was completed.  
 
Table 4.2: Central composite design template of the 13 statistically derived formulations 
for the fabrication of the gastric-responsive mucoadhesive layer of the MMDDS. 
Experimental 
Formulation 
Independent variables 
CHT(%w/v) : PVP(%
w/v) PVA(%
w/v) 
1 2.0 : 8.0 2.000 
2 2.0 : 8.0 3.375 
3 1.0 : 4.0 3.375 
4 1.5 : 6.0 3.375 
5 1.5 : 6.0 4.750 
6 1.0 : 4.0 4.750 
7 2.0 : 8.0 4.750 
8 1.5 : 6.0 3.375 
9 1.5 : 6.0 2.000 
10 1.0 : 4.0 2.000 
11 1.5 : 6.0 3.375 
12 1.5 : 6.0 3.375 
13 1.5 : 6.0 3.375 
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4.2.4 Mucoadhesive analysis through textural profiling 
In order to evaluate the mucoadhesive properties of the mucoadhesive layer, the Work of 
Adhesion (WA) required to detach a hydrated mucoadhesive layer from a portion of 
Simulated Gastric Membrane (SGM) was determined, using Texture Analyser TA.XTplus 
(Stable Microsystems, England), as described in Section 3.2.7. The polymeric and 
simulated gastric membranes were pre-impregnated with PBS; pH 1.2±0.1 prior to 
mucoadhesive testing; simulating the gastric region of the GIT.  
 
4.2.5 Variations in mucoadhesive characteristics of the gastric-targeted 
experimental formulations as a function of time 
In order to determine the effects of the GIT on the mucoadhesive characteristics of the 
formulation as a function of time, the formulations were subject to conditions typical of in 
vitro drug release or dissolution studies in a USP Dissolution Apparatus (Erweka DT 700 
GmbH Germany). The USP 25 rotating paddle method of dissolution was selected where 
the mucoadhesive layers were exposed to 900mL of PBS (pH 1.2±0.1) for 12 hours at 
37±0.5°C and 50rpm. At two hour intervals, the layers were removed from the dissolution 
media and subject to mucoadhesive analysis as described in Chapter 3, Section 3.2.7. 
Fresh samples were used for each individual time point. 
 
4.2.6 Constrained statistical optimization of the gastric-targeted mucoadhesive 
layer of the MMDDS 
Following generation of the polynomial equations relating the dependent and independent 
variables, the formulation components were optimized under constrained conditions for 
the measured response using RSM. Simultaneous equation solving for optimization of the 
formulation process was performed to obtain the levels of independent variables, which 
would accomplish the most desired mucoadhesive characteristics. The factor levels or the 
polymer quantity represented the independent variables while the mucoadhesive 
characteristics (specifically the Work of Adhesion in mJ) represented the dependent 
variables (i.e. the response parameters). The Work of Adhesion (mJ) was identified as the 
dependant variable to be optimized, since it offers a truer representation of the adhesion 
process than the Maximum Detachment Force (N). Analysis of Variance (ANOVA), 
correlation analysis and regression analysis was employed for data analysis and 
determination of the statistical acceptability of the models proposed.  
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4.3 Results and Discussion 
 
4.3.1 Central Composite Experimental Design for optimization of the gastric-
targeted mucoadhesive layer of the MMDDS  
4.3.1.1 Measured responses for experimental optimization 
The mucoadhesive layer experimental design formulations demonstrated relatively 
consistent mucoadhesion over the duration of the study, as illustrated in Figure 4.1a-d.  
Typically, formulations containing large concentrations of the incorporated polymers 
demonstrated relatively poorer mucoadhesive characteristics. This finding may be 
attributed to the large degree of chain entanglements (present from higher polymeric 
concentrations) which reduces the rate and degree of swelling, ultimately mitigating 
mucoadhesion. The measured response selected for optimization was determined from 
the Area Under the Curve (AUC) of the Work of Adhesion (mJ) vs. Time (hours) curve. 
The AUC, calculated employing SigmaPlot® V10.0 software, are depicted in Table 4.3. 
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Figure 4.1: Variations in AUCFD of the Experimental Formulations a) 1-3; b) 4-6; c) 7-9; 
and d) 10-13 as a function of time (n=3; SD < 0.072 in all cases). 
 
a) b) 
c) d) 
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Table 4.3: Measured responses of the experimental runs for the optimization of the 
gastric-targeted mucoadhesive layer of the MMDDS. 
Formulation CHT:PVP 
(%w/v) 
PVA 
(%w/v) 
Measured 
Response (AUC) 
1 2.0 : 8.0 2.000 3.5003 
2 2.0 : 8.0 3.375 1.7609 
3 1.0 : 4.0 3.375 2.6871 
4 1.5 : 6.0 3.375 2.5686 
5 1.5 : 6.0 4.750 5.0404 
6 1.0 : 4.0 4.750 2.3802 
7 2.0 : 8.0 4.750 1.6213 
8 1.5 : 6.0 3.375 2.4040 
9 1.5 : 6.0 2.000 3.1287 
10 1.0 : 4.0 2.000 2.0786 
11 1.5 : 6.0 3.375 2.3017 
12 1.5 : 6.0 3.375 2.4354 
13 1.5 : 6.0 3.375 2.4674 
 
 
4.3.1.2 Correlation of the experimental and fitted response values 
A comparative analysis of the experimental vs. the fitted response values, i.e. the 
mucoadhesive characteristics, was plotted to establish the applicability of the regression 
models and the robustness of the Central Composite Design employed for the 
optimization of the gastric-targeted mucoadhesive layer. The plot depicting the AUC (of 
the Work of Adhesion vs. Time profiles) of the experimental vs. the fitted values of each 
formulation show a general conformity with a correlation coefficient (R2) of 0.714 (Figure 
4.2). An acceptable correlation between the experimental and fitted responses was 
determined verifying the central composite experimental design for the responses of 
mucoadhesive properties, aiding in the determination of an optimized gastric-targeted 
mucoadhesive layer. 
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Figure 4.2: Regression plots of Area Under the Curve of the Work of Adhesion (mJ) vs. 
Time (hours) profile for the determination of the correlation between the experimental vs. 
the fitted response values. 
 
4.3.1.3 Analysis of the Central Composite Surface Design 
The AUC (of the Work of Adhesion (mJ) vs. Time profile) was the response measured for 
the gastric-targeted mucoadhesive system. Surface plot analysis validated the 
relationship between the independent variables PVA and CHT:PVP concentrations on the 
response of AUC in Figure 4.3a. A positive or maximal response of the AUC (±3.5) was 
established from the response curve at concentrations of 1-1.5%w/v of CHT:PVP and 
4.750% w/v of PVA. For PVA concentrations ranging from 3-4%
w/v, a minimal response on 
the AUC was observed. However, formulations containing greater than 4%w/v PVA also 
demonstrated a maximal response on the AUC. Any increase in the CHT:PVP 
concentration to a point of ±1.75%w/v influenced a positive effect on the measured 
response. Any further increase beyond this point influenced a negative effect on the 
response. For the purposes of optimizing the response of AUC, manipulation of the PVA 
concentrations had a more positive effect. These responses are also evident in the 
contour plot (Figure 4.3b), where a positive effect on the AUC was observed at 
concentrations of PVA > 4%w/v and between 1-1.5
w/v CHT:PVP.    
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Figure 4.3: Illustration of the relationship between independent variables and the 
response of mucoadhesive properties through a) 3-D surface plots and b) contour plots 
for the gastric-targeted mucoadhesive layer. 
 
In contrast to preliminary studies, increasing the PVA concentration proved to provide the 
maximal response required for the AUC. Upon analysis of the Work of Adhesion vs. time 
profiles of the experimental design formulations (Figure 4.1), a decrease in the WA was 
observed over time in formulations containing less than 4.75%w/v of PVA. These findings 
can be attributed to the mucoadhesive polymers diffusing or dissolving out of the 
mucoadhesive membranes. With the increase in chain entanglements occurring as PVA 
concentration increases, the mucoadhesive characteristics remain constant for longer 
durations of time since the mucoadhesive polymer is no longer able to diffuse or erode 
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out of the mucoadhesive layer as easily. However, increasing the concentration of the 
CHT beyond 1.5%w/v caused an even higher degree of chain entanglements to occur, 
thus abating mucoadhesion (due to the resultant decrease in swelling and thus preventing 
accessibility of the adhesive sites on the mucoadhesive polymer). 
 
4.3.1.4 Residual Analysis of the Central Composite Experimental Design for the 
optimization of the gastric-targeted mucoadhesive layer 
The suitability of the model was assessed employing residual analysis. A comparison 
between observed and fitted responses of the model was linearly compared, and the fit of 
the model was determined employing regression models. Ideally, response values should 
be normally distributed with constant variance and means (Deschepper et al., 2006; 
Larsen and McCleary, 1972).  
 
As illustrated in Figure 4.4, the normal probability plots of the residuals fell on a straight 
line indicating that the data was normally distributed with no evidence of unidentified 
variables. The plot of residuals vs. the fitted values tests the assumption of constant 
variance. A random arrangement of data points was demonstrated, with the presence of a 
small cluster, signifying an acceptable and normal fit with a linear regression model. The 
data points were plotted close to the zero axis, while demonstrating no discernible 
pattern, thus validating the assumption of constant variance. These assumptions were 
further validated by the histogram of residuals, where a constant variance was observed 
and that the residuals had a normal distribution. Furthermore, the residuals vs. the order 
of data plot, demonstrated a random distribution between the consecutive points, with 
some clustering of Formulations 6-9 and 10-13. 
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Figure 4.4: Residual plots of AUC of the Work of Adhesion (mJ) vs. Time (hours) profile 
for the gastric-targeted mucoadhesive layer of the MMDDS. 
 
 
Based on a full ANOVA analysis of the measured formulation responses it was 
determined that none of the factors exhibited any significant influence (p≤0.05). Only the 
PVA*PVA (p=0.097) term of the AUC response possessed a notable effect, even though 
p≥0.05 (Table 4.4). The complete regression equations generated for AUC of the WA vs. 
Time profile is depicted in Equation 4.1.  
 
Table 4.4: Estimated p-values for the response: AUC of the WA: Time profile. 
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Term Coef SE Coef T p-value 
[CHT:PVP] -0.04390 0.3274 -0.134 0.897 
[PVA] +0.05572 0.3274 +0.170 0.870 
[CHT:PVP]*[CHT:PVP] -0.92495 0.4826 -1.917 0.097 
[PVA]*[PVA] +0.93560 0.4826 +1.939 0.094 
[CHT:PVP]*[PVA] -0.54515 0.4010 -1.360 0.216 
Constant +2.63929 0.3330 +7.926 0.000 
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4.3.1.5 Constrained optimization of the gastric-targeted mucoadhesive layer 
Optimization of the gastric-targeted mucoadhesive layer was performed employing 
Minitab® V15 statistical software (Minitab® Inc., PA, USA) to determine the optimum level 
for each variable. The optimization approach resulted in the attainment of a formulation 
with a desirability of 0.999 and the fabrication of this formulation included the employment 
of a 1.0014%w/v of CHT and a PVA concentration of 4.750%
w/v as depicted in Figure 4.5. 
Since the ratio of CHT:PVP was kept constant at 1:4, the final PVP concentration 
employed was 4.004%w/v in the optimized formulation. The resultant fitted and 
experimental values for the response parameters are provided in Table 4.5. 
  
 
 
Figure 4.5: Optimization plots displaying factor levels and desirability values for the 
optimized gastric-targeted mucoadhesive layer of the MMDDS. 
 
Table 4.5: Comparison of the fitted and experimental values of the response parameter. 
Response 
parameter 
Fitted 1Desirability 
(%) 
Experimental 2Deviation 
(%) 
AUC 3.2982 0.999 3.2310 2.037 
1
 Statistical desirability values of the fitted optimized formulation (%)  
2
 Deviation of the experimental response values from the fitted 
 
The fitted optimized formulation had a statistical desirability of ≥90% for the response 
parameter. An experimental AUC of 3.210 was achieved with the optimized formulation, 
with a deviation of 2.037% from the fitted response value of 3.2982, thereby 
demonstrating that the experimental response parameters achieved with the constrained 
settings for the optimized formulation were in close agreement with the fitted response 
values. This identified the reliability of the optimization process in predicting the maximal 
AUC and identifying an optimized formulation. Figure 4.6 represents the variations in the 
WA as a function of time. The shape of the curve was observed to possess a similar trend 
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that was typical of the experimental design formulations analyzed (Figure 4.1a-d), thus 
demonstrating that similar processes occur which promote or mitigate mucoadhesion as 
for the experimental design formulations.  The variations in the mucoadhesion of the 
formulation can be attributed to the simultaneous swelling and erosion, which is further 
elaborated in Part III of the present chapter.  
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Figure 4.6: Variations in AUCFD of the optimized gastric-targeted mucoadhesive layer as 
a function of time (n=3; SD < 0.071 in all cases). 
 
Part II – Fabrication and statistical optimization of the intestinal-targeted 
mucoadhesive layer of the MMDDS 
 
4.4 Materials and Methods 
 
4.4.1 Materials 
The materials included pectin (PEC), polyvinylpyrrolidone-40 (PVP), polyvinyl alcohol 
(PVA), glycerol, silicone, dialysis flat sheet membranes, sodium hydroxide, potassium 
dihydrogen phosphate and liquid paraffin, were obtained as described in Section 3.2.1. All 
other reagents employed were of analytical grade and used as purchased without further 
purification. Double-deionised water was obtained from a Milli-Q Water Purification 
System (Millipore, Bedford MA, USA).   
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4.4.2 Construction of a randomized central composite design for the 
optimization of the intestinal-targeted component 
A Face-centered Central Composite experimental Design (FCCCD), as detailed in 
Section 4.2.2, was generated to statistically optimize the intestinal-targeted mucoadhesive 
layer of the MMDDS. The input factors or independent variables, concentration of 
PEC:PVP, and concentration of PVA, generated 13 experimental runs (or formulations), 
as illustrated in Table 4.6. The experimental range of each variable was selected based 
on the results of preliminary experiments detailed in Chapter 3. The dependent variable 
was identified as the Area Under the Curve (AUC) of the Work of Adhesion (WA) profile 
plotted against a time of 12 hours.  
 
4.4.3 Fabrication of the intestinal-targeted mucoadhesive layer 
The mucoadhesive layer was fabricated using the film-casting technique of membrane 
fabrication, as detailed in Section 3.2.2. Briefly, the film-casting method included 
solubilising the required quantity of the polymers in accordance with the randomized 
central composite design template (Table 4.6), followed by glycerol and silicone addition.  
40mL aliquots of the polymeric solution was then film-cast into moulds and subject to 
ambient conditions for 24 hours, resulting in the formation of thin, transparent and uniform 
polymeric membranes, which were cut into 20x30mm dimensions. Membranes were 
stored with desiccants in airtight containers until further testing was completed. 
 
Table 4.6: Central composite design template of the 13 statistically derived formulations 
for the fabrication of the intestinal-responsive mucoadhesive layer of the MMDDS. 
Experimental  
Formulation 
Independent Variables 
PEC(%
w
/v) : PVP(%
w
/v) PVA(%
w
/v) 
1 2.7 : 8.1 2.000 
2 2.7 : 8.1 3.375 
3 1.3 : 3.9 3.375 
4 2.0 : 6.0 3.375 
5 2.0 :6.0 4.750 
6 1.3 : 3.9 4.750 
7 2.7 : 8.1 4.750 
8 2.0 : 6.0 3.375 
9 2.0 : 6.0 2.000 
10 1.3 : 3.9 2.000 
11 2.0 : 6.0 3.375 
12 2.0 : 6.0 3.375 
13 2.0 : 6.0 3.375 
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4.4.4 Mucoadhesive analysis through textural profiling 
In order to evaluate the mucoadhesive properties of the mucoadhesive layer, the Work of 
Adhesion (WA) and the Maximum Detachment Force (MDF) required to detach a 
hydrated mucoadhesive layer from a portion of Simulated Intestinal Membrane (SIM) was 
determined, using Texture Analyser TA.XTplus (Stable Microsystems, England), as 
described in Section 3.2.7. The polymeric and SIMs were pre-impregnated with PBS; pH 
6.8±0.1 prior to mucoadhesive testing; simulating the intestinal region of the GIT.  
 
4.4.5 Variations in the mucoadhesive characteristics of the intestinal-targeted 
experimental formulations as a function of time 
In order to determine the effects of the GIT on the mucoadhesive characteristics of the 
formulation as a function of time, the formulations were subject to conditions typical of in 
vitro drug release or dissolution studies, as described in Section 3.2.8. The USP 25 
rotating paddle method of dissolution was selected where the mucoadhesive layers were 
exposed to 900mL of PBS (pH 6.8±0.1) for 12 hours at 37±0.5°C and 50rpm. At two hour 
intervals, the layers were removed from the dissolution media and subject to 
mucoadhesive analysis as described in Chapter 3, Section 3.2.7. Fresh samples were 
used for each individual time point. 
 
4.4.6 Constrained statistical optimization of the intestinal-targeted 
mucoadhesive layer of the MMDDS 
Following generation of the polynomial equations relating the dependent and independent 
variables, the formulation components were optimised under constrained conditions for 
the measured response using response surface methodology. Simultaneous equation 
solving for optimisation of the formulation process was performed to obtain the levels of 
independent variables, which would accomplish the most desired mucoadhesive 
characteristics. The factor levels or the polymer quantity represented the independent 
variables while the mucoadhesive characteristics in terms of the Work of Adhesion (mJ) 
represented the dependent variables (i.e. the response parameters). 
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4.5 Results and Discussion 
 
4.5.1 Central Composite Experimental Design for optimization of the gastric-
targeted mucoadhesive layer of the MMDDS  
4.5.1.1 Measured responses for experimental optimization 
The mucoadhesive layer experimental design formulations demonstrated relatively 
consistent mucoadhesion over the duration of the study, as illustrated in Figure 4.7a-d.  
Typically, formulations containing large concentrations of the incorporated polymers 
demonstrated relatively poorer mucoadhesive characteristics. This finding may be 
attributed to the large degree of chain entanglements (present from higher polymeric 
concentrations) which reduces the rate and degree of swelling, ultimately mitigating 
mucoadhesion. The measured response selected for optimization was determined from 
the Area Under the Curve (AUC) of the Work of Adhesion (mJ) vs. Time (hours) curve. 
The AUC, calculated employing SigmaPlot® V10.0 software, are depicted in Table 4.7. 
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Figure 4.7: Variations in AUCFD of the Experimental Formulations a) 1-3; b) 4-6; c) 7-9; 
and d) 10-13 as a function of time (n=3; SD < 0.067 in all cases). 
a) b) 
c) d) 
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Table 4.7: Measured responses of the experimental runs for the optimization of the 
gastric-targeted mucoadhesive layer of the MMDDS. 
Experimental 
Formulation 
PEC:PVP 
(%w/v) 
PVA 
(%w/v) 
Measured 
Response (AUC) 
1 2.7 : 8.1 2.000 6.9781 
2 2.7 : 8.1 3.375 7.6332 
3 1.3 : 3.9 3.375 7.9610 
4 2.0 : 6.0 3.375 7.1162 
5 2.0 :6.0 4.750 3.7886 
6 1.3 : 3.9 4.750 5.0135 
7 2.7 : 8.1 4.750 4.1901 
8 2.0 : 6.0 3.375 6.4782 
9 2.0 : 6.0 2.000 5.6758 
10 1.3 : 3.9 2.000 6.2951 
11 2.0 : 6.0 3.375 7.1351 
12 2.0 : 6.0 3.375 7.5982 
13 2.0 : 6.0 3.375 8.0183 
 
4.5.1.2 Correlation of the experimental and fitted response values 
A comparative analysis of the experimental vs. the fitted response values, i.e. the 
mucoadhesive characteristics, was plotted to establish the applicability of the regression 
models and the robustness of the Central Composite Design employed for the 
optimization of the intestinal-targeted mucoadhesive layer. The plot depicting the AUC (of 
the Work of Adhesion vs. Time profiles) of the experimental vs. the fitted values of each 
formulation show a general conformity with a correlation coefficient (R2) of 0.968 (Figure 
4.8). The R2 values provide evidence of the success and robustness of the Central 
Composite Experimental Design and thus the efficiency of the design in aiding the 
determination of an optimized intestinal-targeted mucoadhesive layer. 
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Figure 4.8: Regression plots of Area Under the Curve of the Work of Adhesion (mJ) vs. 
Time (hours) profile for the determination of the correlation between the experimental vs. 
the fitted response values. 
 
4.5.1.3 Analysis of the central composite surface design 
The AUC (of the Work of Adhesion (mJ) vs. Time profile) was the response measured for 
the intestinal-targeted mucoadhesive system. Surface plot analysis validated the 
relationship between the independent variables PVA and PEC:PVP concentrations on the 
response of AUC in Figure 4.9a. A positive or maximal response of the AUC (>7.5) was 
established from the response curve at concentrations of ±3.375%w/v of PVA at differing 
PEC:PVP concentrations. Any further increase beyond this point influenced a negative 
effect on the response. For the purposes of optimizing the response of AUC, manipulation 
of the PVA concentrations had a more pronounced effect on the AUC, which is clearly 
illustrated in Figure 4.9. These responses are also evident in the contour plot (Figure 
4.9b), where a positive effect on the AUC was observed at concentrations of PVA 
=3.375%w/v.    
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Figure 4.9: Illustration of the relationship between independent variables and the 
response of mucoadhesive properties through a) 3-D surface plots and b) contour plots 
for the intestinal-targeted mucoadhesive layer. 
 
4.5.1.4 Residual Analysis of the Central Composite Experimental Design for the 
optimization of the intestinal-targeted mucoadhesive layer 
The normal probability plots of the residuals fell on a straight line (Figure 4.10), with 2 
outliers, indicating that the data was normally distributed with no evidence of unidentified 
variables. The residuals vs. fitted values plots demonstrated a random arrangement of 
data points, with the presence of a small cluster, signifying an acceptable and normal fit 
with a linear regression model. The data points were plotted close to the zero axis, 
demonstrating no discernible pattern, validating the assumption of constant variance. 
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These assumptions were further validated by the histogram of residuals, where a constant 
variance with normal distribution of the residuals was observed. Furthermore, the 
residuals vs. the order of data plot demonstrated a random distribution between the 
consecutive points, rapidly alternating between positive and negative values, was 
observed.  
 
 
Figure 4.10: Residual plots of AUC of the Work of Adhesion (mJ) vs. Time (hours) profile 
for the intestinal-targeted mucoadhesive layer of the MMDDS. 
 
Based on a full ANOVA analysis of the measured formulation responses it was 
determined that the PVA and PVA*PVA factors had statistically significant effects (p<0.05) 
(Table 4.8) on the measured response (AUC). The complete regression equations 
generated for AUC of the WA vs. Time profile is depicted in Equation 4.2.  
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Table 4.8: Estimated p-values for the response: AUC of the WA: Time profile. 
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Equation 4.2 
 
4.5.1.5 Constrained optimization of the intestinal-targeted mucoadhesive layer of 
the MMDDS 
Optimization of the intestinal-targeted mucoadhesive layer was performed employing 
Minitab® V15 statistical software (Minitab® Inc., PA, USA) to determine the optimum level 
for each variable. The optimization approach resulted in the attainment of a formulation 
with a desirability of 1.000 and the fabrication of this formulation included the employment 
of a 2%w/v of PEC and a PVA concentration of 3.3750%
w/v as depicted in Figure 4.11. 
Since the ratio of PEC:PVP was kept constant at 1:3, the final PVP concentration 
employed was 6%w/v in the optimized formulation. The resultant fitted and experimental 
values for the response parameters are provided in Table 4.9. 
  
 
Figure 4.11: Optimization plots displaying factor levels and desirability values for the 
optimized gastric-targeted mucoadhesive layer of the MMDDS. 
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Term Coef SE Coef T p-value 
[PEC:PVP] +0.00850 0.2153 +0.039 0.970 
[PVA] -0.99280 0.1879 -5.284 0.001 
[PEC:PVP]*[PEC:PVP] +0.79423 0.3230 +2.459 0.044 
[PVA]*[PVA] -2.51125 0.3113 -8.066 0.000 
[PEC:PVP]*[PVA] -037660 0.2301 -1.637 0.146 
Constant +7.30529 0.1803 +40.517 0.000 
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Table 4.9: Comparison of the fitted and experimental values of the response parameter. 
Response 
parameter 
Fitted 1Desirability 
(%) 
Experimental 2Deviation  
(%) 
AUC 7.3053 1.000 7.6332 4.488 
1 Statistical desirability values of the fitted optimized formulation (%)  
2 Deviation of the experimental response values from the fitted 
 
The fitted optimized formulation had a statistical desirability of 100% for the response 
parameter. An experimental AUC of 7.6332 was achieved with the optimized formulation, 
with a deviation of 4.488% from the fitted response value of 7.3053, thereby 
demonstrating that the experimental response parameters achieved with the constrained 
settings for the optimized formulation were in close agreement with the fitted response 
values. This identified the reliability of the optimization process in predicting the maximal 
AUC and identifying an optimized formulation. Figure 4.12 represents the variations in the 
WA as a function of time. Mucoadhesive characteristics were successfully maintained 
throughout the duration of the study. The shape of the curve was observed to possess a 
similar trend that was typical of the experimental design formulations analyzed (Figure 
4.1a-d), thus demonstrating that similar processes occur which promote or mitigate 
mucoadhesion as for the experimental design formulations, which is further elaborated in 
Part III of the present chapter.   
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Figure 4.12: Variations in AUCFD of the optimized intestinal-targeted mucoadhesive layer 
as a function of time (n=3; SD < 0.094 in all cases). 
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Part III: Physicochemical and physicomechanical characterization of the optimized 
gastric- and intestinal-targeted mucoadhesive layers 
 
4.6 Materials and Methods 
 
4.6.1 Materials 
The materials employed were as described in Section 4.2.1 and Section 4.4.1 for the 
optimized gastric- and intestinal-targeted mucoadhesive layers. 
 
4.6.2 Fabrication of the optimized mucoadhesive layers 
Membranes were fabricated as described in Section 4.2.3 and Section 4.4.3 for the 
optimized gastric- and intestinal-targeted mucoadhesive layers respectively. The 
polymers were combined in the ratios defined via optimization studies and included: 
1.001%w/v of CHT, 4.750%
w/v PVA and 4.004%
w/v of PVP for the gastric-targeted 
mucoadhesive layer and 2%w/v of PEC, 3.375%
w/v of PVA and 6%
w/v of PVP for the 
intestinal-targeted mucoadhesive layer. Membranes were cut into dimensions of 
20x30mm and thereafter stored with desiccants in airtight containers until further testing 
was completed. 
  
4.6.3 Physical characterization of the optimized mucoadhesive layers: 
Evaluation of membrane uniformity 
The uniformity of the mucoadhesive layer was determined by accurately weighing a 
number of samples (n=10) on a calibrated Mettler Toledo Balance (Model AB104-S, 
Mettler Toledo, Switzerland). The average mass was then calculated followed by 
determination of the standard deviation. The thickness of the membranes was determined 
using an electronic digital calliper (n=10). Different points within a single membrane was 
also measured for thickness to determine the consistency of individual membranes 
(n=10). Similarly, the average thickness was then determined and the standard deviation 
calculated. All samples were previously cut into 20x30mm dimensions. Membranes were 
also visually assessed for colour, formation of air bubbles, and clarity. 
 
4.6.4 Determination of the tensile properties and Young’s Modulus of the 
optimized gastric-targeted mucoadhesive layer  
Young’s Modulus and other tensile properties of the optimized mucoadhesive layers were 
determined using the nanoTensile® 5000 (Hysitron Inc. Nanomechanical Test Instrument, 
Minneapolis, MN). The nanotensile (NT) apparatus was calibrated before samples were 
tested to ensure accuracy. Samples, cut into approximately 2x15mm strips, were 
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mounted on the specially designed NT mounting brackets, as illustrated in Figure 4.13. 
The brackets were held together with a rigid cardboard frame, aiding in sample alignment, 
and the samples were attached to the brackets using a rigid cyanoacrylate-based 
adhesive, thus holding the sample firmly in place during the test procedure. Samples were 
allowed to cure and accurate measurements of the sample width, thickness and length 
were recorded using digital callipers. 
 
  
The upper sample bracket was secured to the upper sample gripper of the NT head, the 
cardboard frame was snipped at the points demarcated in red in Figure 4.13 (to prevent 
any interference from the frame during analysis), and the mass measured. The NT head 
was lowered and the lower sample bracket secured to the lower sample gripper on the NT 
stage. The mounting brackets were moved apart at a constant rate of displacement of 
100μm/sec and the tensile properties of the sample were measured and recorded.   
 
4.6.5 Simultaneous qualitative and quantitative analysis of the mucoadhesive 
layer surface morphology and porosity 
The surface area and porosity of the optimized mucoadhesive layers were analyzed on a 
Micromeritics Porositometer (Micromeritics ASAP 2020, GA, USA) by employing the 
Brunauer-Emmett-Teller (BET) isotherm of adsorption/ desorption of nitrogen. Samples 
were initially degassed, which includes an evacuation and heating phase (Table 4.10). 
Approximately 0.285g and 0.275g of the gastric- and intestinal-targeted mucoadhesive 
layers was inserted into sample tubes, degassed and thereafter subject to the adsorptive 
properties listed in for analysis. Amongst the porositometric profiles the following were 
analyzed: i) the single point surface area (at point P.Po); and ii) the Barrett-Joiner-
Halenda (BJH) computation that allowed for the determination of the mesopore 
NT mounting 
brackets 
Rigid 
cardboard 
frame 
Frame attached 
to bracket for 
sample 
alignment 
Sample 
attachment with 
cyanoacrylate-
based adhesive 
Sample: 
2x15mm  
Figure 4.13: Sample preparation procedure for analysis on a Hysitron nanoTensile® 
analyzer. 
Adhesive  
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volume/area and size distribution which accounts for both the change in adsorbate layer 
thickness and the liquid condensed in the membrane pore cores. All analyses were 
conducted in triplicate (n=3).  
 
Table 4.10: Parameters and settings employed during degassing and analysis of the 
optimized mucoadhesive layers. 
Parameters Settings 
Degassing Conditions during the Evacuation Phase  
Temperature ramp rate 10°C/min 
Target temperature 30°C 
Evacuation rate 50.0mmHg/s 
Unrestricted evacuation from 30.0mmHg 
Vacuum set-point 500μmHg 
Evacuation time 60 min 
 
Degassing Conditions during the Heating Phase 
 
Ramp rate 10°C/min 
Hold temperature 30°C 
Hold time 900min 
 
Hold pressure during the evacuation and heating phases 
 
100mmHg 
 
Analysis Conditions (Adsorptive Properties) 
 
Adsorptive Nitrogen gas (N2) 
Maximum manifold pressure 925kPa 
Non-ideality factor 0.0000620 
Density conversion factor 0.0015468 
Hard sphere diameter 3.860Å 
Molecular cross-sectional area 0.162nm2 
 
Surface morphology of the mucoadhesive layers were analyzed on a PhenomTM Scanning 
Electron Microscope (SEM) (FEI Company, Hillsboro, Oregon, USA). Different 
magnifications at 10kV were employed to view the overall and in-depth surface structure 
to qualitatively elucidate the surface morphology of the mucoadhesive layer in relation to 
its surface area and porosity. The photomicrographs were then placed as insets on the 
porositometric profiles for the simultaneous qualitative and quantitative analysis of the 
mucoadhesive layer surface morphology and porosity. 
 
4.6.6 Evaluation of the polymeric structural and vibrational frequency variations 
of the mucoadhesive layer relative to its exposure to simulated GIT conditions 
The vibrational molecular transitions of the mucoadhesive layer relative to exposure in 
simulated gastro-intestinal conditions was characterized for the attainment of important 
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micro-structural data via an Attenuated Total Reflectance Fourier-Transform Infrared 
(ATR-FTIR) spectroscopy, recorded on a PerkinElmer® Spectrum 100 Series fitted with a 
universal ATR polarization accessory (PerkinElmer Ltd., Beaconsfield, UK). Samples 
required no further modification for analysis, and where placed in direct contact with the 
ATR crystal. Spectra were recorded over the range of 4000-650cm-1, with a resolution of 
4cm-1 and 32 iterations. 
 
4.6.7 Evaluation of the degree of swelling and polymeric erosion on the 
mucoadhesive characteristics of the optimized formulation relative to GIT exposure  
The variations in the swelling and erosion of the optimized formulations were evaluated by 
exposing the respective mucoadhesive layer to simulated gastro-intestinal conditions as 
described in Sections 4.2.5 and 4.4.5 for the gastric- and intestinal-targeted 
mucoadhesive layers respectively. The mucoadhesive characteristics, as well as the 
degree of swelling and erosion were determined at 0, 2, 4, 6, 8, 10 and 12 hours. Fresh 
samples were assessed for mucoadhesion, swelling and erosion at each time point. 
 
Swelling of a DDS is known to affect the mucoadhesive properties of the system. If the 
polymer is hydrated and expands, additional adhesive site are exposed to improve 
mucoadhesion. Furthermore, swelling promotes chain entanglement between the 
mucoadhesive layer of the system and mucin in the GIT (Dodou et al., 2005; Smart, 2005; 
Roy et al., 2009; Khutoryanskiy, 2010; Harsulkar et al., 2011; Tangri and Madav, 2011). 
The degree was of swelling was expressed as water absorption capacity or PBS uptake. 
 
Gravimetric analysis was conducted whereby the mucoadhesive layer was subject to the 
conditions identical to those employed in Section 3.2.8. Each mucoadhesive layer was 
removed from the dissolution apparatus at predetermined time intervals (0, 2, 4, 6, 8, 10, 
and 12 hours). Excess phosphate buffer was removed by allowing samples to drip dry for 
a period of 1 minute prior to gravimetric analysis. Fresh samples were used for each 
individual time point. The degree of swelling at each time point, expressed as a 
percentage of PBS uptake, was then determined based on the increase in weight of the 
formulation, and was calculated according to Equation 4.3. 
100
)(
0
0 X
W
WW
PBS tuptake


           
Equation 4.3  
 
where PBSuptake is the percentage of PBS uptake by the mucoadhesive layer at the 
relevant time point, Wt is the weight of the mucoadhesive layer at the relevant time point, 
and W0 is the initial weight of the mucoadhesive layer. 
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Subsequent to establishing the degree of fluid uptake by the mucoadhesive layer, the 
hydrated samples were dried at ambient room conditions for 24 hours after which they 
were re-weighed. The polymers employed in the mucoadhesive layer typically absorb a 
significant quantity of fluid thereby masking the degree of polymeric erosion. Therefore re-
weighing the dried samples enabled the determination of the degree of polymeric erosion 
from the mucoadhesive layer. The degree of erosion, expressed as a percentage, at each 
time point was calculated according to Equation 4.4.  
 
100
)(
(%)
0
0 X
W
WW
Erosion t

  
Equation 4.4 
 where Wt is the weight of the dehydrated mucoadhesive layer at the relevant time point, 
and W0 is the initial weight of the mucoadhesive layer. 
 
4.6.8 Evaluation of the surface morphology variations of the optimized 
mucoadhesive layers relative to exposure to simulated gastro-intestinal conditions 
Surface morphology of the mucoadhesive layer was analyzed on a PhenomTM Scanning 
Electron Microscope (SEM) (FEI Company, Hillsboro, Oregon, USA). Different 
magnifications at 10kV were employed to view the overall and in-depth surface structure 
to qualitatively elucidate the variations in the surface morphology of the mucoadhesive 
layer as a function of time. The optimized gastric-targeted and intestinal-targeted 
mucoadhesive layers were exposed to conditions detailed in Section 3.2.8, Chapter 3 to 
simulate the gastric and intestinal conditions of the GIT respectively. The mucoadhesive 
layer was removed at two-hour intervals, allowed to dry at ambient conditions and 
thereafter subject to SEM analysis as follows. Samples were firmly mounted on aluminium 
stubbs with carbon tape. They were subject to a gold sputter coating under a vacuum of 
0.1Torr with argon gas in a SPI-ModuleTM Sputter Coater and SPI-ModuleTM Control (SPI 
Supplies, Division of Structure Probe Inc., West Chester, PA, USA). Each sample 
required 90 seconds of coating to ensure complete coverage of the sample.  Subsequent 
viewing was thereafter performed at various magnifications under the PhenomTM SEM.  
 
4.6.9 Magnetic Resonance Imaging (MRI) of the swelling behaviour of the 
optimized formulations  
A digital MARAN-ip magnetic resonance system configured with a DRX2 HF 
Spectrometer console (Oxford Instruments Magnetic Resonance, Oxon, UK) was 
employed to confirm the swelling behaviour occurring with exposure to simulated GIT 
conditions. The Maran-ip was equipped with a compact 0.5 Tesla permanent magnet 
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stabilized at 37°C and a dissolution flow through cell. The image acquisition parameters 
are depicted in Table 4.11.  
 
Table 4.11: Image acquisition parameters applied during magnetic resonance imaging 
using MARAN-ip. 
S. No. Parameter Value 
1 Imaging protocol FSHEF 
2 Requested gain (%) 3.31 
3 Signal strength (%) 68.20 
4 Average 2 
5 Matrix size 128 
6 Repetition time (ms) 1000.00 
7 Spin Echo Tau (ms) 6.00 
8 Image acquired after 15min 
9 Total scans 64 
 
A laminar flow of 16mL/min was achieved with the presence of glass beads present in the 
cell. The solvent utilized was PBS (pH 1.2±0.5; 37°C for the gastric-targeted component 
and pH 6.8±0.5; 37°C for the intestinal-targeted component). The mucoadhesive layer 
(20x30mm dimensions) was rolled and placed in position within the cell which in turn was 
positioned in a magnetic core of the system. Magnetic resonance images were acquired 
every 15 minutes over 24 hours with MARAN-ip version V1.0 software. The image was 
acquired after setting the frequency offset and testing gain employing RINMR v5.7 under 
continuous solvent flow conditions. MARAN-ip software comprises image acquisition 
software and image analysis software. 
 
4.7 Results and Discussion 
 
4.7.1 Physical characterization of the optimized mucoadhesive layers: 
Characterization of membrane uniformity 
Uniformity assessment of the mucoadhesive layer provided an indication of the inter- and 
intra-formulation variability. Consistency and uniformity of the mucoadhesive layer were 
important attributes to evaluate as these parameters ultimately influence the 
mucoadhesive characteristics. The average weight and thickness, along with their 
standard deviations are depicted in Figure 4.14. With the standard deviation being <10% 
for all parameters investigated, it was determined that the mucoadhesive layers were 
relatively consistent and uniform in nature with limited inter- and intra-formulation 
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variability. The optimized gastric-targeted membranes were clear with a yellow tint, while 
the optimized intestinal-targeted membranes were clear, both displaying limited air bubble 
formation. 
 
 
 
4.7.2 Determination of the tensile properties and Young’s Modulus of the 
optimized mucoadhesive layers 
The stress-strain relationship of a material is highly dependent on the flexibility of the 
polymer chains and the strength of the material. When only a small amount of stress is  
required to produce a large amount of strain, the material is considered to be flexible and 
the Young’s Modulus, which is the slope of the linear portion of the stress-strain curve, 
highlighted in green in Figure 4.15, will be relatively small (Leung and Ko, 2011). Tensile 
properties were determined as the MMDDS would be ultimately rolled and inserted into a 
capsule to ease oral administration. The average experimental values for Young’s 
Physical properties: 
 
 Average Weight: 
284.72±7.39mg 
 Average Thickness: 
0.243±0.021mm 
 Average thickness 
within membrane: 
0.252±0.019mm 
a) 
b) 
Physical properties: 
 
 Average Weight: 
274.17±7.56mg 
 Average Thickness: 
0.293±0.012mm 
 Average thickness 
within membrane: 
0.288±0.017mm 
Cut into 
20x30mm 
dimensions  
Cut into 
20x30mm 
dimensions  
i) 
i) 
ii) 
ii) 
Figure 4.14: Digital images of a) the optimized gastric-targeted formulation and b) the 
optimized intestinal-targeted formulation i) upon removal from the mould, and ii) when cut 
into predetermined dimensions. 
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Modulus (E), yield stress (σy) (magnitude of stress on the stress-strain curve at which 
appreciable deformation takes place without any appreciable increase in the stress), 
ultimate strength (σu) (the maximum stress a material can withstand), ultimate strain (εu) 
and toughness (uf) are outlined in Table 4.12.  
 
Table 4.12: Experimental values obtained from nanotensile analysis of the optimized 
gastric-targeted mucoadhesive layer. 
Formulation E (MPa) σy (MPa) σu (MPa) εu uf (J/cm
-3
) 
Optimized gastric-
targeted formulation 
11.5167± 
0.249043 
1.2133± 
0.06549 
6.7833± 
1.6481 
0.9063± 
0.1281 
3.55± 
1.1870 
Optimized intestinal-
targeted formulation 
49.7933± 
3.502688 
1.1967± 
0.162138 
7.7233± 
0.6623 
0.365± 
0.0054 
1.6533± 
0.1580 
 
The Young’s Modulus values were relatively low indicating that the membranes 
demonstrated good elasticity. The gastric-targeted membranes, containing CHT, 
demonstrated higher elasticity values (a lower Young’s Modulus) than the intestinal-
targeted membranes containing PEC. Membranes displayed adequate strength and 
toughness to be able to withstand rolling and insertion into capsules for administration as 
depicted in Figure 4.15. 
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Figure 4.15: Typical stress-strain nanotensile profile of a) the optimized gastric-targeted 
component with inset i) digital image illustrating insertion into a capsule, and b) the 
optimized intestinal-targeted component, with inset ii) digital image illustrating insertion 
into a capsule.  
 
a) 
b) 
Breaking 
point 
Breaking 
point 
i) 
ii) 
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4.7.3 Simultaneous qualitative and quantitative analysis of the mucoadhesive 
layer surface morphology and porosity 
Studies were conducted to determine the volume of distribution of pores and pore sizes. 
As discussed previously, micro-cracks or pores promote mucoadhesion by forming an 
interlocked network which promotes adhesion (Dodou et al., 2005; Smart, 2005; Roy et 
al., 2009; Khutoryanskiy, 2010; Harsulkar et al., 2011; Tangri and Madav, 2011). In order 
to insert membranes into the porositometer analysis tubes, they required cutting of the 
membrane, and therefore altered the surface area of the membranes. For 
characterization purposes, it was thus determined that the single point surface area would 
provide a more reliable indication of the surface area. The single point selected for 
analysis of surface area was at P/Po = 0.200450676 and 0.204257893 for the gastric- and 
intestinal-targeted membranes respectively. The resultant single point surface area, and 
pore volume, surface area and diameter are depicted in Table 4.13. The larger pore size 
of the intestinal-targeted membranes may be a potential contributing factor to the 
mucoadhesive properties of the formulation being higher as compared to the gastric-
targeted formulation.  
 
Table 4.13: Quantitative properties of the optimized formulations’ surface structure.  
Measured characteristic Optimized gastric-targeted 
formulation 
Optimized intestinal-targeted 
formulation 
Single Point Surface area 0.8053m²/g 0.4688m²/g 
BJH: cumulative surface area 
of pores            
Adsorption: 1.048m²/g 
Desorption: 1.0339m²/g 
Adsorption: 1.019m²/g 
Desorption: 1.0508m²/g    
BJH: cumulative volume of 
pores 
Adsorption: 1.098x10
-3
cm³/g 
Desorption: 0.996x10
-3
cm³/g 
Adsorption: 1.162x10
-3
cm³/g 
Desorption: 1.162x10
-3
cm³/g 
BJH Adsorption average pore 
diameter (4V/A) 
Adsorption: 41.892Å    
Desorption: 38.521Å 
Adsorption: 45.609Å 
Desorption: 44.221Å       
 
The mechanical theory of mucoadhesion (Section 3.1.1.6) postulates that surface 
irregularities and roughness promotes mucoadhesion through an increase in contact area. 
As illustrated in the SEM images at a magnification of x4000 (Figure 4.16), both the 
gastric- and intestinal-targeted formulations possess surface morphology ideal for 
promoting mucoadhesion. It was also noted that were no large variations in the surface 
morphology that would cause drastic differences in the overall membrane performance, 
either within an individual membrane or between differing membranes.   
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4.7.4 Evaluation of the polymeric structural and vibrational frequency variations 
of the mucoadhesive layer relative to its exposure to simulated GIT conditions 
FTIR spectra of the native polymers employed in the respective mucoadhesive layers 
were analyzed in relation to the spectrum attained of the optimized formulations, to 
Figure 4.16: Isotherm plots and scanning electron micrographs depicting the surface 
morphology of a) the optimized gastric-targeted formulation and b) the optimized 
intestinal-targeted formulations.  
a) 
b) 
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determine whether any constituents within the formulation interacted as a result of the 
polymer blending and film-casting procedure. CHT (Figure 4.17a) demonstrates a 
characteristic peak at 1650cm-1 corresponding to the amide groups; the hydroxyl groups 
at 3440cm-1 and the C–O stretching at 1060cm-1. The FTIR spectra of PVA (Figure 4.17b) 
depicts a characteristic C–H broad alkyl stretching band (2850-3000cm-1), a strong 
transmittance band associated with hydroxyl groups stretching at 3200-3600cm-1 and the 
transmittance band at 1060cm-1 is indicative of C–OH bonding of PVA. In the FTIR 
spectra of PVP (Figure 4.17c) a CH stretching at 2900cm-1, C–O stretching at 1650cm-1, 
CH3 scissoring at 1420-1500cm
-1, C–C ring stretching at 1300cm-1 and tertiary amine C–N 
stretching at 1290cm-1 are the characteristic absorbance bands of PVP (Koo et al., 2003). 
Analysis of the optimized gastric-targeted formulation (Figure 4.17d) revealed that all 
characteristic peaks present in the spectra of the native polymers were unaltered proving 
no covalent interactions between the polymers, thus causing no detrimental effects on the 
mucoadhesive properties of the system. 
 
                    
                    
                    
                    
 
 
1600 
%T 
3600 3200 2800 2400 2000 1800 1400 800 1000 1200 650 4000 
cm
-1 
a) 
b) 
c) 
d) 
Figure 4.17: FTIR spectra of the native polymers a) CHT; b) PVA; and c) PVP employed 
in the fabrication of d) the optimized gastric-targeted component. 
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Figure 4.18a illustrates the FTIR spectra of PEC. The characteristic peaks associated with 
PEC includes the carboxylate groups associated with the 1607cm-1 peak and the ester 
group with transmittance band at 1740cm-1. In a similar fashion, analysis of the native 
polymer spectra (Figure 4.18a-c) with the optimized intestinal-targeted formulation (Figure 
4.18d) revealed that there were no alterations to the characteristic peaks of the native 
polymers, proving that no interactions occurred. 
 
                   
                   
                   
                   
 
 
 
 
FTIR spectra (Figure 4.19) of both the optimized gastric- and intestinal-targeted 
formulations illustrated that upon exposure to simulated GIT conditions, the characteristic 
C-O stretching of PVP (highlighted in red at 1650cm-1) decreased in intensity with 
increase in exposure time. The gradual disappearance of the band highlighted in red, can 
be attributed to PVP eroding out of the optimized membrane with time, accounting for the 
eventual decrease in the mucoadhesive characteristics of the formulations (revealed after 
t=8 hours and t=10 hours for the gastric- and intestinal-targeted component in Figure 
4.21a). 
1600 
%T 
3600 3200 2800 2400 2000 1800 1400 800 1000 1200 650 4000 
cm
-1 
a) 
b) 
c) 
d) 
Figure 4.18: FTIR spectra of the native polymers a) PEC; b) PVA; and c) PVP employed 
in the fabrication of d) the optimized intestinal-targeted formulation. 
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T=12 
T=12 
T=0 
T=4 
T=8 T=6 
T=2 
T=0 
Figure 4.19: FTIR spectra demonstrating the changes in band intensities of the formulation in relation to exposure to simulated gastro-
intestinal conditions of a) the optimized gastric-targeted formulation and b) the optimized intestinal-targeted formulation with the characteristic 
C-O peak of PVP highlighted in red. 
1600 
%T 
3600 3200 2800 2400 2000 1800 1400 800 1000 1200 650 4000 
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1600 
 
3600 3200 2800 2400 2000 1800 1400 800 1000 1200 650 4000 
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-1 
a) 
b) 
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4.7.5 The influence of exposure to simulated gastro-intestinal conditions on the 
degree of swelling and polymeric erosion 
Through gravimetrical analysis it was revealed that with increased exposure to simulated 
gastro-intestinal conditions, the optimized formulations tended to swell, resulting in an 
increase in the weight of the mucoadhesive layer. The expanded or hydrated nature of the 
polymeric network permits mutual interpenetration between the mucoadhesive membrane 
and mucin molecules, subsequently establishing stabilizing interactions and thus 
strengthening the mucoadhesive characteristics of the formulations (Salamat-Miller et al., 
2005; Sudhakar et al., 2006; Roy et al., 2009). With exposure of the surface layer of the 
mucoadhesive membrane to simulated gastro-intestinal conditions, polymeric chains 
present on the surface, swelled, promoting both mucoadhesion and weight gain (Figure 
4.20a). With continuous exposure, the surface layer eventually disintegrates and erodes 
out of the membrane, causing a decrease in both the mucoadhesion and weight gain 
(swelling) (Figure 4.20b).  The underlying polymeric chains would then become exposed 
to the surrounding fluid (Figure 4.20c), and swell further, promoting swelling and hence 
mucoadhesion (Figure 4.20d). As a result, fluctuating degrees of swelling was observed 
at different time points, causing the resultant variations in the mucoadhesive 
characteristics of the respective formulations, as illustrated in Figure 4.21.  
 
 
 
For the intestinal-targeted component, the rate of erosion was considerably higher than 
that of the gastric-targeted formulation. As a result, an overall decrease in the weight and 
a) Surface 
layer of the 
membrane 
exposed to 
surrounding 
fluid 
b) Swelling of 
polymeric 
chains within 
surface layer, 
promoting 
mucoadhesion 
c) Eventual 
erosion of 
surface layer 
chains, 
mitigating 
mucoadhesion. 
Underlying 
polymer chains 
now exposed.  
d) Swelling of 
underlying 
layers, 
promoting 
mucoadhesion 
= polymeric chains with a low 
degree of swelling  
= polymeric chains with a high 
degree of swelling 
Figure 4.20: Schematic illustration of the proposed processes causing the fluctuations 
observed in the swelling and hence mucoadhesive characteristics of the formulations.  
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hence swelling was observed as a function of time. However, the decrease in swelling did 
not affect the mucoadhesive characteristics of the formulation, as results indicated a 
consistent increase in the mucoadhesion of the formulation over time (Figure 4.21a).  It 
can therefore be deduced that the mucoadhesive characteristics optimized intestinal-
targeted formulation is not detrimentally affected by GIT conditions, ensuring that the 
optimal mucoadhesion over prolonged periods of time. 
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Figure 4.21: Graphic illustration of the variations in a) the AUCFD (n=3; SD < 0.094 in all 
cases); b) the degree of swelling (n=3; SD < 11.5% in all cases) and c) degree of erosion 
(n=3; SD < 7.25% in all cases) of optimized gastric-(highlighted in red) and intestinal-
targeted (highlighted in green) mucoadhesive formulations as a function of time. 
 
a) 
b) c) 
Digital images 
illustrating the degree 
of erosion at t = 12 
hours 
Digital images illustrating 
the degree of swelling at  
t = 12 hours 
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4.7.6 Analysis of the surface morphology variations of the optimized 
mucoadhesive layers relative to exposure to simulated gastro-intestinal conditions 
Scanning electron micrographs revealed that with exposure to simulated GIT conditions, 
drastic alterations were observed in the surface morphology of the gastric-targeted 
mucoadhesive layer (Figure 4.22a). At t=2 hours, a fissure-like surface appearance of the 
mucoadhesive layer was observed. As these fissures were not seen at the other time 
point, and considering that the main physical alteration occurring with exposure to 
simulated GIT conditions between 0 and 2 hours is swelling, it can be concluded that the 
fissuring may be attributed to the swelling process. The fissures may have resulted with 
slower swelling areas of the layer forming the troughs of the fissures while the faster 
swelling areas forming the higher regions or peak areas as illustrated in Figure 4.22a. 
After six hours of exposure to simulated gastro-intestinal conditions, pores began to 
develop in the surface structure of the formulation, resulting from polymeric erosion from 
the mucoadhesive membrane. The pore distribution and depth increased with time as 
observed after 12 hours (Figure 4.22a). 
 
A similar phenomenon is observed in the optimized intestinal-targeted mucoadhesive 
layer, where the swelling process caused an irregular surface appearance with areas of 
larger degrees of swelling (Figure 4.22b).  Polymer erosion from the membrane may be a 
potential contributing factor to the tearing and pore formation occurring after six hours of 
exposure to simulated gastro-intestinal conditions as illustrated in Figure 4.22. After 12 
hours of exposure, the surface morphology was drastically altered, with numerous pores 
and tears present. With the resultant polymer erosion from the mucoadhesive layer, it 
would be postulated that a decline in the mucoadhesion should be observed. Since the 
mucoadhesion was not drastically affected (a small loss in the mucoadhesive 
characteristics was observed after 10 hours) it can be concluded that these pores may 
improve the mucoadhesion of the mucoadhesive layer due to the increase in the contact 
area available for mucoadhesion. 
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6hrs, x2000 0hrs, x4000 2hrs, x2040 
12hrs, x2020 6hrs, x2080 0hrs, x4000 
a) 
b) 
12hrs, x1940 
2hrs, x2000 
Figure 4.22: Scanning electron micrographs of a) the optimized gastric-targeted formulation in simulated gastric conditions and b) the optimized 
intestinal-targeted formulation at various time points and magnifications in simulated intestinal conditions. 
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4.7.7 Magnetic Resonance Image analysis of the swelling behaviour of the 
optimized formulations  
Magnetic resonance imaging (MRI) was also employed to observe and confirm the 
swelling and erosion behaviours that occurred during mucoadhesive studies. Figure 4.23 
displays the images obtained for the optimized gastric-targeted and intestinal-targeted 
formulations, where the displayed images were obtained at zero, 15 and 30 minutes, 1, 4, 
8 12 and 24 hours. The light grey part surrounding the formulation is the dissolution 
medium (PBS: pH 1.2±0.1; or 6.8±0.1). As the optimized gastric- or intestinal-targeted 
formulation swelled, the darker grey, un-hydrated portions of the formulation turned white 
due to hydration.  
 
As illustrated in Figure 4.23a, the optimized gastric-targeted formulation became 
progressively larger in size between the zero to one hour time points. Thereafter the 
formulation remained relatively consistent in size throughout the study, with slight size 
variations as a result of the simultaneous swelling and erosion processes occurring within 
the polymeric structure. The simultaneous swelling and erosion occurring with the gastric-
targeted formulation with time, caused significant variations in the hydration state of the 
formulation in relation to time, thus causing variations in the mucoadhesive properties of 
the formulation, as confirmed in Section 4.7.5. 
 
A clear succession of swelling was observed between zero to one hour of the optimized 
intestinal-targeted formulation, followed by an observed decline in the formulation size, as 
illustrated in Figure 4.23b,. As confirmed in previous studies, (Section 4.7.5) erosion 
occurred at a fairly larger degree in the intestinal-targeted formulation. The rapid erosion 
did not, however, detrimentally affect the mucoadhesive properties of the intestinal-
targeted formulation. Therefore, MRI scans confirmed the swelling and erosion behaviour 
of the optimized mucoadhesive formulations.  
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a) 
b) 
Figure 4.23: Magnetic resonance images of the hydration state and accompanying weight 
changes of the a) optimized gastric-targeted formulation and b) the optimized intestinal 
formulation when exposed to simulated gastro-intestinal conditions at different time points.  
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4.8 Concluding Remarks 
 
The mucoadhesive layer of both the gastric- and intestinal-targeted components of the 
MMDDS were successfully developed, optimized and characterized. The Face-centered 
Central Composite Experimental Design generated 13 test formulations, of which effects 
of the independent variables on the dependent response variable was analyzed and an 
optimized formulation was mathematically produced. The experimental and fitted values 
(generated during optimization studies) achieved good correlation, demonstrating a good 
fit of the design model. Analysis of Variance (ANOVA), correlation analysis, and 
regression analysis was used to analyze the dataset, proving the statistical acceptability 
of the models proposed. Both the optimized formulations provided the necessary 
mucoadhesive properties required in their respective pH ranges, ensuring that the 
formulations will provide site-specific drug delivery. Both optimized formulations achieved 
a high desirability with optimization. 
 
Furthermore, this chapter demonstrated the manner in which the optimized formulations 
would react upon exposure to simulated GIT conditions, providing useful information 
required to predict the formulations’ in vivo performance. Tensile analysis revealed that 
the optimized formulations posses suitable elasticity and flexibility, required for insertion 
into capsules. Vibrational and SEM analysis demonstrated that the mucoadhesive 
polymer PVP eroded out of the membranes with extended exposure to simulated GIT 
conditions, which was further confirmed by swelling and erosion studies and MRI 
analysis. The variations observed in the mucoadhesive characteristics were related to the 
physical alteration (i.e. simultaneous swelling and erosion) of the system occurring with 
exposure to simulated gastro-intestinal conditions.  
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CHAPTER 5  
PRELIMINARY DESIGN OF THE DRUG-LOADED NANOFIBROUS MATRICES 
OF THE MULTI-COMPONENT MEMBRANOUS DRUG DELIVERY SYSTEM 
 
 
5.1 Introduction 
 
Electrospinning has gained much popularity in recent years as a versatile and relatively 
simple technique that produces nanofibrous matrices or membranes with fibres ranging in 
the submicron (micrometre) to nanometre size range. The electrospun product, a 
nanofibrous matrix of polymeric fibres, has been investigated extensively for application in 
areas of protective clothing, catalysis, electronic systems, biomedical devices, filtration 
systems, agriculture and composites (Xie and Wang, 2006).  These polymeric fibres can 
be utilized in health care as carriers for drug delivery (Zeng et al., 2003), prevention of 
post-surgical adhesions and infections or wound healing in the form of medicated 
scaffolds (Kim et al., 2004; Jia et al., 2007) or as implantable systems containing 
nanofibres for delivery of bioactive agents over prolonged periods of time (Xie and Wang, 
2006). Other common uses for polymeric nanofibres or nanofibrous matrices are depicted 
in Figure 5.1. 
 
Figure 5.1: Common nanofibre applications (Sourced from Huang et al., 2003; Venugopal 
et al., 2004; Lu and Ding, 2008; Sill and Von Recum, 2008). 
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Granted there are other methods of producing ultra-thin fibres such as mechanical 
drawing or conventional spinning which rely on rheological, gravitational, tensile, inertial 
and aerodynamic forces (Reneker and Chun, 1996) or template synthesis, self-assembly 
and phase separation, it should be noted that these methods require specialized 
equipment, can only be applied to certain materials, cannot always produce continuous 
fibres or are extremely time-consuming (Huang et al., 2003). The electrospinning method 
on the other hand, is a relatively versatile and simpler technique that is able to produce 
thinner, continuous nanofibres by applying an electrical potential to a polymeric solution 
(Reneker and Chun, 1996; Li and Xia, 2004; Li et al., 2006b, Baji et al., 2010).  
 
Electrospun fibrous matrices possess a three dimensional porous structure ideal for 
controlling drug delivery due to their relatively large surface area and porosity. Several 
studies have examined the possibility of utilizing electrospun matrices as a controlled 
release system for the delivery of antibiotics, anti-cancer drugs, vitamins and proteins or 
DNA (tissue engineering applications) (Luu et al., 2003; Kim et al., 2004; Casper et al., 
2005; Chew et al., 2005; Zeng et al., 2005a; Taepaiboon et al., 2007). Electrospun 
membranous matrices have been fabricated using various polymers and solvents, (Table 
5.1), with the necessary physicochemical/physicomechanical properties to achieve the 
desired application (Kim et al., 2007).   
 
Table 5.1: Polymers electrospun drug for delivery applications (Adapted from Sill and Von 
Recum, 2008). 
Polymer Solvents Applications 
Poly(D,L-lactic-co-glycolic 
acid), PEG-b-PLA, and 
PLA 
DMF Electrospun fibres for the sustained delivery of 
drugs (Mefoxin
®
 and cefoxitin sodium) with 
successful retention of the structure and bioactivity 
of the drug molecules (Kim et al., 2004).  
Poly(D,L-lactic-co-glycolic 
acid) 
DCM An implantable electrospun device for the delivery 
of Paclitaxel to cancer cells in vitro (Xie and Wang, 
2006). 
Poly(L-lactide-co-
glycolide) and PEG-PLLA 
Chloroform An implantable electrospun device for the delivery 
of BCNU (Xu et al., 2006). 
(a) Poly(ϵ-caprolactone) 
(b) Poly(ethylene glycol)  
 
(a) TFE  
(b) Water 
 
TE and drug delivery of BSA, core/shell nanofibres 
were prepared via coaxial spinning capable of 
higher protein loading (Zhang et al., 2006b). 
(a) Poly(ϵ-caprolactone) 
and Poly(ethylene glycol)  
(b) Dextran 
 
(a) Chloroform and DMF 
 
(b) Water 
Drug delivery of BSA, core/shell nanofibres were 
prepared via coaxial spinning capable of higher 
protein loading, PEG addition improved control 
over protein release (Jiang et al., 2006). 
(a) Poly(ϵ-caprolactone) 
(b) Poly(ethylene glycol) 
(a) Chloroform and DMF 
(b) Water 
Drug delivery of BSA and lysozyme, core/shell 
nanofibres were prepared via coaxial spinning 
(Jiang et al., 2005). 
Poly(ϵ-caprolactone-co-
ethyl ethylene phosphate) 
DCM and PBS Core/shell nanofibres were prepared via coaxial 
spinning for delivery of β-nerve growth factor and 
BSA, PEG addition improved control over protein 
release (Chew et al., 2005). 
DDS: Drug Delivery Systems; DCM: dichloromethane; THF: Tetrahydrofurane; PBS: Phosphate buffered 
saline; DMF: Dimethyl Formamide; HFP: 1,1,1,3,3,3-hexafluoro-2-propanol; TFE: 2,2,2-trifluoroethanol; BSA: 
Bovine serum albumin 
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The focus of this chapter lies in the selection of a suitable polymer for electrospinning, as 
well as the appropriate parameters employed in the electrospinning procedure. The 
nanofibrous matrix was investigated for its drug release characteristics of both rifampicin 
and isoniazid. Prior to the selection and identification of appropriate polymers for the 
development of the electrospun matrices, it was important to fully comprehend the 
electrospinning procedure, any parameters which would affect electrospinning and the 
ultimate fibre morphology as well as the different methods of drug-loading.   
  
5.1.1 The electrospinning procedure 
Electrospinning is fundamentally based on inducing an electric charge into a polymeric 
solution followed by ejecting the charged solution through a fine capillary tip. The force 
generated by the syringe pump or gravitational forces allows the polymeric solution to 
pass through a capillary of small-diameter, resulting in the formation of a pendant drop at 
the tip. When an electrical potential is applied to the pendant drop the rounded drop 
elongates, becoming conical in shape (Baumgarten, 1971; Doshi and Reneker, 1995; Sill 
and Von Recum, 2008), which is now termed the Taylor cone as illustrated in Figure 5.2 
(Sill and Von Recum, 2008). A fine fibre jet is eventually ejected from the tip of the Taylor 
cone, particularly when the electrical field exceeds the polymeric solution’s surface 
tension (Zeleny, 1935; Liang et al., 2007; Sill and Von Recum, 2008; Baji et al., 2010). 
The fibre jet travels towards the collecting surface, which is typically of opposite polarity. 
Electric forces then accelerate and stretch the fibre jet, causing a reduction in diameter 
and a subsequent increase in length. As the fibre travels through the atmosphere, the 
high electric fields cause the jet to become unstable, which begins to whip at a high 
frequency, and the fibre undergoes further bending and stretching. The solvent then 
evaporates and the resultant solid fibres are deposited on the collecting surface. This 
eventually leads to the formation of a membranous structure through the continuous 
deposition of polymeric fibres on the collecting surface, closing the electrical circuit 
(Deitzel et al., 2001; Pham et al., 2006; Sill and Von Recum, 2008; Baji et al., 2010). The 
resultant product is typically a highly porous matrix or matrix-like structure, possessing a 
high surface area to volume ratio (Liang et al., 2007; Reneker and Yarin, 2008). 
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Figure 5.2: Schematic illustration of the horizontal electrospinning process, where d = 
distance between capillary tip and collecting surface and θ = Capillary angle. 
 
For successful determination of the optimal parameters for the preparation of 
membranous matrices, processing parameters (i.e. the distance of the needle from the 
collecting surface, applied voltage, solution flow-rate) and solution parameters, (i.e. 
viscosity, elasticity, surface tension, solution conductivity) must be carefully manipulated, 
and thus electrospun membranous matrices can be customized to achieve desired drug 
release patterns or other physicochemical properties (Kim et al., 2007; Sill and Von 
Recum, 2008). 
 
5.1.2 Parameters affecting the electrospinning procedure 
In order to successfully apply any electrospun product to a specific target, the nanofibrous 
scaffold must exhibit suitable physical and biological properties closely matching the 
desired application requirements (Liang et al., 2007). As discussed previously, there are 
various factors which affect the ultimate fibre morphology, which can be carefully 
manipulated to achieve electrospun products with finely tuned properties and 
characteristics. These factors can be classified into three broad categories, i.e. solution, 
processing and ambient parameters. These parameters have varying degrees of effects 
on the final fibre morphology as illustrated in Table 5.2. 
 
θ d 
High voltage 
power supply 
Grounded aluminium 
collecting surface 
Taylor cone 
Copper Rod 
Fibre jet 
Whipping 
instability 
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Table 5.2: Effects of electrospinning parameters on fibre morphology. 
Parameter   Effects on fibre morphology References 
Solution Parameters  
Doshi and 
Reneker, 1995; 
Hohman et al., 
2001; Yao et al., 
2003; Mit-
Uppatham  et al., 
2004, Casper et 
al., 2005; Gupta 
et al., 2005; Lu 
and Ding et al., 
2006; Pham et al., 
2006; Sawicka 
and Gouma, 
2006;  Liu et al., 
2008; Sill and Von 
Recum 2008; 
Kriegel et al., 
2009; Bhardwaj 
and Kundu, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Viscosity or polymer 
concentration  
The ability of a solution to form a fibre jet or the electrospinnability of a solution ultimately relies on the 
polymer concentration. Dependant on the viscosity, is the degree of chain entanglements, which is 
responsible for ensuring that the fibre jet remains stable during the electrospinning procedure, without 
breaking up into droplets before deposition on the collecting surface. Very dilute solutions cause the fibre jet 
to break up into droplets before reaching the collector due to the effects of surface tension and a lower 
degree of chain entanglements. Very high concentrations cause very high viscosities, resisting fibre jet 
formation. Within the optimal range of concentrations, electrospun fibre diameter increases with increases in 
the polymer concentration, however with concentrations at the lower end of the range, there is incomplete 
drying of the fibre which leads the presence of junctions and bundles.  Doshi and Reneker (1995) reported 
that solution viscosities of less than 800 centipoises broke up into droplets before reaching the collecting 
surface while solutions with viscosity greater than 4000 centipoises were too thick to electrospin. Thus the 
concentration of the polymer solution should ideally be high enough, causing an adequate degree of chain 
entanglements, while the viscosity should be low enough to allow fibre jet formation. 
Conductivity/ solution 
charge density 
Generally, solutions with a high conductivity tend to have greater charge carrying capacity than solutions 
with low conductivity, subjecting the fibre jet to greater tensile forces. Highly conductive solutions are 
extremely unstable when subject to strong electric fields, ultimately leading to dramatic bending instability as 
well as a broad diameter distribution. However, manipulating the charge density within an optimal range 
may result in the formation of more uniform fibres with lower incidence of bead defects and smaller fibre 
diameters. Solution conductivity can be altered by the addition of alcohol or salts.  
Surface tension Surface tension is more likely to be a function of solvent composition rather than the polymer. Typically, 
solutions with lower surface tensions prevent the formation of bead defects. However, solutions with 
extremely low surface tensions cause the fibre jet to break down into drops before reaching the collecting 
surface, resulting in the formation of beaded fibres and droplets. If the solution has a high surface tension, 
the fibre jets become unstable and eventually breaks up, depositing on the collecting surface as droplets. 
Surface tension can successfully be lowered by addition of surfactants. 
Polymer molecular 
weight 
As the molecular weight of a polymer increases, the optimal concentration range for electrospinning is 
lowered. Gupta and co-workers (2005) managed to isolate the effect of the molecular weight on 
electrospinning while maintaining other parameters constant. Their studies revealed that as the molecular 
weight increased, a reduction in bead defects was observed. Typically, fibres with high molecular weights 
have larger fibre diameters. Furthermore, polymers with lower molecular weight distributions resulted in 
uniform fibres at a lower concentration than those with larger molecular weight distributions. The polymers 
molecular weight may have an effect on surface tension and conductivity. 
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Solvent volatility Typically, solutions containing solvents with higher volatilities produce fibres with higher densities of pores. 
On the other hand, for successful electrospinning the solvent requires adequate volatility to ensure 
adequate drying of the fibre before it deposits on the collecting surface.  
 
 
 
 
 
Doshi and 
Reneker, 1995; 
Hohman et al., 
2001; Yao et al., 
2003;  Mit-
Uppatham  et al., 
2004, Casper et 
al., 2005; Gupta 
et al., 2005; Lu 
and Ding et al., 
2006; Pham et al., 
2006; Sawicka 
and Gouma, 
2006; Liu et al., 
2008; Sill and Von 
Recum 2008; 
Kriegel et al., 
2009; Bhardwaj 
and Kundu, 2010 
Controlled Variables 
Flow rate Polymer flow rate can impact on fibre sizes, shape and porosity. Fibre diameters and porosity tend to 
increase with higher flow rates. Bead defects may also occur at extremely high flow rates, due to incomplete 
drying. Flattened or ribbon-like fibre shapes are also achieved with incomplete drying as opposed to fibres 
with circular cross-sections. With extremely slow flow rates, the Taylor cone cannot be maintained as there 
insufficient solution to replace what has been ejected as the fibre jet. 
 
Applied voltage Suboptimal field strengths lead to bead defects in the spun fibres or even failure in jet formation. Typically, 
fibre diameters decrease in diameter with an increase in the applied voltage until a threshold is reached. 
When the threshold is surpassed, fibre diameters increase with greater likelihood of bead defects. Many 
authors agree that an optimal range of applied voltage is required for any polymer and solvent system. 
 
Capillary-collector 
distance 
Fibre diameters tend to decrease with increased distances. If the distance is not sufficient, incomplete 
drying may lead to bead defects within the polymer fibres, clumping or droplet formation.  
 
Collector 
composition, motion 
and geometry 
Collectors (metals) with a high conductivity dissipate the charge of fibre jets, allowing nanofibres to pack 
more densely. When non-conductive collectors are used, this charge is not dissipated and the fibres repel 
one another, yielding a more porous structure. Porous collectors, such as paper and copper mesh, produce 
less-packed nanofibrous structures as compared to fibres collected on aluminium foil. If the collecting 
surface rotates, i.e. a rotating drum collector, the fibres collect in an aligned fashion.  
 
Ambient parameters 
Temperature If the surrounding temperature is increased, the polymeric solution viscosity decreases, causing a reduction 
in the fibre diameters. 
 
Humidity An increase in the surrounding humidity may result in the appearance of small circular pores on the surface 
of fibres produced.  
Table 5.2 continued 
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5.1.3 Methods of drug incorporation 
There are various methods employed to incorporate drug into nanofibres for drug delivery 
applications (Chew et al., 2005; Luong-Van et al., 2006; Natu et al., 2010). The method of 
drug incorporation, which impacts the drug release behaviour, depends on both the 
polymer and drug solubility. Furthermore, the drug compatibility with the polymer solution 
can potentially affect the release behaviour, i.e. lipophilic drugs should be incorporated in 
lipophilic polymers in order to prevent surface deposition of drug which causes burst 
release characteristics (Natu et al., 2010; Zeng et al., 2005b). Nevertheless, any 
interaction occurring between the drug and the polymer can provide sustained release of 
the drugs, due to changes in the crystallinity of the drug molecules (Taepaiboon et al., 
2006; Yu et al., 2009a; Natu et al., 2010). The various methods of drug incorporation are 
illustrated in Figure 5.3 with the resultant nanofibre morphology.  
 
As discussed in Section 1.2, rifampicin (RIF) and isoniazid (INH) were selected as model 
drugs to determine the efficacy of the drug delivery system. RIF and INH are prescribed 
concurrently in the treatment of TB. However, these drugs are not compatible when 
administered simultaneously, since RIF bioavailability is detrimentally affected by the 
presence of INH. The above and many other drugs would therefore benefit from site-
specific drug delivery (Singh et al., 2000a; Singh et al., 2000b; Singh et al., 2001; Shishoo 
et al., 2001; Mohan et al., 2003; Mariappan et al., 2004; Gohel and Sarvaiya, 2007; du 
Toit et al., 2008; Tanno et al., 2008; Pund et al., 2010; Pund et al., 2011 et al; 2011). 
 
The proposed MMDDS will ensure segregated drug delivery, by delivering RIF to the 
upper gastric region of the GIT, while INH is delivered exclusively to the intestinal areas of 
the GIT. The sites selected were based on RIF being well absorbed from the stomach, 
while INH is relatively well absorbed in the intestinal region of the GIT (Mariappan and 
Singh, 2003). By incorporating the drug into the polymer solution before electrospinning, 
as illustrated in Figure 5.3, a simplistic approach was employed achieving a single step 
drug-loading procedure, while even drug distribution was achieved. 
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Drug can be incorporated by dissolving the drug 
into the polymer solution prior to electrospinning. 
Even drug encapsulation is achieved. However, 
drug solubility and compatibility with the solvent is 
important to ensure minimal surface deposition of 
drug, thus avoiding burst release characteristics 
(Zeng et al., 2005b).  
When the drug and polymer are not soluble in the 
same solvent, the drug is solubilised prior to 
addition to the polymer solution and thereafter 
electrospun. Drug is generally encapsulated within 
the fibre, with some surface deposition that may 
cause burst release (Zeng et al., 2005b; Kim et al., 
2007; Natu et al., 2010).  
The drug and polymer solutions can be kept 
separate and subjected to co-axial spinning. The 
drug solution is fed through an inner capillary tip, 
while polymer solution is ejected from the outer tip. 
During electrospinning, the drug is encapsulated 
within the polymer fibre. No burst release is 
observed due to the absence of surface drug (He et 
al., 2006; Huang et al., 2006). 
If the drug and polymer is not soluble in the same 
solvent, and the respective solvents are not 
miscible, an emulsion is produced which is subject 
to electrospinning. Complete drug encapsulation is 
achieved and controlled drug release is achieved 
by diffusion of the drug molecules out of the fibres 
(Xu et al., 2005; Qi et al., 2006; Maretschek et al., 
2008).  
Drug loading can be conducted after 
electrospinning has occurred. The electrospun 
product is submerged in a drug solution and the 
drug is adsorbed onto the surface of the fibres. 
Typically, positive or negative ions are initially 
adsorbed onto the surfaces, followed by immersion 
into the drug solution. The drug would then form 
and electrostatic interaction with the ions. Release 
is achieved as the interaction is weakened 
(Chunder et al., 2007).  
Figure 5.3: Methods of nanofibre drug incorporation and resultant fibre morphology, where 
the red particles indicate the drug molecules and the green indicates the nanofibre. 
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5.1.4 Preliminary formulation design  
The rational identification of a candidate system for further development was the principle 
focus of the current chapter. The ensuing experimental investigations were conducted to 
provide a logical comparison of the electrospinnability of various polymers, identify the 
most appropriate drug-loading method and determining the need for post-treatments. 
Preliminary formulation studies (Part I) involved, initially selecting and evaluating various 
potential polymers for electrospinning potential and identifying the optimal parameter 
range. Further modification and inclusion of excipients/other polymers was then 
undertaken to develop a candidate system (Part II). This led to the identification of 
candidate formulations of both the rifampicin and isoniazid-loaded nanofibres that would 
achieve the most desirable drug release characteristics.      
 
PART I: Identification of a suitable polymer for electrospinning followed by 
determination of the optimal electrospinning parameters 
 
5.2 Materials and Methods 
 
5.2.1 Materials 
Polymers investigated for electrospinning included poly(vinyl alcohol) (Mw 146000-
186000g/mol, 87-89% hydrolyzed) (PVA), ethylcellulose (Ph Eur viscosity 9m.Pa.sS), 
chitosan (medium molecular weight), cellulose acetate phthalate (CAP) obtained from 
Sigma-Aldrich (Milwaukee, WI, USA); poly(ethylene oxide) (PEO) (PolyoxTM WSR 205-NF 
grade) obtained from The Dow Chemicals Company, (Danbury, CT, USA); 
hydroxypropylcellulose (HPC) (Klucel Type EF) purchased from Hercules (Wilmington, 
Delaware, USA); poly(ethylene glycol) (4000; 6000) (PEG) purchased from Merck 
chemicals (Halfway House, Gauteng, South Africa), Eudragit® RS 100 (Röhm GmbH, 
Pharma Polymers, Kirschenallee, Darmstadt, Germany), carboxymethylcellulose sodium 
salt and cellulose acetate (CA) obtained from Fluka®, (Sigma-Aldrich, GmbH Chemie, 
Steinheim, Germany). Diphenhydramine HCl (DPH) obtained from Sigma-Aldrich (St. 
Louis, Missouri, USA) was employed as a model drug to determine the drug entrapment 
efficiency of the nanofibrous matrices (DPH was initially employed in preliminary studies 
not only to reduce costs associated with INH and RIF use, but also to ensure the 
versatility in application of the MMDDS in terms of drug incorporation). Solvents employed 
included isopropanol purchased from Rochelle Chemicals (Johannesburg, South Africa), 
acetone obtained from Merck (Pty) Ltd. (Merck, Wadeville, Gauteng, South Africa), acetic 
acid purchased from (Sigma Aldrich Chemie GmbH (Steinheim, Germany) and water 
obtained from a Milli-Q water purification system (Milli-Q, Millipore, Billerica, MA, USA). 
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5.2.2 Preparation of nanofibrous matrices by electrospinning 
Homogenous polymeric solutions, employing the solvents and polymer concentrations 
detailed in Table 5.3, were electrospun as follows: The electrospinning setup, as 
illustrated in Figure 5.2, involved applying 5-20kV, supplied by a Glassman High Voltage, 
INC (High Bridge, NJ, USA) to the polymer solutions via a copper rod. The polymer 
solution, placed in 5mL Goldline glass pipettes, was mounted at varying distances from 
the collecting surface. The distance between the capillary tip to collector and applied 
potentials were selected based on Taylor cone formation, and were adjusted accordingly 
during the process of electrospinning to ensure fine fibre jet formation. The solution was 
fed through a capillary size of ±1.2mm from a horizontal electrospinning setup, with 
differing capillary angles (θ) from the horizontal surface. The electrospun fibres were 
collected on an aluminium sheet connected to a grounded counter electrode. 
Electrospinning was carried out at ambient room conditions for periods ranging between 
5-8 hours. The fibres were carefully removed from the aluminium collector and stored in 
air-tight containers, in the presence of a desiccant, until further testing was conducted.  
 
Table 5.3: Polymers and their respective parameters investigated for the development of 
a nanofibrous matrix. 
Polymer Polymer 
Concentration 
(%w/v) 
Solvent Electrospinning variables 
Distance (cm) Applied Voltage (kV) 
CMC 3.5-5.0 Water 18-25  5-20 
PEG 4000 80 Water 15-28  5-20 
PEG 6000 80 Water 15-28  5-20 
CHT 0.5-2.0 0.1M acetic acid 10-30 5-20 
HPC 15 Water: Isopropanol 
(1:1) 
20-25 
 
20 
CA 5-10 Water: Acetone (1:3) 18-25  
 
20 
CAP 5-10 Water: Acetone (1:3) 18-25  
 
20 
Eudragit
®
 
RS 100 
30 Water: Acetone (1:1) 18-25 20 
PVA 6-12 Water 17-20 20 
PEO 3-5 Water 18 5-20 
CMC: Carboxymethylcellulose; PEG: Poly(ethylene glycol); CHT: Chitosan; PVA: Poly(vinyl  alcohol); PEO: 
Poly(ethylene oxide); HPC: Hydroxypropyl cellulose; CA: Cellulose acetate; CAP: Cellulose acetate phthalate 
 
5.2.3 Analysis of nanofibre morphology employing scanning electron 
microscopy  
Surface morphology of the nanofibrous matrices was analyzed on a PhenomTM 
Microscope (FEI Company, Hillsboro, Oregon, USA). Samples were firmly mounted on 
aluminium stubbs with carbon tape. They were subject to a gold sputter coating under a 
vacuum of 0.1Torr with argon gas in a SPI-ModuleTM Sputter Coater and SPI-ModuleTM 
Control (SPI Supplies, Division of Structure Probe Inc., West Chester, PA, USA). Each 
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sample required 90 seconds of coating to ensure complete coverage of the sample.  
Subsequent viewing was thereafter performed at various magnifications under the 
PhenomTM desktop Scanning Electron Microscope. Different magnifications at 10kV were 
employed to view the overall and in-depth surface structure to qualitatively elucidate 
factors such as the nanofibre shape, size range and fibre packing density. The presence 
of bead defects was also determined from the resultant micrographs. 
 
5.2.4 Construction of a calibration curve for UV spectroscopic determination of 
DPH 
A calibration curve for DPH was conducted in PBS (pH 1.2; 37°C) by analysing a known 
series of concentrations of DPH (0-0.7mg/mL) in PBS on a UV spectrophotometer 
(Lambda 25, UV/VIS Spectrometer, PerkinElmer®, Waltham, MA, USA) at a wavelength of 
254nm. A linear curve was generated with the observed absorbance plotted on the y-axis 
and the corresponding concentrations (mg/mL) on the x-axis. With the intercept set at 0, 
the R2 value was determined to be 0.998. 
 
5.2.5 Drug entrapment efficiency 
DPH was employed as a model drug to determine the drug entrapment efficiency (DEE) 
of the resultant nanofibrous matrices, therefore identifying the polymer with the highest 
drug entrapment potential. DPH was incorporated into the polymeric solutions in a 1%w/v 
concentration prior to electrospinning. Accurately weighed samples of DPH-loaded 
nanofibres were dissolved in 100mLs of phosphate buffered saline (PBS) (37ºC; pH 1.2). 
The drug content was analyzed by UV spectrophotometry (Lambda 25, UV/VIS 
Spectrometer, PerkinElmer®, Waltham, MA, USA) and computed from a standard linear 
curve of the drug in PBS (pH 1.2) at a λmax of 254nm for determination of drug content. All 
tests were performed in triplicate (n=3) and presence of the polymer was taken into 
account.  Equation 5.1 was used to compute the DEE, where the theoretical drug (mg) in 
the formulation was determined as a function of the fibre weight. In order to ensure that 
the nanofibers were completely dissolved, the solution was subject to agitation with the 
Sonics Vibra CellTM Sonicator (Sonics and Materials Inc, Newtown, CT, USA) for 15 
minutes at a 60% amplitude. 
 
100% 
t
a
D
D
DEE  
Equation 5.1 
where DEE% = Percentage of drug entrapped; aD = Actual drug quantity (mg) measured 
by UV spectrophotometry and 
tD  = Theoretical drug (mg) added to the formulation.  
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5.3 Results and Discussion 
 
5.3.1 Analysis of the degree of success of polymers investigated for 
electrospinning 
The polymers investigated for electrospinning had varying degrees of success in 
nanofibre fabrication. Successful electrospinning was determined by the fulfilment of two 
factors, namely,  
 
a) The deposition of continuous nanofibres, thus forming a three dimensional matrix;  
b) Achieving consistent electrospinning over a prolonged duration of time, without the 
need for repeated unblocking of the pipette tip.  
 
Generally, when employing solvents with higher volatility, the Taylor cone tended to 
solidify frequently during the electrospinning procedure, preventing any fibre jet formation. 
As a result, electrospinning could not proceed until the blockage was manually removed. 
Furthermore, as the nanofibrous matrix is ultimately rolled and inserted into a capsule, a 
denser packed nanofibrous matrix was preferred as opposed to the more porous 
matrices. The porous nanofibrous matrices were brittle and prone to breakage when 
removed from the collecting surface. Microscopic and scanning electron micrographic 
analysis distinguished polymer electrospinning from electrospraying, and identified any 
deposition of droplets within the nanofibre structure. Droplets typically deposit on the 
collecting surface in a more hydrated state than the nanofibres, and thus cause 
agglomeration of the fibres surrounding the area of droplet deposition. This defect has the 
potential to drastically alter the release characteristics of the nanofibrous matrix, due to 
vastly differing shapes or sizes, and was thus deemed undesirable. Polymers which were 
unable to form three dimensional nanofibrous matrices may be as a result of improper 
solvent choice, polymer concentration or solution viscosity, very low or high surface 
tension or conductivity.  
 
5.3.1.1 Carboxymethyl cellulose 
When attempting to electrospin higher concentrations of the carboxymethylcellulose 
(CMC) solution (5%w/v), a fibre jet was unable to form due to the high viscosity of the 
solution. However, when attempting to electrospin the 3.5%w/v CMC solution, some form 
of electrospraying intermingled with electrospinning occurred, depositing droplets on the 
collecting surface in a very random and erratic manner. Furthermore, an insufficient 
quantity of the droplets was obtained regardless of electrospinning duration. Upon 
microscopic analysis (Figure 5.4), it was revealed that the CMC solution did not produce 
132 
 
any continuous fibres, but rather a collection of randomly scattered bead-like particles of 
varying sizes and shapes. Further alterations in the solution or processing parameters 
demonstrated no success fibre formation. Further electrospinning investigations 
employing CMC as a polymer for the production of nanofibrous matrices were thus not 
conducted. 
 
Figure 5.4: Microscopic analysis of CMC electrospun at a concentration of 3.5%w/v CMC.  
 
5.3.1.2 Poly(ethylene glycol) 4000 
Electrospinning of poly(ethylene glycol) (PEG) 4000 solutions required significantly 
prolonged electrospinning periods before a sufficient quantity of the electrospun product 
was obtained. Furthermore, the product was very randomly distributed, with no formation 
of a three dimensional matrix structure. The resultant electrospun product was rather 
powdery in nature and extremely prone to disintegrating when handled for further 
analysis. Altering the processing parameters demonstrated no success in improvement 
fibre formation. Microscopic and scanning electron micrographic analysis (Figure 5.5) 
revealed that continuous fibres were not formed, but rather highly porous and elongated 
bead-like particles about 500μm in length were randomly deposited. Further 
electrospinning investigations employing PEG 4000 were therefore not conducted. 
 
 
Figure 5.5: a) Microscopic and b) Scanning electron micrographic analysis at a 
magnification of 2400x depicting the surface morphology of PEG 4000 electrospun at a 
concentration of 60%w/v. 
a) 
b) 
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5.3.1.3 Poly(ethylene glycol) 6000 
Electrospinning PEG 6000 for significant periods of time did not produce a sufficient 
quantity of the electrospun product. Furthermore, the quantity that was present was 
randomly and erratically distributed, which did not form any sort of three dimensional 
matrix or structure. The product had a waxy feel and appearance, and was very brittle and 
prone to breakage and/or disintegration. Altering the processing parameters 
demonstrated no success in fibre formation. Microscopic and SEM analysis (Figure 5.6) 
revealed irregular-shaped porous structures with random distribution and with size ranges 
of 100-200μm in diameter. Further electrospinning investigations employing PEG 6000 
were thus absolved. 
 
 
 
5.3.1.4 Chitosan 
Typically, high concentrations of chitosan (CHT) were unable to form any type of Taylor 
cone, and could thus not be electrospun. However, during electrospinning of lower 
concentrations of CHT solutions, the fibre jet that was able to form, was extremely 
unstable, producing erratic periods of electrospraying rather than electrospinning. 
Attempts at altering the processing and solution parameters demonstrated no success in 
improving fibre formation. However, some large and randomly scattered droplets were 
deposited on the collecting surface. CHT was thus deemed to be unsuitable for further 
electrospinning investigations. 
 
Figure 5.6: a) Microscopic analysis and b) Scanning electron micrographic analysis at a 
magnification of 8600x depicting the surface morphology of PEG 6000 electropsun at a 
concentration of 80%w/v. 
a) b) 
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5.3.1.5 Hydroxypropyl cellulose 
Electrospinning of hydroxypropyl cellulosic (HPC) solutions was consistent, with uniform 
and even deposition of the electrospun product (Figure 5.7). However, frequent blocking 
of the pipette tip occurred, necessitating manual removal of the blockage before the 
electrospinning process could continue. Although macroscopically it appeared as if the 
polymer was being electrospun into fibres, microscopic and SEM evaluation revealed that 
no fibres, but rather many bead-like particles were deposited on the collecting surface. 
The size range of the particles varied drastically, from the deposition of extremely fine 
particles, to larger particles of 3-6μm in diameter. The particles were typically spherical in 
shape, however, some particles collapsed as it was deposited, concaving in certain areas 
of the particle surface. Further electrospinning investigations employing HPC were thus 
absolved. 
 
 
 
5.3.1.6 Cellulose acetate 
Cellulose acetate (CA) electrospun as a 5%w/v solution demonstrated very random and 
erratic deposition of bead-like particles with the presence of some fibres. Blockage of the 
pipette tip was extremely frequent due to rapid evaporation of the solvent, and therefore 
prevented any further solution from being electrospun. Microscopic analysis revealed that 
some fibres were present with diameters of less than 1μm. However, these fibres 
demonstrated beaded defects as depicted in Figure 5.8. Furthermore, the fibres were not 
continuous in its length, and no three dimensional structure or matrix was obtained. 
Figure 5.7: a) Microscopic analysis and b) Scanning electron micrographic analysis at a 
magnification of 8600x depicting the surface morphology of HPC electropsun at a 
concentration of 15%w/v. 
a) b) 
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Microscopic and SEM analysis revealed that the particles deposited were extremely 
porous in nature, which can be attributed to rapid evaporation of the solvent, and varied 
drastically in both size (smaller particles ranging in 2-5μm in diameter and larger particles 
ranging from 100-300μm in diameter) and shape (spherical to elongated particles), with 
no clear pattern of deposition, where large amounts of deposition occurred in some 
regions while little or no deposition occurred in other areas. CA was therefore not included 
in further electrospinning investigations. 
 
 
 
5.3.1.7 Cellulose acetate phthalate 
A larger degree of electrospraying rather than electrospinning occurred with the 5%w/v 
solution of cellulose acetate phthalate (CAP) as depicted in Figure 5.9a-b. The particles 
deposited were extremely porous, with the larger particles ranging in diameters of 30-
60μm, while the smaller particles possessed diameters of <10μm. Increasing the 
b) 
c) 
a) 
Figure 5.8: a) Microscopic; and scanning electron micrographic analysis at  
magnifications of b) 445x and c) 2400x depicting the surface morphology of CA 
electropsun at a concentration of 5%w/v. 
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concentration to 10%w/v caused some degree of fibre deposition as illustrated in Figure 
5.9c-d while a reduction in the larger particle size to 15-30μm was observed. The fibres 
however, were not continuous in length and erratically deposited. The quantity of fibres 
deposited was not sufficient to ensure adequate drug-loading and therefore, an increase 
in the polymer concentration was attempted to obtained greater quantities of fibres. 
However, these solutions were too viscous to electrospin and blockages occurred almost 
instantaneously. Furthermore, electrospinning of CAP failed to produce the three-
dimensional structure required for drug delivery applications. Further electrospinning 
investigations employing CAP were thus absolved. 
 
 
 
Figure 5.9: Scanning electron micrographic analysis depicting the surface morphology of 
the 5%w/v CAP at magnifications of a) 495x and b) 2400x; and 10%
w/v CAP at 
magnifications of c) 480x and d) 2400x. 
a) b) 
b) d) 
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5.3.1.8 Eudragit® RS 100 
Electrospinning of a 30%w/v solution of Eudragit
® RS 100 was extremely rapid and erratic, 
producing a highly porous, three dimensional matrix with a ‘candyfloss’ appearance. 
Although electrospinning was rapid, blockages tended to occur often, halting the 
electrospinning process intermittently. The resultant matrix was extremely brittle and 
prone to breakage. Microscopic and SEM analysis (Figure 5.10) revealed that the fibres 
produced were flat and ribbon-shaped (due to inadequate drying prior to deposition), with 
a very wide diameter distribution of 2-50μm. The fibres appeared to have a crystalline 
appearance, which may be attributed to the brittle nature of the matrix. Alterations to the 
solution or processing parameters provided no further improvement in fibre formation. 
Eudragit® was thus not employed in any further studies. 
 
 
 
 
 
5.3.1.9 Poly(vinyl alcohol) 
Electrospinning of poly(vinyl alcohol) (PVA) proved to be the most successful in producing 
a uniform and consistent three dimensional matrix. The electrospinning procedure was 
rarely halted by blocking of the pipette tip. An optimal concentration range of 7-12%w/v of 
PVA for electrospinning was identified, with a 10%w/v solution providing the most 
consistent nanofibrous matrix. The matrix was relatively consistent and densely packed. 
Electrospinning for periods of 3-5 hours produced an adequate quantity of fibres in the 
form a nanofibrous matrix. The matrix was relatively easy to handle, and did not 
disintegrate easily when handled. Furthermore, fibres were successfully produced, 
regardless of alterations in the solution or processing parameters. Therefore PVA was 
Figure 5.10: a) Microscopic analysis and b) scanning electron micrograph at a 
magnification of 440x depicting the surface morphology of electrospun Eudragit® RS 100 
at a 30%w/v solution. 
a) 
b) 
138 
 
identified as the most suitable and versatile polymer to be employed in the development 
of the drug-loaded nanofibrous matrix. Scanning electron microscopic analysis revealed 
that thin, cylindrical, continuous and uniform fibres were deposited as depicted in Figure 
5.11. There was however, deposition of some large, wet droplets which caused fusing of 
the nanofibres in certain regions, therefore necessitating minor adjustments to the 
solution and/or processing parameters. The fibre diameter was determined to be within a 
range of 400nm.  
 
 
 
5.3.1.10 Poly(ethylene oxide) 
Attempts at electrospinning of poly(ethylene oxide) (PEO) solutions at concentrations of  
3, 4 and 5%w/v were successful in the production of three dimensional nanofibrous 
matrices. However, fibres were deposited in an inconsistent manner, with some areas of 
larger fibre accumulation than others. In comparison to electrospinning of PVA solutions, 
there was a greater frequency in blockages occurring which necessitated manual removal 
before electrospinning could proceed. Furthermore, the quantity of the electrospun 
quantity obtained for the duration of electrospinning of a 3%w/v or 5%
w/v PEO solution was 
not feasible for scale-up procedures. However, a 4%w/v solution produced a sufficient 
quantity of fibres during the electrospinning procedure. The resultant matrix was, 
nevertheless, extremely prone to disintegration when being handled for further 
processing. Scanning electron microscopic analysis (Figure 5.12) revealed that only the 
5%w/v produced a nanofibrous matrix containing fibres with consistent diameters of 200-
Figure 5.11: Scanning electron micrographs at magnifications of a) 455x and b) 2420x 
depicting the surface morphology of PVA electrospun at a 10%w/v concentration.  
a) 
b) 
Droplets causing agglomeration of 
surrounding fibres 
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300nm. There was a notable absence of bead defects and droplet deposition in the 
resultant matrix, resulting in the production of a uniform and consistent three-dimensional 
nanofibrous matrix. 
 
 
  
5.3.2 Calibration curves for UV spectrophotometric determination of DPH  
Figure 5.13 displays the calibration curve obtained for DPH in PBS (pH 1.2; 37°C), with 
an R2 value of 0.998, demonstrating good linearity, and the equation determined as 
y=1.304x. 
 
Figure 5.12: Scanning electron micrographs depicting the surface morphology of PEO 
electrospun at concentrations of a) 3%w/v at a magnification of 2040x; b) 4%
w/v at a 
magnification of 2080x and c) 5%w/v at a magnification of 2060x. 
b) 
c) 
a) 
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5.3.3 Drug entrapment efficiency of electrospun nanofibres 
Studies indicated that the DEE value was considerably higher in PVA nanofibres 
(93.5±2.12%) as compared to PEO nanofibres (54±1.41%) (Figure 5.14), thus indicating 
that PVA possessed a greater potential for entrapping DPH due to its hydrophilic nature. 
Furthermore, high drug entrapment was achieved with a single step drug-loading and 
electrospinning process, identifying the method of drug incorporation suitable for scale-up 
purposes.  
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Figure 5.14: Comparison of Diphenhydramine HCl entrapment efficiency within PVA and 
PEO nanofibres. 
 
Figure 5.13: Diphenhydramine HCl calibration curves in PBS (pH 1.2 at 37°C). 
y=1.304x 
R2=0.998 
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Following the identification of PVA possessing superior DEE properties, it was determined 
the PVA would be selected as a suitable polymer for electrospinning. Granted, some 
droplets were observed within the nanofibrous matrix; however, minor adjustments to the 
solution and or processing parameters can be made to reduce such defects. Although 
electrospinning of PEO produced uniform nanofibres, the resultant matrix demonstrated 
poorer drug entrapment properties, while the matrix possessed inferior physical 
characteristics (i.e. disintegrated when being handled); thus mitigating any further studies 
employing PEO for electrospinning. 
 
Part II: Improving the electrospinnability of poly(vinyl alcohol) solutions with the 
incorporation of excipients 
 
5.4 Materials and Methods 
 
5.4.1 Materials 
All electrospinning experiments conducted employed the polymer PVA (Sigma Aldrich, 
Milwaukee, WI, USA), with a typical average molecular weight (Mw) of 146000-186000 
and degree of hydrolysis of 87-89%. Isoniazid (INH) and rifampicin (RIF) purchased from 
Sigma (Sigma Aldrich Chemie GmbH, Steinheim, Germany) were utilized as the model 
drugs to determine drug entrapment and drug release. Excipients investigated for 
improving PVA electrospinning included silicone antifoaming agent (BDH, VWR 
International Ltd, London, UK); Tween® 80 (polysorbate) and Span® 80 (sorbitan oleate) 
uniLAB® (Merck Chemicals (Pty) Ltd, Wadeville, Gauteng, RSA); sodium chloride (NaCl, 
Mw=58.44g/mol; Saarchem, Wadeville, Gauteng, South Africa); poly(ethylene oxide) 
(PolyoxTM WSR 205-NF grade) obtained from The Dow Chemicals Company, (Danbury, 
CT, USA); silicone antifoaming agent, Silicone, purchased from BDH (BDH, VWR 
International Ltd, London, UK and glycerol (Associated Chemical Enterprises (Pty) Ltd. 
Southdale, South Africa).  
   
Hydrochloric acid (32%w/v), used to dissolve RIF, was purchased from Merck Chemicals 
(Merck Chemicals (Pty) Ltd, Wadeville, Gauteng, RSA). All chemicals utilised were of 
analytical grade and used without further purification. Phosphate buffered saline (PBS) 
was prepared using sodium hydroxide (NaOH, Mw=40.00g/mol) and sodium chloride 
(NaCl, Mw=58.44g/mol; Saarchem, Wadeville, Gauteng, South Africa), hydrochloric acid 
(HCl, 32%w/v) purchased from Rochelle Chemicals (Johannesburg, South Africa) and 
potassium dihydrogen phosphate (KH2PO4, Mw=136.09g/mol) obtained from Riedel-de 
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Haen (Sigma-Aldrich Laborchemikalein GmbH, Germany) in double-deionised water 
(Milli-Q System, Millipore, Bedford MA, USA). 
 
5.4.2 Preparation of PVA nanofibrous matrices by electrospinning 
Preliminary studies identified PVA as the most suitable polymer to be employed for the 
preparation of the nanofibrous matrices. Differing concentrations (6, 7, 8, 10 and 12%w/v) 
of PVA were dissolved in water. The clear PVA solution was thereafter electrospun 
according to the method depicted in Section 5.2.2. Briefly, a horizontal electrospinning 
setup was employed while the electrospun fibres were collected on an aluminium sheet 
connected to a grounded counter electrode. Electrospinning was carried out at ambient 
room conditions for periods ranging between 5-8 hours. The fibres were carefully 
removed from the aluminium collector, cut into 20x30mm dimensions and stored in air-
tight containers, in the presence of a desiccant, until further testing was conducted.  
 
5.4.3 Influence of sodium chloride addition on the electrospinnability PVA 
Following the identification of the optimal concentration for PVA, the effects of sodium 
chloride (NaCl) addition on the electrospinnability of PVA was investigated. NaCl was 
incorporated to the PVA solution at a concentration of 2%w/v to investigate the effects of 
conductivity variations on the electrospinning potential. The solution was then electrospun 
according to the method described in Section 5.4.2. The influence of NaCl on nanofibre 
formation was investigated by scanning electron microscopic analysis. 
 
5.4.4 Influence of Tween® 80 addition on the electrospinnability of PVA  
Lowering the surface tension of the PVA solution by incorporating surfactants mitigates 
the formation of bead defects (Table 5.2). Furthermore, is stabilizes the fibre jet, ensuring 
fibre, rather than droplet deposition. Tween® 80, a hydrophilic surfactant, was 
incorporated into the PVA solution at a concentration of 5%w/v and the resultant 
homogenous solution was electrospun according to the method depicted in Section 5.4.2. 
The influence of Tween® 80 on nanofibre formation was investigated by scanning electron 
microscopic analysis. 
 
5.4.5 Influence of Span® 80 addition on the electrospinnability of PVA 
Span® 80, a hydrophobic surfactant was incorporated into the PVA solution to determine 
the effect of a hydrophobic surfactant on the electrospinnability of PVA solutions as 
opposed to a hydrophilic surfactant. Span® 80 at a concentration of 5%w/v was initially 
dissolved in the solvent (water), followed by addition of PVA. When a homogenous 
solution was obtained, it was subject to the electrospinning method depicted in Section 
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5.4.2. The influence of Span® 80 on nanofibre formation was investigated by scanning 
electron microscopic analysis. 
 
5.4.6 Influence of silicone addition on the electrospinnability of PVA 
Addition of an antifoaming agent, silicone was also investigated for potentially improving 
the electrospinnability of the PVA solution. Silicone was added in a concentration of 
0.1%w/v to the solvent, water, prior to PVA addition. When silicone was satisfactorily 
distributed throughout the solvent, PVA was then incorporated and the solution was 
agitated until a clear and homogenous solution was obtained. The silicone-PVA solution 
was electrospun according to the method described in Section 5.4.2. The influence of 
silicone addition on nanofibre formation was analyzed employing scanning electron 
microscopy. 
 
5.4.7 Influence of glycerol addition on the electrospinnability of PVA 
The effects of plasticizer addition on the electrospinnability of PVA solution was 
investigated by the addition of glycerol. Glycerol was added to the solvent (water) at a 
concentration of 5%w/v, followed by PVA addition. When a clear solution was obtained it 
was subject to electrospinning as detailed in Section 5.4.2. The influence of glycerol 
addition on nanofibre formation was analyzed employing scanning electron microscopy. 
 
5.4.8 Influence of drug incorporation on the electrospinnability of PVA 
Drug-polymer solutions were prepared by initially dissolving the drug in their respective 
solvents (RIF in 0.01M HCl; INH in water) at concentration of 2%w/v. PVA was then added 
and the solution was agitated. The homogenous drug-polymer solution was then subject 
to electrospinning as described in Section 5.4.2. The variations arising from the addition 
of drugs RIF and INH on the electrospinnability of PVA was identified and alterations to 
the solution and processing parameters were made accordingly. Various excipients 
including Tween® 80 (5%w/v) and silicone (0.1%
w/v) were added to PVA solutions to 
improve the electrospinning procedure and outcome. The influence of drug addition on 
nanofibre formation was analyzed employing scanning electron microscopy. 
 
5.4.9 Elucidation of pertinent rheological properties of the polymer solutions 
employed in electrospinning 
The variations in the rheological properties of PVA solutions with excipient addition were 
determined with the use of a Modular Advanced Rheometer System (ThermoHaake 
MARS Rheometer, Thermo Fischer Scientific, Karlsuhe, Germany). The stress-strain 
rheological parameters of the polymer solution have an influence on electrospinning, and 
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are important factors when considering the desired characteristics of a solution to be 
electrospun. In particular, changes in the viscosity of the solution to be electrospun results 
in variations in nanofibre diameter. Samples were analyzed by placing the polymer 
solution on the sample stage and immersing the C35/1° titanium rotor in the polymeric 
solution while the temperature was maintained at 24°C. The shear rate was maintained at 
100/s for 360 seconds and the viscosity was quantified for each solution.  
 
5.4.10 Determination of the electrical conductivity of the polymer solutions 
employed in electrospinning 
The variations in the electrical conductivity of the PVA solutions with excipient addition 
were determined with the use of an OAKTON® TDS TesterTM (Model UD-35661-70, 
Solon, OH, USA). The electrode was immersed in the polymer solution at 25°C and the 
electrical conductivity, measured in μSiemens, was determined.  
 
5.5 Results and Discussion 
 
5.5.1 Determination of the optimal PVA concentration for the electrospinning of 
three-dimensional nanofibrous matrices 
Solution concentrations of 8-10%w/v PVA exhibited the most desirable electrospinning 
properties and outcomes. The resultant matrices were uniform and consistent, and fibre 
diameters increased from 297.5±29.47nm to 345.00±30.41nm with an increase in PVA 
concentration from 8%w/v to 10%
w/v. Minimal droplet formation was observed when 
electrospinning PVA solution concentrations within said range as opposed to other 
solution concentrations. Furthermore, the quantity of electrospun fibres produced within 
the same time frame was considerably greater than those produced at other 
concentrations, with a PVA concentration of 10%w/v producing the largest quantity of 
fibres that possessed the highest packing density. Scanning electron micrographic 
analysis (Figure 5.15) revealed that electrospinning of PVA concentrations less than that 
of 8%w/v caused a large degree of droplet formation within the nanofibrous structure due 
to the decreased incidence of chain entanglements. As a result, the degree of chain 
entanglements was not adequate to allow the fibre to maintain a fibre while travelling to 
the collecting surface. It was thus deduced that the viscosity of these solutions was not 
conducive to electrospinning. PVA solutions of concentrations greater than 10%w/v 
produced fibres that demonstrated a wide diameter distribution (less than 1μm to 5.5μm). 
Furthermore, fibre deposition was extremely haphazard and erratic, with areas of larger 
fibre deposition that others. Electrospinning of a 10%w/v PVA solution demonstrated the 
greatest success in the formation of a uniform and consistent three-dimensional 
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nanofibrous matrix, and was thus selected as the optimal concentration for the fabrication 
of the drug-loaded layer of the MMDDS. 
 
 
a) 
c) d) 
e) 
Figure 5.15: Scanning electron micrographs illustrating the surface morphology of PVA 
electrospun at concentrations of a) 6%w/v; b) 7.5%
w/v; c) 8%
w/v; d) 10%
w/v and e) 12%
w/v at 
magnifications of 2020x, 2080x, 2420x, 2380x, 2000x respectively. 
b) 
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5.5.2 Effect of excipient addition on the electrospinnability of PVA 
Typically, addition of excipients caused undesirable alterations in the surface morphology 
of the PVA nanofibres. Some viscosity and electrical conductivity changes (Table 5.4) 
were also observed which caused the variations in the both the electrospinnability of the 
solution and surface morphology of the resultant nanofibrous matrix.  
 
 
a) b) 
Figure 5.16: Scanning electron micrographs depicting the changes in surface morphology 
of PVA nanofibres with the addition of a) sodium chloride at 2400x; b) Tween® 80 at 
2380x; c) Span® 80 at 2400x, d) silicone at 2480x and e) glycerol at 2480x. 
c) 
d) 
e) 
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Table 5.4: Effects of excipient addition on the viscosity of PVA solutions. 
Electrospinning solution 
parameters 
Viscosity at shear rate 
of 100/s (mPas) 
Conductivity of Solution 
(μSiemens) 
10%
w
/v PVA 830.53±26.41 635 
10%
w
/v PVA + 2%
 w
/v NaCl  1137.29±4.40 484 (after a 1:100 dilution) 
10%
w
/v PVA + 5%
w
/v Tween
®
 80 351.59±13.78 740 
10%
w
/v PVA + 5%
w
/v Span
®
 80 838.77±8.08 646 
10%
w
/v PVA + 0.1%
 w
/v Silicone 1098.46±9.91 692 
10%
w
/v PVA + 5%
w
/v Glycerol 748.68±3.93 500 
 
Attempts to increase the conductivity of the solution with the addition of salts caused an 
increase in the incidence of droplet formation (Figure 5.16a). Furthermore, fibre 
deposition was erratic, with varying degrees of accumulation. This can be attributed to the 
increase in the electric potential (Table 5.4) caused by the addition of salts, resulting in 
the formation of an unstable fibre jet during electrospinning. This instability is known to 
cause an increased incidence of defects such as beaded fibre morphology and droplet 
formation (Table 5.2). Furthermore, the resultant fibres typically possess a wide fibre 
distribution as illustrated in Figure 5.16a, which is related to the increase in the viscosity 
of the solution with NaCl addition (Table 5.4). 
 
Both Tween® 80 and Span® 80 were investigated as potential non-ionic surfactants which 
may improve the electrospinnability of the PVA solution. Surfactants typically lower the 
surface and interfacial tension of the solution, preventing the formation of both droplets 
and beaded fibre morphology (Table 5.2). However, scanning electron micrographic 
analysis revealed the presence of bead defects and formation of droplets within the 
nanofibrous matrix with surfactant addition (Figure 5.16b-c), with a larger degree of 
defects occurring with Tween® 80 addition. Therefore the addition of the surfactants 
caused a reduction in the surface tension of the solution to a suboptimal level, causing the 
fibre jet to break up into droplets before reaching the collecting surface (Table 5.2).  
 
Rheological and conductivity analysis of the surfactant incorporated solutions provides 
further evidence that surfactant addition caused detrimental effects on the 
electrospinnability of the solutions. As depicted in Table 5.4, the conductivity of the 
solution increased slightly with Tween® 80 addition, thus promoting fibre jet instability and 
hence the presence of defects increased. Furthermore, rheological analysis revealed that 
a dramatic decrease in the viscosity of the PVA solution occurred with the addition of 
Tween® 80 (from 830.53±26.41 to 351.59±13.78mPas) detrimentally affecting the 
electrospinnability of the solution. This resulted in a higher incidence of bead defects 
relative to Span® 80 addition, where an increase in the viscosity was observed. The 
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increase in the viscosity after the addition of Span® 80 can be related to the likelihood of 
the surfactant associating with the polymer molecules via electrostatic and/or 
hydrophilic/hydrophobic interactions, causing the notable increase solution viscosity 
(Goddard and Hannan, 1976; Manglik et al., 2001; Jung et al., 2005). As a result, the 
presence of a larger degree of chain entanglements causes the fibre jet to deposit as 
droplets and not continuous fibres (Table 5.2). Furthermore, fibre deposition was highly 
erratic and haphazard, with a reduced quantity of nanofibres collected. 
 
In contrast, silicone addition improved the electrospinnability of the PVA solution by 
preventing both droplet deposition and the incidence of beaded fibre morphology. 
Furthermore, consistent, uniform fibres were deposited with random orientation, while the 
fibre diameters were maintained within a small range (350-400nm). A sufficient quantity of 
nanofibres were formed which were deposited as a consistent, uniform three dimensional 
matrix. Antifoaming agents, such as silicone are able to prevent foam formation through 
several forces resulting from its inherently low surface tension. To successfully displace 
foam, the antifoaming agent spreads over the liquid surface and displaces the foam 
stabilizing film surrounding the surface, while causing an increase in the film elasticity of 
foam (Kulkarni et al., 1977; Pape, 1983).  
 
Therefore, it can be postulated that during electrospinning, these forces may allow easier 
fibre jet formation by destabilizing the film surrounding the Taylor cone, thus increasing 
the rate of fibre deposition (i.e. less effort is required to induce and maintain the fibre jet, 
increasing fibre jet production). Furthermore, increasing the elasticity of the film 
surrounding the Taylor cone ensures that the film surrounding the fibre jet possess a 
higher elasticity, and when subject to whipping instability, forms fibres with uniform 
diameter distribution. In drug delivery systems, a uniform structure and size distribution 
are important factors to ensure that reproducible and consistent rates of drug release are 
achieved (Liu et al., 2010). Therefore, the resultant nanofibrous matrix was deemed 
suitable for the delivery of RIF and INH, and further studies employed the use of silicone 
(0.1%w/v) in the formation of the drug-loaded nanofibrous matrices. 
 
Glycerol addition resulted in the formation of an extremely porous matrix with an 
increased incidence of beaded fibre morphology. Addition of plasticizers such as glycerol 
typically breaks down any inter- and intra-molecular interactions of the polymer chains, 
hence facilitating their flow by decreasing the degree of chain entanglements. As a result, 
the viscosity of the solution is lowered (Pakraven et al., 2011).  Rheological evaluation of 
the glycerol incorporated solution reveals said viscosity decrease (from 830.53±26.41 to 
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748.68±3.93mPas), causing a detrimental effect on the electrospinnability of the PVA 
solution by decreasing the degree of chain entanglements which preventing the formation 
of a stable fibre jet. Furthermore, the decrease in the conductivity occurring after glycerol 
addition affected the whipping instability of the fibre jet. This in turn, affected the 
dimensions of the nanofibres formed (Table 5.2). The effects of both the reduction in 
viscosity and conductivity caused a non-uniform deposition of the nanofibres on the 
collecting surface, while an increased incidence of beaded defects was also observed. 
 
5.5.3 Effect of drug incorporation on the electrospinnability of PVA solutions 
Electrospinning of a solution containing RIF (2%w/v) and PVA (10%
w/v) was unsuccessful. 
Through qualitative assessment, the viscosity of the solution was observed to dramatically 
increase with drug incorporation. This viscosity increase detrimentally affected the 
electrospinning process, causing failure in fibre jet formation. When a fibre jet did form, it 
was highly unstable, with erratic deposition tendencies. Furthermore, a higher incidence 
of beaded defects was observed. PVA was thus reduced to a concentration of 8%w/v to 
ensure a lower viscosity, thus improving the electrospinnability of the RIF-PVA solution. 
Although the RIF-PVA solution was successfully electrospun (Figure 5.17b), it was 
observed that fibre deposition was highly erratic with a high incidence of beaded defects. 
As illustrated in Figure 5.17c, addition of Tween® 80 (5%w/v) dramatically improved the 
electrospinnability of the RIF-PVA solution, and uniform, consistent fibres were deposited 
with minimal beaded defects and droplet formation. A solution containing 10%w/v PVA and 
2%w/v INH was successfully electrospun (Figure 5.17e). Silicone addition improved the 
electrospinnability of the solution by preventing droplet formation and producing a 
consistent and uniform three-dimensional structure. The quantity of nanofibres obtained 
was sufficient to ensure an adequate drug quantity was obtained.  
 
The effects of incorporating drugs RIF and INH on the viscosity of the electrospinning 
solution as well as the tensile, fibre diameter distribution and drug entrapment efficiency 
of the resultant nanofibrous matrices are further detailed in Chapter 6 of the present 
dissertation.   
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Figure 5.17: Scanning electron micrographs depicting the surface morphology of a) an 8%w/v PVA solution; b) an 8%
w/v PVA solution 
containing 2%w/v RIF; c) an 8%
w/v PVA solution containing 2%
w/v RIF and 5%
w/v Tween 80; d) 10%
w/v PVA solution; e) a 10%
w/v PVA solution 
containing 2%w/v INH, and f) a 10%
w/v PVA solution containing 2%
w/v INH and 0.1%
w/v silicone at magnifications of 2420x, 2400x, 2480x, 2380x, 
2400x, and 1200x respectively. 
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5.6 Concluding Remarks 
 
Electrospun membranous systems have the advantage of increasing the surface area 
available for drug release due to the porous, nonwoven structure of the membranous 
system. Nanofibrous structures are produced with relative ease ensuring a single step 
drug entrapment process. Porosity, strength, surface functionality and fibre diameter, and 
hence drug release, can be manipulated by varying certain parameters during 
electrospinning, i.e. such as polymer and concentration or applied voltage (Frenot and 
Chronakis, 2003; Kim et al., 2007). 
 
Various polymers were investigated in order to develop the drug-loaded nanofibrous layer 
for application in the MMDDS. PVA and PEO demonstrated the most success in forming a 
relatively consistent three-dimensional nanofibrous matrix. Drug entrapment efficiency 
studies revealed that PVA demonstrated a greater efficiency for entrapping DPH 
molecules when electrospun. Therefore, based on both the electrospinnability and drug 
entrapment efficiency, PVA was identified as the most suitable polymer and further 
studies were therefore undertaken to improve the electrospinnability of the PVA solution. 
An optimal concentration range of 8-10%w/v for PVA electrospinning was identified, and 
any increase within the optimal range caused an increase in the nanofibre diameter. 
Ineffective solution parameters were also identified by determining the effects of excipient 
incorporation prior to electrospinning. Silicone was identified as the only excipient that 
improved the electrospinning characteristics of the PVA solution by minimizing both bead 
defects and the deposition of droplets. A RIF-PVA (2-8%w/v) solution containing 5%
w/v 
Tween® 80 was identified as the candidate formulation for the production of RIF-loaded 
nanofibrous matrices, while an INH-PVA solution (2-10%w/v) containing 0.1%
w/v silicone 
was selected as a candidate formulation for the development of the INH-loaded 
nanofibres matrices to be incorporated in the MMDDS. 
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CHAPTER 6  
FABRICATION, MODIFICATION AND CHARACTERIZATION OF THE DRUG-
LOADED NANOFIBROUS MATRICES OF THE MULTI-COMPONENT 
MEMBRANOUS DRUG DELIVERY SYSTEM 
 
 
6.1 Introduction 
 
Many synthetic and natural polymers have been investigated for their potential in 
developing electrospun drug delivery devices. Amongst these polymers includes 
poly(vinyl alcohol) (PVA), which has been widely investigated in the production of 
electrospun nanofibres intended for water filtration or solvent separation applications 
(Wang et al., 2006), fuel cells (Lin et al., 2010), tissue engineering (Kim et al., 2008) and 
drug and protein delivery (Zeng et al., 2005a). PVA is exploited for use in drug delivery 
due to its high hydrophilicity, ease of processing, good mechanical and thermal stability, 
high biocompatibility, and its non-toxic and biodegradable nature (Koski et al., 2004). This 
chapter focuses on the use of PVA nanofibres as potential drug delivery devices, for the 
prolonged release of model drugs RIF and INH.  
 
Depending on the processing parameters, electrospun PVA fibres may dissolve instantly 
upon contact with aqueous mediums. As a result, there has been limited use of 
electrospun PVA nanofibres in biomedical applications and in particular, controlled drug 
release systems (Liu et al., 2009; Cai et al., 2010). However, nanofibres can be modified 
after the electrospinning procedure through various post-treatments to alter the 
physicochemical properties of the nanofibres or to functionalize nanofibre surfaces to 
provide various functionalities (Yu et al., 2009b). Several studies have investigated the 
potential of crosslinking PVA membranes post-electrospinning, thereby producing a 
structure with poorer solubility characteristics and increased mechanical properties, which 
is ideal for both water filtration systems and biomedical devices (Bolto et al., 2009; Liu, et 
al., 2009; Tang et al., 2010).  
 
Glutaraldehyde (GA) solutions are commonly used to crosslink PVA, thereby retarding 
dissolution in physiological fluids. The mechanism of crosslinking (Figure 6.1) involves the 
chemical bonding of the hydroxyl groups present in PVA with the aldehyde groups of GA. 
A strong acid acts as a catalyst in this reaction (Tang et al., 2010). However, GA is highly 
toxic to physiological tissues and therefore post-treatment and other methods of 
detoxification are required to prevent the harmful effects of residual GA. A study by 
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Ramires and Milella (2002) confirmed that crosslinking PVA using GA vapours produced 
membranes with no residual GA. This allows for safer alternative in producing a 
biocompatible crosslinked PVA intended for biomedical applications without necessitating 
post detoxification processes (Ramires and Milella, 2002).  Many studies have been 
performed investigating the potential applications of GA vapour-induced crosslinking of 
polymers and are summarized in Table 6.1.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Polymers crosslinked with GA vapours and their intended application. 
Substrate crosslinked Intended application Reference 
Hard and Soft Gelatin 
Capsules 
Modified capsules for DD Meyer et al., 2000 
PVA-HA and PVA-GEL 
membranes 
Biocompatibility assessments Ramires and 
Milella; 2002 
Electrospun PVA membrane Investigation of enzyme (cellulase) 
immobilization (TE)  
Wu et al., 2005 
Electrospun PVA scaffolds UF membranes Wang et al., 2006 
Electrospun Gelatin fibres Biomedical Applications particularly 
TE, WH and DD 
Zhang et al., 2006c 
Electrospun PLGA, PLLA, 
PCL, and PLCL scaffolds 
Vascular grafts in TE Lee et al., 2007 
Electrospun COL-GAG 
scaffold 
TE Scaffolds Zhong et al., 2007 
Electrospun CHT-PLA mats WD and WH applications Ignatova et al., 
2009 
Electrospun PAN/HEC 
membranes 
UF membranes Zhang et al., 2009 
Electrospun CHT-SF 
composites 
WD and WH applications Cai et al., 2010 
PVA: Polyvinyl alcohol; HA: Hyaluronic acid; GEL: Gellan; PLGA: Poly (D,L-lactide-co-glycolide); PLLA: 
poly(L-lactide); PCL: poly(e-caprolactone); PLCL: poly(D,L-lactide-co-ε-caprolactone); COL: Collagen; 
PAN/HEC: polyacrylonitrile/hydroxyethyl cellulose; CHT: Chitosan; PLA: Poly[(L-lactide)-co-(D,L-lactide)]; SF: 
Silk Fibroin; TE: Tissue Engineering; WH: Wound Healing; WD: Wound dressing; DD: Drug Delivery; UF: 
Ultrafiltration; GAG: glycosaminoglycan 
Figure 6.1: Crosslinking reaction occurring between PVA and Glutaraldehyde in the 
presence of HCl. 
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6.2 Materials and Methods 
 
6.2.1 Materials 
All electrospinning experiments conducted employed the polymer PVA (Sigma Aldrich, 
Milwaukee, WI, USA), with a typical average molecular weight (Mw) of 146000-186000 
and degree of hydrolysis of 87-89%. Isoniazid (INH) and rifampicin (RIF) purchased from 
Sigma (Sigma Aldrich Chemie GmbH, Steinheim, Germany) were utilized as the model 
drugs to determine drug entrapment and drug release. An antioxidant, ascorbic acid 
(Sigma Ultra, Sigma Aldrich, St Louis, MO, USA), was incorporated in the nanofibres to 
prevent degradation of RIF. An antifoaming agent, Silicone, purchased from BDH (BDH, 
VWR International Ltd, London, UK) was utilized to enhance electrospinning of INH-
loaded nanofibres while Tween® 80 uniLAB® (Merck Chemicals (Pty) Ltd, Wadeville, 
Gauteng, RSA) was used to improve the electrospinnability of RIF-loaded nanofibres. 
Hydrochloric acid (32%w/v), used to dissolve RIF, was purchased from Merck Chemicals 
(Merck Chemicals (Pty) Ltd, Wadeville, Gauteng, RSA). Glutaraldehyde Solution Grade II 
25%w/v was purchased from Sigma Aldrich Co (St Louis, MO, USA). All chemicals utilised 
were of analytical grade and used without further purification. Water was purified and 
deionised using an Elix 5UV Millipore Filter. 
 
6.2.2 Electrospinning of drug-loaded nanofibres 
Drug solutions were prepared at ambient room conditions in their respective solvents at 
concentrations illustrated in Table 6.2. When a clear and homogenous drug solution was 
obtained, the antioxidant, ascorbic acid was added. The antioxidant-drug solution was 
then further agitated to produce a homogenous solution, followed by the addition of 
silicone/Tween® 80. Lastly PVA was incorporated into the solution in its respective 
concentrations. The homogenous drug-polymer solution was then electrospun as follows: 
The electrospinning setup, as illustrated in Figure 5.2, involved applying 20kV, supplied 
by a Glassman High Voltage, INC (High Bridge, NJ, USA) to the drug-polymer solutions 
via a copper rod. The drug-polymer solution, placed in 5mL Goldline glass pipettes, was 
mounted at distances of 21-28cm from the collecting surface. The solution was fed 
through a capillary size of ±1.2mm from a horizontal electrospinning setup, with the 
capillary being angled at 10°-11.5° from the horizontal surface. The electrospun fibres 
were collected on an aluminium sheet connected to a grounded counter electrode. 
Electrospinning was carried out at ambient room conditions for periods ranging between 
5-8 hours. The fibres were carefully removed from the aluminium collector and stored in 
air-tight containers, in the presence of a desiccant, until further processing was carried 
out. 
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Table 6.2: Electrospinning parameters of INH- and RIF-loaded nanofibres. 
Parameters RIF-loaded nanofibres INH-loaded nanofibres 
Solution Parameters   
PVA Concentration 8%
w
/v 10%
w
/v 
Drug concentration 2%
w
/v 2%
w
/v 
Solvent  Weak HCl solution Deionised water 
Surfactant Tween
®
 80 at 5%
w
/v  None added 
Antioxidant Ascorbic acid at 1%
w
/v None added 
Anti-foaming agent None added Silicone anti-foaming agent  
(0.1%
w
/v) 
   
Electrospinning Parameters   
Voltage Supplied 20kV 20kV 
Distance between capillary tip and 
collecting surface (d) 
28cm 21-24cm 
Capillary size 1.2mm 1.2mm 
Capillary angle (θ) 11.5° 10° 
 
6.2.3 Modification of the drug-loaded nanofibrous matrices through crosslinking 
Crosslinking was carried out in the presence of GA vapours. HCl (32%w/v), as a catalyst, 
was added to the GA solution on a 3:1 ratio of GA:HCl. The GA-HCl was placed in the 
lower portion of desiccant jars while accurately weighed samples of drug-loaded PVA 
nanofibres were suspended approximately 5cm over the solution using a fine mesh sieve. 
Formulations were crosslinked according to parameters illustrated Table 6.3. The system 
was kept closed to impart a vapour-rich environment as illustrated in Figure 6.2. Drug-
loaded membranes were allowed to crosslink in the vapour-rich environment for periods 
ranging from 6 to 24 hours at ambient room conditions, and thereafter stored in airtight 
containers with the presence of a desiccant until further testing was performed.  
 
Table 6.3: Crosslinking variables of non-drug and drug-loaded PVA nanofibres. 
Formulation Drug 
Concentration 
PVA 
Concentration 
Concentration 
GA:HCl (mL) 
Time (hours) 
1 - 10% w/v - - 
2 INH : 2%w/v 10%
 w/v - - 
3 INH : 2%w/v 10%
 w/v 15: 5 24 
4 INH : 2%w/v 10%
 w/v 30:10 12 
5 INH : 2%w/v 10%
 w/v 60: 15 6 
6 - 8% w/v - - 
7 RIF : 2%w/v 8%
 w/v - - 
8 RIF : 2%w/v 8%
 w/v 15: 5 24 
9 RIF : 2%w/v 8%
 w/v 30:10 12 
10 RIF : 2%w/v 8%
 w/ 60: 15 6 
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Figure 6.2: Schematic illustration of the crosslinking procedure of PVA nanofibre 
membranes. 
 
6.2.4 Construction of calibration curves for the UV spectroscopic determination 
of RIF and INH 
A calibration curve for RIF and INH was conducted in PBS (pH 1.2 and pH 6.8 
respectively) by analysing a known series of concentrations of the respective drug in PBS 
on a UV spectrophotometer (Lambda 25, UV/VIS Spectrometer, PerkinElmer®, Waltham, 
MA, USA). The content of RIF and INH was analyzed at wavelengths of 237 and 263nm. 
A linear curve was generated with the observed absorbance plotted on the y-axis and the 
corresponding concentrations (mg/mL) on the x-axis. With the intercept set at 0, the R2 
values were determined to be 0.998 for RIF and 1.00 for INH. 
 
6.2.5 Determination of the Drug Entrapment Efficiency of PVA nanofibres 
In order to determine the DEE of RIF- and INH-loaded PVA nanofibres, accurately 
weighed samples of INH- and RIF-loaded nanofibres were dissolved in 100mLs of 
phosphate buffered saline (PBS) (37ºC) at pH 1.2 and 6.8 respectively. In order to ensure 
that the nanofibres were completely dissolved, the solution was subject to agitation with 
the Sonics Vibra CellTM Sonicator (Sonics and Materials Inc, Newtown, CT, USA) for 15 
minutes at a 60% amplitude. The drug content was analyzed by UV spectrophotometry 
(Lambda 25, UV/VIS Spectrometer, PerkinElmer®, Waltham, MA, USA) (parameters 
illustrated in Table 6.4) and computed from a standard linear curve of the drug in PBS. All 
tests were performed in triplicate (n=3) and presence of the polymer was taken into 
account. The DEE equation depicted in Section 5.2.5 was used to compute the DEE.  
 
Table 6.4: Parameters employed to determine DEE of drug-loaded PVA nanofibres. 
Drug RIF INH 
PBS pH 1.2; 37ºC pH 6.8; 37ºC 
Wavelength  237nm 263nm 
Standard linear curve RIF in PBS (pH 1.2; 37ºC) INH in PBS (pH 6.8; 37ºC) 
R
2
 value R
2
=0.9998 R
2
=1.00 
 
Vapour rich 
environment 
(closed system)
Fine mesh sieve
GA-HCl solution
PVA nanofibre 
membranes
Vapour rich 
environment 
(closed system) 
Fine mesh sieve 
PVA nanofibre 
matrices 
GA-HCl solution 
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6.2.6 In vitro drug release studies 
In vitro drug release studies were conducted using a six-station USP apparatus II (Erweka 
DT 700 GmbH Germany), in which a single nanofibrous membrane of known mass was 
placed within the vessel under a stainless steel ring mesh assembly. This prevents the 
paddle inflicting physical/mechanical damage to the nanofibrous matrices which can 
potentially alter the drug release characteristics, in addition to preventing any erratic 
fluctuation due to unstable hydrodynamics (Pillay and Fassihi, 2000). Each vessel 
contained 900mL of PBS at pH 6.8 or pH 1.2 for INH- and RIF-loaded nanofibres 
respectively. The PBS was heated to a temperature of 37°C prior to the addition of the 
nanofibrous membranes and the stainless steel ring mesh assembly. The apparatus was 
calibrated for a 12 hour run, and the rotating paddle method was selected with a rotational 
speed of 50rpm. Sampling occurred at hourly intervals and involved the drawing of 5mL of 
now drug incorporated solution from the dissolution vessel. An equal quantity of the 
removed buffer was replaced with fresh buffer to maintain sink conditions. Samples were 
then subject to UV spectrophotometry and drug quantity was determined using a standard 
calibration curve. 
 
6.2.7 Influence of drug-loading and crosslinking on the surface morphology and 
network density of the nanofibrous membranes 
Surface morphology of the nanofibrous matrices were analyzed on a PhenomTM 
Microscope (FEI Company, Hillsboro, Oregon, USA). Samples were firmly mounted on 
aluminium stubbs with carbon tape. They were subject to a gold sputter coating under a 
vacuum of 0.1Torr with argon gas in a SPI-ModuleTM Sputter Coater and SPI-ModuleTM 
Control (SPI Supplies, Division of Structure Probe Inc., West Chester, PA, USA). Each 
sample required 90 seconds of coating to ensure complete coverage of the sample.  
Subsequent viewing was thereafter performed at various magnifications under the 
PhenomTM desktop scanning electron microscope. Different magnifications at 10kV were 
employed to view the overall and in-depth surface structure to qualitatively elucidate 
factors such as the nanofibre size range and density, as these factors affect drug release 
from the nanofibrous membrane system. Denser nanofibrous networks tend to entrap 
drug particles within its network structure and these molecules may only be released upon 
slow disentanglement of the network system.  
 
6.2.8 Image processing using MathematicaTM 8.0 
SEM (.tif) images of electrospun nanofibres were processed using MathematicaTM 8.0 
(Wolfram Research, Champaign, IL) using a sequential procedure of blurring, 
colorquantizing and generating an image histogram. Initially, the area of interest was 
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cropped to restrict image content to that of the scaffold. The whole analysis was 
performed on an HP Pavilion dv5-1102TU with an Intel Pentium Dual-Core (2.0 GHz, 3 
GB RAM) running Microsoft Vista Basic. 
 
6.2.9 Determination of PVA:GA structural interactions as a result of nanofibre 
crosslinking with GA 
The vibrational molecular transitions of the non-crosslinked and crosslinked electrospun 
nanofibrous membrane systems were characterized for the attainment of important micro-
structural data via an Attenuated Total Reflectance Fourier-Transform Infrared (ATR-
FTIR) spectroscopy, recorded on a PerkinElmer® Spectrum 100 Series fitted with a 
universal ATR polarization accessory (PerkinElmer Ltd., Beaconsfield, UK).  Spectra were 
recorded over the range of 4000-625cm-1, with a resolution of 4cm-1 and 32 iterations. 
Furthermore, the FTIR spectra of the native polymer (PVA), and drugs RIF and INH were 
analyzed in relation to the electrospun and crosslinked formulations to determine whether 
the electrospinning or crosslinking procedure caused any structural changes or 
interactions between the drug and native polymer. 
 
6.2.10 Elucidation of pertinent rheological properties of the polymer solutions 
employed in electrospinning 
The rheological properties of PVA solutions at various concentrations were determined 
with the use of a Modular Advanced Rheometer System (ThermoHaake MARS 
Rheometer, Thermo Fischer Scientific, Karlsuhe, Germany). The stress-strain rheological 
parameters of the polymer solution have an influence on electrospinning, and are 
important factors when considering the desired characteristics of a solution to be 
electrospun. In particular, changes in the viscosity of the solution to be electrospun results 
in variations in nanofibre diameter. Samples were analyzed by placing the polymer 
solution on the sample stage and immersing the C35/1° titanium rotor in the polymeric 
solution while the temperature was maintained at 24°C. The shear rate was maintained at 
100/s for 360 seconds and viscosity was quantified for each solution. The aforementioned 
shear rate was selected for comparative purposes only and a constant shear rate was 
selected to reduce sample variability.   
 
6.2.11 Determination of the tensile properties and Young’s Modulus of 
crosslinked and non-crosslinked nanofibrous membranes  
Young’s Modulus and other tensile properties of the crosslinked and non-crosslinked 
nanofibres were determined using the nanoTensile® 5000 (Hysitron Inc. Nanomechanical 
Test Instrument, Minneapolis, MN). The nanotensile (NT) apparatus was calibrated before 
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samples were tested to ensure accuracy. Samples, cut into approximately 2x15mm strips, 
were mounted on the specially designed NT mounting brackets as illustrated in Chapter 4, 
Figure 4.13. The brackets were held together with a rigid cardboard frame, aiding in 
sample alignment, and the samples were attached to the brackets using a rigid 
cyanoacrylate-based adhesive, thus holding the sample firmly in place during the test 
procedure. Samples were allowed to cure and accurate measurements of the sample 
width, thickness and length were recorded using digital callipers. The upper sample 
bracket was secured to the upper sample gripper of the NT head and the mass 
measured. The NT head was lowered and the lower sample bracket secured to the lower 
sample gripper on the NT stage. The mounting brackets were moved apart at a constant 
rate of displacement of 100μm/sec and the tensile properties of the sample were 
measured and recorded. The test was performed in triplicate (n=3).  
 
6.2.12 Static lattice atomistic simulations 
All modelling procedures and calculations, including energy minimizations in molecular 
mechanics, were performed using the HyperChemTM 8.0.8 Molecular Modeling System 
(Hypercube Inc., Gainesville, Florida, USA) and ChemBio3D Ultra 11.0 (CambridgeSoft 
Corporation, Cambridge, UK) on an HP Pavilion dv5 Pentium Dual CPU T3200 
workstation. The structure of PVA (ten monomer units) was generated from standard 
bond lengths and angles employing polymer builder tools using ChemBio3D Ultra in its 
syndiotactic stereochemistry as 3D models and was saved in .skc file format readable to 
HyperChemTM 8.0.8. Structures of GA, INH and RIF were built up with natural bond 
angles as defined in the HyperChemTM software. The models were initially energy-
minimized using MM+ force field and the resulting structures were again energy-
minimized using the AMBER 3 (Assisted Model Building and Energy Refinements) force 
field. The conformers having the lowest energy were used to create the polymer-
crosslinker and polymer-drug complexes. A complex of one molecule with another was 
assembled by disposing the molecules in a parallel way, and the same procedure of 
energy-minimization was repeated to generate the final models: PVA-PVA, PVA2-INH, 
PVA2-RIF and PVA2-GA3. Full geometry optimization was carried out in vacuum 
employing the Polak-Ribiere conjugate gradient algorithm until an RMS gradient of 
0.001kcal/mol was reached. Force field options in the AMBER (with all hydrogen atoms 
explicitly included) and MM+ (extended to incorporate non-bonded cut-offs and restraints) 
methods were the HyperChemTM 8.0.8 defaults (Kumar et al., 2011b). 
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6.3 Results and Discussion 
 
6.3.1 Calibration curves for UV spectrophotometric determination of RIF and INH 
Figure 6.3a displays the calibration curve obtained for RIF in PBS (pH 1.2; 37°C); and 
Figure 6.3b displays the calibration curve obtained for INH in PBS (pH 6.8; 37°C), with an 
R2 value of 0.9998 and 1.00 respectively. The regression equations were determined to 
be y=33.905x and y=29.947x for the RIF and INH calibration curves respectively. 
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Figure 6.3: Constructed calibration curves of a) RIF in PBS (pH1.2; 37°C) at a 
wavelength of 237nm and b) INH in PBS at a wavelength of 263nm (pH 6.8; 37°C). 
 
a) 
b) 
y = 33.905x 
R
2
 = 0.998 
y = 29.947x 
R
2
 = 1.00 
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6.3.2 Drug Entrapment Efficiency (DEE) of PVA nanofibres 
A drug entrapment value of 98.77±1.384% and 95.07±1.988% was calculated for the INH- 
and RIF-loaded PVA nanofibres respectively (Figure 6.4). DEE results indicate that drug-
loading of nanofibres, as opposed to other nanoparticulate structures, is considerably 
higher. This can be attributed to the method of nanofibre formation, where electrospinning 
of the drug-polymer solution ensures that drug is entrapped within the nanofibres during 
fibre formation and therefore drug is embedded within the solid nanofibres. Various other 
nanoparticulate systems involve drug loading after the nanoparticulate structure is 
formed, and thus drug-loading is dependent on the diffusion of the drug through the 
nanoparticulate structure into the core. This results in variable drug-loading capacities 
between drugs of differing sizes and solubility. As RIF and INH have differing solubility’s 
but similar DEE, it should be noted that DEE of PVA nanofibres is not determined by the 
solubility of the drugs, but rather through the process of electrospinning, and the 
parameters employed during this process. 
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Figure 6.4: Graphical representation of the Drug Entrapment Efficiency of RIF- and INH-
loaded nanofibres. 
 
6.3.3 In vitro drug release from crosslinked nanofibrous matrices 
Non-crosslinked nanofibrous matrices dissolve instantaneously upon contact with a 
dissolution medium. As a result, drug release from these matrices is immediate 
(Formulations 2 and 7). Vapour-induced crosslinking of the PVA fibres imparted water-
insoluble properties on the fibrous network, resulting in slower drug release rates. Drug 
release from nanofibrous membranes is typically a biphasic process, with initial 
desorption of drugs from the fibre surface occurring alongside fast diffusion into the 
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aqueous phase (burst release), followed by solid-state diffusion of drug from within the 
solid nanofibres (slower release rate) (Leung and Ko, 2011).  
 
The burst release of INH and RIF, demonstrated in all formulations investigated for drug 
release, can be attributed to the initial desorption and fast diffusion of drug from the 
nanofibre surface into the dissolution medium (Figure 6.5). This is followed by a reduced 
rate of drug release due to the solid-state diffusion of drugs through the solid PVA 
nanofibres.  INH-loaded nanofibrous matrices demonstrated slower drug release over 12 
hours in formulations crosslinked for longer durations, indicating that sufficient time is 
required to ensure adequate crosslinking of the PVA nanofibres. Formulation 3 
demonstrated the most ideal drug release characteristics with 81.11±2.35% of the total 
drug being released in a controlled manner over 12 hours. Since a longer duration of 
crosslinking was required to ensure the most ideal release properties, it can be concluded 
that crosslinking time, rather than crosslinker quantity, was integral to modify nanofibrous 
matrices with appropriate degree of crosslinking required to achieve the desired drug 
release characteristics. The total quantity of drug release of Formulation 4 and 
Formulation 5 (94.95%±0.0011 98.653%±0.0086 respectively) occurred at a relatively 
quicker rate than Formulation 1 (60% of drug was released by the third hour in 
Formulation 4 and 5 as compared to Formulation 3, where seven hours were required to 
release 60% of the total drug quantity). These findings further reiterate the conclusion that 
the duration of crosslinking was a more important factor than quantity of crosslinker for 
modifying PVA nanofibres. 
 
Of the RIF-loaded formulations, Formulation 9 demonstrated optimal drug release kinetics 
with 59.31±2.57% being release over 12 hours in a controlled manner. Formulations 
crosslinked for longer durations than 12 hours (Formulation 8) released notably lower 
quantities of drug (46.34%±0.0336) during the study period. As a result, PVA nanofibres 
had crosslinked to a degree that was beyond necessary, and the remainder drug was 
entrapped within the formulation, rather than being released. As such, it was determined 
that the duration of crosslinking for RIF-loaded nanofibres should not be greater than 12 
hours to ensure maximum drug quantities are released in a controlled manner.   
 
The variations in the drug release between the INH-loaded and RIF-loaded nanofibrous 
membranes can be attributed to the hydrophilicity of the respective drug molecules. INH, 
a hydrophilic drug molecule, required longer crosslinking periods as compared to RIF, 
which has a hydrophobic nature, to obtain prolonged drug release characteristics. The 
hydrophobic nature of RIF ultimately resulted in slower drug release of RIF-loaded 
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nanofibrous membranes than INH-loaded formulations of the same crosslinking quantity 
and time. These findings are depicted in Figure 6.5 where Formulation 3 released 
81.11±2.35% of INH over 12 hours as opposed to Formulation 8 where only 46.34±3.35% 
of RIF was released over 12 hours. 
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Figure 6.5: In vitro fractional drug release of a) Formulations 3-5 in PBS (pH 1.2) at 37°C 
and b) Formulations 8-10 in PBS (pH 6.8) at 37°C. 
 
6.3.4 Surface Morphology and network density of the nanofibrous membranous 
system 
Scanning electron microscopic evaluation revealed the formation of solid, uniform, 
cylindrical nanofibres of a non-porous surface with random orientation. The absence of 
pores on the surface of the nanofibres is principally dependant on the type of solvent 
used. In this case water was the solvent employed, and with its relatively low volatility 
a) 
b) 
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prevented the formation of pores. The absence of surface pores on the nanofibres aided 
in slowing the release rate of the incorporated drugs (Leung and Ko, 2011). As discussed 
in Section 6.3.7, the effects of increasing the polymer concentration on the diameter of the 
nanofibres is clearly illustrated on comparison of Figure 6.6a and Figure 6.7a. Increasing 
the polymer concentration from 8%w/v (Figure 6.7a) to 10%
w/v PVA (Figure 6.6a) caused 
an increase in the fibre diameter from 297.5±29.47nm to 345.00±30.41nm as was 
demonstrated. 
 
Figure 6.6a and Figure 6.6b demonstrates that the addition of INH had negligible affects 
in the fibre morphology and fibre diameter. A relatively smaller increase in the diameter 
from 345.00±30.41nm to 372.5±28.61nm was observed. However, the addition of RIF 
caused a drastic increase in the fibre diameter of 297.5±29.47nm to 631±57.78nm (Figure 
6.7a-b). The increase in diameter correlates to the large increase in the viscosity of the 
RIF-loaded PVA solution (Section 6.3.7). Furthermore, RIF-loaded nanofibres were 
deposited on the aluminium collector in a rather haphazard fashion with many bends and 
kinks in the fibre structure, as opposed to straighter and more uniform fibres deposited in 
non-drug loaded nanofibres. 
 
Crosslinking “contracted” nanofibres within the nanofibre matrices, producing a denser 
structure with closely packed nanofibres (Figure 6.6c-d and Figure 6.7c-d). The change in 
the nanofibre structure may also contribute to delaying drug release due to the decrease 
in surface area available for dissolution.  
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Figure 6.6: Scanning electron micrographs of a) Formulation 1; b) Formulation 2; c) 
Formulation 3; and d) Formulation 4. 
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Figure 6.7: Scanning electron micrographs of a) Formulation 6; b) Formulation 7; c) 
Formulation 8; and d) Formulation 9. 
 
6.3.5 Image processing algorithm for electrospun nanofibres 
According to Wolfram Research Inc., “MathematicaTM provides broad and deep built-in 
support for both programmatic and interactive modern industrial-strength image 
processing—fully integrated with Mathematica's powerful mathematical and algorithmic 
capabilities. Mathematica's unique symbolic architecture and notebook paradigm allow 
images in visual form to be included and manipulated directly both interactively and in 
programs.” (MathematicaTM Image Processing and Analysis Guide, 2011). Here we used 
MathematicaTM to evaluate the influence of addition of drugs and crosslinking on the 
morphological characteristics of PVA electrospun nanofibres. Gray level images show a 
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complex structure in which, either an uneven illumination, or a lack of contrast or other 
sources of noise, hide the real pattern. In order to carry out the surface and fibre density 
analysis, fibre edges were extracted from the gray level images and histographical 
analysis was carried out for the modified images (Figure 6.8a-d).  
 
Sixteen-bit greyscale images obtained by SEM polymeric scaffolds were low in contrast 
(Figure 6.6 and Figure 6.7). This may have happened due to the non-uniform gold 
coating. In addition, the background appeared uneven due to inconsistent illumination 
across the field of view. Since thresholding of such images was unable to capture all of 
the required details, we employed some image-processing steps to even out the 
background and increase contrast between the fibres, pores in the fibrous matrix and the 
rest of the image. Images in .tif format were imported as shown in Expression 1 (Exp1) 
and converted to MathematicaTM 8.0 format (Figure 6.8a-d original): 
 
Exp1: SEMimage = Import[“X:\\directory\\folder\\filename.tif”]; 
 
The first processing step, blurring the image, created an unfocused image, which can be 
obtained by convolving the image with a low pass filter. In this work, the amount of 
blurring is increased by increasing the pixel radius (r) to 10 without compromising image 
detail. This was achieved in MathematicaTM 8.0 by applying a custom blurring function 
(Exp2) (Figure 6.8a-d blurred): 
 
Exp2: BLURimage = Blur[SEMimage,10]; 
 
After blurring the image, the next step was to ColorQuantize the blurred image at 5 which 
provided an approximation to the image that uses only 5 distinct colours. This was 
achieved in MathematicaTM 8.0 by applying a custom colorquantize function (Exp3) 
(Figure 6.8a-d colorquantized): 
 
Exp3: CQimage = ColorQuantize[BLURimage,5]; 
 
The third step consisted of analysing the images by plotting a histogram (Figure 6.9). The 
histogram expressions for original and processed images are denoted as OrgHistoSep 
and ProHistoSep, respectively. This default function plots a histogram of the pixel levels 
for each channel in image. Furthermore, separate histograms for each color channel were 
also constructed. This was achieved in MathematicaTM 8.0 by applying the custom 
ImageHistogram functions for default and separated algorithms as displayed in Exp 4: 
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Exp4:OrgHistoSep = ImageHistogram[SEMimage,Appearance→”Transparent”] 
 
Exp5:ProHistoSep = ImageHistogram[CQimage,Appearance→”Transparent”] 
 
The comparative analysis of histograms obtained before (Figure 6.9a-d) and after (Figure 
6.9e-h) image processing revealed the striking effect of these steps on image histogram’s 
clarity such that the presence of fibre uniformity and distribution is more obvious.  
 
 
Figure 6.8: Image processing of PVA nanofibre micrographs representing a) Formulation 
6; b) Formulation 7; c) Formulation 3; and d) Formulation 4 in MathematicaTM 8.0 format. 
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An analysis of the histogram is essential for the best choice of the threshold for 
discriminating between different morphological features seen in the SEM of electrospun 
nanofibres. Figure 6.9e (placebo nanofibres) displays a tetramodal distribution having 
peaks at 103, 119, 141 and 158 (voxel intensities) representing voxels for air-filled deep 
pores (porous throughout), pores reaching the second or third layer of the fibrous matrix, 
solid fibres in second or third layers and solid fibres in the top layer, respectively, in the 
order of increasing linear absorption coefficients. The peaks on either side of these pores 
and solid interfaces are blurred because of the finite spatial resolution of the scanning 
system creating an undesirable partial-volume effect. We assumed that the probability of 
finding intensity at a pore-fibre boundary should be equal for both the features. Therefore, 
the average of these peaks was chosen as the threshold (i.e., intensity ~130), implying 
that the voxels with an intensity equal to or smaller than 130 are pores. It is true for 103 
and 119 which we assumed as pores earlier. This very assumption was used for the 
interpretation of the effect of addition of RIF to the nanofibres (Figure 6.9f) where the 
distribution became pentamodel with peaks at 63, 88, 104, 128 and 158 voxel intensities. 
The new threshold shifted from 130 voxel (original) to 108 voxel implying that intensities 
below 108 will represent porous structure. The above shifts towards air-filled pores may 
be attributed to an increase in fibre diameter (decreased solid area covered) leading to 
formation of larger pores causing an increase size of pores (increased porosity).  
 
In the next part of ImageAnalysis, effect of variation of crosslinking on the morphological 
features of electrospun scaffold was evaluated. As evident from Figure 6.9g, the 
histogram of SEM image of fibres exposed to 15mL of glutaraldehyde represented a 
trimodal distribution having peaks at 64, 93 and 127 (voxel intensities) corresponding to 
voxels for air-filled deep pores and the solid fibrous matrix, in the order of increasing 
linear absorption coefficients. As in previous case, the peaks on either side of these pores 
and solid interfaces are blurred because of the finite spatial resolution of the scanning 
system creating an undesirable partial-volume effect. The average of these peaks was 
chosen as the threshold (i.e., intensity ~94), implying that the voxels with an intensity 
equal to or smaller than 94 are pores and greater ones are solid fibres. However in case 
of Figure 6.9, corresponding to SEM image of fibres exposed to 30mL of glutaraldehyde, 
the trimodal distribution culminated in a threshold value of 119 (average of voxel 
intensities of 68, 122 and 168). This means that there are more pores in Figure 6.9g than 
Figure 6.9h and Figure 6.9h is more fibrous than Figure 6.9g. Furthermore, the shift of 
histogram threshold from 94 to 119 may be attributed to the presence of dense network of 
fibres and hence less porous structure when amount of crosslinking agent is increased. 
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Figure 6.9: ImageHistograms of scanning electron micrographs representing a) 
Formulation 6-original, b) Formulation 7-original, c) Formulation 3-original, d) Formulation 
4-original; e) Formulation 6-processed, f) Formulation 7-processed, g) Formulation 3-
processed and h) Formulation 4-processed. Note that each channel is only capable of 
highlighting most of the pores and fibres. 
 
6.3.6 PVA:GA structural interactions as a result of nanofibre crosslinking 
The possibilities of chemical and physical interactions as a result of crosslinking were 
evaluated using FTIR. Furthermore, if one considers the process of electrospinning of 
aqueous polymer solutions, it is of interest to ascertain to what extent the nature of the 
native polymer is modified. Examination of the FTIR spectra generated for the non drug- 
loaded PVA nanofibres (Figure 6.10) demonstrated that the electrospinning procedure 
had a minimal impact on conferring inter- or intra-molecular arrangements, with no band 
shifts or enhancements observed as compared to pure PVA (Figure 6.10).  
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Figure 6.10: FTIR spectra of a) Pure PVA and b) an electrospun PVA nanofibrous matrix. 
  
Crosslinking, on the other hand, had an impact on the establishment of inter- or intra-
molecular crosslinks and is demonstrated by the variations in band intensities. The 
crosslinking of PVA with GA generally occurs through the formation of a –C–O–C– 
between the –OH of a typical PVA structure and the –C– of a GA molecule. As illustrated 
in Figure 6.11a-b, the transmittance bands at 1380cm-1 and 1030cm-1 (highlighted with a 
red arrow), indicative of C–OH bonding and the transmittance band at 3348cm-1 
(highlighted by green arrows), indicative of an O–H bond decreases in intensity after 
crosslinking. The appearance of a peak/shoulder at 1150cm-1 (highlighted by a blue 
arrow) is indicative of –C-O-C- bonds which are formed during the crosslinking reaction. 
Furthermore, the strengthening of the transmittance band at 800cm-1 and 1720cm-1 is 
indicative of CH out of plane bending and C=O bonds respectively, which is characteristic 
of GA. These results indicate the decrement of C-OH bonds in the PVA molecular 
structure allowing for the increment of C–H alkyl groups, thereby confirming that 
crosslinking between PVA and GA occurs. 
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The drug molecules contain functional groups which are also known to crosslink with the         
–CHO groups of glutaraldehyde. Figure 6.11 displays that the FTIR spectra of the INH in 
the formulation, before and after crosslinking, were analogous to each other. The amine 
group of INH within the nanofibrous matrix is represented by the transmittance bands at 
1665.cm-1; 1633cm-1 and 1601cm-1 (Figure 6.11b). Nanofibrous matrices that were 
crosslinked, displayed no shift in the amine related transmittance bands. It was thus 
postulated that the mechanism of drug incorporation ensured that the drug molecules 
were embedded within the nanofibrous matrix, restricting exposure of the drug to the 
vapours. Furthermore, once the surface is crosslinked, the vapours may not be able to 
access the drug efficiently. Similarly, Figure 6.12 illustrates that the FTIR spectra of RIF-
loaded nanofibres, before and after crosslinking were comparable with each other. The 
C–OH groups of RIF which interact with glutaraldehyde indicated by the transmittance 
bands at 1646cm-1 and 1371cm-1 did not shift or change in intensity after exposure to the 
GA vapours, indicating that minimal interactions occurred between RIF and GA. The 
decrease in the band intensities at 3348cm-1, 1347cm-1 and 1023cm-1, as well as the 
appearance of the shoulder at 1150cm-1 reaffirms that crosslinking has occurred between 
GA vapours and PVA molecules.  
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Figure 6.11: FTIR spectra of a) INH, b) INH-loaded nanofibres (Formulation 2) and c) 
crosslinked INH-loaded nanofibres (Formulation 4). The red arrow indicates transmittance 
bands at 1380cm-1 and 1030cm-1 associating with C–OH stretching of PVA; the green 
arrow indicates transmittance band at 3348cm-1 associating with O-H bonding in PVA, the 
blue arrow indicates transmittance band 1150cm-1 associating with C–O–C groups formed 
through crosslinking. The areas highlighted in purple demonstrate minimal change, before 
and after crosslinking, to the –NH2 related transmittance bands of INH. 
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Figure 6.12: FTIR spectra of a) RIF, b) RIF-loaded nanofibres (Formulation 7) and c) 
crosslinked RIF-loaded nanofibres (Formulation 9). The red arrow indicates transmittance 
bands at 1347cm-1 and 1023cm-1 associating with C–OH stretching of PVA; the blue 
arrow indicates transmittance band 1150cm-1 associating with C–O–C groups formed 
through crosslinking. The green arrow indicates the transmittance bands at 3348cm-1, 
associated with the –OH bonding of PVA.  The areas highlighted in purple demonstrate 
minimal change, before and after crosslinking, to the –OH related transmittance bands of 
RIF. 
 
The degree of crosslinking can be associated with the extent of change in the band 
intensities. As illustrated in Figure 6.13, the transmittance band at 3348cm-1 (green 
arrows) indicative of the O-H functionality of PVA (responsible for crosslinking with GA), 
consistently decreases as the duration of crosslinking increased. The transmittance bands 
at 1023cm-1 indicating the C-OH stretching of PVA also appears to decrease as the 
duration of crosslinking increased.  Furthermore the shoulder at 1150cm-1, indicating the 
formation of the –C-O-C- bond appears to increase in intensity as the duration of 
crosslinking increased.  The formulations displaying the highest extent of change in their 
band intensities corresponds to having the highest degree of crosslinking. Hence, it can 
be concluded that the degree of crosslinking was affected largely by the duration of 
crosslinking, rather than the quantity of crosslinker employed. 
 
 
PURE RIF_1_1
Ruby RIF 8% no cx-l
Ruby RIF 8% cx-l 12hrs n
Name Description
4000 6503500 3000 2500 2000 1500 1000
cm-1
95
43
50
60
70
80
%
T
102
44
50
60
70
80
90
%
T
100
56
60
70
80
90
%
T
a)
b)
c)
a) 
b) 
c) 
174 
 
 
Figure 6.13: FTIR spectra of a) RIF-loaded nanofibres (Formulation 7); b) Formulation 8 
(crosslinking for 6 hours); c) Formulation 9 (crosslinked for 12 hours) and d) Formulation 
10 (crosslinked for 24 hours). The red arrow indicates transmittance bands at 1023cm-1 
associating with C–OH stretching of PVA; the blue arrow indicates transmittance band 
1150cm-1 associating with C–O–C groups formed through crosslinking. The green arrow 
indicates the transmittance bands at 3348cm-1, associated with the –OH bonding of PVA.  
The areas highlighted in purple demonstrate minimal change, before and after 
crosslinking, to the –OH related transmittance bands of RIF. 
 
6.3.7 Rheological characteristics of the non-drug loaded and drug loaded 
polymeric solutions employed in electrospinning  
The rheological characteristics, and in particular the viscosity, of polymeric solutions 
determines whether the solution can be electrospun, and further influences the fibre 
morphology (such as size) and quality once electrospun. Several studies have 
demonstrated that polymeric solutions can be electrospun only within an optimal range of 
polymer concentrations or solution viscosity. If a polymer solution is too dilute, the 
polymeric fibre breaks up into droplets before reaching the collecting surface. When 
solutions are too concentrated, fibres are unable to form due to very high viscosities (Tao 
and Shivkumar, 2007; Sill and Von Recum, 2008). Increasing the polymer concentrations 
within said range causes an increase in the diameter of the nanofibres formed (Sill and 
Von Recum, 2008). 
 
The respective viscosities, determined through rheological analysis of the drug-loaded 
and non-drug loaded polymeric solutions, are listed in Table 6.5. As illustrated in the 
table, addition of RIF causes a drastic increase in the viscosity of the 8%w/v PVA solution. 
During preliminary investigations, when RIF was added to a 10%w/v solution, the viscosity 
increase fell outside the optimal viscosity range for electrospinning of PVA solutions. This 
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necessitated lowering the PVA concentration in RIF-loaded solutions from 10%w/v PVA to 
8%w/v PVA solution, which had better electrospinnable characteristics. In addition, 
incorporation of Tween® 80 to the RIF-loaded PVA solutions caused a further decrease in 
the viscosity, further improving the electrospinning characteristics of the solution.  INH 
addition demonstrated a minor increase in the polymer concentration, which had no 
drastic changes in the morphology or diameters of the fibres formed.   
 
Table 6.5: Effect of drug and/or excipient addition on the viscosity of PVA solutions 
employed during electrospinning. 
Solution Parameters Viscosity at shear rate of 100/s (mPas) 
10%
w
/v PVA  830.53±26.41 
10%
w
/v PVA + 2%
w
/v INH  945.29±5.62 
8%
w
/v PVA  443.14±13.90 
8%
w
/v PVA + 2%
w
/v RIF  707.27±13.60 
8%
w
/v PVA; 2%
w
/v RIF + Tween
®
 80 647.92±10.31 
 
6.3.8 Tensile properties and Young’s Modulus of crosslinked and non-
crosslinked nanofibrous membranes 
The stress-strain relationship of a material is highly dependent on the flexibility of the 
polymer chains and the strength of the material. When only a small amount of stress is  
required to produce a large amount of strain, the material is considered to be flexible and 
the Young’s Modulus, which is the slope of the linear portion of the stress-strain curve, as 
illustrated in Figure 6.14, will be relatively small (Wu and McGinity, 2000). A material is 
considered to be considerably stronger than another when the ultimate strength, which is 
the maximum point on the stress-strain curve, is relatively higher. The average 
experimental values for Young’s Modulus (E), yield stress (σy) (magnitude of stress on the 
stress-strain curve at which appreciable deformation takes place without any appreciable 
increase in the stress), ultimate strength (σu) (the maximum stress a material can 
withstand), ultimate strain (εu) and toughness (uf) are outlined in Table 6.6. 
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Figure 6.14: Typical stress-strain nanotensile profile where a) is the linear portion of the 
slope from which Young’s Modulus is determined; and b) depicts the fracture point of the 
sample. 
 
Table 6.6: Experimental values obtained from nanotensile analysis of the crosslinked and 
non-crosslinked fibres. 
Formulation E (MPa) σy (MPa) σu (MPa) εu uf (J/cm
-3) 
1 401.295 8.555 10.78 0.399 3.89 
2 91.330 3.960 4.860 0.4455 1.465 
3 254.755 8.375 9.845 0.2595 0.81 
4 253.155 6.220 8.710 0.4370 2.970 
5 283.440 6.465 9.245 0.5605 4.320 
6 111.545 2.31 3.745 0.609 1.63 
7 37.695 1.495 3.755 1.3130 3.990 
8 267.865 3.965 4.535 0.0400 3.965 
9 284.98 2.575 7.90 0.206 0.88 
10 189.760 4.750 6.335 0.6280 3.545 
 
As illustrated in Figure 6.15, addition of drug caused a drastic decrease in the Young’s 
Modulus of the PVA nanofibres, which is related to an increase in the elasticity of the 
nanofibrous membranes. The elasticity increase may be due to the plasticizing effect the 
drugs have on the nanofibres. 
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Figure 6.15: Vertical bar chart each outlining variations between the 10 formulations of a) 
Young’s Modulus (E; MPa); b) Yield Stress (σy : MPa); c) Ultimate Strength (σu : MPa); d) 
Ultimate Strain (εu); e) Toughness (uf : J/cm
-3) of Formulations 1-10. 
 
Non-crosslinked drug-loaded nanofibres demonstrated high variation in the elastic 
properties when differing concentrations of PVA were electrospun. A Young’s Modulus of 
91.330±4.67MPas and 37.695±6.02MPas were obtained for fibres electrospun from PVA 
solutions of concentrations 10%w/v and 8%
w/v respectively. This variation in elasticity can 
be attributed to the differing fibre diameters illustrated in Figure 6.6b and Figure 6.7b. 
Non-crosslinked drug loaded nanofibres demonstrated higher elasticity properties than 
crosslinked drug loaded nanofibres. This can be attributed to the nanofibres slipping pass 
one another, and aligning along the tensile pull axis. Crosslinking showed a distinct 
decrease in the elasticity of the nanofibres, which can be attributed nanofibres being 
unable to slip pass each other due to crosslinks formed between individual fibres, thus 
increasing the stiffness of the nanofibres.  
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Addition of INH caused a substantial decrease in the ultimate strength of the nanofibres 
from 10.78±1.26MPas to 4.86±0.20MPas, whereas addition of RIF showed an 
insignificant change in the ultimate strength of the material, the findings which are 
discussed in further detail in Section 6.3.9.3. Crosslinking improved the strength of the 
drug-loaded nanofibres from 3.755±0.015MPas to ultimate strengths ranging from 
4.535±0.345MPas to 7.92±0.02MPas for RIF-loaded nanofibres and 4.86±0.2MPas to 
ultimate strengths ranging from 8.71±1.12MPas to 9.245±0.415MPas for INH-loaded 
nanofibres. Although, crosslinking improved the ultimate strength and stiffness of drug-
loaded samples, crosslinking of RIF-loaded nanofibrous membranes produced very brittle 
membranes, as they failed in tension at relatively low values of strain. 
 
6.3.9 Molecular Mechanics Assisted Model Building and Energy Refinements 
A molecular mechanics conformational searching procedure was employed to acquire the 
data employed in the statistical mechanics analysis, and to obtain differential binding 
energies of a Polak–Ribiere algorithm and to potentially permit application to polymer 
composite assemblies. MM+ is a HyperChemTM modification and extension of Norman 
Allinger's Molecular Mechanics program MM2 (Warhurst et al., 2003) whereas AMBER, is 
a package of computer programs for applying molecular mechanics, normal mode 
analysis, molecular dynamics and free energy calculations to simulate the structural and 
energetic properties of molecules (Pearlman et al., 1995). 
 
6.3.9.1 MMER analysis 
Molecular mechanics energy relationship (MMER), a method for analytico-methematical 
representation of potential energy surfaces, was used to provide information about the 
contributions of valence terms, noncovalent Coulombic terms, and noncovalent Van der 
Waals interactions in tensile properties and drug release kinetics. The MMER model for 
potential energy factor in various molecular complexes can be written as: 
 
Emolecule/complex = V∑ = Vb + Vθ + Vφ + Vij + Vhb + Vel   
Equation 6.1 
where, V∑ is related to total steric energy for an optimized structure, Vb corresponds to 
bond stretching contributions (reference values were assigned to all of a structure's bond 
lengths), Vθ denotes bond angle contributions (reference values were assigned to all of a 
structure's bond angles), Vφ represents torsional contribution arising from deviations from 
optimum dihedral angles, Vij incorporates
 Van der Waals interactions due to non-bonded 
interatomic distances, Vhb symbolizes hydrogen-bond energy function and Vel stands for 
electrostatic energy (Choonara et al., 2011). 
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In the present MM study, the global energy relationships for the various complexes 
derived after assisted model building and energy refinements are as follows: 
 
EPVA = 18.517V∑ = 1.067Vb + 5.969Vθ + 9.212Vφ + 4.086Vij - 1.818Vhb  
Equation 6.2 
 
EPVA-PVA = 26.483V∑ = 2.187Vb + 17.167Vθ + 12.1Vφ - 1.254Vij - 3.717Vhb  
Equation 6.3 
 
EINH = 6.445V∑ = 0.422Vb + 0.691Vθ + 7.482Vφ + 5.499Vij - 0.168Vhb  
Equation 6.4 
 
EPVA2-INH = 15.761V∑ = 2.349Vb + 14.804Vθ + 12.726Vφ - 9.021Vij - 5.096Vhb  
Equation 6.5 
 
ERIF = 70.743V∑ = 4.040Vb + 28.166Vθ + 32.796Vφ + 6.737Vij - 0.998Vhb  
Equation 6.6 
 
EPVA2-RIF = 76.781V∑ = 6.170Vb + 44.409Vθ + 43.893Vφ - 11.463Vij - 6.228Vhb  
Equation 6.7 
 
EGA = 1.425V∑ = 0.0291Vb + 0.0622Vθ + 0.804Vφ + 0.529Vij  
Equation 6.8 
 
EPVA2-GA3 = 15.176V∑ = 2.540Vb + 18.135Vθ + 17.081Vφ - 18.088Vij - 4.492Vhb  
Equation 6.9 
 
6.3.9.2 Formulation of drug-loaded PVA fibres 
The first part of the present study involved the elucidation of the effect of addition of drugs 
on the nanotensile properties of PVA nanofibres, drugs viz. INH and RIF were 
sandwiched between two PVA polymeric rings as shown in Figure 6.16. The addition of 
individual drugs significantly affected the tensile properties of nanofibres with a substantial 
decline in Young’s Modulus. 
 
The drug incorporation results presented in this study are in line with the previously 
reported work by Wu and McGinity, 1999, where chlorpheniramine maleate and ibuprofen 
were used to influence the mechanical properties of polymeric films and termed the drugs 
as “non-traditional plasticizers” causing a reduction in Young’s Modulus. Interestingly, all 
the energy values viz., bonding and non-bonding energies underwent stabilization with all 
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ΔE values in negative (Table 6.7) confirming the conformational stability and compatibility 
as well as thermodynamic and steric rationality of the three molecules in conjugation with 
each other.  
 
6.3.9.3 Tensile analysis of drug-loaded PVA nano fibres 
For the prediction of the effect of addition of drugs on the tensile properties of PVA fibres, 
there have not been many fully atomistic simulations of drug-loaded polymers in which 
tensile properties have been calculated as a function of energy values of the complexed 
molecular structure. To explain the mechanism underlying the performance of drug-
loaded nanofibrous matrix, we hereby propose that the mechanical properties of the 
nanofibres may be predominantly dependent on the available volume and cohesive 
energy density (CED) of/between the polymer fragments based on the various intra- and 
inter-molecular interactions both in terms of bonded and non-bonded energy terms. A 
typical relation between Young’s Modulus (E) and molar volume can be derived based on 
bulk Modulus/Young’s Modulus equations derived by Roberts et al., 1991 as follows: 
 
    
    
 
 
Equation 6.10 
  
 
       
 
Equation 6.11 
where, K is bulk modulus, Ecoh is energy of vaporization (J.mol
-1), V is the molar volume 
(cm3.mol-1), ν is Poisson’s ratio and x is a constant related to the cubic lattice of the 
molecule under investigation. 
 
Equating Equation 6.10 and Equation 6.11, 
  
 
 
 
Equation 6.12 
Also,  
    
 
 
 
Equation 6.13 
 
From Equation 6.12 and Equation 6.13, it is clear that molar volume defines the elastic as 
well cohesive properties of a polymeric architecture. 
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Table 6.7: Calculated energy parameters (kcal/mol) of polymer-crosslinker and drug 
loaded crosslinked-polymer assemblies. 
Name ΔEnergiesa 
ΔTotalb ΔBondc ΔAngled ΔDihedrale ΔVdwf ΔH-bondg 
PVA2
h -10.551 0.153 5.229 -6.324 -9.426 -0.081 
PVA2-GA3
i
 -15.582 0.1657 0.7814 2.569 -18.421 -0.775 
PVA2-INH
j -17.167 -0.36 -3.054 -6.856 -13.266 -1.211 
PVA2-RIF
k -20.445 -0.157 -0.924 -1.003 -16.946 -1.513 
a
 ΔEbinding = E(Host.Guest) - E(Host) - E(Guest); 
b 
Total steric energy for an optimized structure 
c 
Bond stretching contributions; 
d
 Bond angle contributions; 
e
 Torsional contribution; 
f 
Van der 
Waals interactions; 
g 
Hydrogen-bond energy function; 
h
 Two PVA molecules in conjugation; 
i 
Three 
GA molecules in conjugation with two PVA molecules; 
j 
An INH molecule in conjugation with two 
PVA molecules; 
k 
An RIF molecule in conjugation with two PVA molecules 
 
Conceptually, the addition of a plasticizer may lead to lowering of rigidity of the polymer 
matrix thereby lowering of elastic modulus and ultimate strength as is evident from the 
experimental results and is in line with previous studies (Gil et al., 2006). The 
complexation of PVA molecules with the drug molecules lead to a decrease in vdWf by 
~13kcal/mol and ~17kcal/mol for INH and RIF, respectively, (Table 6.7) which in turn may 
lead to a decrease in CED thereby decreasing the Young’s Modulus (Equation 6.10-
Equation 6.13). This reduction in cohesion may help the adjacent polymer chains to 
stretch/slide over each other thereby increasing the elongation of the fibres. Apart from 
this, the drugs may impart different volumes fraction to the polymeric matrix dependent of 
the molecular size of the drug molecule.  
 
 
Figure 6.16: Visualization of energy minimized geometrical preferences of two PVA 
molecules in conjugation with a) an isoniazid molecule; and b) a rifampicin molecule 
showcasing the intra- and inter-molecular interactions after molecular simulations in 
vacuum. Color codes for elements: C (cyan), O (red), N (blue) and H (white). 
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In the case of INH, acting as a soluble plasticizer, it showed a high affinity to diffuse into 
and interact with the polymer molecules (as shown in Figure 6.16a; Equation 6.2 and 
Equation 6.3) by forming non-bonding interactions in terms of hydrogen bonding 
contribution (because of the presence of amine groups) and vdWf (the ΔE of all these 
energies is negative; Table 6.7) and hence lead to an increasing in polymer’s mobility. In 
this way, the brittle character of the polymer may decrease with an increase in 
plasticizer’s concentration (Gutierrez-Rocca and McGinity, 1994). 
 
On the other hand, the effect of RIF incorporation on nanotensile properties was not 
significant as compared to drug free fibres. Although the energy of stabilization was 
highest in this case (Equation 6.2, Equation 6.3, Equation 6.6 and Equation 6.7; ΔE =-
20.445kcal/mol), the plasticizer effect was not as pronounced as in the case of INH. The 
below mentioned three reasons may be responsible for the ultimate strength regain in 
case of RIF thereby retaining the tensile properties of the initially optimized fibres: 
 
1. Firstly, because of poor aqueous solubility of RIF, the drug particles may cause filling 
up of pores leading to a decrease in porosity of the polymer matrix. According to 
Spriggs’ equation (Spriggs, 1961): 
 
              
Equation 6.14 
where, E is the Young’s Modulus, E0 is the Young’s Modulus at zero porosity, P is the 
porosity and b is a constant in Spriggs’ equation.  
 
It is clear from the above exponential relationship that a decrease in porosity will lead 
to a comparative increase in Young’s Modulus as observed in the experimental 
results. 
 
2. Secondly, the drug crystals (superfluous) may cause filling of the existing cracks, 
notches, voids or crazing in the polymeric fibre being tested leading to a increase in 
rigidity and decrease in movability of the adjacent PVA chains finally leading to a 
increase in Young’s Modulus (Gutierrez-Rocca and McGinity, 1994). 
 
3. Thirdly, the large molecular size of RIF than INH may reduce the volume between two 
polymer chains leading to an increase in Young’s Modulus as compared to INH 
loaded fibres (Equation 6.10-Equation 6.13). 
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4. As depicted in Figure 6.16b, the RIF molecule is forming a complex with PVA 
molecules in form of a crosslinker connecting two molecules together further 
decreasing the volume and hence increasing the young’s Modulus. 
 
The experimental rheological results can also be substantiated based on the above 
mentioned points. The poor solubility and large molecular size of RIF molecule as 
compared to better solubility and smaller molecular size seems to be responsible for the 
more viscosity imparted by RIF to the PVA solution. It can be visualized from Figure 6.16a 
that INH being soluble acted as “highly penetrable” molecule resulting in homogeneous 
increase of concentration. However, poorly soluble RIF particles acted as a partially 
penetrable particles resulting in an  increased concentration located in the inter-particles 
shared zone making the viscosity dissipation less predominant in that area (Figure 6.16b) 
(Omari et al., 2006). Additionally, RIF being a mild crosslinker (see point 4 above), 
decreased the “elastic-to-viscous force ratio” as a function of crosslink density causing a 
more viscous solution with higher Young’s Modulus than the drug free polymer solution 
further necessitating the use of an 8%w/v PVA solution for electrospinning. 
 
Hence, we can say that the drugs influenced the nanotensile characteristics by acting as 
“non-traditional biomedical tensile modifiers of polymeric nanofibres”. 
 
6.3.9.4 Performance of crosslinked PVA electrospun fibres 
In the next part of the molecular static study, the fabrication of PVA based electrospun 
nanofibrous system and the post-fabrication crosslinking of formed nanofibrous matrix 
with glutaraldehyde vapours was simulated. The energy changes brought about by 
crosslinking of the polymeric system are given in Equation 6.2, Equation 6.3, Equation 6.8 
and Equation 6.9 and the resulting energy and geometrical minimizations are depicted in 
Table 6.7 and Figure 6.17, respectively. As the tensile analysis was conducted on both 
non-crosslinked and crosslinked nanofibres, we elucidated the conformational effect 
addition of individual components in form of two PVA chains in conjugation with each 
other and three glutaraldehyde molecules in conjugation with the two PVA chains, 
respectively,  during the initial stage of static simulations. 
 
PVA is known to exhibit interactions with dialdehydes such as glutaraldehyde (with an 
acid solution which catalyzes acetalization reaction) where it display concentration-
dependent intra- and inter-molecular crosslinking and complexation of the polymer matrix 
(Peng et al., 2011). It is evident from Table 6.7, PVA2 was energetically stabilized by 
10.551kcal/mol (Equation 6.2 and Equation 6.3) in terms of london-dispersion forces due 
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to presence of vinyl groups (ΔE = -9.426) and torsional stabilization (ΔE = -6.324kcal/mol) 
leading to the formation of a network structure - with smaller intermolecular H-bonds 
measuring 2.168A° creating space (~volume) between two chains to slide over each 
other. Once the polymer network was geometrically optimized and energetically 
minimized, we disposed three glutaraldehyde molecules in close proximity of two PVA 
chains (PVA2-GA3) in such a way that the crosslinker molecules sandwiched the polymer 
chains (Figure 6.17). 
 
 
Figure 6.17: Visualization of energy minimized geometrical preferences of a) PVA-
glutaraldehyde showing the double linking; b) PVA in conjugation with two glutaraldehyde 
molecules showcasing the intra- and inter- molecular interactions; and c) Two PVA 
molecules in conjugation with three glutaraldehyde molecules showcasing the intra- and 
inter- molecular interactions after molecular simulations in vacuum. Color codes for 
elements: C (cyan), O (red) and H (white). 
 
After energy minimization, PVA2-GA3 was stabilized by 15.582kcal/mol as compared to 
PVA/GA summation because of non-bonding interactions in terms of strong Van der 
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Waals forces (vdWf; ΔE = -18.421kcal/mol) along with intra- and inter-molecular H-
bonding energy (ΔE =-0.775kcal/mol). Although the total steric energy was –ve in 
magnitude, the interesting feature of PVA2-GA3 energy minimization was an increase in all 
the three bonding interaction energies, viz. bond stretching, bond angle and torsional 
contributions, causing the formation of a strained network structure - with smaller 
intramolecular H-bonds averaging 1.9855A°. This crosslinking may further bring two PVA 
chains closer leading to formation of some more inter-polymeric H-bonds, as shown in 
Figure 6.17, further forming a dense polymer network. These results are in line with the 
earlier reported studies where the glutaraldehyde crosslinked PVA membranes displayed 
better strength and the stereospecificity in presence of glutaraldehyde molecules (Peng et 
al., 2011). 
 
The complexation of two 10-monomer units’ PVA chains with three glutaraldehyde 
molecules lead to an increase in torsional strain causing a decrease in volume available 
for movement of polymer chains w.r.t. each other. This decrease in volume may have 
caused a substantial increase in Young’s Modulus and ultimate strength of Formulations 3 
and 8 as compared to Formulations 2 and 7, respectively.  This seems obvious as an 
increase in cohesion will restrain the adjacent polymer chains to stretch/slide over each 
other thereby decreasing the elongation of the fibres. Apart from this, the water soluble 
crosslinker-glutaraldehyde, used in this investigation showed a high affinity to diffuse into 
and interact with the polymer molecules (as shown in Figure 6.17a-b) by forming non-
bonding interactions in terms of hydrogen bonding contributions and vdWf and hence lead 
to a decreased polymer’s mobility. In this way, the crystalline character of the polymer 
may decrease with an increase in crosslinker concentration (Peng et al., 2011). 
Regarding the effect of crosslinker concentration on the tensile properties, Griebel et al., 
2005, reported a logarithmic dependency of the Young’s Modulus on the amount of cross-
links and deduced the following relationship: 
 
                
Equation 6.15 
where, P was a estimator to predict Young’s Modulus, α a constant and E0 a parameter 
with units of GPa.  
 
Furthermore, in accordance with the Lennard-Jones energy potential, the elastic modulus 
is a measure of the rigidity of materials and is directly related to the energy of interaction 
between molecules and their distance of separation (Roberts et al., 1991). Our simulation 
results showed that increased chemical cross-links may cause disturbance at high 
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crosslink densities resulting in distortion of bond lengths, angles, and torsions from their 
equilibrium values eventually causing strained and rigid-framework (Figure 6.17c). 
Additionally, the build-up of increased cohesion between adjacent polymer chains 
(intermolecular crosslinking) may initiate a significant axial stress providing a reasonable 
explanation for the experimentally observed reinforcement and rigidification of the 
formulations with increased crosslinker concentrations. 
 
These results are coherent with earlier reported results where the inclusion of chemical 
and physical cross-links, increases the Young’s Modulus of a crosslinked composite as 
fitted in the experimental results (Griebel et al., 2011).  
 
6.4 Concluding Remarks 
 
In the recent decade, tremendous efforts have been placed on investigating PVA 
nanofibres for biomedical applications. Electrospinning proved to be a versatile technique 
in fabricating drug-loaded PVA nanofibres, ideal for prolonged drug delivery. Modification 
through crosslinking using GA vapours may produce relatively less-toxic PVA nanofibres 
possessing properties which are ideal for prolonged drug delivery. The PVA nanofibres 
demonstrated good-drug loading capabilities, and drug release kinetics which are 
important factors in drug delivery, and showed an improvement in the overall strength of 
the nanofibrous membranes. 
 
Formulation 3 was identified as the most suited formulation for INH release, by 
demonstrating the most control of INH release over a period of 12 hours, while 
Formulation 9 was selected as the ideal formulation most suited for RIF release, by 
demonstrating the most control of RIF release over a period of 12 hours. These 
formulations were thus selected for further in vivo analysis in a pig model. The addition of 
drugs had a significant effect on the Young’s Modulus values effecting both the plastic 
and elastic deformation of the fibres by acting as non-traditional biomedical tensile 
modifiers of polymeric nanofibres. Finally, molecular mechanistic studies as well as image 
processing analysis corroborated well with the experimental findings and the influence of 
formulation variables as well as that of drugs on the performance of vapour crosslinked 
PVA nanofibres was determined on the basis of energy transformations and voxel 
intensities, respectively. 
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CHAPTER 7   
IN VITRO AND IN VIVO ANALYSIS OF THE MULTI-COMPONENT 
MEMBRANOUS DRUG DELIVERY SYSTEM IN RELATION TO A MARKETED 
GOLD STANDARD FORMULATION 
 
 
7.1 Introduction 
 
Achieving a predictable and reproducible therapeutic response to a drug that is included 
in a formulation is the primary objective of dosage form design (Aulton, 2002). The 
application of new technologies has enabled the resurrection of older molecules and the 
term ‘new drugs from old’ was coined. As previously discussed in Chapter 1, ‘old’ or 
established drugs are reformulated through a variety of means to ensure enhanced safety 
and efficacy, thus ‘resurrecting’ older drugs. Novel modes of drug delivery are employed 
to develop an ideal drug delivery system which provides the correct quantity of drug to the 
appropriate part of the body, at the right time and for the required period. Formulation 
strategies to attain such objectives include delivering the same drug by a different route, 
prolonging the therapeutic effect (with the use of prolonged release systems), providing 
unique dosage regimens (i.e. once daily administration) or plasma profiles, or by 
improving patient compliance (easing complicated therapeutic regimens) (Crowley and 
Martini, 2004). The proposed MMDDS boasts such resurrection of rifampicin and 
isoniazid by delivering both drugs in a single dosage form, providing enhanced 
bioavailability through targeted drug delivery and ensuring consistent drug release over a 
prolonged period of time.  
 
The preceding chapters of the present dissertation described the formulation, 
development and in vitro behavior of the individual components comprising the MMDDS, 
however, the in vitro drug release behavior of the MMDDS in its entirety is yet to be 
determined. The current chapter therefore focuses on the behavior of the MMDDS in its 
entirety. A marketed gold standard formulation containing rifampicin and isoniazid was 
selected and investigated for both in vitro and in vivo drug release behaviour and 
subsequently compared to the efficacy of the proposed MMDDS.   
 
7.1.1 Overview of MMDDS formulation components 
The purpose of this study was the development of a “smart” multi-layered membranous 
system intended to deliver multiple drugs to their respective sites of absorption within the 
GIT. The preceding chapters of the present dissertation identified the various formulation 
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variables to be employed in the fabrication of the drug delivery system and are 
summarised in Figure 7.1. The membranous system is composed of two components, 
intended for drug delivery at the upper gastric or intestinal region of the GIT respectively. 
CHT and PEC were selected as the pH-responsive polymers as CHT is pH-responsive to 
low (±pH1.2) pH ranges while PEC is pH-responsive to higher (±pH6.8) pH ranges. The 
water insoluble backing layer is further discussed in the present chapter and was 
formulated employing the hydrophobic polymer, ethylcellulose. 
 
 
 
7.1.2 Selection of an appropriate animal model for in vivo analysis 
 “The use of animal models in science, and in particular, biomedical research, is accepted 
by the majority of lay people and scientists alike as being necessary to the advancement 
of useful knowledge that brings about relief from suffering.”  
 
The above statement by Chow and co-authors (2008) adequately summarizes the 
importance of the use of animal models in research and development. Animal model use 
will remain a necessity in the research and development of countless drugs and newer 
therapies for the relief of human suffering, until science is able to develop alternative 
models and systems that are equally reliable and robust. Prior to being accepted and 
utilized in common medical practice as safe and effective therapies, there are legislative 
requirements that require that all new drug delivery devices and therapies undergo 
rigorous clinical trials, which determine the safety and efficacy of the new product. Such 
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Figure 7.1: Schematic overview of the componential architecture of the MMDDS. 
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regulations are required since basic in vitro analysis of therapies is non-physiological and 
pose significant limitations. Although information obtained from in vitro analysis is 
especially important in establishing mechanisms and behavior of a drug or delivery 
system, in vivo analysis can identify how the mechanisms and behaviour are affected 
under clinical conditions, and animal models are therefore important for “proof of principle” 
research. This form of research, and the information obtained from it, is especially 
important when assessing the safety and efficacy of both the drug and the delivery 
system (Chow et al., 2008). 
 
Animal models, specifically in biomedical research, can be defined as “a living organism 
with an inherited, naturally acquired or induced pathological process that in one way or 
another closely resembles the same phenomenon in man” (Wessler, 1976). When 
experimenting with animals, it is a fundamental requirement to ensure the aptness of an 
animal model that would allow human-related validation of the important data and 
information gathered from them (Nunoya et al., 2007). The use of the swine model in 
biomedical research has become increasingly common as an alternative to the dog or 
primate species, based not only on the regulatory and ethical pressure questioning the 
use of other models, but also due to their comparative anatomy and physiology in relation 
to humans  (Swindle and Smith, 2000; Nunoya et al., 2007). It should be noted that even 
though animal models are unable to perfectly mimic the human condition, the pig has 
been identified as a suitable non-primate animal model for preclinical evaluation due to its 
much closer resemblance to humans (Patterson et al., 2008).  
 
Therefore, in vivo analysis of the biocompatibility and drug release behaviour of the 
MMDDS was conducted employing a swine model, based on the premise that the swine 
model demonstrates the closest similarity to gastro-intestinal human anatomy and 
physiology (Nunoya et al., 2007). Appropriate ethics approval was obtained from the 
relevant ethical committee (Appendix C) prior to commencing the study. Ultra 
Performance Liquid Chromatography (UPLC) was employed to analyze the drug content 
in the blood samples obtained during animal studies. 
 
7.2 Materials and Methods 
 
7.2.1 Materials 
The materials described in Section 4.2.1 and Section 4.4.1 were employed in the 
fabrication of the gastric- and intestinal-targeted mucoadhesive layers respectively, while 
the RIF- and INH-loaded nanofibrous matrices were fabricated employing the materials 
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described in Section 6.2.1. Polymers ethylcellulose (Ph Eur viscosity 9m.Pa.s) purchased 
from Fluka® (Sigma Aldrich (Pty) Ltd., St Louis, MO, USA) and Eudragit® RS PO obtained 
from Evonik Industries (Evonik Röhm GmbH, Pharma Polymers, Kirschenallee, P-64 293, 
Darmstadt, Germany) were utilized to assemble the MMDDS. The solvents 2,2,2-
Trifluoroethanol (purity ≥99,0% GC grade); isopropanol and acetone were purchased from 
Sigma (Sigma Aldrich Chemie GmbH, Steinheim, Germany). All other reagents employed 
were of analytical grade and used as purchased without further purification. Double-
deionised water was obtained from a Milli-Q Water Purification System (Millipore, Bedford 
MA, USA).  
 
UPLC-grade solvents, employed for UPLC measurements included Acetonitrile (ACN) 
200 (ROMIL-SpSTM Super Purity Solvent (CH3CN), Assay>99.9%) and Methanol 215 
(ROMIL-SpSTM Super Purity Solvent (MeOH) Assay >99.9%) which were purchased from 
Romil Pure Chemistry (Waterbeach, Cambridge, England) and double de-ionized water 
which was obtained from a Milli-Q water purification system (Milli-Q, Millipore, Billerica, 
MA, USA). Oases HLB cartridges, for solid phase extraction, were provided by Waters 
(Milford, MA, USA). Isoniazid (INH) (Sigma Aldrich (Pty) Ltd., St. Louis, Missouri, USA), 
rifampicin (RIF) and the internal standards including methylparaben (MP) employed for in 
vitro analysis and furosemide (FUR) employed for in vivo analysis were obtained from 
Sigma (Sigma Aldrich (Pty) Ltd., St. Louis, Missouri, USA) and were of analytical grade 
and employed without further purification. A total of 5 female white pigs were employed in 
the study, each healthy and with an average weight of 35kg. Fresh blank plasma was 
routinely drawn and supplied from the catheterized pigs. Rifinah®, a marketed gold 
standard formulation was obtained from Sanofi-Aventis (Sanofi-Aventis (Pty) Ltd., 
Midrand, South Africa). The Acquity UPLC® BEH RP18 1.7μm column (2.1x100mm) was 
utilized to separate analytes, while Sep-Pak® Vac ICC (100mg) CN Cartridges were 
obtained from Waters Corporation (Milford, MA, USA). The sample vials employed was 
2mL ANSI48 vials which were LCMS certified and clear, pre-slit PTFE silicone screw-top 
vials. 
  
7.2.2 Fabrication of the MMDDS 
7.2.2.1 Mucoadhesive layer 
Membranes were fabricated as described in Section 4.2.3 and Section 4.4.3 for the 
optimized gastric- and intestinal-targeted mucoadhesive layers respectively. Briefly, the 
polymers were combined in the ratios defined via optimization studies and included: 
1.001%w/v of CHT, 4.750%
w/v PVA and 4.004%
w/v of PVP for the gastric-targeted 
mucoadhesive layer and 2%w/v of PEC, 3.375%
w/v of PVA and 6%
w/v of PVP for the 
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intestinal-targeted mucoadhesive layer. Film-cast membranes were cut into dimensions of 
20x30mm and thereafter stored with desiccants in airtight containers until further 
processing was completed. 
 
7.2.2.2 Drug-loaded layer 
Drug-loaded nanofibrous matrices were electrospun employing the solution and 
processing parameters described in Section 6.2.2. Briefly, the solution parameters 
included an 8%w/v solution of PVA containing 2%
w/v RIF and 5%
w/v Tween
® 80 for the 
gastric-targeted component, and 10%w/v PVA containing 2%
w/v RIF and 0.1%
w/v silicone 
for the intestinal-targeted component. The electrospinning setup, as illustrated in Figure 
5.2, involved applying 20kV, supplied by a Glassman High Voltage, INC (High Bridge, NJ, 
USA) to the drug-polymer solutions. The resultant electrospun fibres were collected on an 
aluminium sheet connected to a grounded counter electrode. Electrospinning was carried 
out at ambient room conditions for periods ranging between 5-8 hours, cut into 20x30mm 
dimensions and stored with a desiccant until further processing was conducted. The 
nanofibrous matrices were thereafter modified via a post-treatment involving 
glutaraldehyde (GA) vapour induced crosslinking. Crosslinking was conducted employing 
the method described in Section 6.2.3. RIF-loaded nanofibres were crosslinked for a 
period of 12 hours in the presence of 30:10mL of GA:HCl while INH-loaded nanofibres 
were crosslinked for a period of 24 hours in 15:5mL GA: HCl. In vitro drug release studies 
indicated that these crosslinking parameters demonstrated the most control over the 
release of the entrapped drugs, an ideal characteristic in the development of the MMDDS.  
 
7.2.2.3 Assembling the MMDDS 
The individual layers of the MMDDS were assembled as follows (Figure 7.2): the drug-
loaded nanofibrous matrix was attached to the respective mucoadhesive layer by 
employing a 60%w/v solution of Eudragit
® RS PO (i.e. the RIF-loaded nanofibrous matrix 
was attached to the gastric-targeted mucoadhesive layer for the gastric delivery of RIF, 
while the INH-loaded nanofibrous matrix was attached to the intestinal-targeted 
mucoadhesive layer for the intestinal delivery of INH). Thereafter, a 30%w/v solution of 
ethylcellulose (prepared in a 1:1 solution of isopropanol: acetone) was then film-cast over 
the existing layers to form the water-insoluble backing layer or coating which would 
protect the entrapped drug from the harsh gastrointestinal environment. The coating was 
thereafter allowed to dry for a period of 24 hours and the MMDDS was thereafter stored in 
an airtight container with a desiccant until further analysis was conducted. 
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Figure 7.2: Schematic illustration of the fabrication of the MMDDS in its entirety. The 
gastric- and intestinal-targeted components differed with regard to the polymer type and 
quantity, and crosslinking procedure. 
 
7.2.3 Comparative analysis of the in vitro drug release behaviour of the MMDDS 
in relation to a marketed gold standard formulation 
7.2.3.1 In vitro dissolution 
In vitro drug release studies were conducted using a six-station USP apparatus II (Erweka 
DT 700 GmbH Germany), in which an MMDDS containing 150mg of RIF and 75mg of INH 
was placed within the vessel under a stainless steel ring mesh assembly. This prevented 
the paddle from inflicting physical/mechanical damage to the drug delivery system which 
can potentially alter the drug release characteristics, in addition to preventing any erratic 
fluctuation due to unstable hydrodynamics (Pillay and Fassihi, 2000). Each vessel 
contained 900mL of PBS, which was heated to a temperature of 37°C prior to the addition 
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of the MMDDS and the stainless steel ring mesh assembly. The apparatus was calibrated 
for a 12 hour run, and the rotating paddle method was selected with a rotational speed of 
50rpm. Sampling occurred at hourly intervals and involved the drawing of 5mL of now 
drug incorporated solution from the dissolution vessel. An equal quantity of the removed 
buffer was replaced with fresh buffer to maintain sink conditions. Samples were then 
subject to UV spectrophotometry and drug quantity was determined using a standard 
calibration curve.  
 
To determine whether the MMDDS prevents INH release in upper gastric conditions, 
complete MMDDS was subject to in vitro conditions typical of the upper gastric region for 
3 hours (900mL of PBS, 1.2 pH; 37°C), corresponding to the duration that the MMDDS 
would be present in the gastric region. Thereafter, only the intestinal-targeted component 
was transferred to a corresponding vessel for 12 hours which simulated the intestinal 
region of the GIT (900mL of PBS, 6.8 pH; 37°C), while the gastric-targeted component 
was maintained in conditions typical of the upper gastric region of the GIT for the 
remainder of the study. The above method was identified to closely resemble the 
conditions the MMDDS would be exposed to. Based on the architectural design of the 
MMDDS, the gastric-targeted component is maintained in the upper gastric region for a 
prolonged period of time through mucoadhesion, and was therefore maintained in 
simulated gastric conditions for the entire duration of the study. In contrast, the intestinal-
targeted component was subject to 3 hours of simulated gastric conditions (simulating the 
duration required for the intestinal-targeted component to pass through the upper gastric 
region),  and thereafter transferred to a fresh dissolution vessel which subjected the 
intestinal-targeted component to conditions which simulate the intestinal region of the 
GIT.  The samples were thereafter analyzed via the UPLC method depicted in Section 
7.2.3.2. The test was performed in triplicate (n=3). 
 
For comparative purposes, a marketed gold standard formulation, Rifinah®, containing 
150mg of RIF and 75mg of INH was also subject to the in vitro dissolution test. Rifinah® 
tablets disintegrated within the first three hours of the study, and were thus exposed only 
to conditions simulating the upper gastric region of the GIT (900mL of PBS, 1.2 pH; 
37°C). Samples were thereafter analysed employing Ultra Performance Liquid 
Chromatography (UPLC) analysis. 
 
7.2.3.2 UPLC analysis of in vitro dissolution samples 
A Waters Acquity™ Ultra Performance Liquid Chromatography (UPLC) system employing 
Empower Pro Software (Waters®, Milford, MA, USA) coupled with a PDA detector was 
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utilized to determine the quantity of the individual drugs present in the dissolution 
samples. UPLC is useful in the simultaneous quantification of multiple drugs (analytes) 
present in a single sample. UPLC typically requires a mobile and stationery phase for 
separation of multiple analytes, which in turn is detected by a photodiode-array (PDA) 
detector. A sample, which contains the analyte is dissolved in the mobile phase and 
thereafter pumped through the stationery phase (a chromatographic column packed with 
the stationery phase). Depending on the degree of interactions between the stationery 
phase and the analytes, the retention time of the various analytes or drugs will vary, and 
thus allow for identification, quantification and separation of multiple drugs in one sample 
(Chey, 2011). 
 
7.2.3.2.1 Priming solvents employed in the washing protocol 
Prior to analysis of samples, the UPLC system was primed by a ‘washing protocol’ of two 
cycles of 10 minutes each. The solvents employed in the priming of the UPLC pumps 
included a weak needle wash solution containing 10%v/v acetonitrile and 90%
v/v double 
de-ionized water, and a strong needle wash solution of 90%v/v acetonitrile and 10%
v/v 
double de-ionized water. These solutions were also used to equilibrate the system after 
sample analysis, removing any analytes which may have lodged in the column during the 
analysis of the previous sample. 
 
7.2.3.2.2 Mobile phases employed for sample analysis 
The binary mobile phase employed for sample analysis included pure acetonitrile (ACN) 
and 0.1% formic water (FW) at differing ratios (gradient method). The formic water was 
prepared by dissolving 1mL of formic acid in 999mL of double de-ionized water.  
 
In all instances, only double de-ionized water obtained from a Milli-Q filtration system 
(Millipore, Johannesburg) with a resistivity of 18.2MΩcm-1 was used to prepare the UPLC 
solvents employed in both UPLC priming and sample analysis. Furthermore, all mobile 
phases, needle washes (both strong and weak), and any solvents employed in sample 
preparation were filtered using a 0.22μm pore size Cameo Acetate membrane filter 
(Millipore Co., Bedford, MA, USA). 
 
7.2.3.2.3 UPLC-PDA analysis for drug content quantification 
UPLC separation was achieved on an Acquity UPLC® BEH RP18 1.7μm column (2.1 x 
100mm) set at a temperature of 25°C. The column was initially primed following a 
washing protocol which included a strong needle wash and a weak needle wash. The 
binary mobile phase consisted of formic water (0.1% formic acid) and acetonitrile (ACN) 
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following the gradient  analysis run time as indicated in Table 7.1. A flow rate of 
0.40mL/min was selected with an injection volume of 2μL. The run time was three minutes 
and the system was allowed to equilibrate for 5 minutes prior to analyzing the next 
sample, thus removing any late eluting interferences. The photodiode-array (PDA) 
detector was set to detect and quantify drug content at a wavelength of 263nm. 
Methylparaben was employed as the internal standard to compensate for sample 
preparation losses and drug content was quantified by determining the ratio of the Area 
Under the Curve of the drug to be quantified vs. the Area Under the Curve of the internal 
standard (AUCD / AUCIS).  
 
Table 7.1: UPLC Gradient method parameters for the simultaneous quantification of 
isoniazid and rifampicin. 
Time (minutes) Flow Rate (mL/min) %A %B 
0 0.40 100 0 
0.63 0.40 95 5 
1.5 0.40 20 80 
1.6 0.40 0 100 
1.94 0.40 60 40 
2.8 0.40 100 0 
%A= 0.1%v/v formic water and %B= pure acetonitrile 
 
7.2.3.3 Construction of calibration curves employing a known series of analytical 
standards 
Stock solutions of INH (0.083mg/mL); RIF (0.1668mg/mL) and MP (1.0mg/mL) were 
prepared in PBS (RIF – pH 1.2; INH – pH 1.2 and 6.8). Working standard solutions were 
prepared by a series of dilutions (5 dilutions each) of INH and RIF with known 
concentrations for analytical evaluation in the preparation of the calibration curve. 1.5mL 
of each dilution was combined with 0.5mL of the internal standard solution and passed 
through a 0.22μm Cameo Acetate membrane filter (Millipore Co., Bedford, MA, USA) into 
2mL ANSI48 vials, which were then subject to analysis. The content of RIF and INH was 
analyzed at wavelengths of 263nm. A linear curve was generated on SigmaPlot® V10.0 
software, with the observed AUC ratio (ratio of the Area Under the Curve (AUC) of the 
drug peak (AUCD) vs. the internal standard peak (AUCIS) plotted on the y-axis against the 
corresponding concentrations (mg/mL) plotted on the x-axis. With the intercept set at 0, 
the R2 values were determined to be 0.9983 of RIF and 0.9980 of INH. 
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7.2.4 Comparative analysis of the in vivo drug release behaviour of the MMDDS 
in relation to a marketed gold standard formulation employing a swine model 
Prior to commencement of the in vivo studies, clearance was obtained from the Animal 
Ethics Clearance Committee (Appendix C1), University of the Witwatersrand. 
 
7.2.4.1 Surgical implantation of the jugular vein catheter  
Upon arrival at the Central Animal Services lab, pigs were habituated to ensure efficient 
and accurate blood sampling. Pigs were anesthetized with ketamine (11mg/kg I.M.) and 
midazolam, (0.3mg/kg I.M.) prior to the surgery. Buprenorphine (0.05mg/kg I.M.) and 
carpofen (4mg/kg I.M.) were administered for both analgesia and inflammation. The 
surgical area (the left neck and shoulder area) of the pigs were thereafter prepared for 
surgery by shaving the area, followed by sterilization. Once intubated, the anaesthesia 
was maintained with 2% isoflurane in 100% oxygen. In an aseptic environment, the 
jugular vein was exposed by an incision made dorsal to the jugular groove on the left 
lateral aspect of the neck. To prevent the jugular vein from collapsing during the surgery, 
the catheter (a 7 French gauge double lumen 35cm catheter (CS-28702) obtained from 
Arrow Deutschland GmdH, Erding, Germany) was first tunnelled subcutaneously to the 
exit point, located on the cranial aspect of the scapular. The externalised injection ports of 
the catheter were sutured to the skin of the pig so as to limit excessive movement and 
bending. Thereafter, the catheter was surgically inserted approximately 10cm into the left 
jugular vein as depicted in Figure 7.3 via blunt dissection. The lumen of the catheter was 
fastened to the wall of the vein using a purse suture technique. Both the incision and exit 
points were sutured. In order to assess the functioning of the catheter, blood was 
removed via the catheter and the catheter was thereafter flushed with heparinised saline 
(1000i.u. of heparin in 1L of 0.9% saline). Throughout the entire duration of the surgery, 
the pigs’ vital signs (i.e. heart rate, blood pressure, respiratory rate and body temperature) 
were kept under constant observation. Following the surgical procedure, the pigs were 
allowed 8-10 days to recover. During this time, the habituation procedure continued to 
facilitate the process of blood sampling. Throughout the study, the catheter was flushed 
with heparinised saline three times a day, while the entry and exit points were 
continuously monitored for any sign of infection, which was treated appropriately. 
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Step 1: Preparation of surgical 
area 
Step 2: Intubation Step 3: Anaesthesia maintenance 
Step 4: Exposing of Jugular vein Step 5: Subcutaneous tunnelling 
of catheter 
Step 6: Exit point created for port 
placement 
Step 7: Placement of externalized 
injection ports  
Step 8: Jugular vein isolation  Step 9: Catheter inserted into 
jugular vein  
Step 10: Surgical site closure  Step 11: Recovery phase (8-10 
days)  
Figure 7.3: Sequential digital images depicting the surgical procedure for the implantation 
of the chronic jugular vein catheter. 
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7.2.4.2 Administration of the MMDDS or marketed gold standard formulation 
To facilitate dosage administration, pigs were sedated in order to insert an intra-gastric 
tube. A total of 5 pigs (n=5) were orally dosed with either the MMDDS or marketed gold 
standard formulation via an intra-gastric tube as illustrated in Figure 7.4. This avoided 
physical alteration of the system which may occur through mastication by the pigs. 
Dormicum® and Anaket® were injected directly into the jugular vein catheter. When 
sedated, anaesthesia was maintained with 2% isoflurane in 100% oxygen and the pigs’ 
vital signs were constantly monitored. The intra-gastric tube was then inserted into the 
stomach of the pig while the pig was held upright. To ensure that the drug delivery system 
was not still lodged in the intra-gastric tube, 50mL of water was poured down the tube 
prior to removal of the tube. While under sedation, all surgical sites were inspected for 
infection and (if required) sutures were repaired. The pig was returned to its pen to 
recover under observation.  
 
 
Step 1: Dormicum
®
 and Anaket
®
 
administration  
Step 2: Anaesthesia maintenance  
Step 3: Intra-gastric tubing and dosage 
administration  
Step 4: Inspection of surgical sites and 
injection ports for infection, and re-suturing 
of damaged sutures  
Figure 7.4: Sequential digital images depicting the process of dosage administration. 
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7.2.4.3 Blood sampling protocol  
Blood sampling occurred at predetermined time points over a 24 hour period (0, 2, 4, 6, 8, 
10, 12, 16, 20 and 24 hours) after the pigs were orally dosed with either the marketed 
gold standard formulation (Rifinah®) or the MMDDS. The pigs were distracted with food 
which eased the blood sampling procedure. The chronic jugular vein catheter was 
disinfected and an aseptic technique was utilised to draw blood from the externalized 
injection ports. This prevented the introduction of any foreign organisms, thus abating 
infection. Prior to removal of blood from the ports, the catheter was flushed with 
heparinised saline to clear any clots and remove old blood, ensuring an efficient sampling 
procedure. 10mL blood samples were then drawn and placed in a lithium heparin 
Vacutainer®. The catheters were once again flushed with heparinised saline, clearing the 
catheters and ports of any blood present, thus preventing future blocking of the ports from 
occurring. Blood samples were centrifuged at 5000rpm for 15 minutes, removing the red 
blood cells. The plasma supernatant was then removed and frozen at -72°C until required. 
 
7.2.4.4 Plasma extraction of drug 
In order to minimize the quantity of blood obtained from the pigs, a single method was 
developed to extract both RIF and INH from a single plasma sample. Briefly, the method 
involved a process of protein precipitation (deproteination), freeze-liquid and solid-phase 
extraction (SPE) for the successful extraction of both drugs as depicted in Figure 7.5. 
Plasma samples (obtained from blood sampling) were thawed at room temperature. 
0.5mL of the thawed plasma was added to 10mL centrifuge tubes. The sample was 
subject to deproteination and freeze-liquid extraction of RIF by adding 3mL of ACN. The 
plasma-ACN mixture was then vigorously vortexed (Vortex genie 2, Bohemia, NY, USA) 
for 60 seconds, facilitating deproteination. Centrifugation at 3000rpm for 15 minutes 
(Optima® LE-80K, Beckman, USA) caused both protein precipitation and the “movement” 
of RIF from the aqueous phase (where it is poorly soluble) to the ACN phase (where RIF 
is relatively more soluble). Freezing at -72°C produced three immiscible layers – the lower 
protein precipitate, the middle aqueous phase (now containing only INH) and the upper 
ACN layer (containing RIF). Upon removal from the -72°C freezer, the upper ACN layer 
thawed faster than the aqueous layer, and was then decanted into a 10mL glass test tube 
and stored until UPLC analysis was conducted. The remaining contents of the centrifuge 
tube, consisting primarily of the aqueous phase (which contains INH), was then subject 
SPE as follows: Sep-Pak® Vac ICC CN Cartridges obtained from Waters (Water 
Corporation, Milford, MA, USA) were conditioned 1mL methanol and 1mL deionized 
water. Thereafter, the aqueous phase of the plasma sample was then loaded onto the 
cartridges post-conditioning. A 2mL quantity of 30%v/v methanol was determined to be the 
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most efficacious elutant that achieved the most desirable recovery of the drug from the 
plasma. The entire SPE procedure (conditioning to elution) was facilitated with the use of 
a Visiprep Vacuum Manifold and Standard Lid (Water Corporation, Milford, MA, USA). 
Once eluted, the INH containing methanol was added to the RIF containing ACN 
(obtained from freeze-liquid extraction) and the sample was spiked with 40μL furosemide 
(FUR) (employed as the internal standard at a concentration of 0.01mg/mL). The spiked 
sample was then passed through a 0.22μm Cameo Acetate membrane filter (Millipore 
Co., Bedford, MA, USA) into 2mL ANSI 48 vials and subjected UPLC analysis as depicted 
in Section 7.2.4.6. 
 
 
Plasma samples thawed 
Addition of ACN for 
deproteination and RIF 
extraction 
Vigorously vortexed for 60 
seconds followed by 
centrifugation for 15 minutes 
at 3000rpm  
Subject to freezing at -72°C 
for 60 minutes.  
Collection of ACN 
phase (containing RIF) 
Aqueous phase decanted 
and loaded onto 
preconditioned SPE 
cartridges 
SPE cartridges 
conditioned with 1mL 
methanol and 1mL 
water 
INH-loaded cartridges eluted 
with a 30%
v
/v methanol in 
water solution  
Addition of ACN-
RIF phase 
Combined sample spiked 
with internal standard and 
subject to UPLC analysis  
Figure 7.5: Schematic depicting the simultaneous plasma extraction method of RIF and 
INH. 
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7.2.4.5 Determination of plasma extraction efficiency   
Three concentrations of RIF and INH were utilized to spike blank plasma for the 
preparation of the extracted samples. An equal concentration of the respective drug was 
prepared in a mixture of 30%v/v methanol and ACN mixture (2:3
v/v) solution as the 
unextracted samples. The recoveries of RIF and INH from plasma were determined by 
comparing the peak area ratios of the extracted standards vs. those of unextracted 
standards at different concentration levels over the relevant concentration range. FUR 
was employed as the internal standard to compensate for sample preparation losses, and 
drug content was quantified by determining the ratio of the Area Under the Curve of the 
drug to be quantified vs. the Area Under the Curve of the internal standard (AUCD / 
AUCIS).  
 
7.2.4.6 UPLC-PDA analysis for drug content quantification 
UPLC separation was achieved on an Acquity UPLC® BEH RP18 1.7μm column (2.1 x 
100mm) set at a temperature of 30°C. The column was initially primed following a 
washing protocol which included a strong and weak needle wash. The binary mobile 
phase consisted of formic water (0.1% v/v formic acid) and acetonitrile (ACN) following the 
gradient method indicated in Table 7.1, Section 7.2.3.2. A flow rate of 0.40mL/min was 
selected with an injection volume of 10μl. The run time was 2.3 minutes and the system 
was thereafter allowed to equilibrate for 5 minutes prior to analyzing the subsequent 
sample. The photodiode array (PDA) detector was set to detect and quantify drug content 
at a wavelength of 272nm. Furosemide was employed as the internal standard and drug 
content was quantified by determining the ratio of the Area Under the Curve of the drug 
(AUCD) to be quantified vs. the Area Under the Curve of the internal standard (AUCIS).  
 
7.2.4.7 Preparation of analytical standards for the construction of the calibration 
curves 
Stock solutions of INH (0.25mg/mL in water); RIF (0.25mg/mL in a 10% ACN solution) 
and FUR (0.01mg/mL in a 10% ACN solution) were prepared and respectively. Working 
standard solutions of RIF and INH were prepared by a series of dilutions (5 each), 
obtaining concentrations ranging from 5 to 30μg/mL, for analytical evaluation of the 
calibration curve. The calibration curves were constructed by spiking 0.5mL of blank 
plasma with 125μl of the respective drug solution. The samples were then subject to 
plasma extraction as detailed in Section 7.2.4.4 and thereafter subject to UPLC analysis 
as depicted in Section 7.2.4.6. A linear curve was generated on SigmaPlot® V10.0 
software, with the observed ratio (ratio of the Area Under the Curve of the drug peak 
(AUCD) vs. the Area Under the Curve of the internal standard peak (AUCIS) plotted on the 
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y-axis against the corresponding concentrations (μg/mL) plotted on the x-axis. With the 
intercept set at 0, the R2 values were determined to be 0.9958 and 0.996 for RIF and INH 
respectively.  
 
7.3 Results and Discussion 
 
7.3.1 In vitro comparison of marketed formulations 
7.3.1.1 Chromatograms obtained through UPLC analysis 
Figure 7.6 demonstrates the resultant chromatograms obtained from UPLC analysis of 
the in vitro dissolution samples. The UPLC method described enabled rapid 
simultaneous measurement of RIF and INH for the in vitro dissolution samples. As 
illustrated in Figure 7.6, use of the gradient method described resulted in sharp and 
symmetrical peaks. Furthermore, good peak resolution and separation was achieved, 
substantiating the appropriateness of the UPLC method for the simultaneous 
quantification of both drugs and complete elution is achieved in less than three minutes 
under the chromatographic conditions described. RIF, INH and methylparaben (MP) 
obtained retention times at 0.621, 1.903 and 2.064 respectively. INH, which is highly 
soluble in water, elutes when the constitution of the mobile phase is primarily formic 
water. RIF and MP, which are readily soluble in the organic phase (ACN), thus elutes 
when the mobile consists of a substantially larger fraction of ACN.  
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Figure 7.6: A typical a) two-dimensional chromatogram and b) three-dimensional 
chromatogram obtained from the UPLC analysis of in vitro dissolution samples at a 
wavelength of 263nm depicting the distinct separation of INH (Rt=0.621), RIF (Rt=1.903) 
and MP (Rt=2.064). 
 
7.3.1.2 Calibration Curves 
Figure 7.7a displays the calibration curve obtained for RIF in PBS (pH 1.2; 37°C); and 
Figure 7.7b displays the calibration curve obtained for INH in PBS (pH 6.8; 37°C), with an 
R2 value of 0.9983 and 0.9980 respectively. The regression equations were determined to 
the y=24.397x and y=35.252x for the RIF and INH calibration curves respectively, and the 
R2 values demonstrate good linearity. 
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7.3.1.3 In vitro drug release  
The MMDDS demonstrated near zero-order release of both incorporated drugs, as 
illustrated in Figure 7.8. In vitro dissolution studies revealed that 59.31±0.0257% of RIF 
was released in a controlled manner over the 12 hour study duration while 
81.11±0.0235% of INH was release in a controlled manner after 12 hours in a simulated 
intestinal environment. Furthermore, Figure 7.8b clearly demonstrates minimal release of 
INH from the MMDDS (<5% of the total drug incorporated), while the MMDDS was 
exposed to conditions simulating the gastric region of the GIT. INH release was only 
Figure 7.7: Constructed calibration curves of a) RIF in PBS (pH1.2; 37°C) at a 
wavelength of 263nm and b) INH in PBS at a wavelength of 263nm (pH 6.8; 37°C). 
R
2 
= 0.9983 
y = 24.397x 
R
2
 = 0.9980 
y = 35.252x 
a) 
b) 
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initiated when the intestinal-targeted component was exposed to conditions typical of the 
intestinal region of the GIT. As such, it can be concluded that the MMDDS successfully 
segregated the delivery of RIF and INH, thereby mitigating any deleterious drug 
interactions. These results substantiate that site-specific drug delivery was successfully 
achieved with the MMDDS. In contrast, the marketed gold standard formulation 
demonstrated extensive dose dumping tendencies (>70% drug released within the first 15 
minutes), demonstrating extremely poor control over drug release. Furthermore, there is 
no segregation of the drugs in terms of release, hence promoting the deleterious drug 
interaction known to occur between RIF and INH in an acidic environment, detrimentally 
affecting the oral bioavailability of RIF from the Rifinah® tablets.   
 
The prolongation and control of drug release obtained from the MMDDS can be primarily 
attributed to crosslinking of the PVA nanofibres employing glutaraldehyde vapours. 
Furthermore, site-specifity was achieved by employing pH-responsive polymers. 
Incorporation of PEC to the intestinal targeted layer not only ensured prolonged 
mucoadhesion of the intestinal targeted component, but also ensured minimal release of 
INH from the MMDDS when exposed to simulated gastric conditions. CHT, on the other 
hand, promotes mucoadhesion of the gastric-targeted component, and thus ensuring 
prolonged release of RIF in the gastric region of the GIT. 
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Figure 7.8: Comparative in vitro dissolution profiles of a) rifampicin and b) isoniazid from 
the Rifinah® (with the digital image highlighted in red) and MMDDS (with the digital image 
highlighted in green) (SD < 0.0336 for all MMDDS cases; and SD < 0.155 for all Rifinah® 
cases). 
 
7.3.2 In vivo analysis 
7.3.2.1 Chromatograms obtained through UPLC analysis 
Figure 7.9 demonstrates the resultant chromatograms obtained from UPLC analysis of 
plasma samples. The UPLC assay method described enabled rapid simultaneous 
measurement of RIF and INH for the in vivo obtained plasma samples. As illustrated 
in Figure 7.9, sharp and symmetrical peaks were obtained. Furthermore, the 
chromatogram demonstrated that sharp peaks with good separation was achieved, 
substantiating the appropriateness of the UPLC assay method for the simultaneous 
quantification of both drugs after extraction from a single plasma sample. The 
chromatogram also displayed a level chromatographic baseline. RIF, INH and FUR 
obtained retention times of 0.674, 1.962 and 2.134 minutes respectively. INH, which is 
highly soluble in water, elutes when the constitution of the mobile phase is primarily formic 
water. RIF and FUR, which are readily soluble in the organic phase (ACN), thus elutes 
when the mobile consists of a substantially larger fraction of ACN.  
 
b) 
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Figure 7.9: A typical a) two-dimensional chromatogram and b) three-dimensional 
chromatogram obtained from UPLC analysis, depicting the distinct separation of INH 
(Rt=0.674), RIF (Rt=1.962) and FUR (Rt=2.134) at 272nm obtained from porcine plasma 
samples. 
 
7.3.2.2 Recovery efficiency 
Recovery was determined to be 84.175±1.095% and 77.93±0.87% for RIF and INH 
respectively. The remaining drug may have been still trapped in the plasma, or did not 
elute during SPE (i.e. was still trapped within the SPE cartridge). Therefore it can be 
deduced that good recovery was obtained when employing the described method for the 
simultaneous extraction of both RIF and INH from a single plasma sample, minimizing 
time, costs and use of materials. 
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7.3.2.3 Calibration curves 
Figure 7.10a displays the calibration curve obtained for RIF when extracted from plasma 
in PBS (pH 1.2; 37°C); and Figure 7.10b displays the calibration curve obtained for INH 
when extracted from plasma in PBS (pH 6.8; 37°C), with an R2 value of 0.9958 and 
0.9960 respectively. The regression equations were determined to the y=0.0684x and 
y=0.0319x for the RIF and INH calibration curves respectively, and the R2 values 
demonstrate good linearity. 
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Figure 7.10: Constructed calibration curves of a) RIF and b) INH when extracted from 
plasma at a wavelength of 272nm.  
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7.3.2.4 Comparative in vivo plasma concentration profiles 
The comparative plasma concentration profiles of RIF and INH reveal marked differences 
when administered as the MMDDS or as Rifinah® tablets as illustrated in Figure 7.11. 
Although Rifinah® tablets achieved a higher maximum plasma concentration (Cmax) of RIF 
(Cmax=1.589±0.389μg/mL) as opposed to the MMDDS, where a Cmax of 
0.478±0.01005μg/mL was achieved, only the MMDDS was able to achieve consistent or 
steady state plasma concentrations throughout the duration of the study (Figure 7.11a). 
As a result, side effects experienced due to high drug concentrations can be avoided, 
ultimately improving patient compliance. To achieve steady state concentrations, Rifinah® 
tablets are typically administered more often throughout the day, resulting in complicated 
treatment regimens. The MMDDS is able to overcome the requirement of multiple doses, 
thus easing complex treatment regimens. Furthermore, the variability in the quantity of 
drug released from the Rifinah® tablets was extremely high as opposed to the MMDDS.  
 
The in vivo plasma concentration profiles of the MMDDS and Rifinah® shown in Figure 
7.11b reveals that for the first 2 hours post-dosing, minimal INH is released from the 
MMDDS (0.369±0.027μg/mL), whereas a concentration of 2.45±0.325μg/mL is achieved 
from Rifinah® within the same time frame. These results obtained within the first two hours 
subsequent to oral dosing provide the fundamental evidence of the efficiency of the 
MMDDS in terms of site-specific drug delivery. Due to enhanced site-specific drug 
delivery, a greater quantity of INH is released in the intestine where a larger degree of 
absorption is acquired. This can be seen from a comparison of the 2 hour blood sample 
where the plasma concentration of INH was considerably lower (0.369±0.027μg/mL) from 
the MMDDS, corresponding to the time when the drug delivery system is yet to pass 
through the gastric region of the GIT, as opposed to the 4 hour blood sample 
(1.7744±0.0473μg/mL), corresponding to when the drug delivery system has entered the 
intestine. Furthermore, the reduced quantity of INH release in the gastric region 
decreased the occurrence of the deleterious drug interaction between RIF and INH from 
occurring, hence improving the bioavailability of RIF. As illustrated in Figure 7.11b, the 
MMDDS achieved consistent plasma levels of INH throughout the duration of the study as 
opposed to Rifinah® tablets, where very erratic plasma concentration of INH were 
observed, demonstrating desirable release behaviour of the MMDDS in the swine model. 
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Figure 7.11: Comparative plasma concentration profiles of a) RIF and b) INH with 
corresponding digital images of the MMDDS and Rifinah® formulations which were orally 
administered to a swine model (SD < 0.0473 for all MMDDS cases; SD < 0.389 for all 
Rifinah® cases). 
 
7.4 Concluding Remarks 
 
The primary goal of the present chapter was to determine whether the MMDDS was able 
to achieve improved drug release characteristics of RIF and INH as opposed to a 
marketed gold standard formulation, Rifinah®. Both in vitro and in vivo analysis clearly 
identified the MMDDS as a superior formulation in terms of both the rate of drug delivery 
and ensuring segregated drug delivery of the drugs incorporated. In vitro analysis 
demonstrated that greater control over drug release was achieved with the MMDDS as 
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opposed to Rifinah® where extreme dose dumping was observed. Furthermore, in vitro 
studies highlighted the ability of the MMDDS in segregating drug delivery, which was 
further corroborated with data presented with in vitro analysis. In addition to providing 
targeted and segregated delivery of the respective drugs, the MMDDS further benefited 
the therapeutic efficacy of the respective drugs by providing release behaviour that was 
more reproducible and consistent with minimal fluctuations. It should be noted that the in 
vivo analysis of the MMDDS in pigs caused no notable side-effects or other detrimental 
circumstances in the pigs acquired (See Appendix C2). 
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CHAPTER 8   
CONCLUSIONS AND RECOMMENDATIONS 
 
 
8.1 Conclusions 
 
The dynamic and rapidly advancing field of drug delivery has led to numerous 
innovations, all improving the safety and efficacy of modern day drug therapies. Many 
new modes of drug administration have been identified and improved throughout the 
years. However, of the global drug delivery market share, a hefty fraction deals with 
improving the bioavailability or orally administered drugs. Apart from the benefits 
associated with oral drug delivery in terms of patient compliance, the limitations which 
affect oral bioavailability can be easily overcome. Furthermore, the physiology of the 
human gastro-intestinal system can be exploited for targeted and site-specific drug 
delivery, by employing smart polymers which respond to changes in the surrounding 
environment.  
 
Patient compliance has been identified as a major success-limiting factor in the 
eradication of many diseases (e.g. TB, HIV). In addition, poor patient compliance has 
been identified as a leading cause for many drug-resistant strains of many infectious 
diseases such as TB. The fundamental basis for poor patient compliance can largely be 
attributed to the complex dosing regimens imposed on them as part of a standard 
therapeutic intervention. Multiple doses taken several times a day generally makes 
standard treatment regimens “a difficult pill to swallow” for many patients, ultimately 
threatening compliance, and ultimately the patients therapeutic outcome. 
 
The present dissertation therefore aimed to develop a novel multi-component 
membranous drug delivery system (MMDDS), which is able to overcome the limitations of 
oral drug delivery and improve patient compliance by ensuring site-specific and 
segregated delivery of multiple drugs, in a controlled manner, while protecting the drug 
delivery system from the harsh gastric environment. The MMDDS comprised of two 
components, a gastric- and intestinal-targeted membrane system, each comprising of a 
pH-responsive mucoadhesive layer, a drug containing layer, and a water insoluble coat. 
rifampicin and isoniazid were identified as the model drugs, to investigate the efficacy of 
the formulation. The MMDDS was developed in a logical step-wise manner (i.e. each 
layer at a time), and each component was developed and optimized separately after 
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exhaustive preliminary studies identified the appropriate method, polymer combinations 
and quantities required to impart the desired properties. 
 
Extensive in vitro analysis led to the identification of formulation variables for the 
respective gastric- and intestinal-targeted mucoadhesive layers which comprise the 
MMDDS. A Central Composite Design generated 13 formulations for each component, 
which were analyzed and the respective mucoadhesive layers were subsequently 
optimized for prolonged mucoadhesion in their respective regions within the GIT. The 
optimized formulations underwent further in vitro analysis to determine the behaviour of 
the system under conditions which simulate the human gastro-intestinal environment, and 
to determine the effect of simulated human gastro-intestinal conditions on the MMDDS. 
 
The second layer of each component, containing the model drugs, was developed 
through modification of polymeric nanofibres, synthesized via a horizontal electrospinning 
setup. Drug entrapment efficiency and uniformity of nanofibres produced via the 
electrospinning of poly(vinyl alcohol) solutions closely met the desirable criteria, and was 
therefore employed for further modification via vapour-induced crosslinking. Crosslinking 
caused provided the qualities necessary for the controlling drug release in a prolonged 
release fashion. The formulation closely meeting the desired criteria was identified and 
subject to further in vitro characterization and modelling, providing useful information in 
predicting the behaviour of the MMDDS in vivo. 
 
Each component was then assembled to form the MMDDS, while a water insoluble coat 
was employed to protect the incorporated drugs from the harsh gastric environment. 
Subsequent to in vitro analysis, which proved both efficacy of the system in terms of both 
site-specific and prolonged drug delivery, the MMDDS was subject to in vivo analysis in a 
swine model. For comparative purposes, a marketed gold standard formulation, Rifinah®, 
was also subject to the same in vitro and in vivo studies. Results indicated that MMDDS 
was able to segregate the delivery of the incorporated drugs, rifampicin and isoniazid, 
while ensuring relatively consistent plasma levels of the incorporated drugs in the swine 
model. In conclusion, the marketed formulation demonstrated inferior properties in terms 
of control over drug release as compared to the developed MMDDS.    
 
The fact that drugs with completely different properties were successfully incorporated 
within the system with minor adjustments to the processing parameters, and still 
achieving the desired properties of prolonged release, demonstrates the versatility of the 
system. 
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Overall, the MMDDS was able to overcome many of the limitations associated with oral 
drug delivery, with the potential of site-specific delivery of multiple drugs incorporated in 
one system.  
 
8.2 Recommendations 
 
Subsequent to the success of the developed MMDDS in both in vitro and in vivo 
investigations described in the present dissertation, it is recommended that further 
analysis is conducted to determine the efficacy of the drug delivery system in human 
subjects. It is further recommended that the exact location of mucoadhesion of each 
component is established and the exact site of drug release be identified employing 
techniques such as gamma-scintigraphic technology. For comparative purposes, 
marketed formulations should also be analyzed employing the same techniques, allowing 
identification of which product is superior in terms of drug release and improved 
bioavailability.  
 
Furthermore, the system developed by the present dissertation may be successfully 
applied to any number of bioactives, particularly those that are acid-sensitive, have 
narrow therapeutic absorption windows, bioactives which cause local irritation of the 
gastric mucosa (e.g. NSAIDs), bioactives which are absorbed only within specific regions 
of the GIT, such as the gastric region (e.g. rifampicin), intestinal region (e.g. isoniazid) or 
the colon (5-aminosalicylic acid, prodrugs of mesalazine and sulfasalazine), and 
bioactives which accelerate the degradation of others in acidic media (e.g. isoniazid and  
pyrazinamide cause the degradation of rifampicin).  
 
For scale-up purposes, it is recommended that the preparatory process of the MMDDS be 
simplified. Film-casting can be easily scaled-up; however, an industrial scale 
electrospinner needs to be developed. In this manner, individual membranes need not be 
fabricated, but rather large “sheets” of the MMDDS be fabricated and trimmed to the 
required sizes upon completion of membrane fabrication and assembly.  
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Membranous drug delivery devices for oral administration 
Rubina P. Shaikh, Tasneem Kader, Prof. Viness Pillay, Yahya E. Choonara, Lisa C. du Toit 
University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road,   
Parktown, 2193, Johannesburg, South Africa 
*Correspondence: viness.pillay@wits.ac.za 
 
Purpose: The objective of this study is to compare polymers, polymer concentrations and the 
methods of fabrication of membranous drug delivery systems and their effects on drug release. As 
the oral route of drug administration poses to be one of the most favourable and extensively 
employed routes of administration, these membranous systems will be employed in the oral 
delivery of drugs. 
 
Methods: For comparative reasons, two methods i.e. Immersion Precipitation (IP) and Film-
casting (FC) and two polymers, namely poly(vinyl alcohol) (PVA) and cellulose acetate phthalate 
(CAP) were investigated in the preparation of the membranous systems. PVA membranes were 
prepared using 2.5%, 5%, and 10%w/v concentrations of polymer solutions with water as a solvent 
and CAP membranes were prepared using 10%, 15% and 20%w/v concentrations of polymer 
solutions with acetone as a solvent. Moulds used in the preparation of the membranes were 4 cm 
in diameter with a depth of 0.5 cm. Moulds were lubricated with liquid paraffin to facilitate ease of 
removal. Diphenhydramine HCl was incorporated as a model drug at a concentration of 50µg/ml 
(200µg/membrane). 
FC: 4 mls of the polymer solutions were then pipetted into moulds and allowed to dry for a period 
of 24 hours. The resultant membranes were stored with desiccants prior to undergoing a 
dissolution test. 
IP: 4 mls of the polymer solutions were pipetted into moulds and allowed to dry for a period of 30 
minutes. The moulds were then placed in a coagulation bath containing nonsolvents (Hexane for 
PVA and Water for CAP) and left for a period of 24 hours. These membranes were then allowed to 
dry at ambient conditions for a period of 24 hours. Resultant membranes were stored with 
desiccants prior to undergoing a dissolution test. 
 
Results: Dissolution studies were performed in duplicate at 370.5C in simulated gastric fluid 
(SGF), at pH 1.2, for 2 hours. Samples were analyzed at time intervals of 15 minutes, 30 minutes, 
1 hour, 1.5 hours and 2 hours.  
PVA membranes: Drug encapsulation in PVA membranes were excellent (approx. 
200µg/membrane). PVA membranes prepared using FC showed better control over drug release 
those prepared using IP. The best control was shown with 10% PVA using FC where 45% of drug 
was released in the first 15 minutes and 70% was released in 2 hours. The poorest control was 
shown with 2.5% PVA using IP where 70% of drug was released over the first 15 minutes and 
100% over 2 hours. 
CAP membranes: Drug encapsulation in CAP membranes prepared using IP was much poorer 
than all other membranes produced. This can be attributed to drug being released from the CAP 
membranes into the nonsolvent water when immersed in the coagulation bath during fabrication. 
Drug release from the CAP membranes was very controlled as the CAP membranes do not 
dissolve in pH 1.2. Total drug released ranged from 30-60% over 2 hours with the different 
membranes produced. 10% CAP membranes prepared using IP showed the most controlled 
release with an average of 6% being released in the first 15 minutes, and a total of 30% released 
over 2 hours, while CAP membranes prepared using FC showed the poorest control over drug 
release with 30% being released over the first 15 minutes and 65% 2 hours. 
 
Conclusions: This study demonstrates that CAP membranes show the best control over drug 
release in a pH of 1.2 as compared to PVA membranes. Higher polymer concentrations also 
controlled drug release more effectively than lower concentrations. As drug encapsulation in CAP 
membranes was poor as compared to PVA membranes using IP, FC illustrates a more promising 
method of fabrication in the preparation of CAP membranes. 
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Evaluation of Electrospun Polymeric Membranes for Potential Rate-
Modulated Drug Delivery 
Rubina P. Shaikh, Viness Pillay*, Yahya E. Choonara and Lisa C. du Toit  
University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, 
Parktown, 2193, Johannesburg, South Africa 
*Correspondence: viness.pillay@wits.ac.za 
 
Purpose 
This study evaluated the process of electrospinning for the development of a micro-fibrous 
polymeric membrane system and the potential for rate-modulated drug delivery. 
 
Methods 
Electrospinning: Polymers including polyvinyl alcohol (PVA) and poly(ethylene oxide) (PEO) were 
investigated for electrospun membrane formation. Solutions of PVA and PEO (10-30%
w
/v) were 
prepared. A plasticizer was incorporated, as well as varying concentrations of polymer solvents 
such as water and a water: propan-2-ol solvent system, were investigated. Drug-loading was 
attempted by dissolving model drug, diphenhydramine HCl (DPH) in the polymeric solution prior to 
electrospinning. Polymer solutions were subjected to a predetermined voltage and allowed to 
electrospin for a time period sufficient to produce acceptable membranes. Microscopic evaluation: 
Electrospun fibres underwent microscopic evaluation to assess fibre morphology, size and 
consistency. Fourier Transform Infrared Spectroscopy (FTIR): FTIR spectroscopy was performed 
in order to assess any constituent interactions in the formulation due to electrospinning. Drug 
Entrapment Efficacy (DEE): DEE studies were conducted on the fibres and quantified using a 
standard curve generated for DPH.  
  
Results and Discussion 
Plasticizer addition resulted in a higher elasticity and strength of membranes. Of the polymers 
selected for electrospinning, fibres spun from PEO resulted in poorly formed membranes 
compared to PVA. The physicomechanical properties of membranes prepared using different 
solvents differed vastly. With water as the solvent, resilient membranes were prepared with 
relatively smaller fibre sizes, whereas the fibre sizes of water: propan-2-ol membranes were 
inconsistent and were prone to rupture. Fibres produced were micrometer in size. Parallel, 
nonwoven and uniform fibre membranes were formed from PVA while PEO solutions formed 
woven membranes with inconsistent fibre sizes. An ideal voltage applied to the polymer solution 
during electrospinning promoted adequate elongation of the fibres resulting in smaller fibre 
diameters as seen with the PVA membranes. Electrospinning produced no significant changes on 
the polymer as demonstrated by the FTIR spectra generated, where the polymer backbone 
remained intact upon exposure to the voltage associated with electrospinning. Studies indicated 
that the DEE value was significantly higher with PVA as compared to PEO (93.5% vs. 54% for PVA 
and PEO respectively), thus indicating that PVA possessed a greater potential for entrapping DPH 
due to its hydrophilic nature. 
 
Conclusions 
Electrospinning produced no significant physicochemical changes to the properties of the polymers 
selected. Furthermore, electrospun membranes showed relatively superior drug entrapment and 
fibres were found to have an adequate size range for modulated drug delivery.  
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Development of a pH-responsive, Mucoadhesive Membrane Intended for 
Prolonged Oral Drug Delivery 
Rubina Shaikh, Viness Pillay*, Yahya E. Choonara and Lisa C. du Toit, Valence M.K. Ndesendo 
and Pradeep Kumar 
University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, 
Parktown, 2193, Johannesburg, South Africa. 
*Correspondence: viness.pillay@wits.ac.za 
 
Purpose: Chitosan (CHT) (0.5-3%w/v), which swells only in lower pH ranges, was investigated for 
the development of gastric-responsive mucoadhesive membrane intended for prolonged oral drug 
delivery. 
 
Methods: In addition to CHT, Poly(vinyl alcohol) (1-5%w/v), which improved the membrane’s 
physicomechanical properties and Poly(vinylpyrrolidone) (2-10%w/v) which improved 
mucoadhesive properties were included in the formulation. A 2-Factor Central Composite Design 
(13 formulations) was used to determine the optimal formulation. The polymeric solutions were 
film-cast and dried at ambient conditions to produce mucoadhesive membranes (MM). pH-
responsive mucoadhesion was determined by exposing the MM to Simulated Human Gastric Fluid 
(pH 1.2) and Simulated Human Intestinal Fluid (pH 6.8) for 12 hours, and tested at 2 hour intervals 
using a textural analyzer. Surface morphology, which affects mucoadhesive properties, was 
assessed using SEM analysis. Molecular Mechanics Computations were employed to elucidate the 
intermolecular interactions, responsible for mucoadhesion, involved between the polymers and 
mucosa.  
 
Results: There was a substantial difference in the mucoadhesive properties of the MM when 
exposed to the different pH ranges. The MM’s were highly mucoadhesive at lower pH ranges as 
compared to higher ranges. Membranes were irregular in surface morphology, thus promoting 
mucoadhesion through stronger mechanical interactions. Furthermore, the spatial disposition and 
energetic profile of the sterically constrained and geometrically optimized multi-polymeric complex 
corroborated the experimental results in terms of drug release and mucoadhesive strength of the 
fabricated MM. 
 
Conclusions: The pH-responsive nature of the MM can potentially produce prolonged site-specific 
drug release in the gastric region of the gastrointestinal tract for multiple drug regimens or single 
drug formulations.   
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Synthesis of Multilayered Mucoadhesive Membranes for Prolonged and Site-
Specific Oral Drug Delivery  
Rubina P. Shaikh, Viness Pillay*, Yahya E. Choonara and Lisa C. du Toit. 
Department of Pharmacy and Pharmacology, University of the Witwatersrand, 7 York Road, 
Parktown, 2193 Johannesburg, South Africa 
 *Corresponding author: viness.pillay@.wits.ac.za       
Purpose: 
    The purpose of this study was to formulate and evaluate a novel polymeric drug delivery system 
comprising an upper gastric and intestinal targeted multilayered membrane system, for site-specific 
oral delivery of model drugs rifampicin and isoniazid respectively. 
Methods: 
      Mucoadhesive Membrane Fabrication: Solutions of chitosan (1.0-2.0%
w
/v) for the gastric 
targeted component and pectin (1.3-2.7%
w
/v) for the intestinal targeted component, added to a 
solution containing polyvinylpyrollidone (4.0-8.0%
w
/v) and Poly(vinyl alcohol) (PVA) (2.00-4.75%
w
/v) 
before film-casting and dried at room temperature for membrane formation. 
     Preparation of Electrospun Drug-loaded nanofibrous membranes: Solutions (10%
w
/v PVA with 
2%
w
/v INH and 8%
w
/v PVA with 2%
w
/v RIF) were electrospun on a horizontal electrospinning rig with 
an optimised collector to capillary tip distance of 24cm or 28cm for INH and RIF nanofibrous 
membranes respectively with an applied voltage of 20kV. 
   Modification by Vapour-Induced Crosslinking: Crosslinking was performed in the presence of GA 
vapours in a closed environment. INH- and RIF-loaded PVA nanofibrous membranes were 
suspended over 15-60mL of the GA solution and allowed to crosslink for 6-24 hours. 
      Drug Entrapment Efficiency (DEE) Determination: Accurately weighed samples of drug-loaded 
nanofibrous membranes were dissolved in 100mL of PBS (INH: pH 6.8; RIF: pH 1.2). The drug 
content was analyzed by UV spectrophotometry and computed from a standard linear curve of the 
drug in PBS. 
     In-Vitro Drug Release Study: In vitro drug release studies were performed using a USP 33 
apparatus II rotating paddle method, set at 50rpm, in which a single nanofibrous membrane of 
known mass was placed in 900mL of PBS (INH: pH 6.8;  RIF: pH 1.2) at 37°C. Sampling occurred 
at hourly intervals for 12 hours and with analysis by UV spectroscopy.  
     pH-responsive Mucoadhesivity Analysis: Mucoadhesive membranes were exposed to test 
parameters as described in drug release studies and tested for mucoadhesion at 2 hour intervals 
over 12 hours using a textural analyzer. 
   Scanning Electron Microscopy Studies: Surface morphology of the nanofibrous membranes was 
analyzed by SEM to qualitatively elucidate nanofiber diameter and network density. 
    Elucidation of Tensile properties: Physicomechanical properties of the crosslinked and non-
crosslinked nanofibrous membranes were determined using a nanoTensile
®
 tester.  
Results and Conclusions: 
    DEE tests demonstrated a high entrapment of 98.77±1.384% and 95.07±1.988% of INH and RIF 
respectively. Drug release results showed that the crosslinking time and quantity of GA had a 
profound effect on prolonging the release characteristics of the nanofibrous membranes. SEM 
analysis revealed uniform, cylindrical fibers with diameters of 372.5±28.61nm and 631±57.78nm 
for INH and RIF respectively. Crosslinking produced denser packing of nanofibers within the 
membrane which facilitated prolonged drug release characteristics. Crosslinking notably decreased 
the elasticity and increased the ultimate strength and yield stress of the nanofibrous membrane. 
Mucoadhesion, determined by measuring the Work of Adhesion from a typical force: distance 
obtained from textural analysis was 7.5e
-3
±2.96e
-3
J and 2.03e
-2
±5.43e
-3
J for optimised gastric 
targeted membranes and intestinal targeted membranes respectively. Membranes maintained their 
mucoadhesive properties over 12 hours only showing a decrease in mucoadhesion of 20-40% after 
8 hours.   
Note: Ethics approval for in vivo studies obtained from Wits Animal Ethics Screening Committee, 
AESC No: 2009/01/05.  
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